<SEC-DOCUMENT>0001493152-25-017100.txt : 20251006
<SEC-HEADER>0001493152-25-017100.hdr.sgml : 20251006
<ACCEPTANCE-DATETIME>20251006170030
ACCESSION NUMBER:		0001493152-25-017100
CONFORMED SUBMISSION TYPE:	PRE 14A
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20251006
FILED AS OF DATE:		20251006
DATE AS OF CHANGE:		20251006

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Algorhythm Holdings, Inc.
		CENTRAL INDEX KEY:			0000923601
		STANDARD INDUSTRIAL CLASSIFICATION:	PHONOGRAPH RECORDS & PRERECORDED AUDIO TAPES & DISKS [3652]
		ORGANIZATION NAME:           	04 Manufacturing
		EIN:				953795478
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		PRE 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41405
		FILM NUMBER:		251377471

	BUSINESS ADDRESS:	
		STREET 1:		6301 NW 5TH WAY, STE 2900
		CITY:			FORT LAUDERDALE
		STATE:			FL
		ZIP:			33309
		BUSINESS PHONE:		(954) 596-1000

	MAIL ADDRESS:	
		STREET 1:		6301 NW 5TH WAY, STE 2900
		CITY:			FORT LAUDERDALE
		STATE:			FL
		ZIP:			33309

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SINGING MACHINE CO INC
		DATE OF NAME CHANGE:	19940523
</SEC-HEADER>
<DOCUMENT>
<TYPE>PRE 14A
<SEQUENCE>1
<FILENAME>formpre14a.htm
<DESCRIPTION>PRE 14A
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:RIME="http://algoholdings.com/20241231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_ECD%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_034_RIME_algoholdings.com_20241231 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20240101_20241231 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_054_edei%2D%2DEntityCentralIndexKey_0000923601 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_065_Ratio_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000004" name="dei:EntityCentralIndexKey">0000923601</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0011" name="dei:DocumentType">PRE 14A</ix:nonNumeric>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2024-01-012024-12-31_custom_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember_ecd_PeoMember" id="xdx2ixbrl0061" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2024-01-012024-12-31_custom_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember_ecd_PeoMember" id="xdx2ixbrl0062" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2024-01-012024-12-31_custom_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember_ecd_PeoMember" id="xdx2ixbrl0064" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2023-04-012023-12-31_custom_ReportedValueOfEquityAwardsMember_ecd_PeoMember" id="xdx2ixbrl0067" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2023-04-012023-12-31_custom_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember_ecd_PeoMember" id="xdx2ixbrl0068" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2023-04-012023-12-31_custom_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember_ecd_PeoMember" id="xdx2ixbrl0069" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2022-04-012023-03-31_custom_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember_ecd_PeoMember" id="xdx2ixbrl0076" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2022-04-012023-03-31_custom_FairValueOfAwardsGrantedAndVestedDuringTheYearMember_ecd_PeoMember" id="xdx2ixbrl0077" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2022-04-012023-03-31_custom_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember_ecd_PeoMember" id="xdx2ixbrl0078" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2021-04-012022-03-31_custom_ReportedValueOfEquityAwardsMember_ecd_PeoMember" id="xdx2ixbrl0081" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2021-04-012022-03-31_custom_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember_ecd_PeoMember" id="xdx2ixbrl0082" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2021-04-012022-03-31_custom_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember_ecd_PeoMember" id="xdx2ixbrl0083" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2021-04-012022-03-31_custom_FairValueOfAwardsGrantedAndVestedDuringTheYearMember_ecd_PeoMember" id="xdx2ixbrl0084" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2021-04-012022-03-31_custom_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember_ecd_PeoMember" id="xdx2ixbrl0085" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2024-01-012024-12-31_custom_RichardPerezMember_custom_ReportedValueOfEquityAwardsMember" id="xdx2ixbrl0091" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2024-01-012024-12-31_custom_RichardPerezMember_custom_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember" id="xdx2ixbrl0092" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2024-01-012024-12-31_custom_RichardPerezMember_custom_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember" id="xdx2ixbrl0093" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2024-01-012024-12-31_custom_RichardPerezMember_custom_FairValueOfAwardsGrantedAndVestedDuringTheYearMember" id="xdx2ixbrl0094" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2024-01-012024-12-31_custom_RichardPerezMember_custom_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember" id="xdx2ixbrl0095" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2023-04-012023-12-31_custom_LionelMarquisMember_custom_ReportedValueOfEquityAwardsMember" id="xdx2ixbrl0098" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2023-04-012023-12-31_custom_LionelMarquisMember_custom_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember" id="xdx2ixbrl0099" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2023-04-012023-12-31_custom_LionelMarquisMember_custom_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember" id="xdx2ixbrl0100" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2022-04-012023-03-31_custom_LionelMarquisMember_custom_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember" id="xdx2ixbrl0107" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2022-04-012023-03-31_custom_LionelMarquisMember_custom_FairValueOfAwardsGrantedAndVestedDuringTheYearMember" id="xdx2ixbrl0108" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2022-04-012023-03-31_custom_LionelMarquisMember_custom_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember" id="xdx2ixbrl0109" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2021-04-012022-03-31_custom_LionelMarquisMember_custom_ReportedValueOfEquityAwardsMember" id="xdx2ixbrl0112" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2021-04-012022-03-31_custom_LionelMarquisMember_custom_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember" id="xdx2ixbrl0113" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2021-04-012022-03-31_custom_LionelMarquisMember_custom_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember" id="xdx2ixbrl0114" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2021-04-012022-03-31_custom_LionelMarquisMember_custom_FairValueOfAwardsGrantedAndVestedDuringTheYearMember" id="xdx2ixbrl0115" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2021-04-012022-03-31_custom_LionelMarquisMember_custom_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember" id="xdx2ixbrl0116" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2024-01-012024-12-31_custom_BernardoMeloMember_custom_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember" id="xdx2ixbrl0120" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2024-01-012024-12-31_custom_BernardoMeloMember_custom_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember" id="xdx2ixbrl0121" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2024-01-012024-12-31_custom_BernardoMeloMember_custom_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember" id="xdx2ixbrl0123" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2023-04-012023-12-31_custom_BernardoMeloMember_custom_ReportedValueOfEquityAwardsMember" id="xdx2ixbrl0126" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2023-04-012023-12-31_custom_BernardoMeloMember_custom_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember" id="xdx2ixbrl0127" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2023-04-012023-12-31_custom_BernardoMeloMember_custom_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember" id="xdx2ixbrl0128" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2022-04-012023-03-31_custom_BernardoMeloMember_custom_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember" id="xdx2ixbrl0135" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2022-04-012023-03-31_custom_BernardoMeloMember_custom_FairValueOfAwardsGrantedAndVestedDuringTheYearMember" id="xdx2ixbrl0136" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2021-04-012022-03-31_custom_BernardoMeloMember_custom_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember" id="xdx2ixbrl0142" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2021-04-012022-03-31_custom_BernardoMeloMember_custom_FairValueOfAwardsGrantedAndVestedDuringTheYearMember" id="xdx2ixbrl0143" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2021-04-012022-03-31_custom_BernardoMeloMember_custom_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember" id="xdx2ixbrl0144" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="rime-20241231.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2024-01-01to2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_ecd_PeoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_ecd_PeoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_ecd_PeoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ReportedValueOfEquityAwardsMember_ecd_PeoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:ReportedValueOfEquityAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember_ecd_PeoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember_ecd_PeoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_FairValueOfAwardsGrantedAndVestedDuringTheYearMember_ecd_PeoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueOfAwardsGrantedAndVestedDuringTheYearMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember_ecd_PeoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-12-31_custom_ReportedValueOfEquityAwardsMember_ecd_PeoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:ReportedValueOfEquityAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-12-31_custom_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember_ecd_PeoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-12-31_custom_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember_ecd_PeoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-12-31_custom_FairValueOfAwardsGrantedAndVestedDuringTheYearMember_ecd_PeoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueOfAwardsGrantedAndVestedDuringTheYearMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-12-31_custom_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember_ecd_PeoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_custom_ReportedValueOfEquityAwardsMember_ecd_PeoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:ReportedValueOfEquityAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_custom_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember_ecd_PeoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_custom_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember_ecd_PeoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_custom_FairValueOfAwardsGrantedAndVestedDuringTheYearMember_ecd_PeoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueOfAwardsGrantedAndVestedDuringTheYearMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_custom_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember_ecd_PeoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_ReportedValueOfEquityAwardsMember_ecd_PeoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:ReportedValueOfEquityAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember_ecd_PeoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember_ecd_PeoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_FairValueOfAwardsGrantedAndVestedDuringTheYearMember_ecd_PeoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueOfAwardsGrantedAndVestedDuringTheYearMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember_ecd_PeoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_RichardPerezMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:RichardPerezMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_RichardPerezMember_custom_ReportedValueOfEquityAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:RichardPerezMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:ReportedValueOfEquityAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_RichardPerezMember_custom_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:RichardPerezMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_RichardPerezMember_custom_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:RichardPerezMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_RichardPerezMember_custom_FairValueOfAwardsGrantedAndVestedDuringTheYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:RichardPerezMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueOfAwardsGrantedAndVestedDuringTheYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_RichardPerezMember_custom_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:RichardPerezMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-12-31_custom_LionelMarquisMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:LionelMarquisMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-12-31_custom_LionelMarquisMember_custom_ReportedValueOfEquityAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:LionelMarquisMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:ReportedValueOfEquityAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-12-31_custom_LionelMarquisMember_custom_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:LionelMarquisMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-12-31_custom_LionelMarquisMember_custom_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:LionelMarquisMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-12-31_custom_LionelMarquisMember_custom_FairValueOfAwardsGrantedAndVestedDuringTheYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:LionelMarquisMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueOfAwardsGrantedAndVestedDuringTheYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-12-31_custom_LionelMarquisMember_custom_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:LionelMarquisMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_custom_LionelMarquisMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:LionelMarquisMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_custom_LionelMarquisMember_custom_ReportedValueOfEquityAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:LionelMarquisMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:ReportedValueOfEquityAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_custom_LionelMarquisMember_custom_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:LionelMarquisMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_custom_LionelMarquisMember_custom_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:LionelMarquisMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_custom_LionelMarquisMember_custom_FairValueOfAwardsGrantedAndVestedDuringTheYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:LionelMarquisMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueOfAwardsGrantedAndVestedDuringTheYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_custom_LionelMarquisMember_custom_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:LionelMarquisMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_LionelMarquisMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:LionelMarquisMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_LionelMarquisMember_custom_ReportedValueOfEquityAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:LionelMarquisMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:ReportedValueOfEquityAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_LionelMarquisMember_custom_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:LionelMarquisMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_LionelMarquisMember_custom_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:LionelMarquisMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_LionelMarquisMember_custom_FairValueOfAwardsGrantedAndVestedDuringTheYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:LionelMarquisMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueOfAwardsGrantedAndVestedDuringTheYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_LionelMarquisMember_custom_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:LionelMarquisMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_BernardoMeloMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:BernardoMeloMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_BernardoMeloMember_custom_ReportedValueOfEquityAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:BernardoMeloMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:ReportedValueOfEquityAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_BernardoMeloMember_custom_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:BernardoMeloMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_BernardoMeloMember_custom_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:BernardoMeloMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_BernardoMeloMember_custom_FairValueOfAwardsGrantedAndVestedDuringTheYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:BernardoMeloMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueOfAwardsGrantedAndVestedDuringTheYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_BernardoMeloMember_custom_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:BernardoMeloMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-12-31_custom_BernardoMeloMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:BernardoMeloMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-12-31_custom_BernardoMeloMember_custom_ReportedValueOfEquityAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:BernardoMeloMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:ReportedValueOfEquityAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-12-31_custom_BernardoMeloMember_custom_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:BernardoMeloMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-12-31_custom_BernardoMeloMember_custom_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:BernardoMeloMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-12-31_custom_BernardoMeloMember_custom_FairValueOfAwardsGrantedAndVestedDuringTheYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:BernardoMeloMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueOfAwardsGrantedAndVestedDuringTheYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-12-31_custom_BernardoMeloMember_custom_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:BernardoMeloMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_custom_BernardoMeloMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:BernardoMeloMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_custom_BernardoMeloMember_custom_ReportedValueOfEquityAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:BernardoMeloMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:ReportedValueOfEquityAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_custom_BernardoMeloMember_custom_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:BernardoMeloMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_custom_BernardoMeloMember_custom_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:BernardoMeloMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_custom_BernardoMeloMember_custom_FairValueOfAwardsGrantedAndVestedDuringTheYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:BernardoMeloMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueOfAwardsGrantedAndVestedDuringTheYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012023-03-31_custom_BernardoMeloMember_custom_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:BernardoMeloMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_BernardoMeloMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:BernardoMeloMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_BernardoMeloMember_custom_ReportedValueOfEquityAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:BernardoMeloMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:ReportedValueOfEquityAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_BernardoMeloMember_custom_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:BernardoMeloMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_BernardoMeloMember_custom_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:BernardoMeloMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_BernardoMeloMember_custom_FairValueOfAwardsGrantedAndVestedDuringTheYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:BernardoMeloMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueOfAwardsGrantedAndVestedDuringTheYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_BernardoMeloMember_custom_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000923601</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:BernardoMeloMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Ratio">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="Fact000023" toRefs="Footnote000047"/>
  <ix:relationship fromRefs="Fact000029" toRefs="Footnote000047"/>
  <ix:relationship fromRefs="Fact000035" toRefs="Footnote000047"/>
  <ix:relationship fromRefs="Fact000041" toRefs="Footnote000047"/>
  <ix:relationship fromRefs="Fact000024" toRefs="Footnote000048"/>
  <ix:relationship fromRefs="Fact000030" toRefs="Footnote000048"/>
  <ix:relationship fromRefs="Fact000036" toRefs="Footnote000048"/>
  <ix:relationship fromRefs="Fact000042" toRefs="Footnote000048"/>
  <ix:relationship fromRefs="Fact000025" toRefs="Footnote000049"/>
  <ix:relationship fromRefs="Fact000031" toRefs="Footnote000049"/>
  <ix:relationship fromRefs="Fact000037" toRefs="Footnote000049"/>
  <ix:relationship fromRefs="Fact000043" toRefs="Footnote000049"/>
  <ix:relationship fromRefs="Fact000026" toRefs="Footnote000050"/>
  <ix:relationship fromRefs="Fact000032" toRefs="Footnote000050"/>
  <ix:relationship fromRefs="Fact000038" toRefs="Footnote000050"/>
  <ix:relationship fromRefs="Fact000044" toRefs="Footnote000050"/>
  <ix:relationship fromRefs="Fact000027" toRefs="Footnote000051"/>
  <ix:relationship fromRefs="Fact000033" toRefs="Footnote000051"/>
  <ix:relationship fromRefs="Fact000039" toRefs="Footnote000051"/>
  <ix:relationship fromRefs="Fact000045" toRefs="Footnote000051"/>
  <ix:relationship fromRefs="Fact000060" toRefs="Footnote000087"/>
  <ix:relationship fromRefs="xdx2ixbrl0067" toRefs="Footnote000087"/>
  <ix:relationship fromRefs="Fact000074" toRefs="Footnote000087"/>
  <ix:relationship fromRefs="xdx2ixbrl0081" toRefs="Footnote000087"/>
  <ix:relationship fromRefs="xdx2ixbrl0091" toRefs="Footnote000146"/>
  <ix:relationship fromRefs="xdx2ixbrl0098" toRefs="Footnote000146"/>
  <ix:relationship fromRefs="Fact000105" toRefs="Footnote000146"/>
  <ix:relationship fromRefs="xdx2ixbrl0112" toRefs="Footnote000146"/>
  <ix:relationship fromRefs="Fact000119" toRefs="Footnote000146"/>
  <ix:relationship fromRefs="xdx2ixbrl0126" toRefs="Footnote000146"/>
  <ix:relationship fromRefs="Fact000133" toRefs="Footnote000146"/>
  <ix:relationship fromRefs="Fact000140" toRefs="Footnote000146"/>
  <ix:relationship fromRefs="Fact000096" toRefs="Footnote000147"/>
  <ix:relationship fromRefs="Fact000103" toRefs="Footnote000147"/>
  <ix:relationship fromRefs="Fact000110" toRefs="Footnote000147"/>
  <ix:relationship fromRefs="Fact000117" toRefs="Footnote000147"/>
  <ix:relationship fromRefs="Fact000124" toRefs="Footnote000147"/>
  <ix:relationship fromRefs="Fact000131" toRefs="Footnote000147"/>
  <ix:relationship fromRefs="Fact000138" toRefs="Footnote000147"/>
  <ix:relationship fromRefs="Fact000145" toRefs="Footnote000147"/>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_909_edei--DocumentType_dxL_c20240101__20241231_zlX7ImeSWeJ7" title="::XDX::PRE%2014A"><span style="-sec-ix-hidden: xdx2ixbrl0011">SCHEDULE
14A</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Proxy
Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
by the Registrant &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
by a Party other than the Registrant &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preliminary Proxy Statement</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential, for Use of
    the Commission Only (as permitted by Rule 14a-6(e)(2))</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitive Proxy Statement</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitive Additional Materials</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting Material under
    &#167; 240.14a-12</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_90F_edei--EntityRegistrantName_c20240101__20241231_z9c5pvi6HFha"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000012" name="dei:EntityRegistrantName">ALGORHYTHM
HOLDINGS, INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name
of Registrant as Specified In Its Charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name
of Person(s) Filing Proxy Statement if other than the Registrant)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
of Filing Fee (Check the appropriate box):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No fee required</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees paid previously with
    preliminary materials.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fee computed on table in
    exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="formpre14a_001.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTICE
OF THE 2025 VIRTUAL ANNUAL MEETING OF STOCKHOLDERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TO
BE HELD ON NOVEMBER 20, 2025</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
[&#160;&#160;], 2025</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Stockholders:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is my pleasure to invite you to the 2025 Virtual Annual Meeting of Stockholders (the &#8220;Annual Meeting&#8221;) of Algorhythm Holdings,
Inc., a Delaware corporation (the &#8220;Company,&#8221; &#8220;Algorhythm,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;).
The Annual Meeting will be held on November 20, 2025, at 9:00 a.m. Eastern Time virtually by means of remote communication and can be
accessed by visiting <span style="text-decoration: underline">www.cstproxy.com/algorhythmholdings/2025</span> where you will be able to listen to the meeting live, submit questions
and vote online. You will not be able to attend the meeting in person.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Annual Meeting is being held for the following purposes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    elect seven directors to serve on our board of directors until their respective successors are duly elected and qualified,
    or until their respective earlier death, resignation or removal;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To grant discretionary
    authority to our board of directors to: (i) amend our certificate of incorporation to combine outstanding shares of our common stock
    into a lesser number of outstanding shares, or complete a &#8220;reverse stock split,&#8221; at a specific ratio within a range of
    one-for-two (1-for-2) to a maximum of a one-for-ten (1-for-10), with the exact ratio to be determined by our board of directors in
    its sole discretion; and (ii) effect the reverse stock split, if at all, within one year of the date the proposal is approved by
    stockholders (the &#8220;Reverse Stock Split Proposal&#8221;);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To approve the reincorporation
    of us from the State of Delaware to the State of Nevada by conversion (the &#8220;Nevada Reincorporation Proposal&#8221;);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To approve an amendment
    to our 2022 Equity Incentive Plan (the &#8220;2022 Plan&#8221;) to increase the number of shares of common stock authorized for issuance
    thereunder to 5,000,000 (the &#8220;2022 Plan Amendment Proposal&#8221;);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To approve
    the issuance of shares of common stock to Streeterville Capital, LLC in pre-paid financing transactions that may collectively equal
    or exceed 20% of our issued and outstanding shares of common stock (the &#8220;Pre-Paid Financing Proposal&#8221;);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To ratify the selection
    of M&amp;K CPAs as our independent registered public accounting firm to audit our consolidated financial statements for our fiscal
    year ending December 31, 2025 (the &#8220;Auditor Ratification Proposal&#8221;);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To approve one or more
    adjournments of the Annual Meeting, if necessary or appropriate, to solicit additional proxies in favor of the Reverse Stock Split
    Proposal, the Nevada Reincorporation Proposal, the 2022 Plan Amendment Proposal or the Pre-Paid Financing Proposal if there are not
    sufficient votes at the Annual Meeting to approve and adopt the Reverse Stock Split Proposal, the Nevada Reincorporation Proposal,
    the 2022 Plan Amendment Proposal or the Pre-Paid Financing Proposal (the &#8220;Adjournment Proposal&#8221;); and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To transact such other
    business as may properly come before the Annual Meeting virtually, or any postponement or adjournment thereof.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Only
stockholders of record as of the close of business on September 29, 2025 will be entitled to receive notice of and to vote at the Annual
Meeting, or any postponement or adjournment thereof. The accompanying Proxy Statement contains details concerning the foregoing items,
as well as information on how to vote your shares. Other detailed information about our business and operations, including our audited
financial statements, are included in our Annual Report on Form 10-K for our fiscal year ended December 31, 2024. We urge you to read
and consider these documents carefully.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Your
vote is very important.</b> Whether or not you plan to attend the Annual Meeting, we encourage you to submit your proxy or voting instructions
as soon as possible. For specific instructions on how to vote your shares, please refer to the instructions on the proxy card you received
in the mail, and the additional information in the accompanying Proxy Statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
behalf of the board of directors and the officers and employees of Algorhythm Holdings, Inc., I would like to take this opportunity to
thank you for your continued support.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely,</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt"/>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary Atkinson</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Chairman of the Board of Directors</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ALGORHYTHM
HOLDINGS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROXY
STATEMENT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FOR
ANNUAL MEETING OF STOCKHOLDERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TO
BE HELD ON NOVEMBER 20, 2025</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE
OF CONTENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_001">NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt">ii</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_002">PROXY STATEMENT</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt">1</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_003">ABOUT THE PROXY MATERIALS</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt">1</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_004">PROPOSAL 1 &#8211; ELECTION OF DIRECTORS</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt">8</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_005">INFORMATION ABOUT OUR BOARD OF DIRECTORS AND COMMITTEES</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt">11</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_006">PROPOSAL 2 &#8211;REVERSE STOCK SPLIT</a> </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt">15</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_007">PROPOSAL 3 &#8211;REINCORPORATION INTO THE STATE OF NEVADA</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt">21</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_008">PROPOSAL 4 &#8211; AMENDMENT TO THE 2022 EQUITY INCENTIVE PLAN</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt">40</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_009">PROPOSAL 5 &#8211; ISSUANCE OF SHARES IN PRE-PAID FINANCING</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt">45</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_010">PROPOSAL 6 &#8211;RATIFICATION OF THE COMPANY&#8217;S ACCOUNTING FIRM</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt">48</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_024">AUDIT COMMITTEE REPORT</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt">49</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_011">PROPOSAL 7 &#8211;ADJOURNMENT OF THE ANNUAL MEETING</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt">49</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><a href="#a_025"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MANAGEMENT</b></span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt">50</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_012">EXECUTIVE COMPENSATION</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt">51</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_013">PAY VERSUS PERFORMANCE</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt">55</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_014">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt">58</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_015">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt">59</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_016">ANNUAL REPORT ON FORM 10-K</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt">61</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_017">OTHER BUSINESS</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt">61</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_018"><b>APPENDIX
    A:</b> Certificate of Amendment</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt">A-1</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_019"><b>APPENDIX
    B:</b> Reincorporation Resolutions</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt">B-1</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_020"><b>APPENDIX
    C:</b> Plan of Conversion</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt">C-1</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_021"><b>APPENDIX
    D:</b> Nevada Charter</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt">D-1</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_022"><b>APPENDIX
    E:</b> Nevada Bylaws</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt">E-1</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_023"><b>APPENDIX
    F:</b> Amendment to 2022 Equity Incentive Plan</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt">F-1</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_001"></span>NOTE
REGARDING FORWARD-LOOKING STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Proxy Statement contains forward-looking statements within the meaning of the federal securities laws. Forward-looking statements may
relate to our future financial performance, business operations, and executive compensation decisions, or other future events. You can
identify forward-looking statements by the use of words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221;
&#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; or the negative of such terms, or other comparable
terminology. Forward-looking statements also include the assumptions underlying or relating to such statements. We have based these forward-looking
statements on our current expectations and projections about future events that we believe may affect our business, results of operations
and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
outcomes of the events described in these forward-looking statements are subject to risks, uncertainties and other factors described
in the section titled &#8220;Risk Factors,&#8221; and elsewhere, in the Annual Report on Form 10-K for our fiscal year ended December
31, 2024, as well as the other reports we file with the Securities and Exchange Commission. We cannot assure you that the events and
circumstances reflected in the forward-looking statements will be achieved or occur, and actual results could differ materially from
those expressed or implied in the forward-looking statements. The forward-looking statements made in this Proxy Statement relate only
to events as of the date of this Proxy Statement. We undertake no obligation to update any forward-looking statement to reflect events
or circumstances after the date on which the statement is made.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ALGORHYTHM
HOLDINGS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_002"></span>PROXY
STATEMENT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FOR
THE 2025 VIRTUAL ANNUAL MEETING OF STOCKHOLDERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TO
BE HELD ON NOVEMBER 20, 2025</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Proxy Statement is solicited by the board of directors (our &#8220;Board&#8221;) of Algorhythm Holdings, Inc., a Delaware corporation
(the &#8220;Company,&#8221; &#8220;Algorhythm,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;), for use at our 2025
Virtual Annual Meeting of Stockholders (the &#8220;Annual Meeting&#8221;) to be held on November 20, 2025 at 9:00 a.m. Eastern Time,
or at any adjournment or postponement thereof. The Annual Meeting will be held virtually by means of remote communication and can be
accessed by visiting <span style="text-decoration: underline">www.cstproxy.com/algorhythmholdings/2025</span> where you will be able to listen to the meeting live, submit questions
and vote online. You will not be able to attend the meeting in person. The Annual Meeting is being held for the purposes described herein.
We first mailed these proxy materials to stockholders on or about October , 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_003"></span>ABOUT
THE PROXY MATERIALS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Proxy Statement, the enclosed proxy card, and the Annual Report on Form 10-K for our fiscal year ended December 31, 2024 (the &#8220;Annual
Report&#8221;) are available at <span style="text-decoration: underline">www.cstproxy.com/algorhythmholdings/2025</span>. The Annual Report, however, is not a part of the proxy
solicitation material.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are furnishing proxy materials to our stockholders of record on September 29, 2025. In connection with the solicitation of proxies by
our Board for use at the Annual Meeting of stockholders to be held virtually by means of remote communication and can be accessed by
visiting <span style="text-decoration: underline">www.cstproxy.com/algorhythmholdings/2025</span>. This proxy is being solicited by the Board, and the cost of solicitation of
the proxies will be paid by us. Our officers, directors and regular employees, without additional compensation, also may solicit proxies
by further mailing, by telephone or personal conversations. We have no plans to retain any firms or otherwise incur any extraordinary
expense in connection with the solicitation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Questions
and Answers About the Annual Meeting and Voting</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Who
can vote at the Annual Meeting?</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
can vote if, as of the close of business on September 29, 2025 (the &#8220;Record Date&#8221;), you were a stockholder of record of our
common stock. On the Record Date, there were 2,641,778 shares of our common stock issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stockholder
of Record: Shares Registered in Your Name</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If,
on the Record Date, your shares were registered directly in your name with our transfer agent, Continental Stock Transfer &amp; Trust
Company, then you are a stockholder of record. As a stockholder of record, you may vote at the Annual Meeting or by proxy. Whether or
not you plan to attend the Annual Meeting, we urge you to provide your proxy to ensure your vote is counted. Even if you vote by proxy,
you may still vote if you are able to attend the Annual Meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Beneficial
Owner: Shares Registered in the Name of a Broker or Other Nominee</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If,
on the Record Date, your shares were held in an account at a brokerage firm, bank, dealer, or other nominee, then you are the &#8220;beneficial
owner&#8221; of shares held in &#8220;street name&#8221; and these proxy materials are being forwarded to you by that organization. The
organization holding your account is considered to be the stockholder of record for purposes of voting at the Annual Meeting. As a beneficial
owner, you have the right to direct your broker or other nominee on how to vote the shares in your account. If you do not direct your
broker or other nominee on how to vote your shares, the broker or other nominee will be entitled to vote the shares with respect to &#8220;routine&#8221;
items, but will not be permitted to vote the shares with respect to &#8220;non-routine&#8221; items. Where you do not direct your broker
or other nominee how to vote on &#8220;non-routine&#8221; items it is referred to as a &#8220;broker non-vote.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proposal
1, the election of directors, Proposal 3, the vote to approve the reincorporation of us, Proposal 4, the vote to approve the amendment
to our 2022 Equity Incentive Plan, and Proposal 5, the vote to approve the pre-paid financing transaction, are considered to be &#8220;non-routine&#8221;
matters under applicable rules. Accordingly, any shares held in &#8220;street name&#8221; through a broker or other nominee will not
be voted on these proposals unless you affirmatively provide the nominee with instructions for how to vote. Accordingly, broker non-votes
may result for these proposals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proposal
2, the vote to authorize the reverse stock split, Proposal 6, the ratification of the selection of our independent registered public
accounting firm to audit our consolidated financial statements for the fiscal year ending December 31, 2025, and Proposal 7, the vote
to approve one or more adjournments of the Annual Meeting, are considered to be &#8220;routine&#8221; matters under applicable rules.
Accordingly, any shares held in &#8220;street name&#8221; through a broker or other nominee may be voted by the nominee on Proposals
2, 6 and 7 even if you do not provide the nominee with instructions for how to vote. Accordingly, we do not expect any broker non-votes
will result for these proposals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a beneficial owner of shares, you are also invited to attend the Annual Meeting. However, since you are not the stockholder of record,
you may not vote your shares at the Annual Meeting unless you request and obtain a valid proxy from your broker or other nominee. Please
contact your broker or other nominee for additional information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>How
many votes do I and the other stockholders have?</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as set forth below, on each matter to be voted upon, you have one vote for each share of common stock that you owned as of the Record
Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the foregoing, of the shares of our common stock entitled to vote, 95,694 of the shares of common stock were issued to Streeterville
Capital as Commitment Shares (as defined below) in connection with the Securities Purchase Agreement (as defined below) (as described
in Proposal 5) and are not entitled to vote on Proposal 5 for purposes of the listing rules of the Nasdaq Stock Market. Accordingly,
although we anticipate that the 95,694 shares of common stock held by Streeterville Capital will be voted in favor of Proposal 5 for
purposes of adopting the respective proposals under Delaware law, to comply with Nasdaq rules, to the extent such shares are voted, we
will instruct the inspector of elections to conduct a separate tabulation that subtracts the 95,694 shares held by Streeterville Capital
from the total number of shares voted in favor of Proposal 5 to determine whether the proposal has been adopted in accordance with applicable
Nasdaq rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>What
is the quorum requirement?</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
presence of 33 1/3% of the outstanding shares of common stock entitled to vote at the Annual Meeting must be present at the Annual Meeting,
either virtually or represented by proxy, in order for us to hold the Annual Meeting. This is referred to as a quorum. On the Record
Date, there were 2,641,778 outstanding shares of our common stock entitled to vote. Thus, 880,593 shares of our common stock must be
present at the Annual Meeting, either virtually or represented by proxy, to have a quorum.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Your
shares will be counted towards the quorum only if you submit a valid proxy or vote at the Annual Meeting. Abstentions and broker non-votes
will also be counted towards the quorum requirement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>What
proposals am I being asked to vote upon?</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Annual Meeting is being held for the following purposes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    elect seven directors to serve on our board of directors until their respective successors are duly elected and qualified,
    or until their respective earlier death, resignation or removal;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To grant discretionary
    authority to our board of directors to: (i) amend our certificate of incorporation to combine outstanding shares of our common stock
    into a lesser number of outstanding shares, or complete a &#8220;reverse stock split,&#8221; at a specific ratio within a range of
    one-for-two (1-for-2) to a maximum of a one-for-ten (1-for-10), with the exact ratio to be determined by our board of directors in
    its sole discretion; and (ii) effect the reverse stock split, if at all, within one year of the date the proposal is approved by
    stockholders (the &#8220;Reverse Stock Split Proposal&#8221;);</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To approve the reincorporation
    of us from the State of Delaware to the State of Nevada by conversion (the &#8220;Nevada Reincorporation Proposal&#8221;);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To approve an amendment
    to our 2022 Equity Incentive Plan (the &#8220;2022 Plan&#8221;) to increase the number of shares of common stock authorized for issuance
    thereunder to 5,000,000 (the &#8220;2022 Plan Amendment Proposal&#8221;);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To approve the issuance
    of shares of common stock to Streeterville Capital, LLC in pre-paid financing transactions that may collectively equal or exceed
    20% of our issued and outstanding shares of common stock (the &#8220;Pre-Paid Financing Proposal&#8221;);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To ratify the selection
    of M&amp;K CPAs as our independent registered public accounting firm to audit our consolidated financial statements for our fiscal
    year ending December 31, 2025; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To approve one or more
    adjournments of the Annual Meeting, if necessary or appropriate, to solicit additional proxies in favor of the Reverse Stock Split
    Proposal, the Nevada Reincorporation Proposal, the 2022 Plan Amendment Proposal or the Pre-Paid Financing Proposal if there are not
    sufficient votes at the Annual Meeting to approve and adopt the Reverse Stock Split Proposal, the Nevada Reincorporation Proposal,
    the 2022 Plan Amendment Proposal or the Pre-Paid Financing Proposal (the &#8220;Adjournment Proposal&#8221;).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
vote may also be held on any other business as may properly come before the Annual Meeting, or any postponement or adjournment thereof.
However, as of the date of this Proxy Statement, we are not aware of any other business to be considered or acted upon at the Annual
Meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>What
are my voting choices for each of the items to be voted on at the Annual Meeting?</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; text-align: left; padding-right: 0pt; padding-left: 0pt; width: 14%; vertical-align: bottom"><span style="font-size: 10pt"><b>Proposal</b></span></td>
    <td style="padding-bottom: 1pt; padding-right: 0pt; padding-left: 0pt; width: 2%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; padding-right: 0pt; padding-left: 0pt; width: 14%"><span style="font-size: 10pt"><b>Board Recommendation</b></span></td>
    <td style="padding-bottom: 1pt; padding-right: 0pt; padding-left: 0pt; width: 2%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; padding-right: 0pt; padding-left: 0pt; width: 16%"><span style="font-size: 10pt"><b>Voting Choices</b></span></td>
    <td style="padding-bottom: 1pt; padding-right: 0pt; padding-left: 0pt; width: 2%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; padding-right: 0pt; padding-left: 0pt; width: 16%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Vote Required for</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Adoption</b></p></td>
    <td style="padding-bottom: 1pt; padding-right: 0pt; padding-left: 0pt; width: 2%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; padding-right: 0pt; padding-left: 0pt; width: 16%"><span style="font-size: 10pt"><b>Effect of Abstentions</b></span></td>
    <td style="padding-bottom: 1pt; padding-right: 0pt; padding-left: 0pt; width: 2%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; padding-right: 0pt; padding-left: 0pt; width: 14%"><span style="font-size: 10pt"><b>Effect of Broker Non-Votes</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt"><b>1 &#8211; Election of Seven Directors</b></span></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">&#8220;<b>FOR</b>&#8221; each nominee</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#9679; Vote &#8220;For All&#8221; of the nominees listed</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#9679; Vote &#8220;Withhold All&#8221; to withhold for all of the nominees
    listed</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#9679; Vote &#8220;For All Except&#8221; to vote for all nominees except
    the nominee(s) written</p></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Approved if a plurality of the votes cast by the holders of shares present
    virtually or represented by proxy and entitled to vote at the Annual Meeting votes &#8220;For&#8221; the election of the applicable director</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">Not applicable</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">No effect</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding-right: 0pt; padding-left: 0pt; width: 14%"><span style="font-size: 10pt"><b>2 &#8211; Reverse Stock Split</b></span></td>
    <td style="padding-right: 0pt; padding-left: 0pt; width: 2%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt; width: 14%"><span style="font-size: 10pt"><b>&#8220;FOR&#8221;</b></span></td>
    <td style="padding-right: 0pt; padding-left: 0pt; width: 2%">&#160;</td>
    <td style="padding-right: 0pt; padding-left: 0pt; width: 16%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#9679; Vote &#8220;For&#8221; this proposal</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#9679; Vote &#8220;Against&#8221; this proposal</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#9679; Abstain from voting on this proposal</p></td>
    <td style="padding-right: 0pt; padding-left: 0pt; width: 2%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt; width: 16%"><span style="font-size: 10pt">Approved if a majority of the number of votes cast vote &#8220;For&#8221; this proposal exceeds the number of votes cast &#8220;Against&#8221; this proposal by holders present virtually or represented by proxy and entitled to vote at the Annual Meeting</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt; width: 2%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt; width: 16%"><span style="font-size: 10pt">No effect</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt; width: 2%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt; width: 14%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">No broker non-votes; brokers have discretion to vote</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt"><b>3 &#8211; Reincorporation of us to the State of Nevada by Conversion</b></span></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt"><b>&#8220;FOR&#8221;</b></span></td>
    <td style="padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; padding-left: 0pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#9679; Vote &#8220;For&#8221; this proposal</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#9679; Vote &#8220;Against&#8221; this proposal</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#9679; Abstain from voting on this proposal</p></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">Approved if holders of a majority of the outstanding shares of common stock present virtually or represented by proxy and entitled to vote at the Annual Meeting votes &#8220;For&#8221; this proposal </span></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">Against</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">Against</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt"><b>4 &#8211; Amendment to our 2022 Equity Incentive Plan</b></span></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">&#8220;<b>FOR</b>&#8221;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; padding-left: 0pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#9679; Vote &#8220;For&#8221; this proposal</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#9679; Vote &#8220;Against&#8221; this proposal</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#9679; Abstain from voting on this proposal</p>
    <p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&#160;</p></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">Approved if holders of a majority of the outstanding shares of common stock present virtually or represented by proxy and entitled to vote at the Annual Meeting votes &#8220;For&#8221; this proposal </span></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">Against</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">No effect</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt"><b>5 &#8211; The Pre-Paid Financing</b></span></td>
    <td style="padding-right: 0pt; padding-left: 0pt"/>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt"><b>&#8220;FOR&#8221;</b></span></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#9679; Vote &#8220;For&#8221; this proposal</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#9679; Vote &#8220;Against&#8221; this proposal</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#9679; Abstain from voting on this proposal</p>
    <p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&#160;</p></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">Approved if holders of a majority of the outstanding shares of common stock present virtually or represented by proxy and entitled to vote at the Annual Meeting votes &#8220;For&#8221; this proposal </span></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">Against</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">No effect</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding-right: 0pt; padding-left: 0pt; width: 14%"><span style="font-size: 10pt"><b>6 &#8211; Ratification of the Selection
    of M&amp;K CPAs as our Independent Registered Public Accounting Firm</b></span></td>
    <td style="padding-right: 0pt; padding-left: 0pt; width: 2%"/>
    <td style="padding-right: 0pt; padding-left: 0pt; width: 14%"><span style="font-size: 10pt"><b>&#8220;FOR&#8221;</b></span></td>
    <td style="padding-right: 0pt; padding-left: 0pt; width: 2%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt; width: 16%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#9679; Vote &#8220;For&#8221; this proposal</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#9679; Vote &#8220;Against&#8221; this proposal</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#9679; Abstain from voting on this proposal</p></td>
    <td style="padding-right: 0pt; padding-left: 0pt; width: 2%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt; width: 16%"><span style="font-size: 10pt">Approved if holders of a majority of the outstanding shares of common stock present virtually or represented by proxy and entitled to vote at the Annual Meeting votes &#8220;For&#8221; this proposal </span></td>
    <td style="padding-right: 0pt; padding-left: 0pt; width: 2%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt; width: 16%"><span style="font-size: 10pt">No effect</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt; width: 2%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-right: 0pt; padding-left: 0pt; width: 14%"><span style="font-size: 10pt">No broker non-votes; brokers have discretion to vote</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; padding-left: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7
    &#8211;Adjournment of the Annual Meeting</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b>FOR</b>&#8221;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;
                                            If a quorum is represented at the Annual Meeting, this proposal will be approved if the number
                                            of the votes cast &#8220;For&#8221; this proposal exceeds the number of votes cast &#8220;Against&#8221;
                                            this proposal by holders present virtually or represented by proxy and entitled to vote at
                                            the Annual Meeting</span></p>
                                                                  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
                                                                  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No effect</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No broker
    non-votes; brokers have discretion to vote</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt">If
                                            a quorum is not represented at the Annual Meeting, this proposal will be approved if holders
                                            of a majority of the outstanding shares of common stock present virtually or represented
                                            by proxy and entitled to vote at the Annual Meeting votes &#8220;For&#8221; this proposal</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt">Against</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt">Against</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>How
do I vote?</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stockholder
of Record: Shares Registered in Your Name</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you are a stockholder of record, you may vote using the following methods:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>At
    the Annual Meeting. </b>To vote at the Annual Meeting, attend the Annual Meeting via the Internet and follow the instructions.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>By
    Internet. </b>To vote by proxy via the Internet, follow the instructions described on the proxy card.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>By
    Telephone.</b> To vote by proxy via telephone within the United States and Canada, use the toll-free number on the proxy card.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>By
    Mail. </b>To vote by mail, complete, sign, and date the proxy card and return it in the envelope provided.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whether
or not you plan to attend the Annual Meeting, we urge you to vote by proxy using one of the methods described above to ensure your vote
is counted. You may still attend the Annual Meeting and vote even if you have already voted by proxy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Beneficial
Owner: Shares Registered in the Name of Broker or Other Nominee</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you are a beneficial owner of shares registered in the name of your broker or other nominee, you may vote using the following methods:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>At
    the Annual Meeting. </b>To vote at the Annual Meeting, you must obtain a valid proxy from your broker or other nominee. Follow the
    instructions from your broker or other nominee, or contact them to request a proxy form.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: center; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>By
    Internet. </b>You may vote through the Internet if your broker or other nominee makes this method available, in which case the instructions
    will be included in the proxy materials provided to you.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>By
    Telephone.</b> You may vote by telephone if your broker or other nominee makes this method available, in which case the instructions
    will be included in the proxy materials provided to you.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>By
    Mail. </b>If you received a proxy card and voting instructions from the broker or other nominee holding your shares rather than from
    us, follow the instructions on the proxy card.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>What
if I am a stockholder of record and return a proxy card but do not make specific choices?</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should specify your choice for each matter on the proxy card. If you return a signed and dated proxy card without marking voting selections
for the specific proposals, your shares will be voted:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b>FOR</b>&#8221;
    the seven director nominees under Proposal 1; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b>FOR</b>&#8221;
    the reverse stock split under Proposal 2;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#8220;FOR&#8221;
    </b>the reincorporation of us to the State of Nevada by Conversion under Proposal 3; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b>FOR</b>&#8221;
    the amendment to our 2022 Equity Incentive Plan to increase the number of shares authorized for issuance thereunder under Proposal
    4; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b>FOR</b>&#8221;
    the issuance shares of common stock to Streeterville Capital, LLC in pre-paid financing transactions that may exceed 20% of our issued
    and outstanding under Proposal 5; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b>FOR</b>&#8221;
    the ratification of the selection of M&amp;K CPAs as our independent registered public accounting firm to audit our consolidated
    financial statements for the fiscal year ending December 31, 2025 under Proposal 6;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b>FOR</b>&#8221;
    the approval of one or more adjournments of the Annual Meeting, if necessary or appropriate, to solicit additional proxies in favor
    of the Reverse Stock Split Proposal, the Nevada Reincorporation Proposal, the 2022 Plan Amendment Proposal or the Pre-Paid Financing
    Proposal if there are not sufficient votes at the Annual Meeting to approve and adopt the Reverse Stock Split Proposal, the Nevada
    Reincorporation Proposal, the 2022 Plan Amendment Proposal or the Pre-Paid Financing Proposal.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event any other matters are properly presented at the Annual Meeting, or any postponement or adjournment thereof, the person named
as proxy will vote in accordance with his discretion with respect to those matters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>What
if I am a beneficial owner and do not give voting instructions to my broker or other nominee?</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you fail to provide your broker with voting instructions before the Annual Meeting, your broker will be unable to vote on the non-routine
matters. Your broker may use his or her discretion to cast a vote on any routine matter for which you did not provide voting instructions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Who
is paying for this proxy solicitation?</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will pay for the entire cost of soliciting proxies. In addition to these mailed proxy materials, our directors, officers, and employees
may also solicit proxies by mail, in person, by telephone, or by other means of communication. Directors, officers, and employees will
not be paid any additional compensation for soliciting proxies. We will also reimburse brokerage firms, banks, and other agents for the
cost of forwarding proxy materials to beneficial owners.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>What
is &#8220;householding&#8221;?</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Securities and Exchange Commission (&#8220;SEC&#8221;) has adopted rules that permit companies and intermediaries, such as brokers, to
satisfy the delivery requirements for proxy statements with respect to two or more security holders sharing the same address by delivering
a single copy of a notice and, if applicable, a proxy statement, to those security holders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
single copy of this Proxy Statement will be delivered to multiple stockholders sharing an address unless contrary instructions have been
received from these stockholders. Once you have received notice from your broker, or from us, that they will be &#8220;householding&#8221;
communications to your address, &#8220;householding&#8221; will continue until you are notified otherwise or until you revoke your consent.
If, at any time, you no longer wish to participate in &#8220;householding&#8221; and would prefer to receive a separate Proxy Statement,
please notify your broker and also notify us by sending your written request to: Algorhythm Holdings, Inc., 6301 NW 5<sup>th </sup>Way,
Suite 2900, Fort Lauderdale, FL 33309, Attention: Investor Relations or by calling Investor Relations at (954) 596-1000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
stockholder who currently receives multiple copies of this Proxy Statement at its address and would like to request &#8220;householding&#8221;
should also contact its broker and notify us using the contact information above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Can
I revoke or change my vote after submitting my proxy?</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes.
You can revoke your proxy at any time before the final vote at the Annual Meeting as discussed below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you are a stockholder of record, you may revoke your proxy by:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sending
    written notice of revocation to Algorhythm Holdings, Inc., 6301 NW 5<sup>th</sup> Way, Suite 2900, Fort Lauderdale, FL 33309, Attention:
    Secretary, in time for it to be received before the Annual Meeting;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submitting
    a new proxy with a later date using any of the voting methods described above (subject to the deadlines for voting with respect to
    each method); or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">voting
    at the Annual Meeting (provided that attending the meeting will not, by itself, revoke your proxy).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you are a beneficial owner of shares and have instructed your broker or other nominee to vote your shares, you may change your vote by
following the directions received from your nominee to change those voting instructions or by attending the Annual Meeting and voting.
However, you may not vote your shares at the Annual Meeting unless you request and obtain a valid proxy from your broker or other nominee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Who
will count votes at the Annual Meeting?</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Votes
will be counted by the inspector of election appointed for the Annual Meeting. The inspector of election will also determine the number
of shares outstanding, the number of shares represented at the Annual Meeting, the existence of a quorum, and whether or not the proxies
and ballots are valid and effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>How
can I find out the results of the voting at the Annual Meeting?</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will announce preliminary voting results at the Annual Meeting. We will report the final voting results in a Current Report on Form 8-K
that we expect to file with the SEC within four business days following the date of the Annual Meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>When
are stockholder proposals for the 2026 annual meeting due?</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders
interested in presenting a proposal to be considered for inclusion in the proxy statement relating to the 2026 annual meeting of stockholders
may do so by following the procedures prescribed in Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange
Act&#8221;), and our amended bylaws (the &#8220;Bylaws&#8221;). To be considered for inclusion, stockholder proposals must be submitted
in writing to Algorhythm Holdings, Inc., 6301 NW 5<sup>th</sup> Way, Suite 2900, Fort Lauderdale, FL 33309, Attention: Secretary, before
June 23, 2026, which is 120 calendar days prior to the anniversary of the mailing date of this Proxy Statement. Any such proposal must
meet the requirements of the Bylaws and all applicable laws and regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
stockholder who wishes to have a proposal considered at the 2026 annual meeting of stockholders, or to nominate a director for election
at that meeting, but not submitted for inclusion in the proxy statement relating to that meeting, must give advance notice to us prior
to the deadline for such meeting. In order for a proposal or nomination to be timely, it must be received by us no earlier than 120 days
prior to the anniversary date of the Annual Meeting, or July 23, 2026, and no later than 90 days prior to the anniversary of the Annual
Meeting, or August 22, 2026. In the event the 2026 annual meeting of stockholders is being held more than 30 days before or more than
70 days after the anniversary of the Annual Meeting, the deadline for stockholders to submit proposals or director nominations will be
adjusted. The submission of a stockholder proposal does not guarantee that it will be presented at the annual meeting. Stockholders interested
in submitting a proposal are advised to contact knowledgeable legal counsel with regard to the detailed requirements of applicable federal
securities laws and our bylaws, as applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_004"></span>PROPOSAL
1</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ELECTION
OF DIRECTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board currently consists of seven members. The Nominating and Corporate Governance Committee and the Board seek, and the Board
is comprised of, individuals whose characteristics, skills, expertise, and experience complement those of other Board members. The Nominating
and Corporate Governance Committee and Board have unanimously approved the recommended slate of seven directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows our nominees for election to the Board. Each nominee, if elected, will serve until the next annual meeting of stockholders
or until a successor is duly elected and qualified, or until his earlier resignation or removal. All nominees are members of the present
Board. We have no reason to believe that any of the nominees is unable or will decline to serve as a director if elected. Unless otherwise
indicated by the stockholder, the accompanying proxy will be voted for the election of the seven persons named under the heading
&#8220;Nominees for Director.&#8221; Although we know of no reason why any nominee could not serve as a director, if any nominee shall
be unable to serve, the accompanying proxy will be voted for a substitute nominee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nominees
for Director</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 26%; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of Nominee</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; width: 2%; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%; text-align: center; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; width: 2%; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 40%; text-align: center; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal
    Position</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: center; padding-bottom: 0pt; padding-left: 0pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; padding-bottom: 0pt; padding-left: 0pt; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
    Since</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary
    Atkinson</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: center; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
                                       Executive Officer, Secretary &amp;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    of the Board</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: center; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bernardo
    Melo</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: center; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harvey
    Judkowitz</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">81</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: center; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2004</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jay
    B. Foreman</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: center; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ajesh
    Kapoor</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: center; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scott
    Thorn</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: center; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kapil
    Gupta</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: center; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have set out below biographical and professional information about each of the nominees, along with a brief discussion of the experience,
qualifications, and skills that the Board considered important in concluding that the individual should serve as a current director and
as a nominee for re-election as a member of our Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Gary
Atkinson</b> has served as our Chief Executive Officer since May 2012, as our Secretary since January 2008, and as a member of our board
of directors since August 2022. Prior to that, Mr. Atkinson served as our Interim Chief Executive Officer from November 2009 to May 2012
and as our General Counsel from January 2008 to November 2009. Mr. Atkinson is a licensed attorney in Florida and Georgia. He graduated
from the University of Rochester with a bachelor&#8217;s degree in economics and received a Juris Doctorate and Masters in Business Administration
from Case Western Reserve University School of Law and Weatherhead School of Management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that Mr. Atkinson is qualified to serve on our board of directors because of his strong leadership, business acumen and analytical
skills along with his extensive experience in the capital markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Bernardo
Melo</b> has served as a member of our board of directors since July 2022. He has also served as our Chief Revenue Officer from April
2022 to August 2025 and as our Vice President of Global Sales and Marketing from 2008 to April 2022. He has also served as a member of
our board of directors since July 2022. Prior to that, Mr. Melo held dual roles with us managing the operations, licensing and sales
of the music division while concentrating on hardware sales for the Latin America and Canadian market as well as key U.S. accounts such
as Walmart.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that Mr. Melo is qualified to serve as a member of our board of directors because of his substantial sales and marketing expertise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Harvey
Judkowitz</b> has served as a member of our board of directors since March 2004 and serves as the Chairman of our Audit Committee. He
is licensed as a certified professional accountant in New York and Florida and has owned his own accounting firm since 1988. He also
served as the Chief Executive Officer and Chairman of our board of directors of UniPro Financial Services, a diversified financial services
company, up until the company was sold in September 2005. Prior to that he served as the President and Chief Operating Officer of Photovoltaic
Solar Cells, Inc., a producer of photovoltaic solar cells.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that Mr. Judkowitz is qualified to serve as a member of our board of directors because of his organizational leadership and management
skills and his accounting expertise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Jay
B. Foreman</b> has served as a member of our board of directors since May 2022. Mr. Foreman has served as the Chief Executive Officer
of Basic Fun!, which sells children&#8217;s toys under the Tonka&#8482;, Carebears&#8482;, K&#8217;NEX&#8482;, Lincoln Logs&#8482;, and
Playhut&#8482; brands, since he founded the company in 2009. Prior to that, he founded several toy companies, including Play-By-Play
Toy&#8217;s and Novelties, a designer and distributor of stuffed toys, and more recently Play Along Toys, a leading toy company which
was subsequently sold to Jakks Pacific in 2004. He currently chairs the Toy Industry trade show committee which is responsible for the
world-famous NY Toy Fair, and has also served on the boards of directors of the Toy Association and Licensing Merchandisers association.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that Mr. Foreman is qualified to serve as a member of our board of directors because of his extensive history and experience
in the toy business, including his deep knowledge of licensing, operations, sales and marketing, M&amp;A, and capital markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ajesh
Kapo</b>or has served as the Chief Executive Officer of SemiCab Holdings, a subsidiary of ours that owns and operates our SemiCab AI
logistics and distribution business, since July 2024 and is the Founder and Chief Executive Officer of SemiCab, Inc., a company that
he founded in July 2018 that previously owned our SemiCab AI logistics and distribution business. From April 2015 to July 2018, Mr. Kapoor
served as the Vice President of Product Management of GT Nexus, a division of Infor, the world&#8217;s largest cloud-based B2B multi-enterprise
network and execution platform for global trade and supply chain management, and from April 2012 to March 2015, served as a Senior Director
of GT Nexus. Earlier in his career, Mr. Kapoor served as Global Head of Supply Chain Advisory Services of the Retail, CPG and Transportation
Industry segments of Wipro Technologies, a multi-national technology company that provides information technology, consulting and business
process services. He was also the Co-Founder and Chief Technology Officer of GEOCOMtms, a division of Blue Yonder Group, Inc. that provides
optimization software to manage multiple-stop daily delivery fleet routing and scheduling. Mr. Kapoor received a BE in Mechanical Engineering
from the Indian Institute of Technology, Roorkee, an MBA from Panjab University, and an MS in Operations Research from the Georgia Institute
of Technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that Mr. Kapoor is qualified to serve a member of our board of directors because of his extensive logistics and supply chain
technology innovation and leadership experience.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Scott
Thorn</b> has served as a member of our board of directors since October 2025. Mr. Thorn has served as the President and Chief Operating
Officer of InvitedHome, a leading luxury hospitality and real estate services company operating in premier U.S. ski destinations,
since October 2024. Prior to that, he served as the Co-Founder and Chief Strategy Officer of Open Book Extracts, a cGMP-certified manufacturer
of premium federally legal hemp-derived cannabinoid ingredients and wellness products, from February 2019 to October 2024. Earlier in
his career, Scott served as a Managing Director of Douglas Wilson Companies, a leading provider of specialized business, receivership,
and real estate services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that Mr. Thorn is qualified to serve as a member of our board of directors because of his substantial experience as a strategic
thought leader executing aggressive business and revenue growth strategies for early-stage, high-growth companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Kapil
Gupta</b> has served as a member of our board of directors since October 2025. Mr. Gupta is a seasoned global technology and business
leader with more than 20 years of experience driving innovation, operational excellence, and large-scale digital transformation across
the public and private sectors. He has served as the Service Line Leader for Application Operations &#8211; Public Markets (US) at IBM,
a global technology innovator, since April 2025. He has also served as a Project Executive for California&#8217;s Medicaid Program since
May 2017. Earlier in his career, Mr. Gupta held senior leadership roles at Cambridge Solutions, a leading provider of software solutions
for supply chain, purchasing, and performance management, and Talisma Corporation, a leading provider of a digital customer engagement
platform, and served as a Manager at KPMG LLP, a leading global provider of audit, tax, and advisory services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that Mr. Gupta is qualified to serve as a member of our board of directors because of his extensive experience as a global technology
leader offering deep technical expertise and strategic business acumen.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Family
Relationships</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no family relationships among any of our directors, director nominees or executive officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Involvement
in Certain Legal Proceedings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as set forth below, our directors and executive officers have not been involved in any of the following events during the past ten years:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    bankruptcy petition filed by or against such person or any business of which such person was a general partner or executive officer
    either at the time of the bankruptcy or within two years prior to that time;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    conviction in a criminal proceeding or being subject to a pending criminal proceeding (excluding traffic violations and other minor
    offenses);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">being
    subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction,
    permanently or temporarily enjoining him from or otherwise limiting his involvement in any type of business, securities or banking
    activities or to be associated with any person practicing in banking or securities activities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">being
    found by a court of competent jurisdiction in a civil action, the SEC or the CFTC to have violated a Federal or state securities
    or commodities law, and the judgment has not been reversed, suspended, or vacated;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">being
    subject of, or a party to, any Federal or state judicial or administrative order, judgment decree, or finding, not subsequently reversed,
    suspended or vacated, relating to an alleged violation of any Federal or state securities or commodities law or regulation, any law
    or regulation respecting financial institutions or insurance companies, or any law or regulation prohibiting mail or wire fraud or
    fraud in connection with any business entity; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">being
    subject of or party to any sanction or order, not subsequently reversed, suspended, or vacated, of any self-regulatory organization,
    any registered entity or any equivalent exchange, association, entity or organization that has disciplinary authority over its members
    or persons associated with a member.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Vote
Required</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors
are elected by a plurality of the votes cast by the holders of shares present virtually or represented by proxy and entitled to vote
at the Annual Meeting. You may vote either FOR all of the nominees, WITHHOLD your vote from all of the nominees or WITHHOLD your vote
from any one or more of the nominees. Shares represented by executed proxies will be voted, if authority to do so is not withheld, &#8220;FOR&#8221;
the election of each nominee. Votes that are withheld will not be included in the vote tally for the election of directors. Brokerage
firms do not have authority to vote customers&#8217; unvoted shares held by the firms in street name for the election of directors. As
a result, any shares not voted by a beneficial owner will be treated as a broker non-vote. Such broker non-votes will have no effect
on the results of this vote.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recommendation
of Our Board of Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OUR
BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE &#8220;<span style="text-decoration: underline">FOR</span>&#8221; THE ELECTION OF EACH OF THE SEVEN DIRECTOR NOMINEES.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span style="text-decoration: underline"><span id="a_005"></span>Information
about the Board of Directors and Committees</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Independence</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board evaluates the independence of each nominee for election as a director of our Company in accordance with the Listing Rules (the
&#8220;Nasdaq Listing Rules&#8221;) of the Nasdaq Stock Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board currently consists of seven directors, consisting of Gary Atkinson, Bernardo Melo, Harvey Judkowitz, Jay B. Foreman, Ajesh Kapoor,
Scott Thorn and Kapil Gupta. Messrs. Judkowitz, Foreman, Thorn and Gupta are <i>&#8220;independent directors&#8221;</i> within the meaning
of the Nasdaq Listing Rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
Leadership Structure and Role in Risk Oversight</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Board
Leadership Structure</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board does not have a policy regarding separation of the roles of Chief Executive Officer and Chairman of the Board, as the Board believes
it is in the best interest of us to make that determination based on the position and direction of us and the membership of the Board.
Presently, Gary Atkinson serves as Chief Executive Officer and we currently do not have anyone serving in the role of Chairman of the
Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Four
of the seven members of our Board satisfy the requirements of independence under the Nasdaq Listing Rules, and our audit, compensation,
and nominating committees are composed entirely of independent directors. This structure encourages independent and effective oversight
of our operations and prudent management of risk.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Role
of our Board in Risk Oversight</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board is responsible for the oversight of our operational risk management process. Our Board has delegated authority for addressing certain
risks, and assessing the steps management has taken to monitor, control, and report such risks to the Audit Committee. Such risks include
risks relating to execution of our growth strategy, the effects of the economy and general financial condition and outlook, our ability
to expand our customer base, communication with investors, certain actions of our competitors, the protection of our intellectual property,
sufficiency of our capital, security of information systems and data, integration of new information systems, credit risk, product liability,
and costs of reliance on external advisors. The Audit Committee then reports such risks as appropriate to our Board, which then initiates
discussions with appropriate members of our senior management if, after discussion of such risks, our Board determines that such risks
raise questions or concerns about the status of operational risks then facing us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board relies on the Compensation Committee to address significant risk exposures that we may face with respect to compensation, including
risks relating to retention of key employees, protection of partner relationships, management succession, and benefit costs and, when
appropriate, reports these risks to the full Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Meetings
of our Board and its Committees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board has a standing Audit Committee, Compensation Committee, Nominating and Corporate Governance Committee, and Executive Committee.
Our Board met 12 times, including telephonic meetings, during our fiscal year ended December 31, 2024. Each director attended more than
75% of our Board meetings. Each director who served on a committee of our Board attended more than 75% of the meetings held by the committees
on which they served during that year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is our policy that all of our directors are required to make a concerted and conscientious effort to attend our annual meeting of stockholders
in each year during which that director serves as a member of our Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
Committees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board has established an Audit Committee, Compensation Committee, Nominating and Corporate Governance Committee, and Executive Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the above-referenced committees operates pursuant to a formal written charter. The charters for these committees, which have been
adopted by our Board, contain a detailed description of the respective committee&#8217;s duties and responsibilities and are available
on our website at https://ir.algoholdings.com/investor-governance .</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below
is a description of each committee of the Board of Directors. Each of the committees has authority to engage legal counsel or other experts
or consultants as it deems appropriate to carry out its responsibilities. The Board of Directors has determined that each member of the
Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee meet the independence requirements under the
Nasdaq&#8217;s current listing standards and each member is free of any relationship that would interfere with his individual exercise
of independent judgment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Audit
Committee</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
members of our Audit Committee are Messrs. Judkowitz, Thorn, Gupta and Foreman. Mr. Judkowitz serves as the Chairman of our Audit Committee.
Each of Messrs. Judkowitz, Thorn, Gupta and Foreman is independent under the rules and regulations of the SEC and the listing standards
of the Nasdaq applicable to audit committee members. Our board of directors has determined that Mr. Judkowitz qualifies as an audit committee
financial expert within the meaning of SEC regulations and meets the financial sophistication requirements of the Nasdaq.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Audit Committee has the responsibility for, among other things: (i) selecting, retaining and overseeing our independent registered public
accounting firm, (ii) obtaining and reviewing a report by independent auditors that describe the accounting firm&#8217;s internal quality
control, and any materials issues or relationships that may impact the auditors, (iii) reviewing and discussing with the independent
auditors standards and responsibilities, strategy, scope and timing of audits, any significant risks, and results, (iv) ensuring the
integrity of our financial statements, (v) reviewing and discussing with our independent auditors any other matters required to be discussed
by PCAOB Auditing Standard No. 1301, (vi) reviewing, approving and overseeing any transaction between us and any related person and any
other potential conflict of interest situations, (vii) overseeing our internal audit department, (viii) reviewing, approving and overseeing
related party transactions, and (ix) establishing and overseeing procedures for the receipt, retention and treatment of complaints received
by us regarding accounting, internal accounting controls or auditing matters and the confidential, anonymous submission by our employees
of concerns regarding questionable accounting or auditing matters. The Audit Committee charter can be found online at https://ir.algoholdings.com/investor-governance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Compensation
Committee</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
members of our Compensation Committee are Messrs. Judkowitz, Thorn and Foreman. Mr. Judkowitz serves as the Chairman of our Compensation
Committee. Each of Messrs. Judkowitz, Thorn and Foreman is independent under the rules and regulations of the SEC and the listing standards
of the Nasdaq applicable to compensation committee members. Our Compensation Committee has the responsibility for, among other things:
(i) reviewing and approving the chief executive officer&#8217;s compensation based on an evaluation in light of corporate goals and objectives,
(ii) reviewing and recommending to the Board the compensation of all other executive officers, (iii) reviewing and recommending to the
Board incentive compensation plans and equity plans, (iv) reviewing and discussing with management compensation information and related
information to be included in this report and proxy statements, and (v) reviewing and recommending to the board of directors for approval
procedures relating to say on pay votes. The Compensation Committee charter can be found online at https://ir.algoholdings.com/investor-governance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Nominating
and Corporate Governance Committee</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
members of our Nominating and Corporate Governance Committee are Messrs. Judkowitz, Gupta and Foreman. Mr. Foreman serves as the Chairman
of our Nominating and Corporate Governance Committee. Each of Messrs. Judkowitz, Gupta and Foreman is independent under the rules and
regulations of the SEC and the listing standards of the Nasdaq applicable to nominating committee members. Our Nominating and Corporate
Governance Committee has the responsibility relating to assisting the Board in, among other things: (i) identifying and screening individuals
qualified to become members of our board of directors, consistent with criteria approved by our board of directors, (ii) recommending
to the Board the approval of nominees for director, (iii) developing and recommending to our board of directors a set of corporate governance
guidelines, and (iv) overseeing the evaluation of our board of director. The Nominating and Corporate Governance Committee charter can
be found online at https://ir.algoholdings.com/investor-governance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Executive
Committee</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
members of our Executive Committee are Messrs. Foreman, Judkowitz, Peloquin and Atkinson. Mr. Atkinson serves as the Chairman of our
Executive Committee. Our Executive Committee has the responsibility for evaluating critical matters on behalf of our full board of directors.
This includes but is not limited to: (i) reviewing our monthly financial and operational performance, (ii) reviewing and recommending
prospective capital markets activities, including equity offerings, debt issuances, and other financings, (iii) evaluating and recommending
potential business development activities such as strategic partnerships, joint ventures, mergers, acquisitions, and divestitures, and
(iv) other strategic initiatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
Board Committees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than the Audit Committee, Compensation Committee, Nominating and Corporate Governance Committee, and Executive Committee, we have no
other standing committees of our Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Committee
Composition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below lists each director nominee&#8217;s committee memberships and the Chairman of each Board committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid; padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; padding-left: 0pt; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: black 1pt solid; padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 0pt; padding-left: 0pt; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit
    Committee</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; padding-left: 0pt; width: 18%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Committee</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; padding-left: 0pt; width: 18%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nominating
                                            and</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
    Governance</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Committee</b></span></p></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; padding-left: 0pt; width: 18%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Executive</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Committee</b></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harvey Judkowitz</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: center; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jay B. Foreman</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: center; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary Atkinson</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: center; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bernardo Melo</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: center; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ajesh Kapoor</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: center; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scott Thorn</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: center; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kapil Gupta</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: center; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: center; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nominations
Process and Criteria</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Nominating Committee is responsible for identifying individuals qualified to become directors. The Nominating Committee seeks to identify
director candidates based on input provided by a number of sources, including: (1) the Nominating Committee members, (2) our other directors,
(3) our stockholders, (4) our Chief Executive Officer or Chairman, and (5) third parties such as professional search firms. In evaluating
potential candidates for director, the Nominating Committee considers the entirety of each candidate&#8217;s credentials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Qualifications
for consideration as a director nominee may vary according to the particular areas of expertise being sought as a complement to the existing
composition of the Board. However, at a minimum, candidates for director must possess:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">high
    personal and professional ethics and integrity; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the ability to exercise
    sound judgment; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability to make independent analytical inquiries; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a willingness
    and ability to devote adequate time and resources to diligently perform Board and committee duties; and </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    appropriate and relevant business experience and acumen. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to these minimum qualifications, the Nominating Committee also takes into account the following factors when considering whether
to nominate a potential director candidate:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    the person possesses specific industry expertise and familiarity with general issues affecting our business; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    the person&#8217;s nomination and election would enable the Board to have a member that qualifies as an &#8220;audit committee financial
    expert&#8221; as such term is defined in Item 401 of Regulation S-K (17 CFR &#167; 229.401); </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    the person would qualify as an &#8220;independent director&#8221; as such term in Rule 5605(a)(2) of The Nasdaq Stock Market; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    importance of continuity of the existing composition of the Board to provide long term stability and experienced oversight; and </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    importance of diversified Board membership, in terms of both the individuals involved and their various experiences and areas of
    expertise. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
stockholder wishing to propose that a person be nominated for or appointed to our Board may submit such a proposal to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Algorhythm
Holdings, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6301
NW 5<sup>th</sup> Way, Suite 2900</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fort
Lauderdale, FL 33309</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(954)
596-1000</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
Secretary</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Secretary will forward any such correspondence to the Chairman of the Nominating and Corporate Governance Committee for review
and consideration in accordance with the criteria described above and the requirements set forth in the Bylaws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stockholder
Communications with our Board</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders
and other parties interested in communicating directly with our Board, a committee thereof, or any individual director, may do so by
sending a written communication to the attention of the intended recipient(s) to: Algorhythm Holdings, Inc., 6301 NW 5<sup>th </sup>Way,
Suite 2900, Fort Lauderdale, FL 33309, Attention: Secretary. The Secretary will forward all appropriate communications to the Chairman
of the Board or the appropriate committee or individual.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Code
of Ethics</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted a Code of Ethics that applies to our principal executive officer, principal financial officer, and principal accounting
officer. Our Code of Ethics is available on our website at https://ir.algoholdings.com/investor-governance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Change
of Control Arrangements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not know of any arrangements that may, at a subsequent date, result in a change of control of us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_006"></span>PROPOSAL
2</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REVERSE
STOCK SPLIT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are asking stockholders to approve a proposed amendment to our certificate of incorporation to implement, at the discretion of the Board
at any time prior to the one-year anniversary of the Annual Meeting, a reverse stock split of the outstanding shares of common stock
in a range of not less than one-for-two (1-for-2) shares and not more than one-for-ten (1-for-10) shares, with the exact ratio to be
determined by the Board at its discretion without further approval or authorization of our stockholders (the &#8220;Reverse Stock Split&#8221;).
The Board may effect only one reverse stock split as a result of this authorization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
will effect a reverse stock split ONLY to the extent that it is necessary to maintain compliance with the continued listing requirements
of The Nasdaq Capital Market.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AS
OF THE DATE OF THIS PROXY, WE HAVE <span style="text-decoration: underline">NOT</span> RECEIVED A DEFICIENCY NOTICE REGARDING THE BID PRICE RULE FROM THE LISTING QUALIFICATIONS
STAFF OF NASDAQ.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq
Listing Rule 5550(a)(2) requires listed companies to maintain a minimum bid price (the &#8220;Minimum Bid Price&#8221;) of at least $1.00
per share (the &#8220;Bid Price Rule&#8221;). Failure to meet the continued listing requirement related to the Bid Price Rule is determined
to exist only if the deficiency continues for a period of 30 consecutive business days. Accordingly, even if the closing bid price of
our stock is below the Minimum Bid Price on a particular trading day, we will not be deemed to have violated the continued listing requirement
for the Bid Price Rule unless the closing bid price for our stock remains below $1.00 for 30 consecutive business days. For example,
if our stock price has a closing bid price below $1.00 for four consecutive business days and then on the fifth consecutive business
day it has a closing bid price at or above $1.00, we would continue to be in compliance with the Bid Price Rule and the 30 consecutive
business day period would start over again with &#8220;day 1&#8221; only if the closing bid price for our stock is below $1.00 on a subsequent
trading day.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effecting
the Reverse Stock Split would reduce the number of outstanding shares of common stock should, absent other factors, increase the price
of our common stock by an inversely proportionate amount. The primary purpose for the proposed Reverse Stock Split, should the Board
choose to effect it, is to increase the per share market price of our common stock to meet the Bid Price Rule for continued listing on
The Nasdaq Capital Market in the event a situation arises in which we believe we may in the future violate the Bid Price Rule. The decision
to implement the Reverse Stock Split will be at the Board&#8217;s discretion. The Reverse Stock Split will only be implemented if necessary
to regain or maintain compliance with the Bid Price Rule..</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board has unanimously approved and declared advisable the Reverse Stock Split and recommended that our stockholders approve an amendment
to our certificate of incorporation to effect this proposal. The text of the proposed form of Certificate of Amendment to our Certificate
of Incorporation, which we refer to as the &#8220;Certificate of Amendment&#8221;, is attached hereto as <span style="text-decoration: underline">Appendix A</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are proposing that our Board have the discretion to select the Reverse Stock Split ratio from within a range of not less than one-for-two
(1-for-2) shares and not more than one-for-ten (1-for-10) shares rather than proposing that stockholders approve a specific ratio at
this time in order to give our Board the flexibility to implement the Reverse Stock Split at a ratio that reflects the Board&#8217;s
then-current assessment of the factors described below under &#8220;<i>Criteria to be Used for Determining the Reverse Stock Split Ratio
to Implement</i>.&#8221; We believe that a range of Reverse Stock Split ratios provides us with the most flexibility to achieve the desired
results of the Reverse Stock Split. The Reverse Stock Split is not intended as, and will not effectuate, a &#8220;going private transaction&#8221;
covered by Rule 13e-3 promulgated under the Securities Exchange Act. The Reverse Stock Split is not intended to, and will not, modify
the rights of existing stockholders in any material respect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
actual timing for implementation of the Reverse Stock Split, if one is implemented, will be determined by the Board based upon its evaluation
as to when such action would be most advantageous to us and our stockholders but must be implemented at any time prior to the one-year
anniversary of the Annual Meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Board decides to implement a Reverse Stock Split, we will file the Certificate of Amendment with the Secretary of State of the State
of Delaware. The Certificate of Amendment will contain the Reverse Stock Split ratio determined by the Board. The Reverse Stock Split
will become effective at 12:01 a.m., Eastern Time, on the business day following the date of filing of the Certificate of Amendment with
the office of the Secretary of State of the State of Delaware, or such later time and/or date as is set forth in the Certificate of Amendment.
Except for adjustments that may result from the treatment of fractional shares as described below, each of our stockholders will hold
the same percentage of our outstanding common stock immediately following the Reverse Stock Split as such stockholder holds immediately
prior to the Reverse Stock Split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
Discretion to Effect the Reverse Stock Split</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Reverse Stock Split Proposal is approved by our stockholders, the Reverse Stock Split will only be effected upon a determination
by the Board that filing the Certificate of Amendment to effect the Reverse Stock Split is in the best interests of us and our stockholders.
The determination by the Board will be based upon a variety of factors, including those discussed under &#8220;<i>Criteria to be Used
for Determining the Reverse Stock Split Ratio to Implement</i>&#8221; below. We expect that the biggest factor that the Board will evaluate
when determining whether or not to file the Certificate of Amendment will be whether we will be able to maintain a closing bid price
of at least $1.00 per share of our common stock on The Nasdaq Capital Market for 30 consecutive business days without effecting the Reverse
Stock Split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reasons
for the Reverse Stock Split</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 26, 2024, we received a written notice from Nasdaq notifying us that we were not in compliance with Nasdaq Listing Rule 5550(a)(2),
which requires listed companies to maintain a minimum bid price of $1.00 per share. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), we
were granted a period of 180 calendar days, or until February 24, 2025, to regain compliance with the minimum bid price requirement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 30, 2024, we received notice from the Nasdaq indicating that the bid price for our common stock had closed below $0.10 per share
for the 13-consecutive trading day period ended December 27, 2024 and, accordingly, we would be subject to the provisions contemplated
under Nasdaq Listing Rule 5810(c)(3)(A)(iii) and its securities would be subject to delisting from Nasdaq unless we timely request a
hearing before the Nasdaq hearings panel. On February 10, 2025, we implemented a 200-for-1 reverse stock split. On that day, the closing
price of our common stock was $2.98 per share and the closing bid of our common stock remained above $1.00 for the next 10 consecutive
business days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 25, 2025, we received a letter from the Nasdaq stating that we had regained compliance with the minimum bid price requirement of
$1.00 per share for continued listing on the Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2). We will be subject to a mandatory
panel monitor for a period of one year from March 25, 2025. If, within that one-year monitoring period, the Nasdaq finds that we are
again out of compliance with the minimum bid price requirement, notwithstanding Nasdaq Listing Rule 5810(c)(2), then the Nasdaq will
issue a delist determination letter and we will have an opportunity to request a new hearing with the initial Nasdaq hearing panel or
a newly convened hearing panel if the initial panel is unavailable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reducing
the number of outstanding shares of our common stock should, absent other factors, generally increase the per share market price of our
common stock by an inversely proportionate amount. Although the intent of the Reverse Stock Split is to increase the price of our common
stock, there can be no assurance that the Reverse Stock Split will increase the closing bid price of our common stock sufficiently for
us to regain and maintain compliance with the Bid Price Rule.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also believe that the Reverse Stock Split will make our common stock more attractive to a broader range of investors. Many brokerage
houses and institutional investors have internal policies and practices that either prohibit them from investing in low-priced stocks
or tend to discourage individual brokers from recommending low-priced stocks to their customers. Additionally, some of those policies
and practices may function to make the processing of trades in low-priced stocks economically unattractive to brokers. Moreover, because
brokers&#8217; commissions on low-priced stocks generally represent a higher percentage of the stock price than commissions on higher-priced
stocks, a low average price per share of our common stock can result in individual stockholders paying transaction costs representing
a higher percentage of their total share value than would be the case if the share price was higher. We believe that the Reverse Stock
Split will make our common stock a more attractive and cost effective investment for many investors, which in turn would enhance the
liquidity of the holders of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reducing
the number of outstanding shares of our common stock through the Reverse Stock Split is intended, absent other factors, to increase the
per share market price of our common stock. However, other factors, such as our financial results, market conditions and the market perception
of our business, may adversely affect the market price of our common stock. There can be no assurance that the Reverse Stock Split, if
completed, will result in the market price of our common stock increasing or that, if it does increase, we will be able to meet or maintain
a bid price that complies with the Bid Price Rule. The market price of our common stock may instead decrease due to the above factors.
Additionally, we cannot assure you that the market price per share of our common stock after the Reverse Stock Split will increase in
reverse proportion to the reduction in the number of shares of our common stock outstanding after the Reverse Stock Split. The total
market capitalization of our common stock after the Reverse Stock Split may be lower than the total market capitalization of our common
stock before the Reverse Stock Split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
evaluating whether to seek stockholder approval for the Reverse Stock Split, the Board took into consideration negative factors associated
with reverse stock splits. These factors include: (i) the negative perception of reverse stock splits that investors, analysts and other
stock market participants may hold; (ii) the fact that the stock prices of some companies that have effected reverse stock splits have
subsequently declined, sometimes significantly, following their reverse stock splits; (iii) the possible adverse effect on liquidity
that a reduced number of outstanding shares could cause; and (iv) the costs associated with implementing a reverse stock split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if our stockholders approve the Reverse Stock Split, the Board reserves the right to not effect the Reverse Stock Split if in the Board&#8217;s
opinion it would not be in the best interests of us or our stockholders to effect the Reverse Stock Split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Criteria
to be Used for Determining the Reverse Stock Split Ratio to Implement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
determining which Reverse Stock Split ratio to implement, if any, following receipt of stockholder approval of Proposal 2, our Board
may consider, among other things, various factors, such as:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; width: 0.25in; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; width: 0.25in; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The historical
    trading price and trading volume of our common stock&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The then-prevailing trading
    price and trading volume of our common stock and the expected impact of the Reverse Stock Split on the trading market for our common
    stock in the short and long-term&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our ability to maintain
    our listing on The Nasdaq Capital Market;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Reverse Stock Split
    ratio would result in the least administrative cost to us&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prevailing general market
    and economic conditions&#894; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whether and when the additional
    authorized but unissued shares of common stock that will result from the implementation of a Reverse Stock Split are needed to provide
    the flexibility to use our common stock for business and/or financial purposes or for future equity awards.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Potential
Effects of the Proposed Amendment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our stockholders approve the Reverse Stock Split and the Board effects it, the number of shares of common stock issued and outstanding
will be reduced, depending upon the ratio determined by the Board. The Reverse Stock Split will affect all holders of our common stock
uniformly and will not affect any stockholder&#8217;s percentage ownership interest in us, except to the extent the stockholder is otherwise
entitled to receive a fractional share. Holders of common stock that are entitled to receive a fractional share because they hold a number
of shares not evenly divisible by the Reverse Stock Split ratio will automatically be entitled to receive that additional fraction of
a share of common stock necessary to round up that fraction of a share to the next whole share. See &#8220;Fractional Shares&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Reverse Stock Split will not change the terms of the common stock or affect any stockholder&#8217;s proportionate voting power (subject
to the effect of receiving fractional shares). Additionally, the Reverse Stock Split will have no effect on the number of shares of common
stock that we are authorized to issue. After the Reverse Stock Split, the shares of common stock will remain fully paid and non-assessable,
will have the same voting rights and rights to dividends and distributions, and will be identical in all other respects to the common
stock now has.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
the effective time of the Reverse Stock Split, we will continue to be subject to the periodic reporting and other requirements of the
Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registered
&#8220;Book-Entry&#8221; Holders of Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of our registered holders of common stock hold some or all of their shares electronically in book-entry form with the transfer agent.
These stockholders do not have stock certificates evidencing their ownership of the common stock. They are, however, provided with statements
reflecting the number of shares registered in their accounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders
who hold shares electronically in book-entry form with the transfer agent will not need to take action to receive evidence of their shares
of post-Reverse Stock Split common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Holders
of Certificated Shares of Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders
holding shares of our common stock in certificated form prior to the implementation of the Reverse Stock Split (the &#8220;Old Certificates&#8221;)
will be entitled to receive a new stock certificate evidencing the shares of common stock such stockholder owns on a post reverse stock
split basis. Unless a stockholder specifically requests a new paper certificate or holds restricted shares, upon the stockholder&#8217;s
surrender of all of the stockholder&#8217;s Old Certificates to the transfer agent (together with any required documentation), the transfer
agent will register the appropriate number of shares of post-Reverse Stock Split common stock electronically in book-entry form and provide
the stockholder with a statement reflecting the number of shares registered in the stockholder&#8217;s account. No stockholder will be
required to pay a transfer or other fee to exchange his, her or its Old Certificates. Until surrendered, we will deem outstanding Old
Certificates held by stockholders to be cancelled and only to represent the number of shares of post-Reverse Stock Split common stock
to which these stockholders are entitled. Any Old Certificates submitted for exchange, whether because of a sale, transfer or other disposition
of stock, will automatically be exchanged for the appropriate number of shares of post-Reverse Stock Split common stock. If an Old Certificate
has a restrictive legend on its reverse side, a new certificate will be issued with the same restrictive legend on its reverse side.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>STOCKHOLDERS
SHOULD NOT DESTROY ANY STOCK CERTIFICATE(S) AND SHOULD NOT SUBMIT ANY STOCK CERTIFICATE(S) TO THE TRANSFER AGENT UNTIL REQUESTED TO DO
SO.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fractional
Shares</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will not issue fractional shares in connection with the Reverse Stock Split. Instead, shareholders of record who otherwise would be entitled
to receive fractional shares because they hold a number of shares not evenly divisible by the Reverse Stock Split ratio will automatically
be entitled to receive that additional fraction of a share of common stock necessary to round up to the next whole share. Cash will not
be paid for fractional shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Effect
of the Reverse Stock Split on Outstanding Stock Options, Warrants and Convertible Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
upon the Reverse Stock Split ratio, proportionate adjustments are generally required to be made to the per share exercise price and the
number of shares issuable upon the exercise of all outstanding options, warrants and convertible securities. This will result in approximately
the same aggregate price being required to be paid under the options, warrants and convertible securities upon exercise or conversion,
and approximately the same value of shares of common stock being delivered upon such exercise or conversion, immediately following the
Reverse Stock Split as was the case immediately preceding the Reverse Stock Split. The number of shares reserved for issuance pursuant
to these securities will be reduced proportionately based upon the Reverse Stock Split ratio.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accounting
Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
proposed amendment to our certificate of incorporation will not affect the par value of our common stock. As a result, at the effective
time of the Reverse Stock Split, the stated capital on our balance sheet attributable to the common stock will be reduced in the same
proportion as the Reverse Stock Split ratio, and the additional paid-in capital account will be credited with the amount by which the
stated capital is reduced. The per share net income or loss for prior periods will be restated to conform to the post-Reverse Stock Split
presentation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>No
Dissenters&#8217; or Appraisal Rights</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Delaware General Corporation Law, our stockholders are not entitled to any dissenters&#8217; or appraisal rights with respect to
the Reverse Stock Split, and we will not independently provide stockholders with any such rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain
Federal Income Tax Consequences of the Reverse Stock Split</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summary describes, as of the date of this proxy statement, certain U.S. federal income tax consequences of the Reverse Stock
Split to holders of our common stock. This summary addresses the tax consequences only to a U.S. holder, which is a beneficial owner
of our common stock that is either:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; width: 0.25in; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    individual citizen or resident of the United States;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    corporation, or other entity taxable as a corporation for U.S. federal income tax purposes, created or organized in or under the
    laws of the United States or any state thereof or the District of Columbia;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    estate, the income of which is subject to U.S. federal income taxation regardless of its source; or</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    trust, if: (i) a court within the United States is able to exercise primary jurisdiction over its administration and one or more
    U.S. persons has the authority to control all of its substantial decisions or (ii) it was in existence before August 20, 1996 and
    a valid election is in place under applicable Treasury regulations to treat such trust as a U.S. person for U.S. federal income tax
    purposes</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
summary is based on the provisions of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), U.S. Treasury regulations,
administrative rulings and judicial authority, all as in effect as of the date of this proxy statement. Subsequent developments in U.S.
federal income tax law, including changes in law or differing interpretations, which may be applied retroactively, could have a material
effect on the U.S. federal income tax consequences of the Reverse Stock Split. This summary does not address all of the tax consequences
that may be relevant to any particular investor, including tax considerations that arise from rules of general application to all taxpayers
or to certain classes of taxpayers or that are generally assumed to be known by investors. This summary also does not address the tax
consequences to: (i) persons that may be subject to special treatment under U.S. federal income tax law, such as banks, insurance companies,
thrift institutions, regulated investment companies, real estate investment trusts, tax-exempt organizations, U.S. expatriates, persons
subject to the alternative minimum tax, persons whose functional currency is not the U.S. dollar, partnerships or other pass-through
entities, traders in securities that elect to mark to market and dealers in securities or currencies, (ii) persons that hold our common
stock as part of a position in a &#8220;straddle&#8221; or as part of a &#8220;hedging transaction,&#8221; &#8220;conversion transaction&#8221;
or other integrated investment transaction for federal income tax purposes, or (iii) persons that do not hold our common stock as &#8220;capital
assets&#8221; (generally, property held for investment). This summary does not address backup withholding and information reporting.
This summary does not address U.S. holders who beneficially own common stock through a &#8220;foreign financial institution&#8221; (as
defined in Code Section 1471(d)(4)) or certain other non-U.S. entities specified in Code Section 1472. This summary does not address
tax considerations arising under any state, local or foreign laws, or under federal estate or gift tax laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a partnership (or other entity classified as a partnership for U.S. federal income tax purposes) is the beneficial owner of our common
stock, the U.S. federal income tax treatment of a partner in the partnership will generally depend on the status of the partner and the
activities of the partnership. Partnerships that hold our common stock, and partners in such partnerships, should consult their own tax
advisors regarding the U.S. federal income tax consequences of the Reverse Stock Split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
holder should consult his, her or its own tax advisors concerning the particular U.S. federal tax consequences of the Reverse Stock Split,
as well as the consequences arising under the laws of any other taxing jurisdiction, including any foreign, state, or local income tax
consequences.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General
Tax Treatment of the Reverse Stock Split</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Reverse Stock Split is intended to qualify as a &#8220;reorganization&#8221; under Section 368 of the Code that should constitute a &#8220;recapitalization&#8221;
for U.S. federal income tax purposes. Assuming the Reverse Stock Split qualifies as a reorganization, a U.S. holder generally will not
recognize gain or loss upon the exchange of our ordinary shares for a lesser number of ordinary shares, based upon the Reverse Stock
Split ratio. A U.S. holder&#8217;s aggregate tax basis in the lesser number of ordinary shares received in the Reverse Stock Split will
be the same such U.S. holder&#8217;s aggregate tax basis in the shares of our common stock that such U.S. holder owned immediately prior
to the Reverse Stock Split. The holding period for the ordinary shares received in the Reverse Stock Split will include the period during
which a U.S. holder held the shares of our common stock that were surrendered in the Reverse Stock Split. The United States Treasury
regulations provide detailed rules for allocating the tax basis and holding period of the shares of our common stock surrendered to the
shares of our common stock received pursuant to the Reverse Stock Split. U.S. holders of shares of our common stock acquired on different
dates and at different prices should consult their tax advisors regarding the allocation of the tax basis and holding period of such
shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THE
FOREGOING IS INTENDED ONLY AS A SUMMARY OF CERTAIN FEDERAL INCOME TAX CONSEQUENCES OF THE REVERSE STOCK SPLIT AND DOES NOT CONSTITUTE
A TAX OPINION. EACH HOLDER OF OUR SHARES OF COMMONS STOCK SHOULD CONSULT ITS OWN TAX ADVISOR REGARDING THE TAX CONSEQUENCES OF THE REVERSE
STOCK SPLIT TO IT AND FOR REFERENCE TO APPLICABLE PROVISIONS OF THE CODE</b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Procedure
for Implementing the Amendment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Reverse Stock Split will become effective upon the filing of the Certificate of Amendment with the Secretary of State of the State of
Delaware or such later time as specified in the filing. The form of the Certificate of Amendment is attached hereto as <span style="text-decoration: underline">Appendix A</span>.
The exact timing of the filing of the Certificate of Amendment, if any, will be determined by the Board based on its evaluation as to
when such action will be the most advantageous to us and our stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Interests
of Officers and Directors in this Proposal</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
officers and directors do not have any substantial interest, direct or indirect, in this proposal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Votes
Required</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approval
of Proposal 2 requires the affirmative vote by holders of a majority of votes cast at the Annual Meeting. Abstentions and broker non-votes
will have no effect on Proposal 2. Proposal 2 is a matter on which brokers are expected to have discretionary voting authority. We do
not, therefore, expect any broker non-votes with respect to this proposal. If, however, your shares are represented at the Annual Meeting
and your broker fails to vote your shares on Proposal 2, it will have no effect on Proposal 2.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recommendation
of Our Board of Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>OUR
Board unanimously recommends a vote &#8220;<span style="text-decoration: underline">FOR</span>&#8221; Proposal 2.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_007"></span>PROPOSAL
3</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REINCORPORATION
INTO THE STATE OF NEVADA</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2025, our Board approved a proposal for us to reincorporate, by conversion, from a corporation organized under the laws of
the State of Delaware (the &#8220;Delaware Corporation&#8221;) to a corporation organized under the laws of the State of Nevada (the
&#8220;Nevada Corporation&#8221;) (such conversion of the Delaware Corporation into the Nevada Corporation, the &#8220;Reincorporation&#8221;)
pursuant to the plan of conversion (the &#8220;Plan of Conversion&#8221;) included as Appendix C to this Proxy Statement. The Board recommends
that our stockholders approve the Reincorporation, as more fully described in Proposal 3, the Plan of Conversion, the Nevada Charter
(as defined below), and the Nevada Bylaws (as defined below), and adopt the resolution of the Board approving the Reincorporation, which
is included as Appendix B to this Proxy Statement (the &#8220;Reincorporation Resolution&#8221;). The Board retains the discretion to
abandon the Reincorporation even if Proposal 3 is approved by our stockholders. If the Board elects to complete the Reincorporation,
we will become a Nevada corporation and will continue to operate our business under our current name, &#8220;Algorhythm Holdings, Inc.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal
Terms of the Reincorporation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board has approved, and recommends that our stockholders approve, the Reincorporation pursuant to which we will be converted from the
Delaware Corporation, organized under the laws of the State of Delaware, to the Nevada Corporation, organized under the laws of the State
of Nevada.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Reincorporation, if approved by our stockholders, will be effected through a conversion pursuant to Section 266 of the General Corporation
Law of the State of Delaware, as amended (the &#8220;DGCL&#8221;), and Sections 92A.195 and 92A.205 of the Nevada Revised Statutes, as
amended (the &#8220;NRS&#8221;), as set forth in the Plan of Conversion. Approval of Proposal 3 will constitute approval of the Plan
of Conversion, the Nevada Charter and the Nevada Bylaws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the effectiveness of the Reincorporation pursuant to the Plan of Conversion:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; width: 0.25in; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; width: 0.25in; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    will continue in existence as a Nevada corporation and will continue to operate our business under our current name, &#8220;Algorhythm
    Holdings, Inc.&#8221; The corporate existence of Algorhythm Holdings, Inc. will not cease at any time. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; padding-bottom: 0pt; padding-left: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    internal affairs will cease to be governed by Delaware law and will instead be governed by Nevada law. See &#8220;<i>What Changes
    After Reincorporation? &#8211; Certain Differences in Stockholder Rights under Delaware and Nevada Law</i>&#8221; below. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; padding-bottom: 0pt; padding-left: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    will cease to be governed by our existing Certificate of Incorporation, as amended (the &#8220;Delaware Charter&#8221;), which is
    incorporated by reference to our Form 10-K filed with the SEC on April 15, 2025, and the amended bylaws, as amended (the &#8220;Delaware
    Bylaws&#8221;), which are incorporated by reference to our Form 10-K filed with the SEC on April 15, 2025, and will instead be subject
    to the provisions of the proposed Nevada articles of incorporation (the &#8220;Nevada Charter&#8221;) and the proposed Nevada bylaws
    (the &#8220;Nevada Bylaws&#8221;), forms of which are included as Appendix D and Appendix E, respectively, to this Proxy Statement.
    See &#8220;<i>What Changes After Reincorporation? &#8211; Certain Differences Between the Delaware Charter and Bylaws and Nevada
    Charter and Bylaws</i>&#8221; below. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; padding-bottom: 0pt; padding-left: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Reincorporation will not result in any change in headquarters, business, jobs, management, properties, location of any of our offices
    or facilities, number of employees, obligations, assets, liabilities or net worth (other than as a result of the transaction costs
    related to the Reincorporation). </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; padding-bottom: 0pt; padding-left: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    outstanding share of our common stock will be automatically converted into one outstanding share of common stock of the Nevada Corporation
    pursuant to the Plan of Conversion. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; padding-bottom: 0pt; padding-left: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    book entry credit with our transfer agent, Continental Stock Transfer and Trust Company, will be automatically updated without any
    action required on behalf of the stockholders. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; padding-bottom: 0pt; padding-left: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    outstanding restricted stock award, restricted stock unit (including performance units), option, warrant or other right to acquire
    shares of our common stock, as applicable, will continue in existence and automatically become a restricted stock award, restricted
    stock unit, option, warrant or other right to acquire an equal number of shares of common stock, as applicable, of the Nevada Corporation
    under the same terms and conditions. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; padding-bottom: 0pt; padding-left: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; padding-left: 0pt; text-align: justify; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    common stock will continue to be traded on The Nasdaq Capital Market under the symbol &#8220;RIME.&#8221; We do not expect any interruption
    in the trading of our common stock as a result of the Reincorporation. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Reincorporation may be delayed or abandoned by our Board and the Plan of Conversion may be terminated by our Board (including by any
duly authorized committee thereof) at any time prior to the effectiveness of the conversion (the &#8220;Effective Time&#8221;) if our
Board determines for any reason that such delay, abandonment or termination would be in the best interests of us and our stockholders.
If Proposal 3 is approved by our stockholders, we anticipate that the Board will effectuate or otherwise abandon the Reincorporation
by no later than December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reasons
for the Reincorporation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board believes that reincorporating in Nevada is in the best interests of us and our stockholders. In particular, the Board believes
that it is important for us to be able to operate with flexibility and it would be competitively advantageous for us to have a predictable,
statute-focused legal environment during a time of rapid business change.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board considered Nevada&#8217;s statute-focused approach to corporate law and other merits of Nevada law and determined that Nevada&#8217;s
approach to corporate law is likely to foster more predictability than Delaware&#8217;s approach at the current time. The Board believes
that Nevada can offer more predictability and certainty in decision-making because of its statute-focused legal environment. NRS Chapter
78, which governs Nevada corporations, is generally recognized as a comprehensive and thoughtfully maintained state corporate statute.
Among other things, the Nevada statutes codify the fiduciary duties of directors and officers, which decreases reliance on judicial interpretation
and promotes stability and certainty for corporate decision-making. As we look to our planned growth, strategic decisions and plan for
the years to come, removing ambiguity resulting from the prioritization of judicial interpretation can offer our Board and management
clearer guideposts for action that will benefit our stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board also considered the increasingly litigious environment in Delaware, which has engendered less meritorious and costly litigation
and has the potential to cause unnecessary distraction to our directors and management team and potential delay in our response to the
evolving business environment. The Board believes that a more stable and predictable legal environment will better permit us to respond
to emerging business trends and conditions as needed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
the Reincorporation is expected to provide additional corporate flexibility in connection with certain corporate transactions. The Reincorporation
is not being effected to prevent a change in control, nor is it in response to any present attempt known to our Board to acquire control
of us or obtain representation on our Board. Nevertheless, certain effects of the proposed Reincorporation may be considered to have
anti-takeover implications by virtue of being subject to Nevada law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finally,
the Reincorporation will eliminate our obligation to pay the annual Delaware franchise tax, which we expect will result in substantial
savings to us over the long term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain
Risks Associated with the Reincorporation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
the Board believes that the Reincorporation is in the best interests of us and our stockholders at this time, the Board retains the discretion
to abandon the Reincorporation at any time and will evaluate the then-current laws of Delaware and Nevada prior to determining whether
to effectuate the Reincorporation. Even if the Reincorporation is effected, there can be no assurance that the Reincorporation will result
in all or any of the benefits described in this Proxy Statement, including the benefits of or resulting from incorporation in Nevada
or the application of Nevada law to our internal affairs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
a comparison of stockholders&#8217; rights and the material substantive provisions that apply to the board of directors and executive
officers under Delaware and Nevada law, see &#8220;<i>What Changes After Reincorporation? &#8211; Certain Differences in Stockholder
Rights under Delaware and Nevada Law</i>&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>What
Will Change After the Reincorporation?</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Reincorporation will result in a change in the legal domicile for us and other changes, the most significant of which are described below
under &#8220;<i>What Changes After Reincorporation? &#8211; Certain Differences in Stockholder Rights under Delaware and Nevada Law</i>&#8221;.
Following the Reincorporation, we will be governed by the NRS instead of the DGCL, and we will be governed by the Nevada Charter and
the Nevada Bylaws. Approval of Proposal 3 will constitute approval of the Nevada Charter and the Nevada Bylaws. The Delaware Charter
and the Delaware Bylaws will no longer be applicable following completion of the Reincorporation. Copies of the Delaware Charter and
the Delaware Bylaws are incorporated by reference into this Proxy Statement and copies of the Nevada Charter and the Nevada Bylaws are
included as Appendix D and E, respectively, to this Proxy Statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>What
Will Not Change After the Reincorporation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Apart
from being governed by the Nevada Charter, Nevada Bylaws and the NRS, upon completion of the Reincorporation, we will continue to exist,
without interruption, in the form of a Nevada corporation. By virtue of the Reincorporation, all of the rights, privileges and powers
of us, and all property, real, personal and mixed, and all debts due to us, as well as all other things and causes of action belonging
to us, will remain vested in the Nevada Corporation and will be the property of the Nevada Corporation. In addition, the Nevada Corporation
will have all debts, liabilities and duties of us and the same may be enforced against the Nevada Corporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>No
Change in Business, Jobs or Physical Location</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Reincorporation will not result in any change in business, jobs, management, properties, location of any of our offices or facilities,
number of employees, obligations, assets, liabilities or net worth (other than as a result of the costs related to the Reincorporation).
We intend to maintain our corporate headquarters in Florida.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management, including all directors and officers and the positions they respectively hold, will be unchanged as a result of the Reincorporation.
To the extent that the Reincorporation will require the consent or waiver of a third party, we will use commercially reasonable effects
to obtain such consent or waiver before completing the Reincorporation. We do not expect that any such required consent will impede our
ability to reincorporate to Nevada. The Reincorporation will not otherwise adversely affect any of our material contracts with any third
parties, and our rights and obligations under such material contractual arrangements will continue as rights and obligations of the Nevada
Corporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>No
Securities Law Consequences</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will continue to be a publicly held company following completion of the Reincorporation, and our common stock would continue to be listed
on The Nasdaq Stock Market LLC and traded under the symbol &#8220;RIME.&#8221; We will continue to file required periodic reports and
other documents with the SEC. There is not expected to be any interruption in the trading of the common stock as a result of the Reincorporation.
We and our stockholders will be in the same respective positions under the federal securities laws after the Reincorporation as we and
our stockholders were prior to the Reincorporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>No
Material Accounting Implications</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effecting
the Reincorporation will not have any material accounting implications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>No
Exchange of Stock Certificates Required</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders
will not have to exchange their existing stock certificates for new stock certificates. At the Effective Time, each outstanding share
of our common stock will automatically be converted into one share of the Nevada Corporation&#8217;s common stock, and any stock certificates
you then hold will represent the same number of shares of the Nevada Corporation as they represented of us immediately prior to the Effective
Time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain
Differences Between the Delaware Charter and Bylaws and the Nevada Charter and Bylaws</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Nevada Charter and the Nevada Bylaws have been drafted with an intent to parallel the Delaware Charter and the Delaware Bylaws to the
extent legally possible. However, there are differences between what your rights are under the DGCL and what they will be under the NRS.
In addition, there are differences between the Delaware Charter and Delaware Bylaws and the Nevada Charter and Nevada Bylaws as they
will be in effect after the Reincorporation, particularly with respect to changes: (i) that are required by Nevada law, or (ii) that
are necessary in order to preserve the current rights of stockholders and powers of the Board following the Reincorporation. The following
discussion is a summary of certain differences between the Delaware Charter and Delaware Bylaws and the Nevada Charter and Nevada Bylaws.
This summary does not cover all the differences between the Delaware Charter and Delaware Bylaws and the Nevada Charter and Nevada Bylaws.
This summary is subject to the complete text of the relevant provisions of the DGCL, the Delaware Charter and Delaware Bylaws, the NRS,
the Nevada Charter and Nevada Bylaws. We encourage you to read those documents carefully.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; white-space: nowrap; padding-left: 0pt; width: 16%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Provision</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 1pt; padding-left: 0pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Delaware</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 1pt; padding-left: 0pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nevada</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Charter Regarding Limitation
    of Liability of Directors and Officers</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; padding-bottom: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                    Delaware Charter provides that, to the fullest extent permitted by the DGCL, our directors shall
                                    not be liable to us or our stockholders for monetary damages for breach of fiduciary duty.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; padding-bottom: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                    Nevada Charter provides that directors and officers are not individually liable to us, our stockholders
                                    or creditors, unless the presumption of Nevada&#8217;s codified &#8220;business judgment rule&#8221;
                                    has been rebutted and it is proven that such person has breached such person&#8217;s fiduciary duties
                                    as a director or officer and such breach involved intentional misconduct, fraud or a knowing violation
                                    of law. Note that Nevada law, which covers both directors and officers, does not categorically exempt
                                    breaches of duty of loyalty from exculpation.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Provision</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 1pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Delaware</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-bottom: 1pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nevada</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; padding-bottom: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Bylaws</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Regarding</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Proxies</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; vertical-align: top; padding-right: 0pt; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    the DGCL and the Delaware Bylaws, no proxy authorized by a stockholder shall be valid after three years from the date of its execution
    unless the proxy provides for a longer period.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; padding-bottom: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                    Nevada Bylaws provide that no proxy shall be voted or acted upon after six months from its date,
                                    unless the proxy provides for a longer period, which may not exceed seven years unless the proxy
                                    is deemed irrevocable pursuant to the applicable provisions of the NRS.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Delaware</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nevada</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Charter and Bylaws Regarding
    Removal of Directors</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; vertical-align: top; padding-right: 0pt; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Delaware Charter and the Delaware Bylaws provide that any director may be removed at any time, with or without cause, by the affirmative
    vote of the holders of at least a majority of the voting power of the outstanding shares then entitled to vote for the election of
    directors.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Nevada Bylaws provide that any director may be removed from office at any time, with or without cause, in accordance with the NRS.
    Under the NRS, a director may only be removed by the vote of stockholders representing not less than two-thirds of the voting power
    of the issued and outstanding stock entitled to vote.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain
Differences Between Delaware and Nevada Law</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
our Board believes that the rights of stockholders under the DGCL and the NRS are substantially the same, the DGCL and Delaware case
law collectively are different in certain respects than the NRS and existing Nevada case law in ways that may affect the rights of our
stockholders. See the summary of certain differences in the section titled &#8220;<i>What Changes After Reincorporation? &#8211; Certain
Differences in Stockholder Rights under Delaware and Nevada Law</i>.&#8221; For instance, as further explained in the summary below,
under the NRS, a stockholder may inspect a Nevada corporation&#8217;s articles of incorporation, bylaws and stock ledger, subject to
certain limitations, if such stockholder holds at least five percent of the outstanding shares of stock of the Nevada corporation or
has been a holder of shares for at least six months. In addition, the NRS provides that a stockholder may inspect the books of account
and financial statements of a Nevada corporation if such stockholder holds at least 15% of the outstanding shares of stock of the Nevada
corporation. However, these additional inspection rights are generally not available for stockholders of publicly-traded companies like
us. The DGCL, by comparison, does not require that a stockholder hold a certain number of shares or hold such shares for a stated period
of time prior to exercising their books and records inspection rights. Thus, it is possible that some of our stockholders entitled to
make a books and records demand today (as stockholders in a Delaware corporation) will not be able to make a similar demand following
the Reincorporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the NRS expressly permits directors and officers to consider all relevant facts, circumstances, contingencies or constituencies,
including approving or taking an action that factors in the interests of stakeholders other than the corporation&#8217;s stockholders,
such as employees, suppliers and the community. Under the DGCL, by comparison, there is no express statutory authority to consider such
interests. Under the DGCL, fiduciary duties in most circumstances require directors to seek to maximize the value of the corporation
for the long-term benefit of the stockholders unless the corporation is specifically incorporated as a public benefit corporation. As
a result, as a Nevada corporation, it is possible that our directors and officers may consider the interests of other constituencies
in a manner different from what the DGCL may require.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board has identified certain other areas where the law in Nevada differs in some respect from that of Delaware. These are generally procedural
in nature. The potentially most important area is related to antitakeover protections. Both Delaware and Nevada permit a range of antitakeover
defenses, including poison pills. Both states have prohibitions (unless statutorily mandated conditions are met) on business combinations
with &#8220;interested&#8221; stockholders owning certain proportions of the outstanding shares, though they apply at different ownership
thresholds and have differing moratorium periods. The threshold is 15% of the voting power of the outstanding voting stock for three
years in Delaware and 10% of the voting or investment power of the outstanding voting stock for up to four years in Nevada. Both allow
for classified boards of directors, though there are different default standards for director removal. In Delaware, unless the certificate
of incorporation provides otherwise, directors on a classified board may only be removed for cause and by the holders of at least a majority
of the voting power of the outstanding shares entitled to vote at an election of directors. In Nevada, there is no distinction between
removals for cause and removals without cause, and a two-thirds stockholder vote is generally required to remove any director. Another
potential area of difference involves cash-out merger transactions (i.e., when one company buys another company and pays the stockholders
of the company that was purchased in cash) and directors&#8217; obligations. In such transactions, the NRS allows directors to consider
all relevant facts, circumstances, contingencies or constituencies, which may include the interests of stakeholders other than stockholders.
The DGCL, at least in certain circumstances, requires directors to accept the highest price reasonably available, although in many circumstances
directors are allowed, as directors of a Nevada corporation are, to reject a potential transaction and consider the long-term interests
of the corporation and its stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
may be further changes to the DGCL and/or the NRS that are not currently contemplated. We cannot predict the nature or extent of any
such future changes to the DGCL and/or the NRS. If Proposal 3 is approved, the Board will consider any such future changes when determining
whether it is in the best interests of the Company and its stockholders to effectuate or otherwise abandon the Reincorporation and will
have the discretion to determine whether or not to effectuate or abandon the Reincorporation based, in part, on such future changes.
If Proposal 3 is approved by our stockholders, we anticipate that the Board will effectuate or otherwise abandon the Reincorporation
by no later than December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finally,
there are various important common law doctrines under Delaware law that have not been adopted by Nevada courts or adopted in the Nevada
statutes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain
Differences in Stockholder Rights under Delaware and Nevada Law</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rights of our stockholders are currently governed by the DGCL, the Delaware Charter and the Delaware Bylaws. Following completion of
the Reincorporation, the rights of our stockholders will be governed by the NRS, the Nevada Charter and the Nevada Bylaws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
statutory corporate laws of Nevada, as governed by the NRS, are similar in many respects to those of Delaware, as governed by the DGCL.
However, there are certain differences that may affect your rights as a stockholder, as well as the corporate governance of us. The following
are brief summaries of material differences between the current rights of stockholders of the Delaware Company prior to the completion
of the Reincorporation and the rights of stockholders of the Nevada Company following the completion of the Reincorporation. The following
discussion does not provide a complete description of the differences that may affect you. This summary is qualified in its entirety
by reference to the NRS and DGCL as well as the Delaware Charter and Delaware Bylaws and the Nevada Charter and Nevada Bylaws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Increasing
or Decreasing Authorized Capital Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NRS
78.207 allows the board of directors of a corporation, unless restricted by the articles of incorporation, to increase or decrease the
number of authorized shares of a class or series of the corporation&#8217;s capital stock and correspondingly effect a forward or reverse
split of the outstanding shares of such class or series (and change the par value thereof) without a vote of the stockholders, so long
as the action taken does not adversely change or alter any right or preference of the stockholders and does not include any provision
or provisions pursuant to which only money will be paid or scrip issued to stockholders who collectively hold 10% or more of the outstanding
shares of the affected class and series, and who would otherwise be entitled to receive fractions of shares in exchange for the cancellation
of all of their outstanding shares. Under Delaware law, subject to certain exceptions, such actions typically require a vote of the stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cumulative
Voting</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cumulative
voting for directors entitles each stockholder to cast a number of votes that is equal to the number of voting shares held by such stockholder
multiplied by the number of directors to be elected and to cast all such votes for one nominee or distribute such votes among up to as
many candidates as there are positions to be filled. Cumulative voting may enable a minority stockholder or group of stockholders to
elect at least one representative to the board of directors where such stockholders would not be able to elect any directors without
cumulative voting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
the DGCL provides for cumulative voting rights by default, a Delaware corporation may provide in its certificate of incorporation for
cumulative voting in the election of directors. The NRS also does not generally grant stockholders cumulative voting rights but permits
any Nevada corporation to provide in its articles of incorporation the right to cumulative voting in the election of directors as long
as certain procedures are followed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Delaware Charter does not provide for cumulative voting in the election of directors. Similarly, the Nevada Charter does not provide
for cumulative voting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Vacancies</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
both the DGCL and the NRS, subject to the certificate or articles of incorporation and bylaws, vacancies on the board of directors, including
those resulting from any increase in the authorized number of directors, may be filled by the affirmative vote of a majority of the remaining
directors then in office, even if less than a quorum. Any director so appointed will hold office for the remainder of the term of the
director no longer on the board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Removal
of Directors</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the DGCL, unless the certificate of incorporation provides for a higher voting standard, the holders of a majority of the voting power
of the outstanding shares (or class or series of shares, if the removal without cause is of a director which is elected by only that
class or series) entitled to vote at an election of directors may vote to remove any director or the entire board with or without cause
unless (i) the board is a classified board, in which case (unless the certificate of incorporation otherwise provides) directors may
be removed only for cause, or (ii) the corporation has cumulative voting, in which case, if less than the entire board is to be removed,
no director may be removed without cause if the votes cast against his or her removal would be sufficient to elect him or her. The NRS
requires the vote of the holders of at least two-thirds of the voting power of the shares (or class or series of shares, if the removal
is of a director which is elected by only that class or series) of the issued and outstanding stock entitled to vote at an election of
directors in order to remove a director or all of the directors. The articles of incorporation may provide for a voting threshold higher
than two-thirds of the voting power, but not lower. Furthermore, the NRS does not make a distinction between removals for cause and removals
without cause.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fiduciary
Duties and Business Judgment</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevada,
like most jurisdictions, requires that directors and officers of Nevada corporations exercise their powers in good faith and with a view
to the interests of the corporation but, unlike some other jurisdictions, including Delaware, fiduciary duties of directors and officers
are codified in the NRS. As a matter of statute, directors and officers, in making business decisions, are presumed to act in good faith,
on an informed basis and with a view to the interests of the corporation. In performing such duties, directors and officers may exercise
their business judgment in reliance on information, opinions, reports, financial statements and other financial data prepared or presented
by corporate directors, officers or employees who are reasonably believed to be reliable and competent. Reliance may also be extended
to legal counsel, public accountants, advisers, bankers or other persons reasonably believed to be competent, and to the work of a committee
(on which the particular director or officer does not serve) if the committee was established and empowered by the corporation&#8217;s
board of directors, and if the committee&#8217;s work was within its designated authority and was about matters on which the committee
was reasonably believed to merit confidence. However, directors and officers may not rely on such information, opinions, reports, books
of account or similar statements if they have knowledge concerning the matter in question that would make such reliance unwarranted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Delaware law, a corporation&#8217;s directors are charged with fiduciary duties of care and loyalty. The duty of care requires that directors
act in an informed and deliberate manner and inform themselves, prior to making a business decision, of all relevant material information
reasonably available to them. The duty of loyalty may be summarized as the duty to act in good faith, not out of self-interest, and in
a manner which the director reasonably believes to be in the best interests of the corporation and its stockholder. A party challenging
the propriety of a decision by a board of directors bears the burden of rebutting the applicability of the presumptions afforded to directors
by the &#8216;business judgment rule&#8217;. If the presumption is not rebutted, the business judgment rule attaches to protect the directors
and their decisions, and their business judgments will not be second-guessed. Under Delaware law, members of the board of directors or
any committee designated by the board of directors are similarly entitled to rely in good faith upon the records of the corporation and
upon such information, opinions, reports and statements presented to the corporation by corporate officers, employees, committees of
the board of directors or other persons as to matters such member reasonably believes are within such other person&#8217;s professional
or expert competence, provided that such other person has been selected with reasonable care by or on behalf of the corporation. Such
appropriate reliance on records and other information protects directors from liability related to decisions made based on such records
and other information. Nevada law extends the statutory protection for reliance on such persons to corporate officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Flexibility
for Decisions, Including Takeovers</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board believes that Nevada provides directors with more discretion than Delaware in making corporate decisions, including decisions made
in takeover situations. Under Nevada law, director and officer actions taken in response to a change or potential change in control are
generally granted the benefits of the protections of the business judgment rule. However, in the case of an action to resist a change
or potential change in control that impedes the rights of stockholders to vote for or remove directors, directors will only be given
the benefit of the protections of the business judgment rule if the directors have reasonable grounds to believe a threat to corporate
policy and effectiveness exists and the action taken that impedes the exercise of the stockholders&#8217; rights is reasonable in relation
to such threat; however, the NRS clarifies that this heightened standard does not apply to (i) actions that only affect the time of the
exercise of stockholders&#8217; voting rights or (ii) the adoption or signing of stockholder rights plans commonly referred to as &#8220;poison
pills&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
exercising their powers, including in response to a change or potential change of control, directors and officers of Nevada corporations
may consider all relevant facts, circumstances, contingencies or constituencies, which may include, without limitation, the effect of
the decision on corporate constituencies, including, without limitation, the corporation&#8217;s employees, suppliers, creditors and
customers, the economy of the state or nation, the interests of the community and society in general, and the long-term as well as short-term
interests of the corporation and its stockholders, including the possibility that these interests may be best served by the continued
independence of the corporation. To underscore the discretion of directors and officers of Nevada corporations, the NRS specifically
states that such directors and officers are not required to consider the effect of a proposed corporate action upon any constituency
as a dominant factor. Further, a director may resist a change or potential change in control of the corporation if the board of directors
determines that the change or potential change of control is opposed to or not in the best interest of the corporation upon consideration
of any relevant facts, circumstances, contingencies or constituencies, including that there are reasonable grounds to believe that, within
a reasonable time the corporation or any successor would be or become insolvent or subjected to bankruptcy proceedings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
DGCL does not provide a similar list of statutory factors that corporate directors and officers may consider in making decisions. Delaware
law generally provides that the purpose of directors&#8217; and officers&#8217; fiduciary duties is to advance the best interests of
the corporation and its stockholders, although in many circumstances, directors and officers can take into account a range of factors
in advancing those interests. Delaware courts subject directors&#8217; conduct to enhanced scrutiny in respect of defensive actions taken
in response to a threat to corporate control and approval of a transaction resulting in the sale of control of the corporation. Thus,
the Board believes that the flexibility granted to directors of Nevada corporations when making business decisions, including in the
context of a hostile takeover, are greater than those granted to directors of Delaware corporations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Interested
Directors and Officers and Controlling Stockholder Transactions</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
144 of the DGCL provides safe harbor protection for acts or transactions in which directors, officers or controlling stockholders may
have an interest, so long as the procedures set forth therein are utilized or the acts or transactions are fair to the corporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Interested
Directors and Officers</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
transaction between or involving the corporation (or one or more of its subsidiaries) and a director or officer of the corporation may
not be subject to equitable relief or give rise to an award of damages against a director or officer of the corporation as a result of
the fact that (i) the director or officer is interested in the transaction, (ii) the director or officer received any benefit from the
transaction or (iii) the director or officer is present at or participates in the meeting of the board or committee which authorizes
the transaction, or was involved in the initiation, negotiation or approval of the transaction (including by virtue of the director&#8217;s
vote being counted for such purposes), if any of the following conditions are met: (i) the material facts as to the director&#8217;s
or officer&#8217;s relationship or interest in the transaction, including any involvement in the initiation, negotiation or approval
of the transaction, are disclosed or known to the board or committee of the board, and the board or committee in good faith and without
gross negligence authorizes the transaction by the affirmative vote of a majority of the disinterested directors then serving on the
board or such committee (provided that if a majority of the directors are not disinterested with respect to the transaction, such transaction
shall be approved or recommended for approval by a committee of the board that consists of two or more directors, each of whom the board
has determined to be a disinterested director with respect to the transaction); (ii) the transaction is approved or ratified by an informed,
uncoerced affirmative vote of a majority of the votes cast by the disinterested stockholders; or (iii) the transaction is fair as to
the corporation and its stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Controlling
Stockholder Transactions (Other than a Going Private Transaction)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
transaction between the corporation and a controlling stockholder or a transaction from which a controlling stockholder receives a financial
or other benefit not shared with the corporation&#8217;s stockholders generally (a &#8220;controlling stockholder transaction&#8221;)
may not be the subject of equitable relief or give rise to an award of damages against a director or officer of the corporation or a
controlling stockholder by reason of a breach of fiduciary duty by a director, officer or controlling stockholder if any of the following
conditions are met: (i) the material facts as to the controlling stockholder transaction are disclosed or known to a committee of the
board expressly delegated the authority to negotiate and to reject the controlling stockholder transaction, and such controlling stockholder
transaction is approved (or recommended for approval) in good faith and without gross negligence by a majority of the disinterested directors
then serving on the committee (provided that the committee consists of two or more directors, each of whom the board has determined to
be a disinterested directors with respect to the controlling stockholder transaction); (ii) the controlling stockholder transaction is
conditioned, by its terms, as in effect at the time it is submitted to the stockholders for their approval or ratification, on the approval
or ratification by disinterested stockholders and such controlling stockholder transaction is approved or ratified by an informed, uncoerced
affirmative vote of a majority of the votes cast by the disinterested stockholders; or (iii) the controlling stockholder transaction
is fair as to the corporation and its stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Controlling
Stockholder Transaction Constituting a Going Private Transaction</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
controlling stockholder transaction constituting a going private transaction may not be the subject of equitable relief, or give rise
to an award of damages against a director or officer of the corporation or a controlling stockholder by reason of a breach of fiduciary
duty by a director, officer or controlling stockholder if any of the following conditions are met: (i) the controlling stockholder transaction
is approved (or recommended for approval) in accordance with clause (i) described in the preceding paragraph (related to Controlling
Stockholder Transactions (Other than a Going Private Transaction)) and approved in accordance with clause (ii) described in the preceding
paragraph (related to Controlling Stockholder Transactions (Other than a Going Private Transaction)) or (ii) such controlling stockholder
transaction is fair as to the corporation and its stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Controlling
Stockholder Exculpation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
144 also provides that no person who is a controlling stockholder shall be liable in such capacity to the corporation or its stockholders
for monetary damages for breach of fiduciary duty other than for a breach of the duty of loyalty to the corporation and its stockholders,
acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of the law or any transaction from
which the person derived an improper personal benefit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Disinterested
Directors and Controlling Stockholder Defined</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, Section 144 provides that any director of a corporation that has a class of stock listed on a national securities exchange
shall be presumed to be a disinterested director with respect to a transaction which such director is not a party if the board shall
be determined that such director satisfies the applicable criteria for determining director independent from the corporation, and if
applicable with respect to the transaction of the controlling stockholder, under the rules promulgated under such exchange, which presumption
may only be rebutted by substantial and particularized facts that such director has a material interest in the transaction or has a material
relationship with a person with a material interest in such transaction. For purposes of Section 144, a controlling stockholder means
any person that, together with such person&#8217;s affiliates and associates, (i) owns or controls a majority in voting power of the
outstanding stock entitled to vote generally in the election or directors, (ii) has the right, by contract or otherwise, to cause the
election of nominees who are selected at the discretion or such person and who constitute a majority of the board or (iii) has the power
functionally equivalent to that of a stockholder that owns or control a majority in voting power of the outstanding stock of the corporation
entitled to vote generally in the election of directors by virtue of ownership or control of at least one-third of the voting power of
the outstanding stock of the corporation entitled to vote generally in the election of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NRS
78.140 provides a statutory framework for the approval of transactions between a corporation and a director or officer who has an interest
in such transaction. Under this framework, such an interested transaction will not be void or voidable if: (a) the interest is disclosed
to the board of directors or a committee thereof, and the disinterested directors or committee members approve such transaction in good
faith; (b) the interest is disclosed to the stockholders of the corporation, and the stockholders holding a majority of the voting power
approve or ratify the transaction in good faith; (c) the interest is not known to the interested director or officer at the time the
transaction is brought before the board of directors for action; or (d) the transaction is fair to the corporation at the time it is
authorized or approved. The NRS does not contain specific provisions that specify requirements related to transactions with controlling
stockholders, but the Nevada Supreme Court has clarified that Nevada&#8217;s codified business judgment rule, and not an &#8220;entire
fairness&#8221; standard, applies to judicial review of director and officer actions in the context of a transaction with a controlling
stockholder. However, neither the NRS nor Nevada case law has precisely delineated the scope or extent of the fiduciary duties of controlling
stockholders as such.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Limitation
on Personal Liability of Directors and Officers</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
the DGCL and the NRS, by way of statutory provisions or permitted provisions in corporate charter documents, eliminate or limit the personal
liability of directors and officers to the corporation or their stockholders for monetary damages for breach of a director&#8217;s or
officer&#8217;s fiduciary duty, subject to the differences discussed below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
DGCL precludes liability limitation for directors and executive officers for breach of the duty of loyalty, acts or omissions not in
good faith or involving intentional misconduct, any transaction from which the director or officer derived an improper personal benefit,
with respect to directors only, for paying dividends or repurchasing stock out of other than lawfully available funds and, with respect
to officers only, for any action by or in the right of the corporation. Under the NRS, in order for a director or officer to be individually
liable to the corporation or its stockholders or creditors for damages as a result of any act or failure to act, the presumption of the
business judgment rule, as codified in NRS 78.138(3), must be rebutted and it must be proven that the director&#8217;s or officer&#8217;s
act or failure to act constituted a breach of his or her fiduciary duties as a director or officer and that the breach of those duties
involved intentional misconduct, fraud or a knowing violation of law. Unlike the DGCL, however, the limitation on director and officer
liability under the NRS does not distinguish, as categorically excluded from its protections, breaches of the duty of loyalty or transactions
from which a director derives an improper personal benefit. Personal liability of directors for distributions made in violation of the
NRS is limited by the same standard.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
the DGCL and the NRS permit limitation of liability for both directors and officers, though the NRS expressly also applies this limitation
with respect to individual liabilities of directors or officers to creditors of the corporation. Furthermore, under the NRS, it is not
necessary to adopt provisions in the articles of incorporation limiting personal liability of directors or officers as this limitation
is provided by statute as a default. Under Delaware law, the exculpation of officers (namely, the chief executive officer, president,
chief financial officer, chief operating officer, chief legal officer, controller, treasurer and chief accounting officer, as well as
any other persons identified as &#8220;named executive officers&#8221; in a company&#8217;s most recent SEC filings or any officer who,
by written agreement consented to be identified as an officer for such purposes) is authorized only in connection with direct claims
brought by stockholders, including class actions. Delaware law does not eliminate monetary liability of officers for breach of fiduciary
duty arising out of claims brought by the corporation itself or for derivative claims brought by stockholders in the name of the corporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described above, the NRS provides broader protection from personal liability for directors and officers than the DGCL. Both the Delaware
Charter and the Nevada Charter provide a limitation to director liability to the fullest extent permitted by Delaware and Nevada law,
respectively. The Delaware Charter does not currently provide for exculpation of officers, whereas the Nevada Charter does, in accordance
with Nevada law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Indemnification</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
DGCL and the NRS each permit corporations to indemnify directors, officers, employees and agents in similar circumstances, subject to
the differences discussed below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
suits that are not brought by or in the right of the corporation, both jurisdictions permit a corporation to indemnify current and former
directors, officers, employees and agents for attorneys&#8217; fees and other expenses, judgments and amounts paid in settlement that
the person actually and reasonably incurred in connection with the action, suit or proceeding. The person seeking such statutory indemnity
may recover as long as he or she acted in good faith and believed his or her actions were either in the best interests of or not opposed
to the best interests of the corporation. Under the NRS, the person seeking indemnity under the statutory mechanism may also be indemnified
if he or she would not be individually liable for under NRS 78.138. Similarly, with respect to a criminal proceeding, the person seeking
indemnification must not have had any reasonable cause to believe his or her conduct was unlawful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
derivative suits, a corporation in either jurisdiction may indemnify its directors, officers, employees or agents for expenses that the
person actually and reasonably incurred. A corporation may not indemnify a person pursuant to the statutory mechanism if the person was
adjudged to be liable to the corporation unless a court otherwise orders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
corporation may indemnify a party under the relevant discretionary statutory mechanism unless the party has been successful on the merits
or otherwise in defense of the action, suit or proceeding or the corporation decides that indemnification is proper. Under the DGCL,
the corporation, through its stockholders, disinterested directors or independent legal counsel, will determine whether the conduct of
the person seeking indemnity conformed with the statutory provisions governing indemnity. Under the indemnification mechanism available
under the NRS, the corporation, through its stockholders, disinterested directors or independent counsel, must determine that the indemnification
is proper.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
indemnification pursuant to the statutory mechanisms available under the NRS, as described above, does not exclude any other rights to
which a person seeking indemnification or advancement of expenses may be entitled under the articles of incorporation or any bylaw, agreement,
vote of stockholders or disinterested directors or otherwise, but unless ordered by a court, indemnification may not be made to or on
behalf of any director or officer finally adjudged by a court of competent jurisdiction, after exhaustion of any appeals taken therefrom,
to be liable for intentional misconduct, fraud or a knowing violation of law, and such misconduct, fraud or violation was material to
the cause of action.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
the Delaware Bylaws and the Nevada Bylaws provide for indemnification to the fullest extent permitted by the applicable laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Advancement
of Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
DGCL provides that expenses incurred by an officer or director in defending any civil, criminal, administrative or investigative action,
suit or proceeding may be paid by the corporation in advance of the final disposition of such action, suit or proceeding upon receipt
of an undertaking by or on behalf of such director or officer to repay the amount if it is ultimately determined that he or she is not
entitled to be indemnified by the corporation. A Delaware corporation has the discretion to decide whether or not to advance expenses,
unless its certificate of incorporation or bylaws provide for mandatory advancement. The Delaware Bylaws provide that we shall, to the
fullest extent not prohibited by applicable law, pay the expenses (including attorneys&#8217; fees) incurred by any officer or director
of us, or former officer or director of us, upon receipt of a request and an undertaking by the person to repay all amounts advanced
if it should be ultimately determined that the person is not entitled to be indemnified under the Delaware Bylaws or otherwise. The Delaware
Bylaws further provide that we may pay the expenses incurred by other officers, other current or former employees or agents of us, in
certain covered proceedings in advance of their final disposition; upon such terms and conditions, if any, as the Board, or an officer
or other person delegated with such power by the Board, deems appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the NRS, unless otherwise restricted by the articles of incorporation, the bylaws or an agreement made by the corporation, the corporation
may pay the expenses of officer and directors in advance of the final disposition of an action, suit or proceeding upon receipt of an
undertaking by or on behalf of the director or officer to repay the amount if it is ultimately determined that the director or officer
is not entitled to be indemnified by the corporation. The Nevada Bylaws are substantially similar to the Delaware Bylaws with respect
to the advancement of expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Director
Compensation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
DGCL does not have a specific statute on the fairness of director compensation. In contrast, the NRS provides that, unless otherwise
provided in the articles of incorporation or bylaws, the board of directors, without regard to personal interest, may establish the compensation
of directors for services in any capacity. If the board of directors so establishes the compensation of directors, such compensation
is be presumed to be fair to the corporation unless proven unfair by a preponderance of the evidence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Action
by Written Consent of Directors</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
the DGCL and NRS provide that, unless the certificate or articles of incorporation or the bylaws provide otherwise, any action required
or permitted to be taken at a meeting of the directors or a committee thereof may be taken without a meeting if all members of the board
or committee, as the case may be, consent to the action in writing, provided that, in certain circumstances, the NRS permits a director
to abstain in writing from providing consent to the action.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
the Delaware Charter nor Delaware Bylaws nor the Nevada Charter or Nevada Bylaws limit board action by written consent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Actions
by Written Consent of Stockholders </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
DGCL provides that, unless the certificate of incorporation provides otherwise, any action required or permitted to be taken at a meeting
of the stockholders may be taken without a meeting if the holders of outstanding stock having at least the minimum number of votes that
would be necessary to authorize or take the action at a meeting of stockholders consent to the action in writing. In addition, the DGCL
requires the corporation to give prompt notice of the taking of corporate action without a meeting by less than unanimous written consent
to those stockholders as of the record date for the action by consent who did not consent in writing and who would have been entitled
to notice of the meeting if the action had been taken at a meeting and the record date for the notice of the meeting were the record
date for the action by consent. The DGCL also permits a corporation to prohibit stockholder action by written consent in lieu of a meeting
of stockholders by including such prohibition in its certificate of incorporation. There is no equivalent notice requirement under the
NRS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
NRS provides that unless otherwise provided in the articles of incorporation or the bylaws, any action required or permitted to be taken
at a meeting of the stockholders may be taken without a meeting if, before or after the action, a written consent thereto is signed by
stockholders holding at least a majority of the voting power, except that if a different proportion of voting power is required for such
an action at a meeting, then that proportion of written consents is required. The NRS also permits a corporation to prohibit stockholder
action by written consent in lieu of a meeting of stockholders by including such prohibition in its articles of incorporation or bylaws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
the Delaware Charter or Delaware Bylaws nor the Nevada Charter or Nevada Bylaws limit stockholder action by written consent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dividends
and Distributions </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
further restricted in the certificate of incorporation, the DGCL permits a corporation to declare and pay dividends out of either (i)
surplus or (ii) if no surplus exists, out of net profits for the fiscal year in which the dividend is declared and/or the preceding fiscal
year (provided that the amount of capital of the corporation is not less than the aggregate amount of the capital represented by the
issued and outstanding stock of all classes having a preference upon the distribution of assets). The DGCL defines surplus as the excess,
at any time, of the net assets of a corporation over its stated capital. In addition, the DGCL provides that, subject to certain exceptions,
a corporation may redeem or repurchase its shares only when the capital of the corporation is not impaired and only if such redemption
or repurchase would not cause any impairment of the capital of the corporation, and Delaware law prohibits a corporation from declaring
or paying a dividend, or redeeming or repurchasing shares of its stock, if the corporation is insolvent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
NRS defines a distribution as a direct or indirect transfer of money or other property, other than the corporation&#8217;s own shares
or the incurrence by the corporation of indebtedness, to or for the benefit of all holders of shares of any one or more classes or series
of the capital stock of the corporation, with respect to such shares. A distribution may be in the form of a declaration or payment of
a dividend, a purchase, redemption or other acquisition of shares, a distribution of indebtedness, or otherwise. The NRS provides that
no distribution may be made if, after giving effect to such distribution, (i) the corporation would not be able to pay its debts as they
become due in the usual course of business or (ii) except as otherwise specifically permitted by the articles of incorporation, the corporation&#8217;s
total assets would be less than the sum of its total liabilities plus the amount that would be needed at the time of a dissolution to
satisfy the preferential rights of preferred stockholders. Directors may consider financial statements prepared on the basis of accounting
practices that are reasonable in the circumstances, a fair valuation, including but not limited to unrealized appreciation and depreciation,
and any other method that is reasonable in the circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
the Delaware Charter nor the Nevada Charter contain such provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restrictions
on Business Combinations </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
Delaware and Nevada law provide certain protections to stockholders in connection with certain business combinations. These protections
can be found in Section 203 of the DGCL and NRS 78.411 to 78.444, inclusive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Section 203 of the DGCL, certain &#8220;business combinations&#8221; with &#8220;interested stockholders&#8221; of a corporation are
subject to a three-year moratorium unless specified conditions are met. For purposes of Section 203, the term &#8220;business combination&#8221;
is defined broadly to include (i) mergers with or caused by the interested stockholder; (ii) sales or other dispositions to the interested
stockholder (except proportionately with the corporation&#8217;s other stockholders) of assets of the corporation or a subsidiary equal
to 10% or more of the aggregate market value of either the corporation&#8217;s consolidated assets or its outstanding stock; (iii) the
issuance or transfer by the corporation or a subsidiary of stock of the corporation or such subsidiary to the interested stockholder
(except for transfers in a conversion or exchange or a pro rata distribution or certain other transactions, none of which increase the
interested stockholder&#8217;s proportionate ownership of any class or series of the corporation&#8217;s or such subsidiary&#8217;s stock);
or (iv) receipt by the interested stockholder (except proportionately as a stockholder), directly or indirectly, of any loans, advances,
guarantees, pledges or other financial benefits provided by or through the corporation or a subsidiary. In general, for purposes of Section
203 of the DGCL, an &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns 15% or more of
the voting power of the corporation&#8217;s outstanding voting stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
three-year moratorium imposed on business combinations by Section 203 of the DGCL does not apply if: (i) prior to the time on which such
stockholder becomes an interested stockholder, the board of directors approves either the business combination or the transaction that
resulted in the person becoming an interested stockholder; (ii) the interested stockholder owns 85% of the voting power of the corporation&#8217;s
voting stock upon consummation of the transaction that made him or her an interested stockholder (excluding from the 85% calculation
shares owned by directors who are also officers of the target corporation and shares held by employee stock plans that do not permit
employees to decide confidentially whether to accept a tender or exchange offer); or (iii) at or after the time such stockholder becomes
an interested stockholder, the board approves the business combination, and it is also approved at a stockholder meeting by at least
two-thirds of the outstanding voting power of the voting stock not owned by the interested stockholder. Section 203 only applies to voting
stock that is listed on a national securities exchange or held of record by more than 2,000 stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
NRS 78.411 to 78.444, inclusive, regulate combinations more stringently in certain respects. The NRS imposes a moratorium of up to four
years, depending on the circumstances, versus Delaware&#8217;s three-year moratorium on business combinations. An interested stockholder
is defined as a beneficial owner of 10% or more of the voting power. The initial two-year moratorium can be avoided by advance approval
of the combination, or the transaction by which such person first becomes an interested stockholder, by a corporation&#8217;s board of
directors. Absent such advance approval, however, during the first two years after a person becomes an interested stockholder, a combination
with the interested stockholder must be approved by a corporation&#8217;s board of directors and 60% of the corporation&#8217;s voting
power not beneficially owned by the interested stockholder, its affiliates and associates, at a meeting of the stockholders. After the
initial two-year period, up to four years from the date the person first became an interested stockholder, a combination remains prohibited
unless: (i) the combination or the transaction by which the person became an interested stockholder is approved by the board of directors
before the person became an interested stockholder; (ii) the combination is approved by a majority of the outstanding voting power not
beneficially owned by the interested stockholder and its affiliates and associates; or (iii) the consideration to be received by the
disinterested stockholders satisfies certain requirements. The combinations statutes in Nevada apply only to Nevada corporations with
200 or more stockholders of record.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Companies
are entitled to opt out of the business combination provisions of the DGCL and NRS. We have not opted out of the business combination
provisions of Section 203 of the DGCL, nor have we opted out of the business combination provisions of NRS 78.411 to 78.444, inclusive,
under the Nevada Charter. Unless the opt-out is included in the original articles of incorporation, any opt-out of the business combination
provisions of the NRS must be contained in an amendment to the articles of incorporation approved by a majority of the outstanding voting
power not then owned by interested stockholders and their respective affiliates and associates, but the amendment would not be effective
until 18 months after the vote of the stockholders to approve the amendment and would not apply to any combination with a person who
first became an interested stockholder on or before the effective date of the amendment.</span></p>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Acquisition
of Controlling Interests </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the restrictions on business combinations with interested stockholders, Nevada law also protects a corporation and its stockholders
from persons acquiring a &#8220;controlling interest&#8221; in a corporation. The provisions can be found in NRS 78.378 to 78.3793, inclusive.
Delaware law does not have similar provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to NRS 78.379, any person who acquires a controlling interest in a corporation may not exercise voting rights on any control shares unless
such voting rights are conferred by a majority vote of the disinterested stockholders of the issuing corporation at an annual meeting
or a special meeting of such stockholders held upon the request and at the expense of the acquiring person. NRS 78.3785 provides that
a &#8220;controlling interest&#8221; means the ownership of outstanding voting shares of an issuing corporation sufficient to enable
the acquiring person, individually or in association with others, directly or indirectly, to exercise (i) one-fifth or more but less
than one-third, (ii) one-third or more but less than a majority or (iii) a majority or more of the voting power of the issuing corporation
in the election of directors, and once an acquirer crosses one of these thresholds, shares that it acquired in the transaction taking
it over the threshold and within the 90 days immediately preceding the date when the acquiring person acquired or offered to acquire
a controlling interest become &#8220;control shares&#8221; to which the voting restrictions described above apply. In the event that
the control shares are accorded full voting rights and the acquiring person acquires control shares with a majority or more of all the
voting power, any stockholder, other than the acquiring person, who does not vote in favor of authorizing voting rights for the control
shares is entitled to assert dissenter&#8217;s rights under NRS 92A.300 through 92A.500, inclusive, and demand payment for the fair value
of such person&#8217;s shares in accordance with such statutes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NRS
78.378(1) provides that the control share statutes of the NRS do not apply to any acquisition of a controlling interest in an issuing
corporation if the articles of incorporation or bylaws of the corporation in effect on the 10th day following the acquisition of a controlling
interest by the acquiring person provide that the provisions of those sections do not apply to the corporation or to an acquisition of
a controlling interest specifically by types of existing or future stockholders, whether or not identified. In addition, NRS 78.3788
provides that the controlling interest statutes apply as of a particular date only to a corporation that has 200 or more stockholders
of record, at least 100 of whom have addresses in Nevada appearing on the corporation&#8217;s stock ledger at all times during the 90
days immediately preceding that date, and which does business in Nevada directly or through an affiliated corporation. NRS 78.378(2)
provides that the corporation may impose stricter requirements if it so desires.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporations
are entitled to opt out of the above controlling interest provisions of the NRS. We have not opted out of the business combination provisions
of NRS 78.411 to 78.444, inclusive, under the Nevada Charter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stockholder
Vote for Mergers, Asset Sales and Other Corporate Reorganizations </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the DGCL, unless the certificate of incorporation specifies a higher percentage, the stockholders of a corporation that is being acquired
in certain mergers or selling substantially all of its assets must authorize such merger or sale of assets by vote of the holders of
a majority of outstanding voting power of the shares entitled to vote. The corporation&#8217;s board of directors must also approve such
transaction. Similarly, under the NRS, a merger or sale of all assets requires authorization by stockholders of the corporation being
acquired or selling its assets by at least a majority of the voting power of the outstanding shares entitled to vote, as well as approval
of such corporation&#8217;s board of directors. Although a substantial body of case law has been developed in Delaware as to what constitutes
the &#8220;sale of substantially all of the assets&#8221; of a corporation, it is difficult to determine the point at which a sale of
substantially all, but less than all, of a corporation&#8217;s assets would be considered a &#8220;sale of all of the assets&#8221; of
the corporation for purposes of Nevada law. It is possible that many sales of less than all of the assets of a corporation requiring
stockholder authorization under Delaware law would not require stockholder authorization under Nevada law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
DGCL and NRS have substantially similar provisions with respect to approval by stockholders of a surviving corporation in a merger. The
DGCL does not require a stockholder vote of a constituent corporation in a merger (unless the corporation provides otherwise in its certificate
of incorporation) if (i) the plan of merger does not amend the existing certificate of incorporation, (ii) each share of stock of such
constituent corporation outstanding immediately before the effective date of the merger is an identical outstanding share after the effective
date of merger and (iii) either no shares of the common stock of the surviving corporation and no shares, securities or obligations convertible
into such stock are to be issued or delivered under the plan of merger, or the authorized unissued shares or treasury shares of the common
stock of the surviving corporation to be issued or delivered under the plan of merger plus those initially issuable upon conversion of
any other shares, securities or obligations to be issued or delivered under such plan do not exceed 20% of the shares of common stock
of such constituent corporation outstanding immediately prior to the effective date of the merger. The NRS does not require a stockholder
vote of the surviving corporation in a merger under substantially similar circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Appraisal
or Dissenter&#8217;s Rights </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
both jurisdictions, dissenting stockholders of a corporation engaged in certain major corporate transactions are entitled to appraisal
rights. Appraisal or dissenter&#8217;s rights permit a stockholder to receive cash generally equal to the fair value of the stockholder&#8217;s
shares (as determined by agreement of the parties or by a court) in lieu of the consideration such stockholder would otherwise receive
in any such transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Section 262 of the DGCL, appraisal rights are generally available for the shares of any class or series of stock of a Delaware corporation
in a merger, consolidation, conversion, transfer, domestication or continuance, provided that no appraisal rights are available with
respect to shares of any class or series of stock if, at the record date fixed to determine the stockholders entitled to act without
a meeting or the stockholders entitled to notice of the meeting to approve such transaction, such shares of stock, or depositary receipts
in respect thereof, are either (i) listed on a national securities exchange or (ii) held of record by more than 2,000 holders, unless
the stockholders are required by the terms of an agreement of merger or consolidation, or by the terms of a resolution providing for
conversion, transfer, domestication or continuance to accept in exchange for their shares anything other than shares of stock of the
surviving or resulting corporation, or of the converted entity if such entity is a corporation as a result of the conversion, transfer,
domestication or continuance (or depositary receipts in respect thereof), or of any other corporation that is listed on a national securities
exchange or held by more than 2,000 holders of record, cash in lieu of fractional shares or fractional depositary receipts described
above or any combination of the foregoing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, Section 262 of the DGCL allows beneficial owners of shares to demand an appraisal of such beneficial owner&#8217;s share and
to file a petition for appraisal without the need to name a nominee holding such shares on behalf of such owner as a nominal plaintiff
and makes it easier than under Nevada law to withdraw from the appraisal process and accept the terms offered in the merger, consolidation,
conversion, transfer, domestication or continuance. Under the DGCL, no appraisal rights are available to stockholders of the surviving
or resulting corporation if the merger did not require their approval under certain sections of the DGCL. The Delaware Charter and Delaware
Bylaws do not provide for appraisal rights in addition to those provided by the DGCL.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the NRS, a stockholder is entitled to dissent from, and obtain payment for, the fair value of the stockholder&#8217;s shares in the event
of (i) accordance of full voting rights under certain circumstances in connection with acquisitions of a controlling interest in the
corporation, (ii) consummation of a plan of merger, if approval by the stockholders is required for the merger, regardless of whether
the stockholder is entitled to vote on the merger or if the domestic corporation is a subsidiary and is merged with its parent, or if
the domestic corporation is a constituent entity in a merger pursuant to NRS 92A.133, (iii) consummation of a plan of conversion to which
the corporation is a party, (iv) consummation of a plan of exchange in which the corporation is a party, (v) any corporate action taken
pursuant to a vote of the stockholders, if the articles of incorporation, bylaws or a resolution of the board of directors provides that
voting or nonvoting stockholders are entitled to dissent and obtain payment for their shares or (vi) any corporate action to which the
stockholder would be obligated, as a result of the corporate action, to accept money or scrip rather than receive a fraction of a share
in exchange for the cancellation of all the stockholder&#8217;s outstanding shares, except where the stockholder would not be entitled
to receive such payment pursuant to NRS 78.205, 78.2055 or 78.207. Additionally, under the NRS, a beneficial owner of shares may assert
dissenter&#8217;s rights as to shares held on such beneficial owner&#8217;s behalf only if the beneficial owner: (a) submits to the corporation
the written consent of the stockholder of record to the dissent not later than the time the beneficial owner asserts dissenter&#8217;s
rights; and (b) does so with respect to all shares of which such beneficial owner is the beneficial owner or over which such beneficial
owner has power to direct the vote.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of covered securities (generally those that are listed on a national securities exchange), any shares traded in an organized market and
held by at least 2,000 stockholders of record with a market value of at least $20 million (exclusive of the value of such shares held
by the corporation&#8217;s subsidiaries, senior executives, directors and beneficial stockholders owning more than 10% of such shares),
and any shares issued by an open-end management investment company registered under the Investment Company Act of 1940 and which may
be redeemed at the option of the holder at net asset value are generally not entitled to dissenter&#8217;s rights. However, this exception
is not available if (i) the articles of incorporation of the corporation issuing the shares provide that such exception is not available,
(ii) the resolution of the board of directors approving the plan of merger, conversion or exchange expressly provides otherwise or (iii)
the holders of the class or series of stock are required by the terms of the corporate action to accept for the shares anything except
cash, any security that satisfies the requirements of NRS 92A.390(1) at the time the corporate action becomes effective, or any combination
thereof. The exception is also unavailable in the event of (i) accordance of full voting rights under certain circumstances in connection
with acquisitions of a controlling interest in the corporation and (ii) any corporate action taken pursuant to a vote of the stockholders,
if the articles of incorporation, bylaws or a resolution of the board of directors provides that voting or nonvoting stockholders are
entitled to dissent and obtain payment for their shares. The NRS prohibits a dissenting stockholder from voting his or her shares or
receiving certain dividends or distributions after his or her dissent. The Nevada Charter and Nevada Bylaws do not provide for dissenter&#8217;s
rights in addition to those provided by the NRS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
mechanics and timing procedures vary somewhat between Delaware and Nevada, but both require technical compliance with specific notice
and payment protocols.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Special
Meetings of Stockholders </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
DGCL permits special meetings of stockholders to be called by the board of directors or by any other person authorized in the certificate
of incorporation or bylaws to call a special stockholder meeting. In contrast, the NRS permits special meetings of stockholders to be
called by the entire board of directors, any two directors or the President, unless the articles of incorporation or bylaws provide otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Delaware Charter and Delaware Bylaws, a special meeting of stockholders may be called by resolution of the board or the president
and shall be called by the president or secretary upon the written request of a majority of the directors then in office or of the holders
of a majority of the outstanding shares entitled to vote. Under the Nevada Charter and the Nevada Bylaws, a special meeting of stockholders
may be called by the Board, the chairman of the Board, if any, or the chief executive officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Annual
Meetings Pursuant to Petition of Stockholders </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
DGCL provides that a director or a stockholder of a corporation may apply to the Delaware Court of Chancery if the corporation fails
to hold an annual meeting for the election of directors or there is no written consent to elect directors in lieu of an annual meeting
for a period of 30 days after the date designated for the annual meeting or, if there is no date designated, within 13 months after the
last annual meeting or the last action by written consent to elect directors in lieu of an annual meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the NRS, stockholders having not less than 15% of the voting power may petition the district court to order a meeting for the election
of directors if a corporation fails to call a meeting for that purpose within 18 months after the last meeting at which directors were
elected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Adjournment
of Stockholder Meetings </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the DGCL, a meeting may be adjourned from time to time to reconvene at the same or some other place, and notice need not be given of
any such adjourned meeting if the time and place thereof are announced at the meeting at which the adjournment is taken or are provided
in any other manner permitted by the DGCL. However, if a meeting of stockholders is adjourned and the adjournment is for more than 30
days, or if after the adjournment a new record date to determine stockholders entitled to vote is fixed for the adjourned meeting, notice
of the adjourned meeting must be given to each stockholder of record entitled to vote at the meeting. At the adjourned meeting, the corporation
may transact any business that might have been transacted at the original meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
contrast, under the NRS, a corporation is not required to give any notice of an adjourned meeting or of the business to be transacted
at an adjourned meeting, other than by announcement at the meeting at which the adjournment is taken, unless the board of directors of
the corporation fixes a new record date for the adjourned meeting or the meeting date is adjourned to a date more than 60 days later
than the date set for the original meeting, in which case a new record date must be fixed and notice given.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Duration
of Proxies </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the DGCL, a proxy executed by a stockholder will remain valid for a period of three years, unless the proxy provides for a longer period.
The DGCL provides for irrevocable proxies, without limitation on duration, if such proxy states that it is irrevocable and if, and only
as long as, it is coupled with an interest sufficient in law to support an irrevocable power.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the NRS, a proxy is effective only for a period of six months, unless it is coupled with an interest or unless otherwise provided in
the proxy, which duration may not exceed seven years. The NRS also provides for irrevocable proxies, without limitation on duration,
if such proxy states that it is irrevocable, but the proxy is irrevocable only for so long as it is coupled with an interest sufficient
in law to support an irrevocable power, including interests specified in the NRS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Quorum
and Voting </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
DGCL provides that the certificate of incorporation and bylaws may establish quorum and voting requirements for meetings of stockholders,
but in no event shall quorum consist of less than one-third of the voting power of the shares entitled to vote. If the certificate of
incorporation and bylaws are silent as to specific quorum and voting requirements: (a) a majority of the voting power of the shares entitled
to vote shall constitute a quorum at a meeting of stockholders; (b) in all matters other than the election of directors, the affirmative
vote of the majority of the voting power of the shares present at the meeting and entitled to vote on the subject matter shall be the
act of the stockholders; (c) directors shall be elected by a plurality of the votes of the shares present at the meeting and entitled
to vote on the election of directors; and (d) where a separate vote by a class or series or classes or series is required, a majority
of the outstanding voting power of the shares of such class or series or classes or series shall constitute a quorum entitled to take
action with respect to the vote on that matter and, in all matters other than the election of directors, the affirmative vote of the
majority of the voting power of the shares of such class or series or classes or series present at the meeting shall be the act of such
class or series or classes or series.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the DGCL, a bylaw amendment adopted by stockholders which specifies the votes that shall be necessary for the election of directors shall
not be further amended or repealed by the board. The Delaware Bylaws provide that unless otherwise required by law, the Delaware Charter,
the Delaware Bylaws or the rules of any applicable stock exchange, the holders of shares representing thirty-three and one-third percent
(33 1/3<sup>rd</sup>) of the voting power of our capital stock issued and outstanding and entitled to vote, present in person, by remote
communication, if applicable, or represented by proxy duly authorized, shall constitute a quorum at all meetings of the stockholders
for the transaction of business. The Delaware Bylaws provide that, except as otherwise required by law, the Delaware Charter or the Delaware
Bylaws, the directors are elected by a plurality of the voting power of the shares present in person, by remote communication, if applicable,
or represented by proxy duly authorized at the meeting and entitled to vote on the election of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
NRS provides that, unless the articles of incorporation or bylaws provide otherwise, a majority of the voting power of the corporation,
present in person, by remote communication, if applicable, or by proxy at a meeting of stockholders (regardless of whether the proxy
has authority to vote on any matter), constitutes a quorum for the transaction of business. Under the NRS, unless the articles of incorporation
or bylaws provide for different proportions, action by the stockholders on a matter other than the election of directors is approved
if the number of votes cast in favor of the action exceeds the number of votes cast in opposition to the action. Unless provided otherwise
in the corporation&#8217;s articles of incorporation or bylaws, directors are elected at the annual meeting of stockholders by plurality
vote. The Nevada Bylaws contain quorum and voting provisions substantially similar to those in the Delaware Bylaws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stockholder
Inspection Rights </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
DGCL grants any stockholder or beneficial owner of shares the right, upon written demand under oath stating the proper purpose thereof,
either in person or by attorney or other agent, to inspect and make copies and extracts from a corporation&#8217;s stock ledger, list
of stockholders and certain books and records as defined in Section 220 of the DGCL for any proper purpose. A proper purpose is one reasonably
related to such person&#8217;s interest as a stockholder. Stockholders or beneficial owners may inspect and copy a corporation&#8217;s
books and records only if all of the following apply: (i) the demand is made in good faith and for a proper purpose; (ii) the demand
describes with reasonable particularity the purpose and the books and records sought to be inspected; and (iii) the books and records
sought are specifically related to the purpose.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inspection
rights under Nevada law are more limited. The NRS grants any person who has been a stockholder of record of a corporation for at least
six months immediately preceding the demand, or any person holding, or thereunto authorized in writing by the holders of, at least 5%
of all of its outstanding shares, upon at least five days&#8217; written demand, the right to inspect in person or by agent or attorney,
during usual business hours (i) the articles of incorporation and all amendments thereto, (ii) the bylaws and all amendments thereto
and (iii) a stock ledger or a duplicate stock ledger, revised annually, containing the names, alphabetically arranged, of all persons
who are stockholders of record of the corporation, showing their places of residence, if known, and the number of shares held by them,
respectively. Nevada law further provides that a corporation is not required to keep a list of any person who is a beneficial owner of
any shares who is not simultaneously the stockholder of record of such shares. Any stockholder or other person making a demand under
NRS must furnish an affidavit to the corporation stating that the inspection is not desired for a purpose which is in the interest of
a business or object other than the business of the corporation and that the stockholder or other person has not at any time sold or
offered for sale any list of stockholders of any domestic or foreign corporation or aided or abetted any person in procuring any such
record of stockholders for any such sale or offer for sale.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the NRS grants certain stockholders the right to inspect the books of account and financial statements of a corporation for
any purpose related to the stockholder&#8217;s interest as a stockholder. The right to inspect the books of account and financial statements
of a corporation, to make copies of records and to conduct an audit of such records is granted only to a stockholder of record who owns
at least 15% of the issued and outstanding shares of a Nevada corporation, or who has been authorized in writing by the holders of at
least 15% of such shares. Any person making such a demand shall furnish an affidavit to the corporation stating that the inspection is
not desired for any purpose not related to his or her interest as a stockholder. Further, as a condition to such inspection right, the
board of directors may require the stockholder and each other person exercising such right to enter into and comply with a confidentiality
agreement having such terms and scope as are reasonably related to protecting the legitimate interests of the corporation. However, the
inspection rights discussed in this paragraph do not apply to any corporation, such as us, that furnishes to its stockholders a detailed
annual financial statement or any corporation that has filed during the preceding 12 months all reports required to be filed pursuant
to Section 13 or Section 15(d) of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Business
Opportunities </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Delaware law, the corporate opportunity doctrine holds that a corporate officer or director may not generally and unilaterally take a
business opportunity for his or her own if: (i) the corporation is financially able to exploit the opportunity; (ii) the opportunity
is within the corporation&#8217;s line of business; (iii) the corporation has an interest or expectancy in the opportunity; and (iv)
by taking the opportunity for his or her own, the corporate fiduciary will thereby be placed in a position inimical to his duties to
the corporation. The DGCL permits a Delaware corporation to renounce, in its certificate of incorporation or by action of the board of
directors, any interest or expectancy of the corporation in, or being offered an opportunity to participate in, specified business opportunities
or specified classes or categories of business opportunities that are presented to the corporation or one or more of its officers, directors
or stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Similar
to the DGCL, the NRS permits a Nevada corporation to renounce, in its articles of incorporation or by action of the board of directors,
any interest or expectancy to participate in specified business opportunities or specified classes or categories of business opportunities
that are presented to the corporation or one or more of its officers, directors or stockholders. Neither the Delaware Charter nor the
Nevada Charter renounces any interest or expectancy in business opportunities.</span></p>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Franchise
Tax Savings and Filing Fees </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current status as a Delaware corporation physically located in Florida requires us to comply with franchise tax obligations in both Delaware
and Florida. For the most recent franchise tax period, we paid $162,053 in franchise taxes to the state of Delaware, which will no longer
be required to be paid if the Reincorporation is completed. If the Reincorporation is completed, our current annual fees in Nevada will
be $4,725, consisting of an annual state business license fee of $500 and a fee for filing our annual list of directors and officers,
which is calculated based on the number of authorized shares and their par value, which is currently equal to $4,225.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will continue to pay annual filing fees to qualify as a foreign jurisdiction in Florida, and there are certain immaterial fees associated
with effecting the Reincorporation via conversion that we will be required to pay.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Potential
Future Changes </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
may be further changes to the DGCL and/or the NRS that are not currently contemplated and we cannot predict the nature or extent of any
such future changes to the DGCL and/or the NRS. If Proposal 3 is approved, the Board will consider any such future changes when determining
whether it is in the best interests of us and its stockholders to effectuate or otherwise abandon the Reincorporation and will have the
discretion to determine whether or not to effectuate or abandon the Reincorporation based, in part, on such future changes. If Proposal
3 is approved by our stockholders, we anticipate that the Board will effectuate or otherwise abandon the Reincorporation by no later
than December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Transaction
Costs and Litigation Risk </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred and will in the future incur certain costs in connection with the Reincorporation, including certain filing fees and legal
and other transaction costs. We believe a majority of the costs related to the transaction have already been incurred or will be incurred
in connection with the delivery of this Proxy Statement to stockholders, regardless of whether the Reincorporation is ultimately completed.
Many of the expenses that will in the future be incurred and other potential transaction costs are difficult to accurately estimate at
the present time, and additional unanticipated costs may be incurred in connection with the Reincorporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is also possible that the completion or abandonment of the Reincorporation could result in litigation, regardless of merit, with additional
expense and distraction for us. Further, if a court determines that any such litigation has merit, we may be required to pay substantial
monetary damages or attorneys&#8217; fees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>No
Appraisal Rights </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the DGCL, holders of our common stock are not entitled to appraisal rights with respect to the Reincorporation described in Proposal
3.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Interests
of Officers and Directors in This Proposal</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
officers and directors do not have any substantial interest, direct or indirect, in this proposal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Vote
Required</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
approval of the Nevada Reincorporation requires the affirmative vote by holders of a majority of the outstanding shares of our common
stock present virtually or represented by proxy and entitled to vote at the Annual Meeting. Abstentions, broker non-votes, and other
failures to vote will have the effect of a vote against this proposal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recommendation
of Our Board of Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>The
Board unanimously recommends a vote &#8220;FOR&#8221; Proposal 3.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_008"></span><b>PROPOSAL
4</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AMENDMENT
TO THE 2022 EQUITY INCENTIVE PLAN</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 12, 2022, our Board of Directors approved The Singing Machine Company, Inc. 2022 Equity Incentive Plan, (the&#8221;2022 Plan&#8221;).
The 2022 Plan provides for the issuance of equity incentive awards, such as stock options, stock appreciation rights, stock awards, restricted
stock, stock units, performance awards and other stock or cash-based awards (collectively, the &#8220;Awards&#8221;). Awards may be granted
under the 2022 Plan to our employees, officers, directors, consultants, agents, advisors, and independent contractors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2025, our Board approved, subject to stockholder approval, an amendment to the 2022 Plan to increase the number of shares
authorized for issuance thereunder to 5,000,000 shares of common stock (the &#8220;Baseline Number&#8221;). Prior to Board approval,
the Baseline Number was 1,667 shares of common stock. The proposed amendment to the 2022 Plan is attached hereto as <span style="text-decoration: underline">Appendix F</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board recommends approval of the amendment to the 2022 Plan to enable the continued use of the 2022 Plan for stock-based grants consistent
with the objectives of our compensation program. The 2022 Plan is intended to promote our interests by providing eligible persons in
our service with the opportunity to acquire a proprietary or economic interest, or otherwise increase their proprietary or economic interest,
in us as an incentive for them to remain in service and render superior performance during their service.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
the number of shares of our common stock available for issuance under our 2022 Plan is 484, including the shares of common stock that
are reserved and not yet issued or that have subsequently forfeited, expire or lapse unexercised or unsettled.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
stockholder approval of this proposal, a total aggregate of up to 5,000,000 shares of common stock will be authorized for issuance under
the 2022 Plan with annual increases equal to the least of: (i) 15% of the outstanding common stock on a fully diluted basis as of the
end of our immediately preceding fiscal year, or (ii) such lesser amount as determined by the Board. Currently, equity awards totaling
1,183 shares of common stock have been issued under the 2022 Plan. The 2022 Plan is almost exhausted of shares available for issuance,
leaving insufficient shares available for equity grants in 2025 and future years. By increasing the number of shares authorized for issuance
under the 2022 Plan, a total of 5,000,000 shares will be available immediately for issuance with future increases pursuant to the &#8220;evergreen&#8221;
provision of the 2022 Plan, we expect to have the flexibility to continue to make stock-based grants in amounts deemed appropriate by
our Compensation Committee and Board, as our outstanding common stock increases annually. We believe that our equity incentive program
and grants made under the program are essential to retaining critical personnel and aligning the incentives of our personnel with our
stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
proposed amendment to the 2022 Plan will not be implemented unless approved by our stockholders, and the 2022 Plan will remain in effect
in its present form.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Equity
Compensation Plan Information</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table contains summary information as of December 31, 2024, concerning our 2022 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">Plan Category</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
                                                                               of Securities to be issued upon exercise of outstanding options, warrants and rights</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
                                                                               -average exercise price of outstanding option, warrants and rights</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
                                                                               of securities remaining available for future issuance under equity compensation Plans</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify; padding-bottom: 1pt">Equity compensation plans approved by security holders</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">352</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">1,228</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">318</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Equity compensation plans not approved by security holders</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">352</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,228</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">318</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022
Equity Incentive Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the principal features of our 2022 Plan. The summary does not purport to be a complete description of all provisions
of our 2022 Plan and is qualified in its entirety by the text of the 2022 Plan. A copy of the amendment to the 2022 Plan is attached
to this Proxy Statement as <span style="text-decoration: underline">Appendix F</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purpose of the 2022 Plan is to enhance stockholder value by linking the compensation of our officers, directors, key employees, and consultants
to increases in the price of our common stock and the achievement of other performance objections and to encourage ownership in our company
by key personnel whose long-term employment is considered essential to our continued progress and success. The 2022 Plan is also intended
to assist us in recruiting new employees and to motivate, retain, and encourage such employees and directors to act in our stockholders&#8217;
interest and share in our success.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Term</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2022 Plan became effective upon approval by our stockholders and will continue in effect from that date until it is terminated in accordance
with its terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Administration</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2022 Plan may be administered by the Board or the Compensation Committee. Currently, our Compensation Committee administers the 2022
Plan. The administrator has the power to determine the directors, employees, and consultants who may participate in the 2022 Plan and
the amounts and other terms and conditions of awards to be granted under the 2022 Plan. All questions of interpretation and administration
with respect to the 2022 Plan will be determined by the administrator. The administrator also will have the complete authority to adopt,
amend, rescind, and enforce rules and regulations pertaining to the administration of the 2022 Plan; to correct administrative errors;
to make all other determinations deemed necessary or advisable for administering the 2022 Plan and any award granted under the 2022 Plan;
and to authorize any person to execute, on behalf of us, all agreements and documents previously approved by the administrator, among
other items.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Eligibility</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of our directors, employees, or consultants, or any directors, employees, or consultants of any of our affiliates (except that with respect
to incentive stock options, only employees of us or any of our subsidiaries are eligible), are eligible to participate in the 2022 Plan.
As of the Record Date, approximately 53 individuals would be eligible to participate in the 2022 Plan. However, we have not at the present
time determined who will receive the additional shares that will be authorized for issuance upon the approval of the amendment to increase
the number of shares subject to the 2022 Plan or how they will be allocated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Available
Shares</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
the number of shares of our common stock available for issuance under our 2022 Plan is 484, including the shares of common stock that
are reserved and not yet issued or that have subsequently forfeited, expire or lapse unexercised or unsettled. Shares subject to awards
that have been canceled, expired, settled in cash, or not issued or forfeited for any reason (in whole or in part), will not reduce the
aggregate number of shares that may be subject to or delivered under awards granted under the 2022 Plan and will be available for future
awards granted under the 2022 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Types
of Awards</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may grant the following types of awards under the 2022 Plan: options; stock appreciation rights; stock awards, restricted stock and stock
units; performance awards; and other stock or cash-based awards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Options.
</i>The 2022 Plan authorizes the grant of non-qualified and/or incentive options to eligible participants, which options give the participant
the right, after satisfaction of any vesting conditions and prior to the expiration or termination of the option, to purchase shares
of our common stock at a fixed price. The administrator determines the exercise price for each share subject to an option granted under
the 2022 Plan, which exercise price cannot be less than the fair market value (as defined in the 2022 Plan) of our common stock on the
grant date. The administrator also determines the number of shares subject to each option, the time or times when each option becomes
exercisable, and the term of each option (which term of an Incentive Stock Option cannot exceed ten (10) years from the grant date and
in the case of an Incentive Stock Option granted to a ten percent (10%) stockholder, cannot exceed five (5) years).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Appreciation Rights. </i>The 2022 Plan authorizes the grant of stock appreciation rights to eligible participants, which stock appreciation
rights give the participant the right, after satisfaction of any vesting conditions and prior to the expiration or termination of the
stock appreciation right, to receive in cash or shares of our common stock the excess of the fair market value (as defined in the 2022
Plan) of our common stock on the date of exercise over the exercise price of the stock appreciation right. All stock appreciation rights
under the 2022 Plan shall be granted subject to the same terms and conditions applicable to options granted under the 2022 Plan. Stock
appreciation rights may be granted to awardees either alone or in addition to or in tandem with other awards granted under the 2022 Plan
and may, but need not, relate to a specific option granted under the 2022 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Awards. </i>The 2022 Plan authorizes the grant of stock awards to eligible participants. The administrator determines (i) the number
of shares subject to the stock award or a formula for determining such number, (ii) the purchase price of the shares, if any, (iii) the
means of payment for the shares, (iv) the performance criteria, if any, and the level of achievement versus these criteria, (v) the grant,
issuance, vesting, and/or forfeiture of the shares, (vi) restrictions on transferability, and such other terms and conditions determined
by the administrator.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Unit Awards and Other Stock-Based Awards. </i>In addition to the award types described above, the administrator may grant any other type
of award payable by delivery of our common stock in such amounts and subject to such terms and conditions as the administrator determines
in its sole discretion, subject to the terms of the 2022 Plan. Such awards may be made in addition to or in conjunction with other awards
under the 2022 Plan. Such awards may include unrestricted shares of our common stock, which may be awarded, without limitation (except
as provided in the 2022 Plan), as a bonus, in payment of director fees, in lieu of cash compensation, in exchange for cancellation of
a compensation right, or upon the attainment of performance goals or otherwise, or rights to acquire shares of our common stock from
us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>New
Plan Benefits</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amount of future grants under the 2022 Plan is not determinable, as awards under the 2022 Plan will be granted at the sole discretion
of the administrator. We cannot determinate at this time either the persons who will receive awards under the 2022 Plan or the amount
or types of such any such awards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Transferability</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
determined otherwise by the administrator, an award may not be sold, pledged, assigned, or transferred in any manner other than by beneficiary
designation, will, or by the laws of descent or distribution, including but not limited to any attempted assignment or transfer in connection
with the settlement of marital property or other rights incident to a divorce or dissolution, and any such attempted sale, assignment,
or transfer shall be of no effect prior to the date an award is vested and settled.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Termination
of Service</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
administrator is authorized to establish and set forth in each instrument that evidences an option whether the option shall continue
to be exercisable, and the terms and conditions of such exercise, after a termination of service (as defined in the 2022 Plan), any of
which provisions may be waived or modified by the administrator at any time. If not so established and set forth in the instrument evidencing
the option, the option shall be exercisable according to the following terms and conditions, which may be waived or modified by the administrator
at any time:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    portion of an option that is not vested and exercisable on the date of a participant&#8217;s termination of service will expire on
    such date.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    portion of an option that is vested and exercisable on the date of a participant&#8217;s termination of service will expire on the
    earliest to occur of:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    the participant&#8217;s termination of service occurs for reasons other than cause (as defined in the 2022 Plan), retirement (as
    defined in the 2022 Plan), disability or death (as defined in the 2022 Plan), the date that is three months after such termination
    of service;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    the participant&#8217;s termination of service occurs by reason of retirement, disability or death, the one-year anniversary of such
    termination of service; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    option expiration date.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Change
of Control</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of a change of control (as defined in the 2022 Plan), unless the administrator determines otherwise with respect to a particular
award in the instrument evidencing the award or in a written employment, services or other agreement between the participant and us,
and if and to the extent an outstanding award is not converted, assumed, substituted for or replaced by the successor company, then such
award will terminate upon effectiveness of the change of control. Prior to the change of control, the administrator may approve accelerated
vesting and/or lapse of forfeiture or repurchase restrictions with respect to all or a portion of the unvested portions of such awards,
any such determinations to be made by the administrator in its sole discretion. If and to the extent the successor company converts,
assumes, substitutes for or replaces an outstanding award, all vesting and/or exercisability restrictions and/or forfeiture and/or repurchase
provisions applicable to such award will continue with respect to any shares of the successor company or other consideration that may
be received with respect to such ward. Without the consent of any participant, the administrator may dispose of awards that are not vested
as of the effective date of such change of control in any manner permitted by applicable laws, including (without limitation) the cancellation
of such awards without the payment of any consideration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>U.S.
Federal Income Tax Treatment</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following discussion is intended only as a brief summary of the federal income tax rules that are generally relevant to awards as of
the date of this prospectus. The laws governing the tax aspects of awards are highly technical and such laws are subject to change.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Non-Qualified
Options. </i>With respect to non-qualified options granted to participants under the 2022 Plan, (i) no income is realized by the participant
at the time the non-qualified option is granted, (ii) at exercise, (a) ordinary income is realized by the participant in an amount equal
to the difference between the option exercise price and the fair market value of our common stock on the date of exercise, (b) such amount
is treated as compensation and is subject to both income and wage tax withholding, and (c) we may claim a tax deduction for the same
amount, and (iii) on disposition of the option shares, any appreciation or depreciation after the date of exercise of the non-qualified
option, compared to the disposition price of the option shares will be treated as either short-term or long-term capital gain or loss
depending on the holding period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Incentive
Stock Options. </i>With respect to incentive stock options, there is no tax to the participant at the time of the grant. Additionally,
if applicable holding period requirements (a minimum of both two years from the grant date and one year from the exercise date) are met,
the participant will not recognize taxable income at the time of the exercise. However, the excess of the fair market value of the shares
acquired at the time of exercise over the aggregate exercise price is an item of tax preference income, potentially subject to the alternative
minimum tax. If shares acquired upon exercise of an incentive stock option are held for the holding period described above, the gain
or loss (in an amount equal to the difference between the fair market value on the date of sale and the option exercise price), upon
their disposition, the holding period of the option shares will be treated as a long-term capital gain or loss, and, unlike the treatment
for shares issued pursuant to the exercise of a non-qualified option, we will not be entitled to any tax deduction. If the shares acquired
on option exercise are disposed of in a &#8220;non-qualifying disposition&#8221; (i.e., before the holding period requirements had been
met), the participant will generally realize ordinary income at the time of the disposition of the option shares in an amount equal to
the lesser of (i) the excess of the fair market value of the option shares on the date of exercise of the incentive stock option over
the exercise price thereof or (ii) the excess, if any, of the amount realized upon disposition of the option shares over the exercise
price of the incentive stock option, and, just as the treatment for shares issued pursuant to the exercise of a non-qualified option,
we will be entitled to a corresponding tax deduction. Any amount realized in excess of the value of the shares on the date of exercise
will be capital gain. If the amount realized is less than the exercise price, the participant will not recognize ordinary income, and
the participant will generally recognize a capital loss equal to the excess of the exercise price of the incentive stock option over
the amount realized upon the disposition of the option shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Awards. </i>The current federal income tax consequences of other awards authorized under the 2022 Plan generally follow certain basic
patterns. An award of restricted shares of common stock results in income recognition by a participant in an amount equal to the fair
market value of the shares received at the time the restrictions lapse and the shares then vest, unless the participant elects under
Internal Revenue Code Section 83(b) to accelerate income recognition and the taxability of the award to the grant date. Stock unit awards
generally result in income recognition by a participant at the time payment of such an award is made in an amount equal to the amount
paid in cash or the then-current fair market value of the shares received, as applicable. Stock appreciation right awards result in income
recognition by a participant at the time such an award is exercised in an amount equal to the amount paid in cash or the then-current
fair market value of the shares received by the participant, as applicable. In each of the foregoing cases, we will generally have a
corresponding deduction at the time the participant recognizes ordinary income, subject to Internal Revenue Code Section 162(m) with
respect to covered employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Section
162(m) of the Internal Revenue Code. </i>Internal Revenue Code Section 162(m) denies a deduction to any publicly-held corporation for
compensation paid to certain &#8220;covered employees&#8221; in a taxable year to the extent that compensation to a covered employee
exceeds $1,000,000. &#8220;Covered employees&#8221; generally includes the Chief Executive Officer, the Chief Financial Officer, and
the three other most highly compensated executive officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Section
409A of the Internal Revenue Code. </i>Awards granted under the 2022 Plan will generally be designed and administered in such a manner
that they are either exempt from the application of, or comply with the requirements of, Section 409A of the Internal Revenue Code. Section
409A of the Internal Revenue Code imposes restrictions on nonqualified deferred compensation. Failure to satisfy these rules results
in accelerated taxation, an additional tax to the holder in an amount equal to 20% of the deferred amount, and a possible interest charge.
Options granted with an exercise price that is not less than the fair market value of the underlying shares on the date of grant will
not give rise to &#8220;deferred compensation&#8221; for this purpose unless they involve additional deferral features.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Tax Considerations. </i>This summary is not intended to be a complete explanation of all of the federal income tax consequences of participating
in the 2022 Plan. A participant should consult his or her personal tax advisor to determine the particular tax consequences of the 2022
Plan, including the application and effect of foreign state and local taxes and any changes in the tax laws after the date of this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Amendment
and Termination</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board may amend, suspend or terminate the 2022 Plan or any portion of the 2022 Plan at any time and in such respects as it shall deem
advisable; provided, however, that, to the extent required by applicable law, regulation or stock exchange rule, stockholder approval
shall be required for any amendment to the 2022 Plan. Subject to the terms of the 2022 Plan, the Board may amend the terms of any outstanding
award, prospectively or retroactively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2022 Plan has no fixed expiration date. After the 2022 Plan is terminated, no future awards may be granted under the 2022 Plan, but awards
previously granted shall remain outstanding in accordance with their applicable terms and conditions and the 2022 Plan&#8217;s terms
and conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Votes
Required </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approval
of the amendment to our 2022 Equity Incentive Plan requires the affirmative vote by holders of a majority of the outstanding shares of
our common stock present virtually or represented by proxy and entitled to vote at the Annual Meeting. Abstentions will have the effect
of a vote against this proposal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recommendation
of Our Board of Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>The
Board unanimously recommends a vote &#8220;FOR&#8221; Proposal 4.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_009"></span><b>PROPOSAL
5</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ISSUANCE
OF SHARES IN PRE-PAID FINANCING </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 21, 2025, we entered into a securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;) with Streeterville
Capital, LLC, a Utah limited liability company (the &#8220;Investor&#8221;), pursuant to which we agreed to issue and sell to Streeterville
shares of our common stock, par value $0.01 per share, in one or more pre-paid purchases (each, a &#8220;Pre-Paid Purchase&#8221; and
collectively, the &#8220;Pre-Paid Purchases&#8221;) for an aggregate purchase price of up to $20,000,000. We also agreed to issue 95,694
shares of our common stock to Streeterville (the &#8220;Commitment Shares&#8221;) as consideration for Streeterville&#8217;s commitment.
The transactions closed on August 21, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Initial
Closing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Securities Purchase Agreement provides for an initial Pre-Paid Purchase in the principal amount of $4,390,000, before deducting an original
issue discount of $360,000 and transaction expenses of $30,000 (the &#8220;Initial Pre-Paid Purchase&#8221;), the terms of which are
set forth on secured prepaid purchase #1 (&#8220;Secured Pre-Paid Purchase #1&#8221;). The Initial Pre-Paid Purchase accrues interest
at the rate of nine percent (9%) per annum and has a maturity date of three years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Subsequent
Fundings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Securities Purchase Agreement also provides for a two-year commitment period during which, subject to certain specified conditions, we
may request additional Pre-Paid Purchases from Streeterville provided that the amount requested is no less than $250,000 and the total
outstanding balance of all Pre-Paid Purchases does not exceed $3,000,000. The original issue discount for each additional Pre-Paid Purchase
will be nine percent (9%) of the amount set forth in the applicable request and each additional Pre-Paid Purchase will accrue interest
at the rate of nine percent (9%) per annum.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Placement
Agent</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Univest
Securities, LLC served as the placement agent in the offering (the &#8220;Placement Agent&#8221;). We paid the Placement Agent a cash
fee equal to eight percent (8%) of the aggregate gross proceeds received by us from the Initial Pre-Paid Purchase and reimbursed the
Placement Agent for legal fees in the amount of $40,000. We will pay the Placement Agent a cash fee equal to eight percent (8%) of the
aggregate gross proceeds received by us from any additional Pre-Paid Purchases that we complete.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share
Purchases</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the funding of each Pre-Paid Purchase, Streeterville has the right, but not the obligation, to purchase from us that number of shares
of common stock up to the lesser of: (i) a number of shares of common stock equal in value to the outstanding balance of the funded amount,
and (ii) that number of shares of common stock such that Streeterville will not beneficially own greater than 9.99% of our outstanding
shares of common stock. The price per share used to calculate the number of shares to be issued is equal to 90% of the lowest daily volume-weighted
average price of our common stock during the ten (10) trading days immediately preceding the applicable purchase date, but not less than
the floor price, which is the greater of: (i) 20% of the &#8220;Minimum Price&#8221; as such term is defined under Nasdaq Listing Rule
5635(d) (the &#8220;Minimum Price&#8221;) prior to the applicable closing of the Pre-Paid Purchase, and (ii) $0.10.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Prepayments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may at any time prepay all or any portion of the outstanding balance of a Pre-Paid Purchase. In the event we elect to do so, we must
pay Streeterville an amount equal to 110% multiplied by the portion of the outstanding balance we elected to prepay.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 49; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registration
Statement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Securities Purchase Agreement, we agreed to file a registration statement on Form S-1 under the Securities Act of 1933, as amended
(the &#8220;Securities Act&#8221;), with the SEC to register the resale of the Commitment Shares and all shares of common stock issuable
pursuant to the Pre-Paid Purchases by October 5, 2025. We filed the registration statement with the SEC on October 3, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Events
of Default</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an event of default occurs under a Pre-Paid Purchase, the outstanding balance will become immediately due and payable. At anytime thereafter,
upon written notice given by Streeterville, the outstanding balance will increase by seven-and-a half percent (7.5%) and interest will
begin accruing at a rate of the lesser of 18% per annum or the maximum rate permitted under applicable law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Additional
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
information with respect to the Securities Purchase Agreement and Secured Pre-Paid Purchase #1 and the transactions contemplated thereby
is contained in our Current Report on Form 8-K filed with the SEC on August 27, 2025. The discussion herein relating to the Securities
Purchase Agreement and Secured Pre-Paid Purchase #1 and the transactions contemplated thereby is qualified in its entirety by reference
to Exhibits 10.1, 10.2, 10.3, and 10.4 to such Form 8-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nasdaq
Shareholder Approval Requirements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq
Listing Rule 5635(d) provides that shareholder approval is required prior to the issuance of shares of our common stock equal or greater
in number to 20% of the number of shares of our common stock issued and outstanding immediately prior to the completion of the proposed
issuance (the &#8220;Exchange Cap&#8221;) at a price that is less than the Minimum Price in a transaction that is not a public offering.
Unless and until we obtain shareholder approval for the issuance of such shares, the total number of shares of common stock that we can
issue to Streeterville under all Pre-Paid Purchases cannot exceed the Exchange Cap. Under the Securities Purchase Agreement, we agreed
to seek shareholder approval for the issuance of shares of our common stock equal or greater in number to the Exchange Cap at a price
that is less than the Minimum Price. If we do not obtain shareholder approval of these proposed transactions within 75 days of the closing
date of the Initial Pre-Paid Purchase, we will continue seeking shareholder approval for these proposed transactions every 90 days thereafter
until such shareholder approval is obtained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Effects
if the Pre-Paid Financing Proposal is Approved</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq
Listing Rule 5635(d) provides that shareholder approval is required prior to the issuance of shares of our common stock equal or greater
in number to the Exchange Cap at a price that is less than the Minimum Price in a transaction that is not a public offering. Unless and
until we obtain shareholder approval for the issuance of such shares, the total number of shares of common stock that we can issue to
Streeterville under all Pre-Paid Purchases cannot exceed the Exchange Cap.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Proposal 5 is approved and, thereafter, Streeterville exercises its right to acquire shares of our common stock on the terms described
above and Streeterville agrees to complete additional Pre-Paid Purchases with us, we will be able to access additional capital through
the completion of the Pre-Paid Purchases without further shareholder approval. The proceeds that we receive from the sale of the shares
will be used to fund strategic growth initiatives for and for general working capital purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
sale of shares of our common stock to Streeterville under Pre-Paid Purchases that may be consummated pursuant to the Securities Purchase
Agreement may cause significant dilution to existing shareholders and thereby reduce each existing stockholder&#8217;s proportionate
ownership in our common stock, particularly if our stock price declines. Additionally, the sale of a substantial number of our shares
of common stock in the public market by Streeterville, or the perception that those sales might occur, could result in a significant
decline in the public trading price of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Streeterville exercises its right to purchase shares of our common stock under the Pre-Paid Purchases, the shares may be sold by us to
Streeterville at a price significantly below the prevailing market price. This could lead to substantial dilution of existing stockholders.
This dilution, combined with the potential for downward pressure on our share price if the Streeterville promptly sells the shares in
the open market, could reduce the market value of our common stock</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not seeking the approval of stockholders to authorize us to enter into the Securities Purchase Agreement, Secured Pre-Paid Purchase
#1 or the other transaction agreements, or to issue the Commitment Shares to Streeterville. We have already entered into those agreements
and completed the issuance, which are binding obligations on us. Accordingly, the failure of our stockholders to approve Proposal 5 will
not affect our obligations under these agreements, which will remain binding on us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Effects
if the Proposal is Not Approved</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Proposal 5 is not approved by our stockholders, we will not be able to issue shares of common stock to Streeterville in excess of the
Exchange Cap. This may have the effect of limiting the amount of funds we may be able to obtain in the future from Streeterville under
additional Pre-Paid Purchases. Additionally, if Proposal 5 is not approved by our stockholders, any remaining outstanding balance of
Pre-Paid Purchases that remains after we have issued that number of shares of common stock to Streeterville equal to the Exchange Cap
must be repaid by us in cash. We may not have sufficient cash on hand or available resources to meet such a repayment obligation, which
could force us to seek emergency financing or other arrangements which may not be available or, if available, may be on unfavorable terms.
In the event we do have sufficient funds available, the cash payment obligations, if triggered, could significantly reduce the cash we
have available to fund our operations or make necessary investments. This would adversely affect our financial condition, limit our ability
to pursue growth opportunities, and adversely affect our business prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Securities Purchase Agreement, we agreed to seek shareholder approval for the matters described in the Pre-Paid Purchase Proposal
within 75 days of the closing date of the Initial Pre-Paid Purchase. If we do not obtain shareholder approval of Proposal 5 within 75
days of the closing date of the Initial Pre-Paid Purchase, we are required to continue seeking shareholder approval every 90 days thereafter
until such shareholder approval is obtained. The process of continuing to hold stockholder meetings to obtain the requisite stockholder
approval would cause us to incur significant legal expenses and would divert our management&#8217;s attention from the operation of our
business, which could materially harm our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Appraisal
or Dissenters&#8217; Rights</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the DGCL, stockholders are not entitled to appraisal rights or dissenters&#8217; rights with respect to the Pre-Paid Financing Proposal,
and we are not providing appraisal rights or dissenters&#8217; rights to our stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Vote
Required </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approval
of the Pre-Paid Financing Proposal requires the affirmative vote by holders of a majority of the outstanding shares of our common stock
present virtually or represented by proxy and entitled to vote at the Annual Meeting. Abstentions will have the effect of a vote against
this proposal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recommendation
of our Board of Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OUR
BOARD UNANIMOUSLY RECOMMENDS THAT STOCKHOLDERS VOTE &#8220;<span style="text-decoration: underline">FOR</span>&#8221; PROPOSAL 5.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_010"></span><b>PROPOSAL
6</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RATIFICATION
OF THE COMPANY&#8217;S ACCOUNTING FIRM</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is the responsibility of the Audit Committee to select and retain our independent registered public accounting firm. The Audit Committee
has appointed M&amp;K CPAs PLLC (&#8220;M&amp;K CPAs&#8221;) as our independent registered public accounting firm to audit our consolidated
financial statements for the fiscal year ending December 31, 2025. The Board recommends stockholder ratification of the appointment of
M&amp;K CPAs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
stockholder ratification of the selection of our independent registered public accounting firm is not required by our Bylaws or applicable
law, we are submitting the selection for ratification so our stockholders may participate in this important corporate decision. If not
ratified, the Audit Committee will reconsider the selection, although the Audit Committee will not be required to select a different
independent registered public accounting firm.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Representatives
of M&amp;K CPAs are expected to be present at the Annual Meeting and will have an opportunity to make a statement and respond to
questions from stockholders present at the meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit
Fees and Services</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marcum
LLP served as our independent registered public accounting firm for the year ended December 31, 2024 and for part of our nine-month transition
period ended December 31, 2023. EisnerAmper LLP served as our independent registered public accounting firm for part of our nine-month
transition period ended December 31, 2023. We paid audit fees of $ 404,000 to Marcum LLP for services performed for the year ended December
31, 2024, and $215,000 for services performed for our nine-month transition period ended December 31, 2023. We paid audit fees of $31,000
to EisnerAmper LLP for services performed for our nine- month transition period ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit
Fees consist of fees billed for professional services rendered by our independent registered public accounting firm for the audit of
our annual consolidated financial statements, the review of our interim consolidated financial statements included in our quarterly reports,
the review of our registration statements and services that are normally provided by our principal accountant in connection with statutory
and regulatory filings or engagements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pre-Approval
Policies and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee has adopted policies and procedures to oversee the external audit process and pre-approves all services provided by our
independent registered public accounting firm. All of the above services and fees were reviewed and approved by the Audit Committee,
as applicable, before the respective services were rendered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Required
Vote </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ratification
of the appointment of M&amp;K CPAs as our independent registered public accounting firm requires the affirmative vote by holders of a
majority of the outstanding shares of our common stock present virtually or represented by proxy and entitled to vote at the Annual Meeting.
The ratification of M&amp;K CPAs as our independent registered public accounting firm is a routine matter for brokers that hold their
clients&#8217; shares in &#8220;street name.&#8221; Abstentions will have no effect on the outcome of the vote with respect to this proposal.
Because this is a routine proposal on which a broker or other nominee is generally empowered to vote, no broker non-votes will likely
result from this proposal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recommendation
of Board of Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OUR
BOARD UNANIMOUSLY RECOMMENDS THAT STOCKHOLDERS VOTE &#8220;<span style="text-decoration: underline">FOR</span>&#8221; THE RATIFICATION OF THE SELECTION OF M&amp;K CPAS AS OUR
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR FISCAL YEAR ENDING DECEMBER 31, 2025.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_024"></span><b><span style="text-decoration: underline">Audit
Committee Report</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee is responsible for, among other things, reviewing and discussing our audited financial statements with management, discussing
with our independent registered public accounting firm information relating to its judgments about the quality of our accounting principles,
recommending to our Board that we include the audited financial statements in the Annual Report on Form 10-K, and overseeing compliance
with the SEC requirements for disclosure of our independent registered public accounting firm&#8217;s services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Review
of Fiscal Year Ended December 31, 2024 Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with its review of our Fiscal Year 2024 Consolidated Financial Statements, the Audit Committee has:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewed
    and discussed the audited consolidated financial statements with management;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">discussed
    with Marcum LLP, our former independent registered public accounting firm, the matters required to be discussed by Public Company
    Accounting Oversight Board Auditing Standard No. 1301, <i>Communications with Audit Committees</i>; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">received
    from Marcum LLP the written disclosures and letter required by applicable requirements of the Public Company Accounting Oversight
    Board and discussed with Marcum LLP their independence.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
upon the review and discussions described above, the Audit Committee recommended to the Board of Directors that the audited consolidated
financial statements for the fiscal year ended December 31, 2024 be included in our Annual Report on Form 10-K for the fiscal year ended
December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
the Audit Committee of the Board of Directors,</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harvey
Judkowitz</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
Audit Committee Report shall not be deemed incorporated by reference by any general statement incorporating by reference this Proxy Statement
into any filing under the Securities Act or the Exchange Act except to the extent that we specifically incorporate this information by
reference, and shall not be deemed filed under the Securities Act or the Exchange Act.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="a_011"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROPOSAL
7</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ADJOURNMENT
OF THE ANNUAL MEETING </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the Reverse Stock Split Proposal, the Nevada Reincorporation Proposal, the 2022 Plan Amendment Proposal, and the Pre-Paid
Financing Proposal, our stockholders are also being asked to approve one or more adjournments of the Annual Meeting, if necessary or
appropriate, to solicit additional proxies in favor of any or all of the Reverse Stock Split Proposal, the Nevada Reincorporation Proposal,
the 2022 Plan Amendment Proposal, and the Pre-Paid Financing Proposal, if there are insufficient votes at the time of such adjournment
to approve and adopt any or all of such proposals. If the Adjournment Proposal is approved, the Annual Meeting could be successively
adjourned to another date. In addition, the Board could postpone the Annual Meeting before it commences, whether for the purpose of soliciting
additional proxies or for other reasons. If the Annual Meeting is adjourned for the purpose of soliciting additional proxies, stockholders
who have already submitted their proxies will be able to revoke them at any time prior to their exercise at the adjourned meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 53; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Interest
of Certain Persons in Matters to Be Acted Upon</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
director or executive officer has any substantial interest, direct or indirect, by security holdings or otherwise, in Proposal 7 that
is not shared by all of our other stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Vote
Required</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a quorum is represented at the Annual Meeting, Proposal 7 will be approved if the number of votes cast &#8220;FOR&#8221; this proposal
exceeds the number of votes cast &#8220;AGAINST&#8221; this proposal by holders present virtually or represented by proxy and entitled
to vote at the Annual Meeting. Abstentions are not considered votes cast and will have no effect on the outcome of Proposal 7. Because
a bank, broker, dealer or other nominee may generally vote without instructions on Proposal 7, we do not expect any broker non-votes
to result for Proposal 7.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a quorum is not represented at the Annual Meeting, Proposal 7 will be approved if holders of a majority of the outstanding shares of
our common stock present virtually or represented by proxy and entitled to vote at the Annual Meeting vote &#8220;FOR&#8221; Proposal
7. In this case, abstentions and broker non-votes will have the effect of a vote &#8220;AGAINST&#8221; Proposal 7.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OUR
BOARD UNANIMOUSLY RECOMMENDS A VOTE &#8220;<span style="text-decoration: underline">FOR</span>&#8221; ONE OR MORE ADJOURNMENTS OF THE ANNUAL MEETING, IF NECESSARY OR APPROPRIATE,
TO SOLICIT ADDITIONAL PROXIES IN FAVOR OF <span style="text-transform: uppercase">the Reverse Stock Split Proposal, the Nevada Reincorporation
Proposal, the 2022 Plan Amendment Proposal AND THE PRE-PAID TRANSACTION PROPOSAL </span>IF THERE ARE NOT SUFFICIENT VOTES AT THE ANNUAL
MEETING TO APPROVE AND ADOPT <span style="text-transform: uppercase">THESE PROPOSALS</span>.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROXIES
WILL BE VOTED &#8220;<span style="text-decoration: underline">FOR</span>&#8221; ONE OR MORE ADJOURNMENTS OF THE ANNUAL MEETING, IF NECESSARY OR APPROPRIATE, TO SOLICIT ADDITIONAL
PROXIES IN FAVOR OF <span style="text-transform: uppercase">the Reverse Stock Split Proposal, the Nevada Reincorporation Proposal, the
2022 Plan Amendment Proposal</span> AND THE PRE-PAID TRANSACTION PROPOSAL IF THERE ARE NOT SUFFICIENT VOTES AT THE ANNUAL MEETING TO
APPROVE THESE PROPOSALS, UNLESS OTHERWISE SPECIFIED.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_025"></span>MANAGEMENT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the Record Date, our named executive officers are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 16%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Officer/Director</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Since</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position
    or Office</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary
    Atkinson</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2012/2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer, Secretary and Chairman of the Board</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alex
    Andre</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer and General Counsel</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Gary
Atkinson.</b> For biographical information on Mr. Atkinson, please see Proposal 1, &#8220;Election of Directors.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Alex
Andre</b> has served as our Chief Financial Officer and General Counsel since February 2025. Mr. Andre brings us nearly 25 years of executive
management, financial, legal and operational experience. He most recently served as the Chief Financial Officer of Lemnature AquaFarms
Corporation, a plant-based ingredients manufacturer for the food, beverage and nutrition markets, from October 2022 to September 2023.
Prior to that, Mr. Andre served as the Chief Financial Officer and General Counsel of M.H. Enterprises, Inc., the owner and franchisor
of the Teriyaki Madness<sup>&#174;</sup> restaurant brand, from March 2021 to September 2022. Before that, he served as the Chief Financial
Officer of ARC Group, Inc., a national, multi-brand, multi-unit restaurant holding company, from July 2019 to March 2021, and as its
General Counsel from October 2019 to March 2021. Earlier in his career, Mr. Andre served as an accountant for KPMG LLP, a leading global
provider of audit, tax, and advisory services, before serving as a corporate &amp; securities attorney for regional and international
law firms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 54; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="a_012"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXECUTIVE
COMPENSATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
Compensation Table</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides information regarding the compensation earned by or paid to our named executive officers during our fiscal years
ended December 31, 2024 and the nine-month transition period ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: justify">Name and Principal Position</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Year / Period</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Salary ($)</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Bonus ($)</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All Other</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation <sup>(1)</sup></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total ($)</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; text-align: justify">Gary Atkison</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2024</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">215,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">32,250</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;6,285</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">253,535</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: justify">Chief Executive Officer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">165,385</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-0-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,142</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">169,527</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard Perez <sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">174,596</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-0-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-0-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">174,596</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: justify">Chief Financial Officer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lionel Marquis <sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">134,100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,755</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">152,855</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: justify">Former Chief Financial Officer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">161,538</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,462</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">268,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Bernardo Melo</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">215,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57,552</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,902</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">283,454</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Chief Revenue Officer </i><sup>(4)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">165,385</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47,988</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,535</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">221,908</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of 401(k) matching contributions that we made during the respective years.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(2)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Perez was appointed as our Chief Financial Officer on January 3, 2024 and was terminated as our Chief Financial Officer on February
    13, 2025.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(3)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Marquis resigned as our Chief Financial Officer on December 31, 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(4)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Melo was terminated as our Chief Revenue Officer effective August 1, 2025.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify; text-indent: -13.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
Option and Stock Awards</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information with respect to outstanding grants of options to purchase our common stock under stock option
awards issued to the named executive officers as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Name</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number
of Securities Underlying Unexercised Options (#) Exercisable</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Securities Underlying Unexercised Options (#) Unexercisable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Option Exercise Price ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Option Expiration Date</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Shares or Units of Stock That Have Not Vested (#)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Market Value of Shares or Units of Stock That Have Not Vested ($)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($)</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 9%; text-align: justify">Gary Atkinson</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">8</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 8%; text-align: center">N/A</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">1,440</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 8%; text-align: right">3/31/2026</td><td style="width: 2%">&#160;</td>
    <td style="width: 8%; text-align: center">N/A</td><td style="width: 2%">&#160;</td>
    <td style="width: 8%; text-align: center">N/A</td><td style="width: 2%">&#160;</td>
    <td style="width: 8%; text-align: center">N/A</td><td style="width: 2%">&#160;</td>
    <td style="width: 8%; text-align: center">N/A</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,820</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">5/3/2027</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: center">N/A</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">5/24/2032</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: center">N/A</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,730</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">8/16/2032</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: center">N/A</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Lionel Marquis</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,440</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">3/31/2026</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: center">N/A</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,820</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">5/3/2027</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: center">N/A</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">5/24/2032</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: center">N/A</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,730</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">8/16/2032</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: center">N/A</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Bernardo Melo</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,020</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">6/30/2025</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: center">N/A</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,920</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">8/10/2026</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: center">N/A</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,820</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">5/3/2027</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: center">N/A</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,320</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">12/25/2031</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: center">N/A</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">5/24/2032</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: center">N/A</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,730</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">8/16/2032</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: center">N/A</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employment
Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
April 22, 2022, we entered into employment agreements with Gary Atkinson to serve as our Chief Executive Officer and Bernardo Melo to
serve as our Chief Revenue Officer. The agreements are for a term of three years with automatic renewals for successive one-year terms,
unless either party provides notice of its intention not to extend. As compensation for their service as executives, the executives will
each receive: (i) a base salary per annum of $215,000 that automatically increases to $225,000 on the first anniversary of the effective
date; (ii) eligibility to earn an annual bonus; and (iii) eligibility to participate in our 2022 Equity Incentive Plan, or any successor
plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event the employment of the executives is terminated by us without &#8220;Cause&#8221; or by the executives for &#8220;Good Reason&#8221;
(as each such defined in the employment agreements), Messrs. Atkinson and Melo will receive severance in a lump sum payment equal to
two times the sum of the executive&#8217;s base salary and annual bonus for the year in which the termination occurs. The employment
agreements also provide for payments to the executive of certain amounts in the event of the executive&#8217;s death or disability (as
defined in the employment agreements).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Melo was terminated as our Chief Revenue Officer effective August 1, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
February 13, 2025, we entered into an employment agreement with Alex Andre to serve as our Chief Financial Officer and General Counsel.
Under the terms of the agreement, we agreed to pay Mr. Andre an annual base salary of $275,000 which automatically increases to $300,000
on the six-month anniversary of the effective date. Mr. Andre is eligible to receive an annual bonus of up to 30% of his annual base
salary. Mr. Andre received a non-qualified stock option to purchase 23,818 shares of our common stock and a restricted stock award for
23,818 shares of our common stock on February 13, 2025. The option has a ten-year term, subject to any earlier termination following
cessation of Mr. Andre&#8217;s service with us, and an exercise price per share equal to the closing price of our common stock as reported
by the Nasdaq on February 13, 2025. The restricted stock award and option shall each vest over four years as follows: (a) 25% of the
shares underlying the restricted stock award and option shall vest on the first anniversary of the grant date; and (b) six and one-quarter
percent (6.25%) of the shares underlying the restricted stock award and option shall vest each quarter thereafter, subject to Mr. Andre&#8217;s
continued service with us through each applicable vesting date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Executive
Bonus Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 22, 2022, our Board of Directors approved a bonus plan for our executive officers. Under the plan, our executive officers are eligible
to receive a cash bonus, stock options, and stock grants based on our earnings before interest, taxes, depreciation and amortization
(&#8220;EBITDA&#8221;) for the applicable fiscal year. The value of the cash bonus and number of shares of stock underlying stock options
and stock grants increases as the ratio of EBITDA to net sales increases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth all compensation earned or paid to our directors who served during all or a portion of the year ended December
31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: justify">Name</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Fees Earned or <br/>Paid in Cash ($)</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Awards ($) <sup>(1)</sup></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total ($)</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify">Harvey Judkowitz</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">27,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">10,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">37,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph Kling <sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Jay Foreman</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mathieu Peloquin <sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Gary Atkinson</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-0-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Bernardo Melo</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-0-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">James Turner <sup>(4)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kenneth Cragun <sup>(4)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Henry Nisser <sup>(4)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-0-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    the grant date fair value of the awards calculated in accordance with ASC Topic 718, <i>Compensation - Stock Compensation</i>. A
    summary of the assumptions made in the valuation of these awards is provided in our Form 10-K for the year ended December 31, 2024
    under <i>Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations - Critical Accounting
    Policies</i> and in our consolidated financial statements beginning on page F-1 of our Form 10-K for the year ended December 31,
    2024.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(2)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    August 21, 2025, Mr. Kling resigned from our board of directors.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(3)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    October 3, 2025, Mr. Peloquin resigned from our board of directors.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(4)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    September 5, 2024, Messrs. Turner, Cragun and Nisser resigned from our board of directors.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 57; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
compensate each non-employee member of our board of directors as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">An annual cash retainer of $25,000, payable in quarterly installments on the first day of each quarter in advance of service for such quarter.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">An annual grant of a restricted stock award with a
    value at the time of issuance of $25,000.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">An annual grant of a stock option with a value at the time of issuance of $25,000.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">An annual cash retainer of $5,000 for each committee
    of the board of directors upon which the board member serves, payable in quarterly installments on the first day of each quarter in advance
    of service for such quarter.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">An initial grant of a stock option with a value at
    the time of issuance of $25,000 for each individual who becomes a non-employee director due to either: (i) the initial appointment or
    election to the board of directors, or (ii) a change in status that the board of directors determines results in a previously ineligible
    director qualifying as a non-employee director.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">All expenses are reimbursed for attending board, committee and annual meetings or when their presence at a location away from home is requested.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>401(k)
Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
January 1, 2001, we adopted a voluntary 401(k) plan. All employees with at least 90 days of service are eligible to participate in our
401(k) plan. We make a matching contribution of 100% of the first three percent (3%) of salary deferral contributions, plus 50% of the
next two percent of salary deferral contributions, for each payroll period. The matching contributions that we make are vested in full
immediately.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clawback
Policy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board has adopted a clawback policy relating to recovery of erroneously awarded compensation that complies with the Nasdaq clawback rules
which were required by SEC Rule 10D-1. Under this policy, in the event that we are required to prepare an accounting restatement of our
financial statements due to material noncompliance with any financial reporting requirement under the securities laws, the policy requires
that the administrator of the policy, to the extent legally permitted and pursuant to the terms of the policy, recover from current and
former Section 16 officers any incentive-based compensation, as defined in Nasdaq&#8217;s clawback rules, received by such officers that
exceeds the amount of incentive-based compensation that otherwise would have been received had such incentive based compensation been
determined according to the applicable accounting restatement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Policies
and Practices related to the Grant of Certain Equity Awards Close in Time to the Release of Material Non-public Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eecd--AwardTmgMnpiDiscTextBlock_c20240101__20241231_gIFATMDTB-YRZR_zGVWpkbI7Rv8" class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" continuedAt="ConU000018-01" escape="true" id="Fact000018" name="ecd:AwardTmgMnpiDiscTextBlock">We
have a strict policy of not granting securities to our executive officers, directors and employees when material nonpublic information
is known or a material transaction is anticipated to occur.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><span id="xdx_C06_gIFATMDTB-YRZR_zVRmzbIPFXPh"><ix:continuation continuedAt="ConU000018-02" id="ConU000018-01">The
timing of equity award grants is determined with consideration to a variety of factors, including but not limited to, the achievement
of pre-established performance targets, market conditions and internal milestones. We do not follow a predetermined schedule for the
granting of equity awards. Instead, each grant is considered on a case-by-case basis to align with our strategic objectives and to ensure
the competitiveness of our compensation packages.</ix:continuation></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eecd--MnpiDiscTimedForCompValFlag_dbT_c20240101__20241231_zlHvw37MODH3" class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__"><span id="xdx_C0D_gIFATMDTB-YRZR_zOl3DiTkzna3"><ix:continuation continuedAt="ConU000018-03" id="ConU000018-02"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000019" name="ecd:MnpiDiscTimedForCompValFlag">In
determining the timing and terms of an equity award, our board of directors and compensation committee consider material nonpublic information
to ensure that such grants are made in compliance with applicable laws and regulations. Procedures utilized by our board of directors
and compensation committee to prevent the improper use of material nonpublic information in connection with the granting of equity awards
include consultation with legal counsel and, where appropriate, the delay of the grant of applicable equity awards until the public disclosure
of such material nonpublic information has been completed.</ix:nonNumeric></ix:continuation></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 58; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C0F_gIFATMDTB-YRZR_znyeer9XWQQb"><ix:continuation continuedAt="ConU000018-04" id="ConU000018-03">We
are committed to maintaining transparency in our executive compensation practices and to making equity awards in a manner that is not
influenced by the timing of the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation.
</ix:continuation></span><span id="xdx_907_eecd--AwardTmgPredtrmndFlag_dbT_c20240101__20241231_zKn7di2NGbNg" class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__"><span id="xdx_C07_gIFATMDTB-YRZR_zE7RQq3w8rOa"><ix:continuation continuedAt="ConU000018-05" id="ConU000018-04"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000020" name="ecd:AwardTmgPredtrmndFlag">We regularly review our policies and practices related to equity awards to ensure that they meet the evolving standards of corporate
governance and continue to serve the best interests of us and our stockholders.</ix:nonNumeric></ix:continuation></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C0A_gIFATMDTB-YRZR_zBPCmHSFONa4"><ix:continuation id="ConU000018-05">During
the year ended December 31, 2024, no securities were granted to our named executive officers within four business days prior to, or one
business day following, the filing or furnishing of a periodic or current report by us that disclosed material nonpublic information.</ix:continuation></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_013"></span>PAY
VERSUS PERFORMANCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pay
vs. Performance</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth compensation information for our chief executive officer, referred to below as our CEO, and our other named
executive officers, or NEOs, for purposes of comparing their compensation to the value of our stockholders&#8217; investments and our
net income, calculated in accordance with SEC regulations, for the fiscal year ended December 31, 2024, the nine-month transition period
ended December 31, 2023, and the fiscal year ended March 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000022" name="ecd:PvpTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_883_eecd--PvpTableTextBlock_zUsDuhRhy85i" summary="xdx: Disclosure - Pay vs Performance Disclosure" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_489_eecd--PeoTotalCompAmt_zBIf65RslFb8" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Table Total</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>for CEO<sup id="xdx_F5D_zk7ii5WVE66h">(1)</sup></b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_484_eecd--PeoActuallyPaidCompAmt_z0KreWFuPnD2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Actually Paid</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>to CEO<sup id="xdx_F50_zx18Z5M7zNWa">(2)</sup></b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_48D_eecd--NonPeoNeoAvgTotalCompAmt_znAsXmjRXPO5" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Table Total for</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-CEO</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NEOs<sup id="xdx_F5D_zwVKRKwGas94">(3)</sup></b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_482_eecd--NonPeoNeoAvgCompActuallyPaidAmt_zzFKE6TCmK8k" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Actually Paid</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>to Non-CEO</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NEOs<sup id="xdx_F5F_zJOjxwtVSeYa">(4)</sup></b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_489_eecd--TotalShareholderRtnAmt_pp2d_zil0wnoWVsXd" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value of Initial</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fixed $100</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Investment</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Based On Total</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stockholder</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Return<sup id="xdx_F5E_zh1gfUjTUPCg">(5)</sup></b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_483_eus-gaap--NetIncomeLoss_zSgSxvsvoz54" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net Income (Loss)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_41D_20240101__20241231_zWb4dlIERxO9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left">Fiscal Year 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="ecd:PeoTotalCompAmt" contextRef="From2024-01-01to2024-12-31" id="Fact000023" format="ixt:numdotdecimal" decimals="0" unitRef="USD">253,535</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="ecd:PeoActuallyPaidCompAmt" contextRef="From2024-01-01to2024-12-31" id="Fact000024" format="ixt:numdotdecimal" decimals="0" unitRef="USD">263,535</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="ecd:NonPeoNeoAvgTotalCompAmt" contextRef="From2024-01-01to2024-12-31" id="Fact000025" format="ixt:numdotdecimal" decimals="0" unitRef="USD">203,635</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" contextRef="From2024-01-01to2024-12-31" id="Fact000026" format="ixt:numdotdecimal" decimals="0" unitRef="USD">226,302</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="ecd:TotalShareholderRtnAmt" contextRef="From2024-01-01to2024-12-31" id="Fact000027" format="ixt:numdotdecimal" decimals="2" unitRef="USD">8.74</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000028" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">23,257,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_41E_20230401__20231231_zZUIqKYclAV7" style="vertical-align: bottom; background-color: White">
    <td>Nine-Month Transition Period Ended December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:PeoTotalCompAmt" contextRef="From2023-04-012023-12-31" id="Fact000029" format="ixt:numdotdecimal" decimals="0" unitRef="USD">169,527</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:PeoActuallyPaidCompAmt" contextRef="From2023-04-012023-12-31" id="Fact000030" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,069</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:NonPeoNeoAvgTotalCompAmt" contextRef="From2023-04-012023-12-31" id="Fact000031" format="ixt:numdotdecimal" decimals="0" unitRef="USD">244,954</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" contextRef="From2023-04-012023-12-31" id="Fact000032" format="ixt:numdotdecimal" decimals="0" unitRef="USD">256,856</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:TotalShareholderRtnAmt" contextRef="From2023-04-012023-12-31" id="Fact000033" format="ixt:numdotdecimal" decimals="2" unitRef="USD">63.52</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-12-31" id="Fact000034" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,398,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_41C_20220401__20230331_zImPDYC4LnJ6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fiscal Year 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:PeoTotalCompAmt" contextRef="From2022-04-012023-03-31" id="Fact000035" format="ixt:numdotdecimal" decimals="0" unitRef="USD">307,451</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:PeoActuallyPaidCompAmt" contextRef="From2022-04-012023-03-31" id="Fact000036" format="ixt:numdotdecimal" decimals="0" unitRef="USD">263,866</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:NonPeoNeoAvgTotalCompAmt" contextRef="From2022-04-012023-03-31" id="Fact000037" format="ixt:numdotdecimal" decimals="0" unitRef="USD">415,138</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" contextRef="From2022-04-012023-03-31" id="Fact000038" format="ixt:numdotdecimal" decimals="0" unitRef="USD">388,476</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:TotalShareholderRtnAmt" contextRef="From2022-04-012023-03-31" id="Fact000039" format="ixt:numdotdecimal" decimals="2" unitRef="USD">12.68</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012023-03-31" id="Fact000040" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,638,462</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_416_20210401__20220331_zzzI1Gog4olj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Fiscal Year 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:PeoTotalCompAmt" contextRef="From2021-04-012022-03-31" id="Fact000041" format="ixt:numdotdecimal" decimals="0" unitRef="USD">161,414</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ecd:PeoActuallyPaidCompAmt" contextRef="From2021-04-012022-03-31" id="Fact000042" format="ixt:numdotdecimal" decimals="0" unitRef="USD">161,414</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:NonPeoNeoAvgTotalCompAmt" contextRef="From2021-04-012022-03-31" id="Fact000043" format="ixt:numdotdecimal" decimals="0" unitRef="USD">245,935</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" contextRef="From2021-04-012022-03-31" id="Fact000044" format="ixt:numdotdecimal" decimals="0" unitRef="USD">243,829</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:TotalShareholderRtnAmt" contextRef="From2021-04-012022-03-31" id="Fact000045" format="ixt:numdotdecimal" decimals="2" unitRef="USD">34.15</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012022-03-31" id="Fact000046" format="ixt:numdotdecimal" decimals="0" unitRef="USD">230,471</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: top"><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F0C_zMovGUaQkHg5">(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F12_zHkDN5qfksxe" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000047" xml:lang="en-US">The
    dollar amounts reported are the amounts of total compensation reported for our CEO, Gary Atkinson, in the Summary Compensation Table
    for fiscal years 2024, 2023 and 2022.</ix:footnote></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F09_zidTni2N2pj9">(2)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1B_zaFljni342rh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000048" xml:lang="en-US">The
    dollar amounts reported represent the amount of &#8220;compensation actually paid&#8221;, as computed in accordance with SEC rules.
    The dollar amounts reported are the amounts of total compensation reported for Mr. Atkinson during the applicable year, but also
    include (i) the year-end value of equity awards granted during the reported year, (ii) the change in the value of equity awards that
    were unvested at the end of the prior year, measured through the date the awards vested, or through the end of the reported fiscal
    year, and (iii) value of equity awards issued and vested during the reported fiscal year. See table below for further information.</ix:footnote></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F08_zJkxwC51mnq2">(3)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1D_zr1JKAx7qVC2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000049" xml:lang="en-US">The
    dollar amounts reported are the average of the total compensation reported for our NEOs, other than our CEO, in the Summary Compensation
    Table for fiscal years 2024, 2023 and 2022.</ix:footnote></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F03_zpEVHufTKUL8">(4)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F19_z1k7vjCkPB67" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000050" xml:lang="en-US">The
    dollar amounts reported represent the average amount of &#8220;compensation actually paid&#8221;, as computed in accordance with
    SEC rules, for our NEOs, other than our CEO. The dollar amounts reported are the average of the total compensation reported for our
    NEOs, other than our CEO in the Summary Compensation Table for fiscal years 2024, 2023 and 2022, but also include: (i) the year-end
    value of equity awards granted during the reported year, (ii) the change in the value of equity awards that were unvested at the
    end of the prior year, measured through the date the awards vested, or through the end of the reported fiscal year, and (iii) value
    of equity awards issued and vested during the reported fiscal year.</ix:footnote></span></td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F0D_zGT4cV361kN7">(5)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1E_zChGfBkHiJs7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000051" xml:lang="en-US">Reflects
    the cumulative stockholder return over the relevant fiscal year, computed in accordance with SEC rules, assuming an investment of
    $100 in our common shares at a price per share equal to the closing price of our common stock on the last trading day before the
    commencement of the earliest applicable fiscal year (March 31, 2021) and the measurement end point of the closing price of our common
    stock on the last trading day in the applicable fiscal year. For 2024, the closing price of our common stock on January 2, 2024 was
    $206 and the closing price of our common stock on December 31, 2024 was $18. For 2023, the closing price of our common stock on March
    31, 2022 was $4.20 and the closing price of our common stock on March 31, 2023 was $1.56. For 2022, the closing price of our common
    stock on March 31, 2021 was $12.30 and the closing price of our common stock on March 31, 2022 was $4.20.</ix:footnote></span></td></tr>
</table>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000053" name="ecd:NamedExecutiveOfficersFnTextBlock"><p id="xdx_898_eecd--NamedExecutiveOfficersFnTextBlock_dU_zDhwZROFZW3f" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    dollar amounts reported are the amounts of total compensation reported for our CEO, <span id="xdx_905_eecd--PeoName_c20240101__20241231__ecd--IndividualAxis__ecd--PeoMember_zJgXVKI8rZWc"><span id="xdx_90C_eecd--PeoName_c20220401__20230331__ecd--IndividualAxis__ecd--PeoMember_zmhztkV0wr96"><span id="xdx_901_eecd--PeoName_c20210401__20220331__ecd--IndividualAxis__ecd--PeoMember_zbDxUKgI8e5b"><ix:nonNumeric contextRef="From2024-01-012024-12-31_ecd_PeoMember" id="Fact000054" name="ecd:PeoName"><ix:nonNumeric contextRef="From2022-04-012023-03-31_ecd_PeoMember" id="Fact000055" name="ecd:PeoName"><ix:nonNumeric contextRef="From2021-04-012022-03-31_ecd_PeoMember" id="Fact000056" name="ecd:PeoName">Gary Atkinson</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span></span></span>, in the Summary Compensation Table
    for fiscal years 2024, 2023 and 2022.</span></td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A4_z7yYPz8H6MJg" style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(2)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    dollar amounts reported represent the amount of &#8220;compensation actually paid&#8221;, as computed in accordance with SEC rules.
    The dollar amounts reported are the amounts of total compensation reported for Mr. Atkinson during the applicable year, but also
    include (i) the year-end value of equity awards granted during the reported year, (ii) the change in the value of equity awards that
    were unvested at the end of the prior year, measured through the date the awards vested, or through the end of the reported fiscal
    year, and (iii) value of equity awards issued and vested during the reported fiscal year. See table below for further information.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(3)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    dollar amounts reported are the average of the total compensation reported for our NEOs, other than our CEO, in the Summary Compensation
    Table for fiscal years 2024, 2023 and 2022.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(4)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    dollar amounts reported represent the average amount of &#8220;compensation actually paid&#8221;, as computed in accordance with
    SEC rules, for our NEOs, other than our CEO. The dollar amounts reported are the average of the total compensation reported for our
    NEOs, other than our CEO in the Summary Compensation Table for fiscal years 2024, 2023 and 2022, but also include: (i) the year-end
    value of equity awards granted during the reported year, (ii) the change in the value of equity awards that were unvested at the
    end of the prior year, measured through the date the awards vested, or through the end of the reported fiscal year, and (iii) value
    of equity awards issued and vested during the reported fiscal year.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 59; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(5)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reflects
    the cumulative stockholder return over the relevant fiscal year, computed in accordance with SEC rules, assuming an investment of
    $100 in our common shares at a price per share equal to the closing price of our common stock on the last trading day before the
    commencement of the earliest applicable fiscal year (March 31, 2021) and the measurement end point of the closing price of our common
    stock on the last trading day in the applicable fiscal year. For 2024, the closing price of our common stock on January 2, 2024 was
    $206 and the closing price of our common stock on December 31, 2024 was $18. For 2023, the closing price of our common stock on March
    31, 2022 was $4.20 and the closing price of our common stock on March 31, 2023 was $1.56. For 2022, the closing price of our common
    stock on March 31, 2021 was $12.30 and the closing price of our common stock on March 31, 2022 was $4.20.</span></td></tr>
  </table>
<p id="xdx_8A6_zWRkL647ZQjf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000058" name="ecd:AdjToPeoCompFnTextBlock"><p id="xdx_899_eecd--AdjToPeoCompFnTextBlock_dU_z7XrI8h8PtY5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
calculate the amounts in the &#8220;Compensation Actually Paid to CEO&#8221; column in the table above, the following amounts were deducted
from and added to (as applicable) our CEO&#8217;s &#8220;Total&#8221; compensation as reported in the Summary Compensation Table:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Name and Principal Position</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_489_eecd--PeoTotalCompAmt_z6ftMG61ELhh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Summary Compensation Table Total for CEO</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_48B_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--ReportedValueOfEquityAwardsMember__ecd--IndividualAxis__ecd--PeoMember_zpDLZ1q3Ahe9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reported Value of Equity Awards for CEO </b><sup id="xdx_F58_z5GhudMUb2c4">(1)</sup></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_485_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember__ecd--IndividualAxis__ecd--PeoMember_zyjxr8PkiVXa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value as of Year End for Unvested Awards Granted During the Year</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_483_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember__ecd--IndividualAxis__ecd--PeoMember_zzaOCI9CFNy6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Year over Year Increase or Decrease in Unvested Awards Granted in Prior Years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_48A_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--FairValueOfAwardsGrantedAndVestedDuringTheYearMember__ecd--IndividualAxis__ecd--PeoMember_zbT35384wgS2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value of Awards Granted and Vested During the Year</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_48C_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember__ecd--IndividualAxis__ecd--PeoMember_zjartK9fnHAd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Increase or Decrease from Prior Year end for Awards that Vested during the Year</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_484_eecd--PeoActuallyPaidCompAmt_z2tHWnQll1W3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Compensation Actually Paid to CEO</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_415_20240101__20241231_zFh1KuxefTh6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 10%; text-align: left">Gary Atkinson,</td><td style="width: 2%">&#160;</td>
    <td style="width: 10%; text-align: left">Fiscal Year 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="ecd:PeoTotalCompAmt" contextRef="From2024-01-01to2024-12-31" id="Fact000059" format="ixt:numdotdecimal" decimals="0" unitRef="USD">253,535</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2024-01-012024-12-31_custom_ReportedValueOfEquityAwardsMember_ecd_PeoMember" id="Fact000060" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0061">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0062">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2024-01-012024-12-31_custom_FairValueOfAwardsGrantedAndVestedDuringTheYearMember_ecd_PeoMember" id="Fact000063" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0064">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction name="ecd:PeoActuallyPaidCompAmt" contextRef="From2024-01-01to2024-12-31" id="Fact000065" format="ixt:numdotdecimal" decimals="0" unitRef="USD">263,535</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_41A_20230401__20231231_z2xi7otJujv9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; font-style: italic; text-align: left">Chief Executive Officer</td><td>&#160;</td>
    <td>Nine-Month Transition Period Ended December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:PeoTotalCompAmt" contextRef="From2023-04-012023-12-31" id="Fact000066" format="ixt:numdotdecimal" decimals="0" unitRef="USD">169,527</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0067">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0068">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0069">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2023-04-012023-12-31_custom_FairValueOfAwardsGrantedAndVestedDuringTheYearMember_ecd_PeoMember" id="Fact000070" format="ixt:numdotdecimal" decimals="0" unitRef="USD">112,042</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2023-04-012023-12-31_custom_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember_ecd_PeoMember" id="Fact000071" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">31,500</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:PeoActuallyPaidCompAmt" contextRef="From2023-04-012023-12-31" id="Fact000072" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,069</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_411_20220401__20230331_zyuhymbHCTTa" style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">Fiscal Year 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:PeoTotalCompAmt" contextRef="From2022-04-012023-03-31" id="Fact000073" format="ixt:numdotdecimal" decimals="0" unitRef="USD">307,451</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2022-04-012023-03-31_custom_ReportedValueOfEquityAwardsMember_ecd_PeoMember" id="Fact000074" format="ixt:numdotdecimal" decimals="0" unitRef="USD">58,586</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2022-04-012023-03-31_custom_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember_ecd_PeoMember" id="Fact000075" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,001</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0076">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0077">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0078">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:PeoActuallyPaidCompAmt" contextRef="From2022-04-012023-03-31" id="Fact000079" format="ixt:numdotdecimal" decimals="0" unitRef="USD">263,866</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_419_20210401__20220331_zlcySPRlT1S3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">Fiscal Year 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:PeoTotalCompAmt" contextRef="From2021-04-012022-03-31" id="Fact000080" format="ixt:numdotdecimal" decimals="0" unitRef="USD">161,414</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0081">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0082">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0083">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0084">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0085">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:PeoActuallyPaidCompAmt" contextRef="From2021-04-012022-03-31" id="Fact000086" format="ixt:numdotdecimal" decimals="0" unitRef="USD">161,414</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F09_zoSeDq1U4kTh">(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F13_z9dC7f98hoQ2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000087" xml:lang="en-US">Represents
    the grant date fair value of the equity awards to our CEO, as reported in the Summary Compensation Table</ix:footnote></span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A4_zrnQRfgI1oxf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 60; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000089" name="ecd:AdjToNonPeoNeoCompFnTextBlock"><p id="xdx_895_eecd--AdjToNonPeoNeoCompFnTextBlock_dU_zLkMaeF6HWvl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
calculate the amounts in the &#8220;Compensation Actually Paid to Non-CEO NEOs&#8221; column in the table above, the following amounts
were deducted from and added to (as applicable) the average &#8220;Total&#8221; compensation of our Non-CEO NEOs as reported in the Summary
Compensation Table.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Name and Principal Position</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Year</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_487_eecd--NonPeoNeoAvgTotalCompAmt_zgKjIfPvIfwl" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Summary Compensation Table Total for Non-CEO NEOs</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_48C_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--ReportedValueOfEquityAwardsMember_zFDnepSmXSd4" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><span style="font-size: 10pt"><b>&#160;Reported Value of Equity Awards for Non-CEO NEOs </b><sup id="xdx_F5B_zvOfZbFutHB4">(1)</sup></span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_488_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember_zEK7GtSVSqVe" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Fair Value as of Year End for Unvested Awards Granted During the Year</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_48A_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember_zkTQZqbfNKah" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Fair Value Year over Year Increase or Decrease in Unvested Awards Granted in Prior Years</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_489_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--FairValueOfAwardsGrantedAndVestedDuringTheYearMember_zGuV0c7slFCl" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Fair Value of Awards Granted and Vested During the Year</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_48D_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember_zseSQAfbrjp7" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Fair Value Increase or Decrease from Prior Year end for Awards that Vested during the Year</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_48B_eecd--NonPeoNeoAvgCompActuallyPaidAmt_zWtQLp3tmOja" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><span style="font-size: 10pt"><b>Compensation Actually Paid to Non-CEO NEOs </b><sup id="xdx_F5C_z4Lqt064fnfk">(2)</sup></span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_41C_20240101__20241231__ecd--IndividualAxis__custom--RichardPerezMember_z1s30Q2gFcSh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 9%; text-align: left">Richard Perez, <i>Former Chief Financial Officer</i><br/></td><td style="width: 2%">&#160;</td>
    <td style="width: 10%; text-align: left">Fiscal Year 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="ecd:NonPeoNeoAvgTotalCompAmt" contextRef="From2024-01-012024-12-31_custom_RichardPerezMember" id="Fact000090" format="ixt:numdotdecimal" decimals="0" unitRef="USD">174,596</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0091">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0092">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0093">-</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0094">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0095">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" contextRef="From2024-01-012024-12-31_custom_RichardPerezMember" id="Fact000096" format="ixt:numdotdecimal" decimals="0" unitRef="USD">174,596</ix:nonFraction></td><td style="width: 2%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 12pt">&#160;</td><td style="font-size: 12pt">&#160;</td>
    <td style="font-size: 12pt">&#160;</td><td style="font-size: 12pt">&#160;</td>
    <td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt; text-align: right">&#160;</td><td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt">&#160;</td>
    <td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt; text-align: right">&#160;</td><td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt">&#160;</td>
    <td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt; text-align: right">&#160;</td><td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt">&#160;</td>
    <td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt; text-align: right">&#160;</td><td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt">&#160;</td>
    <td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt; text-align: right">&#160;</td><td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt">&#160;</td>
    <td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt; text-align: right">&#160;</td><td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt">&#160;</td>
    <td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt; text-align: right">&#160;</td><td style="font-size: 12pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_416_20230401__20231231__ecd--IndividualAxis__custom--LionelMarquisMember_zyq7VHgn7QR8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lionel Marquis,<i> Former</i><i> Chief Financial Officer</i></td><td>&#160;</td>
    <td>Nine-Month Transition Period Ended December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:NonPeoNeoAvgTotalCompAmt" contextRef="From2023-04-012023-12-31_custom_LionelMarquisMember" id="Fact000097" format="ixt:numdotdecimal" decimals="0" unitRef="USD">268,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0098">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0099">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0100">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2023-04-012023-12-31_custom_LionelMarquisMember_custom_FairValueOfAwardsGrantedAndVestedDuringTheYearMember" id="Fact000101" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,650</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2023-04-012023-12-31_custom_LionelMarquisMember_custom_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember" id="Fact000102" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">20,998</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" contextRef="From2023-04-012023-12-31_custom_LionelMarquisMember" id="Fact000103" format="ixt:numdotdecimal" decimals="0" unitRef="USD">295,652</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_416_20220401__20230331__ecd--IndividualAxis__custom--LionelMarquisMember_zI1BuFToe6m4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">Fiscal Year 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:NonPeoNeoAvgTotalCompAmt" contextRef="From2022-04-012023-03-31_custom_LionelMarquisMember" id="Fact000104" format="ixt:numdotdecimal" decimals="0" unitRef="USD">468,224</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2022-04-012023-03-31_custom_LionelMarquisMember_custom_ReportedValueOfEquityAwardsMember" id="Fact000105" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,419</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2022-04-012023-03-31_custom_LionelMarquisMember_custom_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember" id="Fact000106" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,400</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0107">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0108">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0109">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" contextRef="From2022-04-012023-03-31_custom_LionelMarquisMember" id="Fact000110" format="ixt:numdotdecimal" decimals="0" unitRef="USD">450,205</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_414_20210401__20220331__ecd--IndividualAxis__custom--LionelMarquisMember_zRPYcDTnPfU8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">Fiscal Year 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:NonPeoNeoAvgTotalCompAmt" contextRef="From2021-04-012022-03-31_custom_LionelMarquisMember" id="Fact000111" format="ixt:numdotdecimal" decimals="0" unitRef="USD">160,638</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0112">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0113">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0114">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0115">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0116">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" contextRef="From2021-04-012022-03-31_custom_LionelMarquisMember" id="Fact000117" format="ixt:numdotdecimal" decimals="0" unitRef="USD">160,638</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_411_20240101__20241231__ecd--IndividualAxis__custom--BernardoMeloMember_zzSHsKDAvDck" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><p style="margin-top: 0; margin-bottom: 0">Bernardo Melo,</p>
                                 <p style="margin-top: 0; margin-bottom: 0"><i>Former</i><i> Chief Revenue Officer</i></p></td><td>&#160;</td>
    <td style="text-align: left">Fiscal Year 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:NonPeoNeoAvgTotalCompAmt" contextRef="From2024-01-012024-12-31_custom_BernardoMeloMember" id="Fact000118" format="ixt:numdotdecimal" decimals="0" unitRef="USD">283,454</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2024-01-012024-12-31_custom_BernardoMeloMember_custom_ReportedValueOfEquityAwardsMember" id="Fact000119" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0120">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0121">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2024-01-012024-12-31_custom_BernardoMeloMember_custom_FairValueOfAwardsGrantedAndVestedDuringTheYearMember" id="Fact000122" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0123">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" contextRef="From2024-01-012024-12-31_custom_BernardoMeloMember" id="Fact000124" format="ixt:numdotdecimal" decimals="0" unitRef="USD">293,454</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_416_20230401__20231231__ecd--IndividualAxis__custom--BernardoMeloMember_zOEkwtgXDn79" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 12pt">&#160;</td><td>&#160;</td>
    <td>Nine Months Ended December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:NonPeoNeoAvgTotalCompAmt" contextRef="From2023-04-012023-12-31_custom_BernardoMeloMember" id="Fact000125" format="ixt:numdotdecimal" decimals="0" unitRef="USD">221,908</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0126">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0127">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0128">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2023-04-012023-12-31_custom_BernardoMeloMember_custom_FairValueOfAwardsGrantedAndVestedDuringTheYearMember" id="Fact000129" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,650</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2023-04-012023-12-31_custom_BernardoMeloMember_custom_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember" id="Fact000130" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">52,498</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" contextRef="From2023-04-012023-12-31_custom_BernardoMeloMember" id="Fact000131" format="ixt:numdotdecimal" decimals="0" unitRef="USD">218,060</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_412_20220401__20230331__ecd--IndividualAxis__custom--BernardoMeloMember_zpLDL6KFLgIg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">Fiscal Year 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:NonPeoNeoAvgTotalCompAmt" contextRef="From2022-04-012023-03-31_custom_BernardoMeloMember" id="Fact000132" format="ixt:numdotdecimal" decimals="0" unitRef="USD">362,051</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2022-04-012023-03-31_custom_BernardoMeloMember_custom_ReportedValueOfEquityAwardsMember" id="Fact000133" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,419</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2022-04-012023-03-31_custom_BernardoMeloMember_custom_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember" id="Fact000134" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,680</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0135">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0136">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2022-04-012023-03-31_custom_BernardoMeloMember_custom_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember" id="Fact000137" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,434</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-size: 10pt"> <ix:nonFraction name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" contextRef="From2022-04-012023-03-31_custom_BernardoMeloMember" id="Fact000138" format="ixt:numdotdecimal" decimals="0" unitRef="USD">326,746</ix:nonFraction> </span></td><td style="text-align: left">&#160;<sup>(2)</sup></td></tr>
  <tr id="xdx_413_20210401__20220331__ecd--IndividualAxis__custom--BernardoMeloMember_zyxJ6VUKUM3j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">Fiscal Year 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:NonPeoNeoAvgTotalCompAmt" contextRef="From2021-04-012022-03-31_custom_BernardoMeloMember" id="Fact000139" format="ixt:numdotdecimal" decimals="0" unitRef="USD">331,232</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2021-04-012022-03-31_custom_BernardoMeloMember_custom_ReportedValueOfEquityAwardsMember" id="Fact000140" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,114</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2021-04-012022-03-31_custom_BernardoMeloMember_custom_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember" id="Fact000141" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,901</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0142">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0143">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0144">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-size: 10pt"> <ix:nonFraction name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" contextRef="From2021-04-012022-03-31_custom_BernardoMeloMember" id="Fact000145" format="ixt:numdotdecimal" decimals="0" unitRef="USD">327,019</ix:nonFraction> </span></td><td style="text-align: left">&#160;<sup>(2)</sup></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F0B_zWYV66QsWZq4">(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1E_zfV7QgQNhAUb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000146" xml:lang="en-US">Represents
    the grant date fair value of the equity awards to our Non-CEO NEOs, as reported in the Summary Compensation Table.</ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F0C_zzRQ9wBBVnAb">(2)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1C_zUyU6jVnJLyl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000147" xml:lang="en-US">Compensation
    actually paid to Bernardo Melo for 2023 and 2022 includes adjustments for accrued bonuses of $7,816 and $4,652, respectively, that
    was reported as compensation but not paid.</ix:footnote></span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A4_z1DRO1UJPiv6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 61; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Relationship
Between Pay and Performance</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
&#8220;total stockholder return,&#8221; as set forth in the above table, decreased by 91.26% during the year ended December 31, 2024,
reducing the value of a $100 investment to just $8.74. This decline follows a prior decrease of 36.48% during the nine-month period ended
December 31, 2023. Over the same period in 2024, &#8220;compensation actually paid&#8221; to our CEO increased slightly from $250,069
in 2023 to $263,535 in 2024, primarily reflecting the value of immediately vested equity grants made under our equity incentive plan.
Average &#8220;compensation actually paid&#8221; to our non-CEO named executive officers decreased from $256,856 in 2023 to $226,302
in 2024. Meanwhile, our net loss attributable to common stockholders increased substantially from $(6,398,000) million in 2023 to $(23,257,000)
million in 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_014"></span>SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table and the notes thereto set forth, as of the Record Date, certain information with respect to the beneficial ownership
of: (i) each of our named executive officers, (ii) each of our directors, (iii) each of our named executive officers and directors as
a group, and (iv) each person or group that is known to us to be the beneficial owner of more than five percent of our common stock.
This table is based upon information supplied by our officers, directors and principal stockholders and Schedules 13D and 13G filed with
the SEC. Where information regarding stockholders is based on Schedules 13D and 13G, the number of shares owned is as of the date for
which information was provided in such schedules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
beneficial owners and number of securities beneficially owned have been determined in accordance with Rule 13d-3 under the Exchange Act
and, in accordance therewith, includes all shares of our common stock that may be acquired by such beneficial owners within 60 days of
the Record Date upon the exercise or conversion of any options, warrants or other convertible securities. Unless otherwise indicated
and subject to community property laws where applicable, we believe that each person or entity named below has sole voting and investment
power with respect to the shares of common stock indicated as beneficially owned by that person or entity, subject to the matters set
forth in the footnotes to the table below, and has an address of c/o Algorhythm Holdings, Inc., 6301 NW 5<sup>th</sup> Way, Suite 2900,
Fort Lauderdale, FL 33309.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Name of Beneficial Owner</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount and Nature of Beneficial Ownership <sup>(1)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percentage of<br/> Beneficial</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ownership </b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary Atkinson, <i>Chief Executive Officer and Chairman of the Board</i> <sup>(2)</sup></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">160</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alex Andre, <i>Chief Financial Officer and General Counsel </i><sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,818</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bernardo Melo, <i>Director</i> <sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">219</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harvey Judkowitz, <i>Director</i> <sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">103</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jay Foreman, <i>Director</i> <sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">337</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ajesh Kapoor, <i>Director</i></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-0-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Scott Thorn, <i>Director</i></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-0-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Kapil Gupta, <i>Director</i></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-0-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">All executive officers and directors as a group (7 persons)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,732</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">__________________________</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Represents less than 1%</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
table has been prepared based on 2,641,778 shares of our common stock outstanding on the Record Date.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"/></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(2)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    as to the person indicated, the following outstanding stock options to purchase shares of our common stock issued under 2022 Plan
    and other stock option awards, which will be vested and exercisable within 60 days of the Record Date: (i) 101 shares of common stock
    underlying stock options held by Gary Atkinson, (ii) 118 shares of common stock underlying stock options held by Bernardo Melo, (iii)
    29 shares of common stock underlying stock options held by Harvey Judkowitz, and (iv) 83 shares of common stock underlying stock
    options held by Jay Foreman.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(3)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    a restricted stock award for 23,818 shares of common stock for which Mr. Andre holds the voting rights.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 62; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="a_015"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">CERTAIN
RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">A
transaction may be a related person transaction if any of our directors, executive officers, owners of more than five percent of our
common stock, or their immediate family were involved in a transaction in which we were or are to be a participant, and the amount involved
exceeds the lesser of $120,000 or one percent of the average of our total assets at the end of our last two completed fiscal years. We
engaged in the following related persons transactions since the beginning of our last fiscal year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Regalia
Ventures Stock Transactions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
November 20, 2023, we entered into a stock purchase agreement with Regalia Ventures pursuant to which we sold 5,495 shares of our common
stock to Regalia Ventures at a purchase price of $182 per share. Net proceeds from the transaction were approximately $950,000, net of
transaction fees of approximately $50,000. On November 1, 2024, we entered into a stock repurchase agreement with Regalia Ventures pursuant
to which we agreed to repurchase the 5,495 shares for $472,527. On February 18, 2025, the date of the closing of the transaction, we
issued a promissory note to Stingray Group in the amount of $472,527. On February 27, 2025, we paid off the note in full. Regalia Ventures
is owned and controlled by Jay B. Foreman, who serves as a member of our board of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Stingray
Group Stock Transactions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
November 20, 2023, we entered into a stock purchase agreement with Stingray Group pursuant to which we sold 5,495 shares of our common
stock to Stingray Group at a purchase price of $182 per share. Net proceeds from the transaction were approximately $950,000, net of
transaction fees of approximately $50,000. On December 3, 2024, we entered into a stock repurchase agreement with Stingray Group pursuant
to which we agreed to repurchase the 5,495 shares for $285,714. We agreed to issue a promissory note to Stingray Group in the principal
amount of the purchase price of the shares at the closing of the transaction. On February 18, 2025, the date of the closing of the transaction,
we issued a promissory note to Stingray Group in the amount of $285,714. On April 3, 2025, we paid off the note in full. Mathieu Peloquin
is the Senior Vice-President, Marketing and Communications of Stingray Group and served as a member of our board of directors until October
3, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Stingray
Holdings Music Subscription Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
have a music subscription sharing agreement with Stingray Group. For the year ended December 31, 2024 and the nine-month transition period
ended December 31, 2023, we received music subscription revenue of 780,000 and $602,000, respectively. As of December 31, 2024 and 2023,
we had $212,000 and $269,000, respectively, due from Stingray Group for music subscription reimbursement. Mathieu Peloquin is the Senior
Vice-President, Marketing and Communications of Stingray Group and served as a member of our board of directors until October 3, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SMCB</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>VIE
Analysis</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
determined that SMCB, which is a subsidiary of SemiCab, Inc., is a VIE as we provide financial support to SMCB. While not contractually
obligated, SMCB currently relies on our reimbursement of certain costs under a intercompany services agreement (&#8220;MSA&#8221;) whereby
SMCB agrees to provide IT software development services to SemiCab, Inc. US operations. In exchange, under the MSA, we grant intellectual
property rights to SMCB to use the software platform in India. Compensation for services is invoiced and paid on a monthly or quarterly
basis as agreed by both parties, with rates subject to periodic review and revision. The agreement is for a term of two years ending
on April 1, 2025 and automatically renews for additional 12-month periods unless prior notice is given by the terminating party. The
agreement automatically renewed for an additional 12-month period on April 1, 2025. As a result of this relationship and the financial
support provided by us under the loan agreement described below, SMCB has been determined to be a VIE prior to May 2, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 63; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
further determined that we are not the primary beneficiary of SMCB because we do not have the power to direct or control SMCB&#8217;s
significant activities related to its business. Accordingly, we have not consolidated SMCB&#8217;s results of operations and financial
position in our consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the asset purchase agreement that we entered into on June 11, 2024, we entered into an option agreement that granted
SemiCab Holdings the right to acquire all of the issued and outstanding equity securities of SMCB for 1,605 shares of our common stock.
We did not exercise this right and the option agreement expired on August 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Loan
Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a party to a loan agreement with SMCB dated March 22, 2024. Under the loan agreement, we agreed to loan up to $2,500,000 to SMCB.
The loans are anticipated to be made in tranches. Disbursements of any tranches are fully at our discretion. Each tranche has a repayment
period of five years. The loans can be repaid at any time prior to the five- year maturity date without penalty. Interest on the loans
accrues at a rate of six percent per year and is payable quarterly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2024, a total of $1,140,000 was outstanding under the loan agreement. During the period beginning January 1, 2025 and ending
May 2, 2025, the date we acquired 99.99% of the equity shares of SMCB, we made advances to SMCB in the amount of $1,172,000. During the
same period, SMCB charged $304,000 for services to us that were performed under the MSA, which charges offset amounts due under the loan
with SMCB. As a result, as of May 2, 2025, a total of $2,008,000 of loans were outstanding under the loan agreement, and a total of $492,000
remained available for future borrowings under the loan agreement as of May 2, 2025. As of May 2, 2025, SMCB had not made any interest
payments due under the loan agreement. As a result, the loans were in default as of May 2, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 2, 2025, the loan payable of $2,008,000 of SMCB and our loan receivable of $2,008,000 were eliminated in consolidation. As a result,
no such loans payable and loans receivable were outstanding on our condensed consolidated balance sheet at June 30, 2025. Also on May
2, 2025, revenue generated by SMCB for services performed by SMCB under the MSA of $304,000, and expenses for us for services performed
by SMCB under the MSA of $304,000, during the period commencing January 1, 2025 and ending May 2, 2025 were eliminated in consolidation
on May 2, 2025. As a result, no such revenue and expenses were reflected on our condensed consolidated statements of operations for the
three and six months ended June 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sale
of Singing Machine to Stingray USA</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 1, 2025, we entered into an asset purchase agreement with Stingray USA, a related party and subsidiary of the Stingray Group,
pursuant to which Stingray USA purchased substantially all of the assets, and assumed most of the liabilities, associated with our Singing
Machine business for $500,000. The transaction closed on August 1, 2025. <span style="background-color: white">Mathieu Peloquin is the
Senior Vice-President, Marketing and Communications of Stingray Group and served as a member of our board of directors until October
3, 2025</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Review,
Approval or Ratification of Transactions With Related Persons</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the terms of all of our transactions with related parties are commercially reasonable and no less favorable to us than we
could have obtained from an unaffiliated third party. Our audit committee is charged with the responsibility to review, approve and oversee
any transaction between us and any related parties and to develop policies and procedures for the audit committee&#8217;s approval of
related-party transactions. While we do not maintain a formal written policy with respect to related-party transactions, our audit committee
and Board routinely review potential transactions that we have identified as related parties prior to the consummation of the transaction
to ensure that the transaction is commercially reasonable and reflects market terms. Each transaction is reviewed to determine that a
related party transaction is entered into by us with the related party pursuant to normal competitive negotiation and on terms no more
favorable than with an unrelated third party. We also generally require, unless prohibited by law, that all related parties recuse themselves
from negotiating and voting on behalf of us in connection with proposed transactions to which they would be a party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 64; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_016"></span><b>ANNUAL
REPORT ON FORM 10-K</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Annual Report on Form 10-K for our fiscal year ended December 31, 2024 is enclosed with this Proxy Statement. Copies of our proxy materials,
including this Proxy Statement and the Annual Report, are available online at <span style="text-decoration: underline">www.proxyvote.com</span>. The Annual Report, however, is
not part of this proxy solicitation material.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
person who was our stockholder on the Record Date (including any beneficial owner of shares) may request a copy of the Annual Report,
and it will be furnished without charge upon receipt of a written request. Requests should be directed to Algorhythm Holdings, Inc.,
6301 NW 5<sup>th</sup> Way, Suite 2900, Fort Lauderdale, FL 33309, Attention: Investor Relations, or by calling Investor Relations at
(954) 596-1000. In addition, copies of this Proxy Statement, the Annual Report, and all other documents filed electronically by us may
be reviewed on the SEC&#8217;s website at: <span style="text-decoration: underline">http://www.sec.gov</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_017"></span>OTHER
BUSINESS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this Proxy Statement, we are not aware of any other business to be considered or acted upon at the Annual Meeting. In
the event any other matters are properly presented at the Annual Meeting, or any postponement or adjournment thereof, the person named
as proxy will vote in accordance with his discretion with respect to those matters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
    Order of the Board of Directors,</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">__________________________________</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary
                                            Atkinson</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    of the Board of Directors</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fort
    Lauderdale, Florida</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    [&#160;&#160;], 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 65; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_018"></span><span style="text-decoration: underline">APPENDIX
A</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CERTIFICATE
OF AMENDMENT TO THE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CERTIFICATE
OF INCORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OF</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ALGORHYTHM
HOLDINGS, INC.,</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>a
Delaware Corporation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Algorhythm
Holdings, Inc. (the &#8220;<b>Corporation</b>&#8221;), a corporation organized and existing under the General Corporation Law of the
State of Delaware, hereby certifies as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">FIRST</span>:
That the undersigned is the duly elected and acting Chief Executive Officer of the Corporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">SECOND</span>:
That, pursuant to Section 242 of the Delaware General Corporation Law (the <b>&#8220;DGCL&#8221;),</b> the first paragraph of Article
Fourth of the Certificate of Incorporation of the Corporation is hereby amended to read in its entirety as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#8220;FOURTH:
</b>The total number of shares of all classes of capital stock that the Corporation is authorized to issue is 801,000,000 shares, consisting
of: (i) 800,000,000 shares of common stock, par value $0.01 per share (the &#8220;<b>Common Stock</b>&#8221;), and (ii) 1,000,000 shares
of preferred stock, par value $1.00 per share (the &#8220;<b>Preferred Stock</b>&#8221;).&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the filing and effectiveness (the &#8220;Effective Time&#8221;) of this Certificate of Amendment to the Certificate of Incorporation
of the Corporation pursuant to the General Corporation Law of the State of Delaware, each [&#160;&#160;] (__) shares of Common Stock either issued
and outstanding or held by the Corporation in treasury stock immediately prior to the Effective Time shall, automatically and without
any action on the part of the respective holders thereof, be combined and converted into one (1) share of Common Stock (the &#8220;<b>Reverse
Stock Split</b>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
fractional shares shall be issued in connection with the Reverse Stock Split. Instead, holders who would be entitled to receive fractional
shares of Common Stock because they hold a number of shares not evenly divisible by the Reverse Stock Split ratio will be issued an additional
fraction of a share of Common Stock to round up to the next whole post-Reverse Stock Split share of Common Stock. Cash will not be paid
in lieu of fractional shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">THIRD</span>:
That the foregoing Certificate of Amendment of the Certificate of Incorporation of the Corporation has been duly adopted and approved
by the Board of Directors and stockholders of the Corporation in accordance with the applicable provisions of Sections 228 and 242 of
the Delaware General Corporation Law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the undersigned hereby further declares and certifies under penalty of perjury that the facts set forth in the foregoing
certificate are true and correct to the knowledge of the undersigned, and that this certificate is the act and deed of the undersigned.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executed
on this [&#160;&#160;]<sup>th</sup> day of [&#160;&#160;], 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary
    Atkinson</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 66; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_019"></span><b><span style="text-decoration: underline">APPENDIX
B</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RESOLUTIONS
OF</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THE
BOARD OF DIRECTORS OF</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ALGORHYTHM
HOLDINGS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Resolutions
Related to Nevada Reincorporation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REINCORPORATION
OF THE COMPANY TO THE STATE OF NEVADA BY CONVERSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>WHEREAS</b>,
as part of its ongoing oversight, direction and management of the business of Algorhythm Holdings, Inc., a Delaware corporation (the
&#8220;<b><i>Company</i></b>&#8221;), the Board of Directors (the &#8220;<b><i>Board</i></b>&#8221;) of the Company has studied and evaluated,
as well as discussed with management and the Board&#8217;s advisors, the relevant information and considerations with respect to a potential
reincorporation of the Company; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>WHEREAS</b>,
following its evaluation of a potential reincorporation of the Company, the Board has determined that approving and effecting a reincorporation
of the Company from the State of Delaware to the State of Nevada by the conversion of the Company from a corporation organized under
the laws of the State of Delaware to a corporation organized under the laws of the State of Nevada, pursuant to and in accordance with
Section 266 of the General Corporation Law of the State of Delaware, as amended (the &#8220;<b><i>DGCL</i></b>&#8221;), Sections 92A.195
and 92A.205 of the Nevada Revised Statutes, as amended (the &#8220;<b><i>NRS</i></b>&#8221;), and the proposed Plan of Conversion (the
&#8220;<b><i>Plan of Conversion</i></b>&#8221;), in substantially the form attached hereto as <span style="text-decoration: underline">Exhibit A</span> (such conversion, the
&#8220;<b><i>Nevada Reincorporation</i></b>&#8221;) and approving and adopting the Plan of Conversion and the proposed Nevada articles
of incorporation (the &#8220;<b><i>Nevada Charter</i></b>&#8221;) and the proposed Nevada bylaws (the &#8220;<b><i>Nevada Bylaws</i></b>&#8221;
and, together with the Nevada Charter, the &#8220;<b><i>Nevada Governing Documents</i></b>&#8221;), substantially in the forms attached
hereto as <span style="text-decoration: underline">Exhibit B</span> and <span style="text-decoration: underline">Exhibit C</span>, respectively, are in the best interests of the Company and its stockholders; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>WHEREAS</b>,
pursuant to the terms of the Plan of Conversion, upon the Nevada Reincorporation, the Company will cease to be governed by the laws of
the State of Delaware and its existing amended certificate of incorporation and amended bylaws and will become a corporation governed
by the laws of the State of Nevada (the &#8220;<b><i>Converted Corporation</i></b>&#8221;) and the Nevada Governing Documents; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>WHEREAS</b>,
upon receipt of stockholder approval of the Nevada Reincorporation (including the Plan of Conversion and the Nevada Governing Documents)
and these resolutions approving the Nevada Reincorporation at the 2025 Annual Meeting of Stockholders (the &#8220;<b><i>Annual Meeting</i></b>&#8221;),
and subject to the Board&#8217;s sole discretion (including any duly authorized committee thereof) to move forward with or abandon the
Nevada Reincorporation, as set forth below, the Nevada Reincorporation will become effective at the date and time (the &#8220;<b><i>Effective
Time</i></b>&#8221;) that is the later of the filing of, or at such later stated effective date and time specified in, each of (i) the
articles of conversion meeting the requirements of Section 92A.205 of the NRS (the &#8220;<b><i>Articles of Conversion</i></b>&#8221;)
to be properly executed and filed in accordance with such section and (ii) a certificate of conversion meeting the requirements of Section
266 of the DGCL (the &#8220;<b><i>Certificate of Conversion</i></b>&#8221;) to be properly executed and filed in accordance with such
section; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>WHEREAS</b>,
at the Effective Time, each share of the Company&#8217;s common stock, par value $0.01 per share, issued and outstanding or held in treasury
immediately prior to the Effective Time will be automatically converted into one share of the common stock, par value $0.01 per share,
of the Converted Corporation; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 67; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>WHEREAS</b>,
at the Effective Time, any warrant, option, restricted stock unit, equity or equity-based award, or other right to acquire any shares
of, or of any instrument to convert into or based on the value of, the common stock of the Company or other equity security of the Company,
whether vested or unvested, which is outstanding immediately prior to the Effective Time (each, a &#8220;<b><i>Convertible Security</i></b>&#8221;),
shall from and after the Effective Time, constitute a warrant, option, restricted stock unit, equity or equity-based award or other right
to acquire any shares of, or of any instrument to convert into or based on the value of, the same amount of the common stock of the Converted
Corporation or other equity securities of the Converted Corporation, respectively, and, if applicable, with the same exercise or purchase
price per share, and shall, to the extent permitted by law and otherwise reasonably practicable, have the same term, exercisability,
vesting schedule, status and all other terms and conditions of the applicable Convertible Security immediately prior to the Effective
Time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOW,
THEREFORE, BE IT RESOLVED</b>, that, after due consideration, the Board hereby determines that the Nevada Reincorporation, the Plan of
Conversion and the Nevada Governing Documents are in the best interests of the Company and its stockholders and approves and adopts the
Nevada Reincorporation, the Plan of Conversion and the Nevada Governing Documents; and be it</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RESOLVED
FURTHER</b>, that the form, terms, provisions, and conditions of the Plan of Conversion be, and the same hereby are, in all respects
approved and adopted; and be it</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RESOLVED
FURTHER</b>, that the Board hereby directs that the Nevada Reincorporation (including the Plan of Conversion and the Nevada Governing
Documents) and these resolutions approving the Nevada Reincorporation be submitted for approval and adoption, respectively, by the stockholders
of the Company at the Annual Meeting; and be it</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RESOLVED
FURTHER</b>, that the Board hereby recommends a vote &#8220;FOR&#8221; the Nevada Reincorporation proposal, including, without limitation,
the Nevada Reincorporation (including the Plan of Conversion and the Nevada Governing Documents), and that the Company&#8217;s stockholders
approve the Nevada Reincorporation (including the Plan of Conversion and the Nevada Governing Documents) and adopt these resolutions
at the Annual Meeting; and be it</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RESOLVED
FURTHER</b>, that upon receipt of stockholder approval of the Nevada Reincorporation (including the Plan of Conversion and the Nevada
Governing Documents) and the adoption of these resolutions, the Chief Executive Officer, Chief Financial Officer, General Counsel and
Secretary of the Company and any other officer authorized by such officers (individually, an &#8220;<b><i>Authorized Officer</i></b>&#8221;
and, collectively, the &#8220;<b><i>Authorized Officers</i></b>&#8221;) be, and each of them hereby is, subject to the Board&#8217;s
sole discretion (including any duly authorized committee thereof) to move forward with or abandon the Nevada Reincorporation, as set
forth below, authorized, empowered and directed, in the name and on behalf of the Company and without further action by the Board, to
prepare, execute, file and deliver all agreements, documents, notices, certificates, consents, approvals or other instruments and take
all such actions that such Authorized Officer deems necessary, desirable or appropriate in order to perform the Company&#8217;s obligations
under the Plan of Conversion and to consummate the Nevada Reincorporation, including, without limitation, (a) the execution and filing
of the Certificate of Conversion, (b) the execution and filing of the Articles of Conversion (including the Nevada Charter); (c) the
filing of the annual franchise tax reports required by the Secretary of State of the State of Delaware and the payment of the applicable
franchise taxes; (d) the payment of any fees that may be necessary in connection with the Nevada Reincorporation; (e) the submission
of all required notifications to the Nasdaq Stock Market LLC or any other applicable stock exchange; and (f) the filing of Current Reports
on Form 8-K and any other regulatory filings that may be necessary, desirable or appropriate in connection with the Nevada Reincorporation;
and be it</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RESOLVED
FURTHER</b>, that, notwithstanding approval by the stockholders of the Company of the Nevada Reincorporation (including the Plan of Conversion
and the Nevada Governing Documents) and the adoption of these resolutions, the Board or any duly authorized committee thereof may, at
any time prior to the Effective Time, abandon the Nevada Reincorporation and the Plan of Conversion without further action by the stockholders
of the Company; and be it</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RESOLVED
FURTHER</b>, that pursuant to the Plan of Conversion, at the Effective Time, any outstanding electronic, uncertificated entries (&#8220;<b><i>Book
Entry</i></b>&#8221;) that immediately prior to the Effective Time represented issued and outstanding shares of common stock of the Company
shall be deemed for all purposes to evidence ownership of and to represent shares of common stock, as applicable, of the Converted Corporation;
and be it</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RESOLVED
FURTHER</b>, that, contingent upon and effective as of the consummation of the Nevada Reincorporation, all shares of common stock of
the Converted Corporation shall be Book Entry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>


<!-- Field: Page; Sequence: 68; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_020"></span><span style="text-decoration: underline">APPENDIX
C</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PLAN
OF CONVERSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OF</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ALGORHYTHM
HOLDINGS, INC.,</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A
DELAWARE CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INTO</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ALGORHYTHM
HOLDINGS, INC.,</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A
NEVADA CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THIS
PLAN OF CONVERSION</b>, dated as of [&#9679;], 2025 (including all of the Exhibits attached hereto, this &#8220;Plan&#8221;), is hereby
adopted by Algorhythm Holdings, Inc., a Delaware corporation, in order to set forth the terms, conditions and procedures governing the
conversion of Algorhythm Holdings, Inc. from a Delaware corporation to a Nevada corporation pursuant to Section 266 of the General Corporation
Law of the State of Delaware, as amended (the &#8220;DGCL&#8221;), and Section 92A.195 of the Nevada Revised Statutes, as amended (the
&#8220;NRS&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RECITALS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>WHEREAS</b>,
Algorhythm Holdings, Inc. is a corporation organized and existing under the laws of the State of Delaware (the &#8220;Converting Entity&#8221;);
and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>WHEREAS</b>,
the Board of Directors of the Converting Entity has determined that it would be advisable and in the best interests of the Converting
Entity and its stockholders for the Converting Entity to convert from a Delaware corporation to a Nevada corporation pursuant to Section
266 of the DGCL and Sections 92A.195 and 92A.250 of the NRS; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>WHEREAS</b>,
the form, terms and provisions of this Plan have been authorized, approved and adopted by the Board of Directors of the Converting Entity;
and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>WHEREAS</b>,
the Board of Directors of the Converting Entity has submitted this Plan to the stockholders of the Converting Entity for approval; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>WHEREAS</b>,
the terms and provisions of this Plan has been authorized, approved and adopted by the holders of a majority of the outstanding shares
of Converting Entity Common Stock (as defined below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOW,
THEREFORE</b>, the Converting Entity hereby adopts this Plan as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PLAN
OF CONVERSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Conversion; Effect of Conversion.</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Upon the Effective Time (as defined in Section 3 below), the Converting Entity shall be converted from a Delaware corporation to a
Nevada corporation pursuant to Section 266 of the DGCL and Sections 92A.195 and 92A.250 of the NRS (the &#8220;Conversion&#8221;)
and the Converting Entity, as converted to a Nevada corporation (the &#8220;Converted Entity&#8221;), shall thereafter be subject to
all of the provisions of the NRS. The existence of the Converted Entity shall be deemed to have commenced on the date the Converting
Entity commenced its existence in the State of Delaware.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 69; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Upon the Effective Time, by virtue of the Conversion and without any further action on the part of the Converting Entity or its
stockholders, the Converted Entity shall, for all purposes of the laws of the State of Delaware, be deemed to be the same entity as
the Converting Entity existing immediately prior to the Effective Time. Upon the Effective Time, by virtue of the Conversion and
without any further action on the part of the Converting Entity or its stockholders, for all purposes of the laws of the State of
Nevada, all of the rights, privileges and powers of the Converting Entity existing immediately prior to the Effective Time, and all
property, real, personal and mixed, of the Converting Entity, and all debts owed by and due to the Converting Entity existing
immediately prior to the Effective Time, as well as all other things and causes of action belonging to the Converting Entity
existing immediately prior to the Effective Time, shall remain vested in the Converted Entity and shall be the property of the
Converted Entity and the title to any real property vested by deed or otherwise in the Converting Entity existing immediately prior
to the Effective Time shall not revert or be in any way impaired by reason of the Conversion; but all rights of creditors and all
liens upon any property of the Converting Entity existing immediately prior to the Effective Time shall be preserved unimpaired, and
all debts, liabilities and duties of the Converting Entity existing immediately prior to the Effective Time shall remain attached to
the Converted Entity upon the Effective Time, and may be enforced against the Converted Entity to the same extent as if said debts,
liabilities and duties had originally been incurred or contracted by the Converted Entity in its capacity as a corporation of the
State of Delaware. The rights, privileges, powers and interests in property of the Converting Entity existing immediately prior to
the Effective Time, as well as the debts, liabilities and duties of the Converting Entity existing immediately prior to the
Effective Time, shall not be deemed, as a consequence of the Conversion, to have been transferred to the Converted Entity upon the
Effective Time for any purpose of the laws of the State of Nevada.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) The Conversion shall not be deemed to affect any obligations or liabilities of the Converting
Entity incurred prior to the Conversion or the personal liability of any person incurred prior to the Conversion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Upon the Effective Time, the name of the Converted Entity shall remain unchanged and continue to be &#8220;Algorhythm Holdings,
Inc.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) The Converting Entity intends for the Conversion to constitute a tax-free reorganization qualifying
under Section 368(a) of the Internal Revenue Code of 1986, as amended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2. Filings.</b>
As promptly as practicable following the adoption of this Plan by the Board of Directors and the stockholders of the Converting Entity,
the Converting Entity shall cause the Conversion to be effective by:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) executing and filing (or causing the execution and filing of) Articles of Conversion pursuant
to Section 92A.205 of the NRS, substantially in the form of <span style="text-decoration: underline">Exhibit A</span> hereto (the &#8220;Nevada Articles of Conversion&#8221;),
with the Secretary of State of the State of Nevada;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) executing and filing (or causing the execution and filing of) a Certificate of Conversion pursuant
to Sections 103 and 266 of the DGCL, substantially in the form of <span style="text-decoration: underline">Exhibit B</span> hereto (the &#8220;Delaware Certificate of Conversion&#8221;),
with the Secretary of State of the State of Delaware; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) executing and filing (or causing the execution and filing of) Articles of Incorporation of
the Converted Entity, substantially in the form of <span style="text-decoration: underline">Exhibit C</span> hereto (the &#8220;Nevada Articles of Incorporation&#8221;), with
the Secretary of State of the State of Nevada.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3. Effective
Time.</b> The Conversion shall become effective upon the last to occur of the filing of: (i) the Nevada Articles of Conversion with the
Secretary of State of the State of Nevada, (ii) the Delaware Certificate of Conversion with the Secretary of State of the State of Delaware,
and (iii) the Nevada Articles of Incorporation with the Secretary of State of the State of Nevada (the time of the effectiveness of the
Conversion, the &#8220;Effective Time&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4. Effect
of Conversion.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<span style="text-decoration: underline">Effect on Common Stock</span>. Upon the Effective Time, by virtue of the Conversion and without any further action on the part of the
Converting Entity or its stockholders, each share of common stock, $0.01 par value per share, of the Converting Entity (&#8220;Converting
Entity Common Stock&#8221;) that is issued and outstanding immediately prior to the Effective Time shall convert into one validly issued,
fully paid and nonassessable share of common stock, $0.01 par value per share, of the Converted Entity (&#8220;Converted Entity Common
Stock&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<span style="text-decoration: underline">Effect on Outstanding Stock Options</span>. Upon the Effective Time, by virtue of the Conversion and without any further action on the
part of the Converting Entity or its stockholders, each option to acquire shares of Converting Entity Common Stock outstanding immediately
prior to the Effective Time shall convert into an equivalent option to acquire, upon the same terms and conditions (including the vesting
schedule and exercise price per share applicable to each such option) as were in effect immediately prior to the Effective Time, the
same number of shares of Converted Entity Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) <span style="text-decoration: underline">Effect on Outstanding Warrants or Other Rights</span>. Upon the Effective Time, by virtue of
the Conversion and without any further action on the part of the Converting Entity or its stockholders, each warrant or other right to
acquire shares of Converting Entity Common Stock outstanding immediately prior to the Effective Time shall convert into an equivalent
warrant or other right to acquire, upon the same terms and conditions (including the vesting schedule and exercise price per share applicable
to each such warrant or other right) as were in effect immediately prior to the Effective Time, the same number of shares of Converted
Entity Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) <span style="text-decoration: underline">Effect on Stock Certificates</span>. All of the outstanding certificates representing shares
of Converting Entity Common Stock immediately prior to the Effective Time shall be deemed for all purposes to continue to evidence ownership
of and to represent the same number of shares of Converted Entity Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) <span style="text-decoration: underline">Effect on Employee Benefit, Equity Incentive or Other Similar Plans</span>. Upon the Effective
Time, by virtue of the Conversion and without any further action on the part of the Converting Entity or its stockholders, each employee
benefit plan, equity incentive plan or other similar plan to which the Converting Entity is a party shall continue to be a plan of the
Converted Entity. To the extent that any such plan provides for the issuance of Converting Entity Common Stock, upon the Effective Time,
such plan shall be deemed to provide for the issuance of Converted Entity Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f) <span style="text-decoration: underline">Effect on Directors and Officers</span>. Upon the Effective Time, by virtue of the Conversion
and without any further action on the part of the Converting Entity or its stockholders, the members of the Board of Directors and the
officers of the Converting Entity holding their respective offices in the Converting Entity existing immediately prior to the Effective
Time shall continue in their respective offices as members of the Board of Directors and officers, respectively, of the Converted Entity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5. Further
Assurances.</b> If, at any time after the Effective Time, the Converted Entity shall determine or be advised that any deeds, bills of
sale, assignments, agreements, documents or assurances or any other acts or things are necessary, desirable or proper, consistent with
the terms of this Plan: (a) to vest, perfect or confirm, of record or otherwise, in the Converted Entity its right, title or interest
in, to or under any of the rights, privileges, immunities, powers, purposes, franchises, properties or assets of the Converting Entity
existing immediately prior to the Effective Time, or (b) to otherwise carry out the purposes of this Plan, the Converted Entity and its
officers and directors (or their designees), are hereby authorized to solicit in the name of the Converted Entity any third-party consents
or other documents required to be delivered by any third party, to execute and deliver, in the name and on behalf of the Converted Entity,
all such deeds, bills of sale, assignments, agreements, documents and assurances and do, in the name and on behalf of the Converted Entity,
all such other acts and things necessary, desirable or proper to vest, perfect or confirm its right, title or interest in, to or under
any of the rights, privileges, immunities, powers, purposes, franchises, properties or assets of the Converting Entity existing immediately
prior to the Effective Time and otherwise to carry out the purposes of this Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6. Nevada
Bylaws.</b> Upon the Effective Time, the bylaws of the Converted Entity shall be the Bylaws of Algorhythm Holdings, Inc., substantially
in the form of <span style="text-decoration: underline">Exhibit D</span> hereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7. Copy
of Plan of Conversion.</b> After the Conversion, a copy of this Plan will be kept on file at the offices of the Converted Entity, and
any stockholder of the Converted Entity (or former stockholder of the Converting Entity) may request a copy of this Plan at no charge
at any time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8. Termination.</b>
At any time prior to the Effective Time, this Plan may be terminated, and the transactions contemplated hereby may be abandoned by action
of the Board of Directors of the Converting Entity if, in the opinion of the Board of Directors of the Converting Entity, such action
would be in the best interests of the Converting Entity and its stockholders. In the event of termination of this Plan, this Plan shall
become void and of no further force or effect</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9. Third-Party
Beneficiaries.</b> This Plan shall not confer any rights or remedies upon any person other than as expressly provided herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10. Severability.</b>
Whenever possible, each provision of this Plan will be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Plan is held to be prohibited by or invalid under applicable law, such provision will be ineffective only
to the extent of such prohibition or invalidity, without invalidating the remainder of this Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<i>Remainder
of page intentionally left blank</i>]</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the undersigned hereby causes this Plan to be duly executed as of the date hereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ALGORHYTHM HOLDINGS, INC.,</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a Delaware corporation</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; width: 47%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary
    Atkinson</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 73; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="a_021"></span>APPENDIX
D</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLES
OF INCORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OF</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>ALGORHYTHM
HOLDINGS, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: center; text-indent: -1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>ARTICLE
I</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NAME</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
name of the corporation is Algorhythm Holdings, Inc. (the &#8220;Corporation&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font: small-caps 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: center; text-indent: -1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>ARTICLE
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REGISTERED
AGENT AND REGISTERED OFFICE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
name of the registered agent of the Corporation is [______________]. The address, including street, number and city, of the registered
agent of the Corporation in the State of Nevada, is [______________].</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: center; text-indent: -1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>ARTICLE
III</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PURPOSE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purpose of the Corporation is to engage in any lawful acts or activities for which corporations may be organized under the laws of the
State of Nevada.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: center; text-indent: -1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>ARTICLE
IV</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: center; text-indent: -1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PERPETUAL
EXISTENCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Corporation shall have a perpetual existence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: center; text-indent: -1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>ARTICLE
V</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INCORPORATOR</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
name and address of the incorporator executing these Articles of Incorporation is:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary
Atkinson</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6301
NW 5<sup>th</sup> Way, Suite 2900</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fort
Lauderdale, FL 33309</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: center; text-indent: -1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: center; text-indent: -1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 74; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: center; text-indent: -1.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: center; text-indent: -1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE
VI</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DIRECTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of directors that constitute the board of directors of the Corporation, and the manner in which the number of directors may be
increased or decreased, shall be designated as set forth in the Bylaws of the Corporation (the &#8220;Bylaws&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: center; text-indent: -1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>ARTICLE
VII</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CAPITAL
STOCK</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <span style="text-decoration: underline">Capitalization</span>.
The total number of shares of capital stock that the Corporation is authorized to issue is eight hundred one million (801,000,000), consisting
of: (i) eight hundred million (800,000,000) shares of common stock, par value $0.01 per share (&#8220;Common Stock&#8221;); and (ii)
one million (1,000,000) shares of preferred stock, par value $1.00 per share (&#8220;Preferred Stock&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) <span style="text-decoration: underline">Common
Stock</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) <span style="text-decoration: underline">Relative
Rights of Common Stock and Preferred Stock</span>. All preferences, voting powers, relative, participating, optional or other special rights
and privileges, and qualifications, limitations, or restrictions of the Common Stock are expressly made subject and subordinate to those
that may be fixed with respect to any shares of the Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) <span style="text-decoration: underline">Fully-Paid
and Nonassessable Shares</span>. All shares of Common Stock that are issued by the Corporation shall be fully-paid and nonassessable shares
of Common Stock. No Common Stock issued by the Corporation as fully-paid shall ever be assessable or assessed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii) <span style="text-decoration: underline">Voting
Rights</span>. Except as otherwise required by law or these Articles of Incorporation, each holder of Common Stock shall have one vote in
respect of each share of stock held by such holder of record on the books of the Corporation for the election of directors and on all
matters submitted to a vote of stockholders of the Corporation. Holders of Common Stock shall not be entitled to cumulative voting of
their shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv) <span style="text-decoration: underline">Dividends</span>.
Subject to the preferential rights of the Preferred Stock, the holders of shares of Common Stock shall be entitled to receive dividends,
when and if declared by the board of directors, out of the assets of the Corporation that are legally available therefor, payable either
in cash, in property or in shares of capital stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v) <span style="text-decoration: underline">No
Pre-Emptive Rights or Further Assessments</span>. The holders of shares of Common Stock shall have no preemptive, subscription, redemption
or conversion rights, and shall not be subject to any sinking fund provisions or any further assessments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi) <span style="text-decoration: underline">Dissolution,
Liquidation or Winding Up</span>. In the event of any dissolution, liquidation or winding up of the affairs of the Corporation, after distribution
in full of the preferential amounts, if any, to be distributed to the holders of shares of Preferred Stock, holders of Common Stock shall
be entitled, unless otherwise provided by law or these Articles of Incorporation, to receive all of the remaining assets of the Corporation
of whatever kind available for distribution to stockholders ratably in proportion to the number of shares of Common Stock held by them
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 75; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) <span style="text-decoration: underline">Preferred Stock</span>. The board of directors is expressly authorized to issue, from time
to time, in one or more series, shares of Preferred Stock and, in the resolution or resolutions providing for such issue, establish for
each such series the number of shares, the designations, powers, privileges, preferences and rights, if any, of the shares of such series,
and the qualifications, limitations and restrictions, if any, of such series, to the fullest extent permitted by the Nevada Revised Statutes
as the same exists or may hereafter be amended. The board of directors is also expressly authorized (unless forbidden in the resolution
or resolutions providing for such issue) to increase or decrease (but not below the number of shares of such series then outstanding)
the number of shares of any series subsequent to the issuance of shares of that series. In case the number of shares of any such series
shall be so decreased, the shares constituting such decrease shall resume the status that they had prior to the adoption of the resolution
originally fixing the number of shares of such series.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: center; text-indent: -1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>ARTICLE
VIII</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: center; text-indent: -1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDEMNIFICATION
AND LIABILITY OF OFFICERS AND DIRECTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <span style="text-decoration: underline">Indemnification
and Advancement of Expenses</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) <span style="text-decoration: underline">Indemnification</span>.
The Corporation shall, to the fullest extent permitted by the Nevada Revised Statutes, indemnify any person who is or was made a party
to, or is threatened to be made a party to, any threatened, pending or completed action, suit or proceeding, whether civil, criminal,
administrative or investigative, by reason of the fact that such person is or was an officer or director of the Corporation, or, while
such person is or was serving as an officer or director of the corporation, such person is or was serving at the request of the Corporation
as an officer, director, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses,
including attorneys&#8217; fees, judgments, fines and amounts paid in settlement, actually and reasonably incurred by such person in
connection with such action, suit or proceeding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) <span style="text-decoration: underline">Advancement
of Expenses</span>. The Corporation shall, to the fullest extent permitted by the Nevada Revised Statutes, advance to any person who is
or was made a party to, or is threatened to be made a party to, any threatened, pending or completed civil or criminal action, suit or
proceeding by reason of the fact that such person is or was an officer or director of the Corporation, or, while such person is or was
serving as an officer or director of the corporation, such person is or was serving at the request of the Corporation as an officer,
director, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, all expenses incurred by such
officer or director in defending against such action, suit or proceeding as they are incurred and in advance of the final disposition
of such action, suit or proceeding, upon receipt of an undertaking by or on behalf of such officer or director to repay the amount if
it is ultimately determined by a court that such officer or director is not entitled to be indemnified by the Corporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii) <span style="text-decoration: underline">Additional
Rights</span>. In the event the Nevada Revised Statutes are hereafter amended to permit the Corporation to provide broader rights to indemnification
or advancement of expenses to officers or directors of the Corporation than those provided herein, then the rights of officers and directors
to indemnification and advancement of expenses, in addition to the rights of officers and directors to indemnification and advancement
of expenses provided herein, shall be broadened to the fullest extent permitted by the Nevada Revised Statutes as so amended. The rights
to indemnification and advancement of expenses granted in this Article VII shall not be deemed exclusive of any other rights to which
a person seeking indemnification or advancement of expenses may be entitled under these Articles of Incorporation, the Bylaws, any agreement,
any vote of stockholders or directors, or otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 76; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) <span style="text-decoration: underline">Limitations
on Liability</span>. To the fullest extent permitted by the Nevada Revised Statutes, an officer or director of the Corporation shall not
be personally liable to the Corporation or its stockholders or creditors for any damages as a result of any act or failure to act in
his or her capacity as an officer or director of the Corporation. In the event the Nevada Revised Statutes are hereafter amended to further
limit or eliminate the liability of officers or directors, then the liability of officers and directors of the Corporation, in addition
to the limitation on personal liability provided herein, shall be limited or eliminated to the fullest extent permitted by the Nevada
Revised Statutes as so amended. The limitations on personal liability <span style="color: black">granted under this Article VIII</span>
shall not be deemed exclusive of any other limitations on personal liability <span style="color: black">to which a person may be entitled
under </span>these Articles of Incorporation, the Bylaws<span style="color: black">, any agreement, any vote of stockholders or directors,
or otherwise</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) <span style="text-decoration: underline">Amendment
or Repeal</span>. <span style="color: windowtext">Neither any amendment nor repeal of this Article VIII, nor the adoption of any provision
of these Articles of Incorporation that is inconsistent with this Article VIII, shall eliminate or reduce the effect of this Article
VIII in respect of any matter occurring, or any action, suit or </span>proceeding accruing or arising or that, but for this Article VIII,
would accrue or arise, prior to such amendment, repeal or adoption of such inconsistent provision.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: center; text-indent: -1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>ARTICLE
IX</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BYLAWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
furtherance of, and not in limitation of, the powers conferred by statute, subject to the provisions of these Articles of Incorporation,
the power to adopt, amend or repeal the Bylaws shall be vested exclusively with the board of directors of the Corporation. The stockholders
of the Corporation shall have no power to adopt, amend or repeal the Bylaws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: center; text-indent: -1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>ARTICLE
X</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AMENDMENTS
TO ARTICLES OF INCORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time any of the provisions of these Articles of Incorporation may be altered, amended or repealed, and other provisions authorized
by the laws of the State of Nevada at the time in force may be added or inserted in the manner and at the time prescribed by said laws.
All rights at any time conferred upon the stockholders of the Corporation by these Articles of Incorporation are granted subject to the
provisions of this Article X.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
* * * *</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 77; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Incorporator has signed these Articles of Incorporation this _____ day of ________________, ________.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary
    Atkinson</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sole
    Incorporator</span></td>
    </tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 78; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="text-decoration: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="a_022"></span>APPENDIX
E</span></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BYLAWS
</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OF
</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ALGORHYTHM
HOLDINGS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(A
Nevada Corporation)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE
I</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CORPORATE
OFFICES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Registered Office</span>.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registered office of corporation shall be as designated in the articles of incorporation of the corporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 23.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Other Offices</span>.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
corporation may also have offices at such other places, either within or without the State of Nevada, as the board of directors may from
time to time designate or as the business of the corporation may require.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MEETINGS
OF STOCKHOLDERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1 <span style="text-decoration: underline"> Place of Meetings</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise provided in the articles of incorporation, meetings of stockholders may be held at such places, within or without the State
of Nevada, as may be determined from time to time by the board of directors. The board of directors may, in its sole discretion, determine
that the meeting of stockholders shall not be held at any place, but may instead be held solely by means of remote communication in accordance
with the provisions of Section 6.6 hereof. In the absence of any such designation or determination, stockholders&#8217; meetings shall
be held at the corporation&#8217;s principal executive office.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2 <span style="text-decoration: underline">Annual Meetings</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
annual meeting of stockholders may be called by the board of directors and shall be held on such date and at such time as may be determined
from time to time by the board of directors. Upon making such determination, the secretary shall cause a notice to be given to the stockholders
entitled to attend the annual meeting and vote thereat in accordance with the provisions of Section 2.4 hereof. At the annual meeting,
directors shall be elected and any other proper business may be transacted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3 <span style="text-decoration: underline">Special Meetings</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Special
meetings of the stockholders, other than those required by statute, may be called for any purpose as is a proper matter for stockholder
action under Nevada law by the board of directors, the chairperson of the board of directors or the chief executive officer. The board
of directors shall determine the date and time of special meetings. Upon making such determination, the secretary shall cause a notice
of special meeting to be given to the stockholders entitled to attend the meeting and vote thereat, in accordance with the provisions
of Section 2.4 hereof. No business may be transacted at the special meeting other than the business specified in the notice of meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 79; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4 <span style="text-decoration: underline">Notice of Meetings</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
notices of meetings of stockholders shall be given in accordance with the provisions of Article VI hereof not less than ten (10) nor
more than sixty (60) days before the date of the meeting to each stockholder entitled to vote at such meeting. The notice shall specify
the place, if any, date and time of the meeting and the means of remote communication, if any, by which stockholders and proxyholders
may be deemed to be present in person and vote at the meeting, and: (i) in the case of an annual meeting, those matters that the board
of directors, at the time of giving the notice, intends to present for action by the stockholders, or (ii) in the case of a special meeting,
the purpose or purposes for which the meeting is called. The notice of any meeting at which directors are to be elected shall include
the name of any nominee or nominees who, at the time of the notice, the board of directors intends to present for election. Notice of
any meeting may be waived by the stockholder in accordance with the provisions of Section 6.5 hereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5 <span style="text-decoration: underline">Quorum</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
all meetings of stockholders, unless the articles of incorporation or these bylaws provide for different proportions: (i) the holders
of thirty-three and one-third percent (33 1/3%) of the voting power of the class or series of stock issued and outstanding and entitled
to vote thereat, present in person or represented by proxy, regardless of whether the proxy has authority to vote on all matters, shall
constitute a quorum for the transaction of business, and (ii) where a separate vote by a class or series of stock is required on a particular
matter, a majority of the voting power of such class or series of stock present in person or represented by proxy, regardless of whether
the proxy has authority to vote on all matters, shall constitute a quorum for the transaction of business. In the event a quorum is established
at a duly called or convened meeting of stockholders, the stockholders may transact business until the meeting is adjourned in accordance
with the provisions of Section 2.6 hereof, notwithstanding the subsequent withdraw of stockholders holding that amount of voting power
sufficient to result in a quorum not being present or represented at the meeting. If a quorum is not present or represented at a meeting
of the stockholders, the meeting may be adjourned in accordance with the provisions of Section 2.6 hereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6 <span style="text-decoration: underline">Adjournments; Postponements and Cancellations</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) If
a quorum is not present or represented at a meeting of stockholders, the chairperson of the meeting or a majority of the stockholders
present in person or represented by proxy at the meeting, though less than a quorum, shall be entitled to adjourn the meeting from time
to time until a quorum is present or represented. When a meeting is adjourned to another place, date or time, notice need not be given
of the adjourned meeting if the date, time and place, if any, thereof and the means of remote communication, if any, by which stockholders
and proxyholders may be deemed to be present in person and vote at such adjourned meeting are announced at the meeting at which the adjournment
is taken; <i>provided</i>, <i>however</i>, that if the date of any adjourned meeting is more than sixty (60) days after the date for
which the meeting was originally noticed, or if, after the adjournment, a new record date is fixed for the adjourned meeting, notice
of the place, if any, date, time and means of remote communications, if any, of the adjourned meeting shall be given in conformity with
the provisions of these bylaws. At any adjourned meeting, any business may be transacted that might have been transacted at the original
meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) The
board of directors may cancel, postpone or reschedule any previously scheduled meeting at any time, before or after the notice for such
meeting has been sent to the stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 80; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.7 <span style="text-decoration: underline">Organization and Conduct of Business</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) Meetings
of stockholders shall be presided over by the chairperson of the board of directors, if any, or in his or her absence by a person designated
by the board of directors, or, in the absence of a person so designated by the board of directors, by the chief executive officer, or
in his or her absence by the chief financial officer, or in his or her absence by the secretary, or in his or her absence by a chairperson
chosen at the meeting by the vote of a majority in interest of the stockholders entitled to vote thereat, present in person or represented
by proxy. The secretary, or in his or her absence, an assistant secretary, if any, or, in the absence of all assistant secretaries, a
person whom the chairperson of the meeting appoints, shall act as secretary of the meeting and keep a record of the proceedings thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) The
board of directors shall be entitled to make such rules or regulations for the conduct of meetings of stockholders as it deems necessary,
appropriate or convenient. Subject to such rules and regulations of the board of directors, if any, the chairperson of the meeting shall
have the right and authority to prescribe such rules, regulations and procedures and to do all such acts as, in the judgment of such
chairperson, are necessary, appropriate or convenient for the proper conduct of the meeting, including, without limitation: (i) establishing
an agenda or order of business for the meeting, (ii) establishing rules and procedures for maintaining order at the meeting and the safety
of those present, (iii) establishing limitations on participation in such meeting to stockholders of record and their duly authorized
and constituted proxies, and such other persons as the chairperson shall permit, (iv) establishing restrictions on entry to the meeting
after the time fixed for the commencement thereof, (v) establishing limitations on the time allotted to questions or comments by participants,
and (vi) regulating the opening and closing of the polls for balloting and matters that are to be voted on by ballot. Unless and to the
extent determined by the board of directors or the chairperson of the meeting, meetings of stockholders shall not be required to be held
in accordance with rules of parliamentary procedure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.8 <span style="text-decoration: underline">Voting</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise provided in the articles of incorporation, or in the resolution providing for the issuance of the stock adopted by the board
of directors pursuant to authority expressly vested in it by the provisions of the articles of incorporation, each stockholder shall
be entitled to one (1) vote for each share of capital stock registered in such stockholder&#8217;s name on the books of the corporation
on the record date fixed for determination of stockholders entitled to notice of and to vote at a meeting of stockholders. Except as
otherwise required by the articles of incorporation or these bylaws, with respect to any matter other than the election of directors,
an action on a matter shall be approved by, and shall be the act of, the stockholders if the number of votes cast in favor of the action
exceeds the number of votes cast in opposition to the action by stockholders present in person or represented by proxy, regardless of
whether the proxy has authority to vote on all matters, at the meeting and entitled to vote on the matter. Except as otherwise required
by the articles of incorporation or these bylaws, where a separate vote by a class or series of stock is permitted or required with respect
to any matter other than the election of directors, an act by the stockholders of the class or series of stock present in person or represented
by proxy, regardless of whether the proxy has authority to vote on all matters, at the meeting and entitled to vote on the matter shall
be the act of the class or series of stock if a majority of the voting power of a quorum of the class or series of stock votes in favor
of the action. Except as otherwise required by the articles of incorporation or these bylaws, with respect to the election of directors
at an annual meeting of stockholders, directors shall be elected by a plurality of the votes cast by stockholders present in person or
represented by proxy, regardless of whether the proxy has authority to vote on all matters, at the meeting and entitled to vote on the
election of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 81; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.9 <span style="text-decoration: underline">Stockholder Action by Written Consent</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the rights of the holders of the shares of any series of preferred stock or any other class of stock or series thereof, any action
required or permitted to be taken at a meeting of the stockholders may be taken without a meeting, without prior notice and without a
vote if, before or after the action, a written consent thereto is signed by stockholders holding at least a majority of the voting power;
<i>provided</i>, <i>however</i>, that if a different proportion of voting power is required for such action at the meeting, then the
written consent must be signed by stockholders holding at least that proportion of voting power.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.10 <span style="text-decoration: underline">Record Dates</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) For purposes of determining the stockholders entitled to notice of and to vote at any meeting
of stockholders, the board of directors may fix a record date, which record date shall not precede the date upon which the resolution
fixing the record date is adopted by the board of directors, and which record date shall not be less than ten (10) days nor more than
sixty (60) days before the date of such meeting, unless otherwise provided in the articles of incorporation. In such event, except as
otherwise provided in the articles of incorporation, these bylaws or any agreement, only stockholders of record on the date so fixed
shall be entitled to notice of and to vote at the meeting, notwithstanding any transfer of any shares on the books of the corporation
after the record date. If the board of directors does not so fix a record date, the record date for determining stockholders entitled
to notice of or to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which the
first notice is given, or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held.
A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment
of the meeting unless the board of directors fixes a new record date for the adjourned meeting; <i>provided</i>, <i>however</i>, that
if the meeting is adjourned to a date that is more than sixty (60) days after the date set for the original meeting, the board of directors
must fix a new record date for the meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) For
purposes of determining the stockholders entitled to receive payment of any dividend or other distribution or allotment of any rights
or the stockholders entitled to exercise any rights in respect of any other lawful action, the board of directors may fix a record date,
which record date shall not precede the date upon which the resolution fixing the record date is adopted by the board of directors, and
which record date shall not be more than sixty (60) days before the date of any such action. In such event, except as otherwise provided
in the articles of incorporation, these bylaws or any agreement, only stockholders of record at the close of business on the date so
fixed shall be entitled to receive the dividend, distribution or allotment of rights, or to exercise such rights, as the case may be,
notwithstanding any transfer of any shares on the books of the corporation after the record date so fixed. If the board of directors
does not so fix a record date, the record date for determining stockholders for any such purpose shall be at the close of business on
the day on which the board of directors adopts the resolution relating thereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 82; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) The
board of directors may adopt a resolution prescribing a date upon which the stockholders of record entitled to give written consent pursuant
to Section 2.9 hereof must be determined. The date prescribed by the board of directors may not precede or be more than ten (10) days
after the date the resolution is adopted by the board of directors. If the board of directors does not adopt a resolution prescribing
a date upon which the stockholders of record entitled to give written consent pursuant to Section 2.9 hereof must be determined and no
prior action by the board of directors is required by Chapters 78 or 92A of the Nevada Revised Statutes before the matter is submitted
for consideration by the stockholders, the date is the first date on which any stockholder delivers to the corporation such consent signed
by the stockholder. If the board of directors does not adopt a resolution prescribing a date upon which the stockholders of record entitled
to give written consent pursuant to Section 2.9 hereof must be determined and prior action by the board of directors is required by Chapters
78 or 92A of the Nevada Revised Statutes before the matter is submitted for consideration by the stockholders, the date is at the close
of business on the day the board of directors adopts the resolution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.11 <span style="text-decoration: underline">Proxies</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) Each
stockholder entitled to vote at a meeting of stockholders may authorize another person or persons to act for such stockholder by proxy.
The proxy may be limited to action on designated matters. Without limiting the manner in which a stockholder may authorize another person
or persons to act for him or her as proxy, a stockholder may sign a writing authorizing another person or persons to act for him or her
as proxy. Any copy, communication by electronic transmission or other reliable reproduction of the writing may be substituted for the
original writing for any purpose for which the original writing could be used, if the copy, communication by electronic transmission
or other reproduction is a complete reproduction of the entire original writing. No proxy shall be valid after the expiration of six
(6) months from the date of its creation unless the stockholder specifies in the proxy the length of time for which it is to continue
in force, which may not exceed seven (7) years from the date of its creation. Any proxy properly created is not revoked and continues
in full force and effect until: (i) another instrument or transmission revoking it or a properly created proxy bearing a later date is
filed with or transmitted to the secretary of the corporation or the corporation&#8217;s proxy solicitor, or (ii)&#8194;in the event of
a meeting of stockholders, the stockholder revokes the proxy by attending the meeting and voting the stockholder&#8217;s shares in person.
A proxy is not revoked by the death or incapacity of the maker unless, before the vote is counted, written notice of such death or incapacity
is received by the secretary of the corporation or the corporation&#8217;s proxy solicitor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) A
proxy shall be deemed irrevocable if the written authorization states that the proxy is irrevocable and if, and only so long as, it is
coupled with an interest sufficient in law to support an irrevocable power. Unless otherwise provided in the proxy, a proxy made irrevocable
pursuant to this subsection is revoked when the interest with which it is coupled is extinguished, but the corporation may honor the
proxy until notice of the extinguishment of the proxy is received by the corporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 83; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.12 <span style="text-decoration: underline">Joint
Owners of Stock</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
shares or other securities having voting power stand of record in the names of two (2) or more persons, whether fiduciaries, joint tenants,
tenants in common or otherwise, or if two (2) or more persons have the same fiduciary relationship respecting the shares or securities,
unless the secretary of the corporation is given written notice to the contrary and is furnished with a copy of the instrument or order
appointing them or creating the relationship, their acts with respect to voting have the following effect: (i) if only one person votes,
that person&#8217;s act binds all, (ii) if more than one person votes, the act chosen by a majority of votes binds all, and (iii) if
more than one person votes, but the vote is evenly split on any particular matter, each faction may vote the shares or securities in
question proportionally.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.13 <span style="text-decoration: underline">Stockholder Lists</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
officer who has charge of the stock ledger of the corporation shall prepare and make, at least ten (10) days before every meeting of
stockholders, a complete list of the stockholders entitled to vote at the meeting; <i>provided</i>, <i>however</i>, that if the record
date for determining the stockholders entitled to vote is less than ten (10) days before the meeting date, the list shall reflect the
stockholders entitled to vote as of the tenth day before the meeting date. The stockholder list shall be arranged in alphabetical order
and show the address of each stockholder and the number of shares registered in the name of each stockholder. The corporation shall not
be required to include electronic mail addresses or other electronic contact information on the stockholder list. The stockholder list
shall be open to the examination of any stockholder for any purpose germane to the meeting: (i) on a reasonably accessible electronic
network, provided that the information required to gain access to such list is provided with the notice of the meeting, or (ii) during
ordinary business hours, at the corporation&#8217;s principal place of business. In the event the corporation makes the stockholder list
available on an electronic network, the corporation may take reasonable steps to ensure that such information is available only to stockholders
of the corporation. If the meeting is to be held at a place, the stockholder list shall be made available at such place throughout the
duration of the meeting, and may be examined by any stockholder who is present. If the meeting is to be held solely by means of remote
communication, the stockholder list shall be made available for examination by any stockholder on a reasonably accessible electronic
network throughout the duration of the meeting and the information required to access such list shall be provided with the notice of
the meeting. Such stockholder list shall presumptively determine the identity of the stockholders entitled to vote at the meeting and
the number of shares held by each of them.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.14 <span style="text-decoration: underline">Inspectors of Elections</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #222222; background-color: white">Before
any meeting of stockholders, the corporation may, and shall if required by law, appoint one or more inspectors of election to act at
the meeting and make a written report thereof. The corporation may designate one or more persons as alternate inspectors to replace any
inspector who fails to appear or fails or refuses to act. If no inspector or alternate is able to act at the meeting of stockholders,
the person presiding at the meeting shall appoint one or more inspectors to act at the meeting. </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such
inspectors shall: (i) determine the number of shares outstanding and the voting power of each, (ii) determine the number of shares represented
at the meeting, the existence of a quorum and the validity of proxies and ballots, (iii) receive and count all votes and ballots, (iv)
<span style="background-color: white">determine any challenges made to any determination by the inspectors, and retain for a reasonable
period a record of the disposition of any such challenges</span>, (v) <span style="background-color: white">certify their determination
of the number of shares represented at the meeting and their count of all votes and ballots</span>, and (vi) do such other acts as are
necessary and appropriate to conduct the meeting of stockholders with fairness to all stockholders. The inspectors of election shall
perform their duties impartially, in good faith, to the best of their ability and as expeditiously as is practical. <span style="background-color: white">The
inspectors may appoint or retain other persons or entities to assist the inspectors in the performance of the duties of the inspectors.</span>
Any report or certificate made by the inspectors of election shall, in the absence of fraud, be <i>prima facie</i> evidence of the facts
stated therein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 84; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE
III</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DIRECTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1 <span style="text-decoration: underline">Powers</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
business and affairs of the corporation shall be managed and exercised by or under the direction of the board of directors, except as
may otherwise be provided in the articles of incorporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2 <span style="text-decoration: underline">Number, Election, Term and Qualifications</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of directors that shall constitute the entire board of directors shall be fixed from time to time by resolution of the board of
directors, but shall never be less than one (1) member. The board of directors may change the authorized number of directors to a number
outside the range specified in this Section 3.2. Except as otherwise provided in the articles of incorporation or these bylaws, directors
shall be elected at the annual meeting of the stockholders or, if not so elected, at any special meeting of stockholders that is called
and held for that purpose. Except as otherwise provided in the articles of incorporation or these bylaws, each director shall hold office
until the expiration of the term for which the director was elected and the director&#8217;s successor is duly elected and qualified,
or until the director&#8217;s earlier resignation or removal. Directors need not be stockholders unless so required by the articles of
incorporation. The articles of incorporation or these bylaws may prescribe other qualifications for directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3 <span style="text-decoration: underline">Enlargement
and Vacancies</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise provided by the articles of incorporation or these bylaws, and subject to the rights of the holders of any series of preferred
stock then outstanding, newly created directorships resulting from any increase in the authorized number of directors or any vacancies
in the board of directors resulting from death, resignation, retirement, disqualification, incapacity, removal from office or other cause
shall be filled solely by a majority vote of the remaining directors, though less than a quorum, or, if only one director remains, by
the sole remaining director, unless otherwise provided in the articles of incorporation. Directors chosen pursuant to any of the foregoing
provisions shall hold office until the next annual meeting and until such director&#8217;s successor is duly elected and qualified or
until such director&#8217;s earlier resignation or removal. In the event of a vacancy in the board of directors, the remaining directors,
except as otherwise provided by the articles of incorporation or these bylaws, may exercise the powers of the full board until the vacancy
is filled. Unless otherwise provided in the articles of incorporation, when one or more directors give notice of resignation to the board,
effective at a future date, the board may fill the vacancy or vacancies to take effect when the resignation or resignations become effective,
each director so appointed to hold office during the remainder of the term of office of the resigning director or directors. If, at any
time, the corporation shall have no directors in office, then an election of directors may be held in the manner permitted in the Nevada
Revised Statutes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 85; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4 <span style="text-decoration: underline">Resignation and Removal</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) Any
director may resign at any time by providing notice in writing or by electronic transmission to the corporation at its principal place
of business addressed to the attention of the board of directors, the chairperson of the board of directors, the chief executive officer
or the secretary; <i>provided</i>, <i>however</i>, that if such notice is given by electronic transmission, such electronic transmission
must either set forth or be submitted with information from which it can be determined that the electronic transmission was authorized
by the director. A resignation is effective when the resignation is delivered unless the resignation specifies a later effective date
or an effective date determined upon the happening of an event or events. Unless otherwise provided in the articles of incorporation,
when one or more directors give notice of resignation to the board, effective at a future date, the board may fill the vacancy or vacancies
to take effect when the resignation or resignations become effective, each director so appointed to hold office during the remainder
of the term of office of the resigning director or directors. Acceptance of such resignation shall not be necessary to make it effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) Subject
to the rights of the holders of the shares of any series of preferred stock or any other class of stock or series thereof, any director
may be removed from the board of directors by the affirmative vote of stockholders representing at least two-thirds (2/3) of the voting
power of the issued and outstanding shares of capital stock entitled to vote at an election of directors. No reduction of the authorized
number of directors shall have the effect of removing any director prior to the expiration of such director&#8217;s term of office.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5 <span style="text-decoration: underline">Regular Meetings</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regular
meetings of the board of directors may be held on such dates, at such times and, unless otherwise provided in the articles of incorporation,
at such places within and without the State of Nevada as may be determined from time to time by the board of directors and publicized
among all directors, either orally, in writing or by electronic transmission. No further notice of regular meetings of the board of directors
shall be required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6 <span style="text-decoration: underline">Special Meetings</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Special
meetings of the board of directors may be called from time to time by the chairperson of the board or by a majority of the directors
then in office, and may be held on such dates, at such times and, unless otherwise provided in the articles of incorporation, at such
places within and without the State of Nevada as such person or persons shall designate. Notice of the time and place, if any, of special
meetings of the board of directors shall be delivered personally or by telephone to each director, or sent by first-class mail, commercial
delivery service or electronic transmission, charges prepaid, at such director&#8217;s business or home address as they appear upon the
records of the corporation. If such notice is sent by mail, it shall be deposited in the United States mail at least four (4) days prior
to the date of the meeting. If such notice is delivered personally or by telephone, or sent by commercial delivery service or electronic
transmission, it shall be delivered sufficiently in advance of the meeting so as to provide the directors with a reasonable opportunity
to participate in the meeting. Any oral notice given personally or by telephone may be communicated either directly to the director or
to a person at the office of the director whom the person giving the notice has reason to believe shall promptly communicate it to the
director. The notice of any special meeting of the board of directors need not specify the purpose of the meeting, nor the place of the
meeting, if the meeting is to be held at the corporation&#8217;s principle executive office.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 86; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7 <span style="text-decoration: underline">Quorum
and Voting</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
all meetings of the board of directors, a majority of the board of directors then in office shall constitute a quorum for the transaction
of business, except to fill vacancies in the board of directors as provided in Section 3.3 hereof or to adjourn the meeting as provided
in Section 3.8 hereof. The act of directors holding a majority of the voting power of the directors present at any meeting at which a
quorum is present shall be the act of the board of directors, except as otherwise provided in the articles of incorporation or these
bylaws. A meeting at which a quorum is initially present may continue to transact business, notwithstanding the withdrawal of directors,
if any action taken at the meeting is approved by at least a majority of the required quorum for the meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.8 <span style="text-decoration: underline">Adjournment;
Postponement or Cancellation</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
majority of the directors present, whether or not constituting a quorum, may, from time to time, adjourn any meeting to another date,
time and place. Notice of the date, time and place of the adjourned meeting shall be given to each of the members of the board of directors;
<i>provided</i>, <i>however</i>, that no such notice need be given to any directors present at the original meeting at the time it was
adjourned if the date, time and place of the adjourned meeting are announced at such meeting. At any adjourned meeting, any business
may be transacted that might have been transacted at the original meeting. The board of directors may cancel, postpone or reschedule
any previously scheduled meeting at any time, before or after the notice for such meeting has been sent to the directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.9 <span style="text-decoration: underline">Committees
and Sub-Committees</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) Unless
otherwise provided in the articles of incorporation, the board of directors may, by resolution adopted by the board of directors, designate
one or more committees from time to time, each committee to consist of one or more members of the board of directors. The board of directors
may at any time increase or decrease the number of members comprising a committee, appoint new members to the committee, remove any member
from the committee, or terminate the existence of a committee. The board of directors may designate one or more directors as alternate
members of a committee to replace any absent or disqualified member at any meeting of the committee. In the absence or disqualification
of a member of a committee, the member or members present at any meeting and not disqualified from voting, whether or not the member
or members present constitute a quorum, may unanimously appoint another member of the board of directors to act at the meeting in the
place of any such absent or disqualified member of the committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) Any
committee, to the extent provided in the resolution of the board of directors, shall have and may exercise all of the lawfully delegated
powers and authority of the board of directors in the management of the business and affairs of the corporation, and may authorize the
seal of the corporation to be affixed to all papers that may require it; <i>provided</i>, <i>however</i>, that no such committee shall
have the power or authority to: (i) approve or adopt, or recommend to the stockholders, any action or matter (other than the election
or removal of directors) required by Chapter 78 of the Nevada Revised Statutes to be submitted to the stockholders for approval, or (ii)
adopt, amend or repeal any bylaw of the corporation. Such committee or committees shall have such name or names as may be determined
from time to time by resolution adopted by the board of directors. Each committee shall keep regular minutes of its meetings and make
such reports to the board of directors as the board of directors may request or the charter, if any, of such committee may require. Except
as the board of directors may otherwise determine, any committee may make rules for the conduct of its business, but unless otherwise
provided by in such rules or by the board of directors, the committee&#8217;s business shall be conducted in a manner that is as close
as possible to the manner by which the corporation&#8217;s business is conducted by the board of directors under these bylaws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 87; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) Unless
otherwise provided in the articles of incorporation, these bylaws, the resolutions of the board of directors designating the committee,
or any charter of the committee, a committee may create one or more subcommittees, each subcommittee to consist of one or more members
of the committee, and delegate to any such subcommittee any or all of the powers and authority of the committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.10 <span style="text-decoration: underline">Organization
of Meetings</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Meetings
of the board of directors shall be presided over by the chairperson of the board of directors, if any. In his or her absence, a majority
of the directors present at the meeting, assuming a quorum, shall designate a president pro tem of the meeting who shall preside at the
meeting. The secretary shall act as secretary of the meeting, but in his or her absence, the chairperson of the meeting may appoint any
assistance secretary, officer, director or other person to act as secretary of the meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.11 <span style="text-decoration: underline">Place of Meetings</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
board of directors, and any committees thereof, may hold meetings, both regular and special, either within or without the State of Nevada.
Regular meetings of the board of directors may be held at any place within or without the State of Nevada that has been designated from
time to time by resolution of the board of directors. In the absence of such designation, regular meetings shall be held at any place
within or outside the State of Nevada that has been designated in the notice of the meeting or, if not stated in the notice or if there
is no notice, at the principal executive office of the corporation. Special meetings of the board of directors may be held at any place
within or without the State of Nevada that has been designated in the notice of the meeting or, if not stated in the notice or if there
is no notice, at the principal executive office of the corporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.12 <span style="text-decoration: underline">Board
Action by Written Consent</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise restricted by the articles of incorporation or these bylaws, any action required or permitted to be taken at a meeting of the
board of directors or a committee thereof may be taken without a meeting if, before or after the action, a written consent thereto is
signed by all of the members of the board of directors or the committee, as the case may be; <i>provided</i>, <i>however</i>, that the
written consent need not be signed by those directors specified in Section 78.315(a) or (b) of the Nevada Revised Statutes to be effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 88; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.13 <span style="text-decoration: underline">Fees and Compensation of Directors</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise provided in the articles of incorporation or these bylaws, the board of directors, without regard to personal interest, may
establish the compensation that directors and members of committees may receive for their services. If the board of directors establishes
the compensation of directors pursuant to this Section 3.13, such compensation is presumed to be fair to the corporation unless proven
unfair by a preponderance of the evidence. Nothing herein shall be construed to preclude any director or member of any committee from
serving the corporation as an officer, employee or agent, or in any other capacity, and receiving compensation therefor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE
IV</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OFFICERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1 <span style="text-decoration: underline">Designated Officers</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 23.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
officers of the corporation shall consist of a chief executive officer, a chief financial officer and a secretary. The corporation may
also have, at the discretion of the board of directors, a chairperson of the board of directors, one or more vice presidents, one or
more assistant vice presidents, a treasurer, one or more assistant treasurers, one or more assistant secretaries, and any other officers
and agents as it may deem necessary and appropriate from time to time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2 <span style="text-decoration: underline">Appointment, Term and Compensation</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
board of directors shall appoint the officers of the corporation. All officers must be natural persons, and any one person may hold any
number of offices of the corporation at any one time. All officers shall have such authority and perform such duties in the management
of the business and affairs of the corporation as may be designated from time to time by the board of directors and, to the extent not
so designated, as generally pertain to their respective offices, subject to the control of the board of directors. Each officer shall
hold office at the pleasure of the board of directors until the expiration of the term for which the officer was appointed and such officer&#8217;s
successor is duly elected and qualified, or until such officer&#8217;s earlier resignation or removal. A vacancy in any office because
of death, resignation, retirement, disqualification, incapacity, removal or any other reason shall be filled by the board of directors.
The term of office and compensation of each officer shall be fixed and determined by the board of directors and may be altered by the
board of directors from time to time, subject to the rights, if any, of such officer under any contract of employment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3 <span style="text-decoration: underline">Resignation and Removal</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
officer may resign at any time by giving notice in writing or by electronic transmission to the board of directors or the chief executive
officer, or in his or her absence the president, or in his or her absence, the secretary. Any resignation shall be effective when received
by the person or persons to whom such notice is given, unless a later date or time is specified therein, in which event the resignation
shall become effect at such later date or time. Unless otherwise specified in the notice, the acceptance of the resignation shall not
be necessary to make it effective. Any resignation shall be without prejudice to the rights, if any, of the corporation under any contract
to which the officer is a party. Any officer may be removed from office at any time, with or without cause, by the affirmative vote of
the majority of the board of directors in office at the time or, in the case of subordinate officers not appointed by the board of directors,
by any officer upon whom such power of removal may be conferred by the board of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 89; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4 <span style="text-decoration: underline">Chairperson</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
chairperson of the board of directors shall have the powers and duties customarily and typically associated with the office of the chairperson
of the board of directors. The chairperson of the board of directors shall, if present, preside at meetings of the stockholders and meetings
of the board of directors. The chairperson of the board of directors shall exercise and perform such other duties as may from time to
time be agreed to by the board of directors. The chairperson of the board of directors shall report to the board of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5 <span style="text-decoration: underline">Chief
Executive Officer</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
chief executive officer shall have, subject to the supervision, direction and control of the board of directors, ultimate authority for
decisions relating to the supervision, direction and management of the business and affairs of the corporation in the manner customarily
and typically associated with the position of chief executive officer, including, without limitation, all powers necessary to direct
and control the organizational and reporting relationships within the corporation. If at any time the office of the chairperson of the
board of directors shall not be filled, or in the event of the absence, inability to act or refusal to act of the chairperson of the
board of directors, the chief executive officer shall perform the duties and exercise the powers of the chairperson of the board unless
otherwise determined by the board of directors. In the event of the absence, inability to act or refusal to act of the chief executive
officer, the board of directors shall meet promptly to confer the powers of the chief executive officer on another elected officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6 <span style="text-decoration: underline">President</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the supervision, direction and control of the board of directors and the chief executive officer, the president shall act in a general
executive capacity and shall assist the chief executive officer with the supervision, direction and management of the affairs and business
of the corporation in the manner customarily and typically associated with the position of president. The president shall have such powers
and perform such duties as may from time to time be assigned to him or her by the board of directors or the chief executive officer.
In the event of the absence, inability to act or refusal to act of the chief executive officer, the president shall perform the duties
and exercise the powers of the chief executive officer unless otherwise determined by the board of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7 <span style="text-decoration: underline">Vice Presidents and Assistant Vice Presidents</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
vice president and assistant vice president shall have such powers and perform such duties as may from time to time be assigned to him
or her by the board of directors, the chief executive officer or the president. Elected vice presidents shall have such other powers
and perform such other duties as may be granted or prescribed by the board of directors. Vice presidents appointed pursuant to Section
4.13 hereof shall have such powers and duties as may be fixed in accordance with that section, except that such appointed vice presidents
may not exercise the powers and duties of the chief executive officer or president.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 90; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8 <span style="text-decoration: underline">Secretary</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
secretary shall attend meetings of the board of directors and stockholders and record all votes and minutes of all such proceedings in
a book or books kept for such purpose. The secretary shall have all such further powers and duties as are customarily and typically associated
with the position of secretary or as may from time to time be assigned to him or her by the board of directors, chief executive officer
or president.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9 <span style="text-decoration: underline">Assistant
Secretaries</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
assistant secretary shall have such powers and perform such duties as may from time to time be assigned to him or her by the board of
directors, the chief executive officer, the president or the secretary. In the event of the absence, inability to act or refusal to act
of the secretary, the assistant secretary (or if there shall be more than one, the assistant secretaries in the order determined by the
board of directors, chief executive officer or chief financial officer) shall perform the duties and exercise the powers of the secretary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10 <span style="text-decoration: underline">Chief
Financial Officer</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
chief financial officer shall have custody of the corporation&#8217;s funds and securities, shall be responsible for maintaining the
corporation&#8217;s accounting records and statements, shall keep full and accurate accounts of receipts and disbursements in books belonging
to the corporation, and shall deposit or cause to be deposited moneys or other valuable effects in the name and to the credit of the
corporation in such depositories as may be designated by the board of directors. The chief financial officer shall also maintain adequate
records of all assets, liabilities and transactions of the corporation, shall render statements of the financial affairs of the corporation,
and shall assure that adequate audits and reviews thereof are regularly made. The chief financial officer shall have all such further
powers and duties as are customarily and typically associated with the position of chief financial officer, or as may from time to time
be assigned to him or her by the board of directors or the chief executive officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11 <span style="text-decoration: underline">Treasurer</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
treasurer shall have such powers and perform such duties as may from time to time be assigned to him or her by the board of directors,
the chief executive officer or the chief financial officer. In the event of the absence, inability to act or refusal to act of the chief
financial officer, the treasurer shall perform the duties and exercise the powers of the chief financial officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12 <span style="text-decoration: underline">Assistant
Treasurers</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
assistant treasurer shall have such powers and perform such duties as may from time to time be assigned to him or her by the board of
directors, the chief executive officer, the president or the chief financial officer. In the event of the absence, inability to act or
refusal to act of the treasurer, the assistant treasurer (or if there shall be more than one, the assistant treasurers in the order determined
by the board of directors, chief executive officer or chief financial officer) shall perform the duties and exercise the powers of the
treasurer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 91; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13 <span style="text-decoration: underline">Subordinate
Officers</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
board of directors may appoint, or empower the chief executive officer or, in the absence of the chief executive officer, the president
to appoint, such subordinate officers and agents as the business of the corporation may require. Each of such subordinate officers and
agents shall hold office for such period, have such authority, and perform such duties as are provided in these bylaws or as the board
of directors, chief executive officer or president may from time to time determine.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14 <span style="text-decoration: underline">Delegation
of Authority</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
board of directors may from time to time delegate the powers or duties of any officer to any other officer or agent, notwithstanding
any provision hereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE
V</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>STOCK</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1 <span style="text-decoration: underline">Stock Certificates</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise provided in these bylaws, every stockholder shall be entitled to have a certificate representing the number of shares registered
in certificate form signed by officers or agents designated by the corporation for such purpose, certifying the number of shares in the
corporation owned by the stockholder. Certificates for shares of capital stock, if any, shall be in such form as is consistent with the
provisions of the articles of incorporation and the Nevada Revised Statutes. Whenever any certificate is countersigned or otherwise authenticated
by a transfer agent or transfer clerk, and by a registrar, then a facsimile of the signatures of the officers or agents, the transfer
agent or transfer clerk or the registrar of the corporation may be printed or lithographed upon the certificate in lieu of the actual
signatures. In case any officer who has signed, or whose facsimile signature has been placed upon, a certificate has ceased to be such
officer, whether because of death, resignation or otherwise, before the certificate is issued, the certificate may nevertheless be issued
by the corporation with the same effect as if such person had not ceased to be such officer on the date of issue. The corporation has
no power to issue a certificate in bearer form, and any such certificate that is issued is void and of no force or effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2 <span style="text-decoration: underline">Special Designation on Certificates</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the corporation is authorized to issue more than one class of stock or more than one series of any class of stock, then the powers, designations,
preferences, rights and privileges of each class of stock or series thereof, and the qualifications, limitations or restrictions of such
class of stock or series thereof, shall be set forth in full or summarized on the face or back of the certificate that the corporation
shall issue to represent such class or series of stock; <i>provided</i>, <i>however</i>, that, in lieu of the foregoing requirements,
there may be set forth, on the face or back of the certificate representing such class or series of stock, a statement that the corporation
shall furnish without charge to each stockholder who so requests, the powers, designations, preferences, rights and privileges of each
class of stock or series thereof and the qualifications, limitations or restrictions of such class of stock or series thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 92; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3 <span style="text-decoration: underline">Lost, Stolen or Destroyed Certificates</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
corporation shall not issue a new stock certificate in place of a previously issued stock certificate unless the latter is surrendered
to the corporation and cancelled at the same time. The corporation may issue a new stock certificate or, if authorized by the board of
directors, uncertificated shares in place of a previously issued stock certificate alleged to have been lost, stolen or destroyed upon
the execution and delivery of an affidavit of that fact to the corporation or its agent by the owner of the stock certificate alleged
to have been lost, stolen or destroyed, or the owner&#8217;s legal representative. The corporation may require, as a condition precedent
to the issuance of a new stock certificate, that the owner of the lost, stolen or destroyed stock certificate, or the owner&#8217;s legal
representative, agree to indemnify the corporation in such manner as the corporation shall require, or to give the corporation a surety
bond or other security in such form and amount sufficient to indemnify the corporation against any claim that may be made against the
corporation with respect to the stock certificate alleged to have been lost, stolen or destroyed or the issuance of a new certificate
or uncertificated shares in place of the stock certificate alleged to have been lost, stolen or destroyed. The board of directors may
adopt such other provisions and restrictions with reference to lost certificates as it deems necessary or appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4 <span style="text-decoration: underline">Uncertificated
Shares</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
board of directors may authorize the issuance of uncertificated shares of some or all of the shares of any or all of its classes or series
of stock. Within a reasonable time after the issuance or transfer of shares without certificates, the corporation shall send the stockholder
a written statement containing the information required to be placed on certificates under these bylaws. At least annually thereafter,
the corporation shall provide to its stockholders of record a written statement confirming the information contained in the informational
statement. The rights and obligations of stockholders are identical whether or not their shares of stock are represented by certificates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.5 <span style="text-decoration: underline">Dividends</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
board of directors may from time to time, subject to the provisions of the articles of incorporation or these bylaws, declare and pay
dividends upon shares of the corporation&#8217;s capital stock in cash, property or shares of the corporation&#8217;s capital stock.
The board of directors may, from time to time, set aside from any funds otherwise available for dividends, a reserve or reserves for
equalizing dividends, repairing or maintaining the corporation&#8217;s property, meeting contingencies, or for any other proper purpose,
and may, from time to time, modify or abolish any such reserve or reserves.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6 <span style="text-decoration: underline">Partly-Paid
Shares</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
corporation may issue the whole or any part of its shares as partly paid and subject to call for the remainder of the consideration to
be paid therefor. Upon the face or back of each stock certificate issued to represent any such partly-paid shares, or upon the books
and records of the corporation in the case of uncertificated partly-paid shares, the total amount of the consideration to be paid therefor
and the amount paid thereon shall be stated. Upon the declaration of any dividend on fully-paid shares, the corporation shall declare
a dividend upon partly-paid shares of the same class, but only upon the basis of the percentage of the consideration actually paid thereon.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 93; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.7 <span style="text-decoration: underline">Transfers of Stock</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transfers
of record of shares of stock of the corporation shall be made upon the corporation&#8217;s books only by the holders thereof, in person
or by an attorney duly authorized, and, if such stock is certificated, upon the surrender of the certificate or certificates for a like
number of shares, properly endorsed or accompanied by proper evidence of succession, assignation or authority to transfer. The corporation
shall have power to enter into and perform any agreement with one or more stockholders of one or more classes or series of stock of the
corporation to restrict the transfer of shares of stock owned by such stockholders or any successors or transferees thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.8 <span style="text-decoration: underline">Registered
Stockholders</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
corporation: (i) shall be entitled to recognize the exclusive right of a person registered on its books as the owner of shares to receive
dividends and to vote as such owner, (ii) shall be entitled to hold liable for calls and assessments the person registered on its books
as the owner of shares, and (iii) shall not be bound to recognize any equitable or other claim to or interest in such shares on the part
of another person, whether or not it shall have express or other notice thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE
VI</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTICE
AND WAIVER; REMOTE PARTICIPATION IN MEETINGS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1 <span style="text-decoration: underline">Notice by Mail or Delivery</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whenever,
under the articles of incorporation, these bylaws or the Nevada Revised Statutes, written notice is required to be given to any stockholder,
written notice: (i) if mailed, is given when deposited in the United States mail, postage prepaid, directed to the stockholder at the
stockholder&#8217;s address as it appears on the corporation&#8217;s records, and (ii) if delivered, is given when left at the address
of the stockholder as it appears on the corporation&#8217;s records. An affidavit of the secretary of the corporation, or of the transfer
agent or other agent of the corporation, that the notice has been given by mail shall, in the absence of fraud, be <i>prima facie</i>
evidence of the facts stated therein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2 <span style="text-decoration: underline">Notice by Electronic Transmission</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Without
limiting the manner by which notice otherwise may be given effectively to stockholders, any notice to stockholders given by the corporation
under any provision of the articles of incorporation, these bylaws or the Nevada Revised Statutes shall be effective if given by a form
of electronic transmission consented to by the stockholder to whom the notice is given, and the electronic transmission contains or is
accompanied by information from which the stockholder can determine the date of the transmission. Any such consent shall be revocable
by the stockholder by written notice or notice by electronic transmission to the corporation. Any such consent shall be deemed revoked
if:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) the stockholder is unable to receive two consecutive notices given by electronic transmission
by the corporation in accordance with such consent; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) such inability becomes known to the secretary of the corporation or to the transfer agent or
other person responsible for the giving of notice;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 94; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>provided</i>,
<i>however</i>, that the inadvertent failure to treat such inability to deliver notice by electronic transmission as a revocation shall
not invalidate any meeting or other action.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
notice given to a stockholder by electronic transmission shall be deemed given when it is received by the stockholder. Unless otherwise
agreed between the corporation and the stockholder, an electronic transmission shall be deemed received by the stockholder when:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
it enters an information processing system that the stockholder has designated or uses for the purpose of receiving electronic
transmissions or information of the type sent; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
it is in a form ordinarily capable of being processed by that system.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 23.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Receipt
of an electronic acknowledgment from an information processing system establishes that an electronic transmission was received but, by
itself, does not establish that the content sent corresponds to the content received. An electronic transmission is received even if
no natural person is aware of its receipt. An affidavit of the secretary of the corporation, or of the transfer agent or other agent
of the corporation, that the notice has been given by a form of electronic transmission shall, in the absence of fraud, be <i>prima facie</i>
evidence of the facts stated therein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
&#8220;electronic transmission&#8221; means any form of communication, not directly involving the physical transmission of paper, that
creates a record that may be retained, retrieved and reviewed by the recipient thereof, and that may be directly reproduced in paper
form by such recipient through an automated process used in conventional commercial practice; <i>provided</i>, <i>however</i>, that such
communication need not be reproducible in such manner if: (i) the electronic transmission is otherwise retrievable in perceivable form,
and (ii)&#8194;the sender and the recipient have consented in writing to the use of such form of electronic transmission.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3 <span style="text-decoration: underline">Notice to Stockholders Sharing and Address</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Without
limiting the manner by which notice may otherwise be given effectively to stockholders, any notice to stockholders given by the corporation
under the provisions of the articles of incorporation, these bylaws or the Nevada Revised Statutes shall be effective if given by a single
written notice to stockholders who share an address if consented to by the stockholders at the address to whom such notice is given.
Such consent shall be deemed to have been given by the stockholders if the stockholders fail to object in writing to the corporation
within sixty (60) days of the date the stockholders were given such notice by the corporation of its intention to send a single notice
to them. The stockholders may revoke any such consent by giving written notice to the corporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4 <span style="text-decoration: underline">Notice to Person With Whom Communication is Unlawful</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whenever
notice is required to be given, under the articles of incorporation, these bylaws or the Nevada Revised Statutes, to any person with
whom communication is unlawful, the giving of such notice to such person shall not be required and there shall be no duty to apply to
any governmental authority or agency for a license or permit to give such notice to such person. Any action or meeting that shall be
taken or held without notice to any such person with whom communication is unlawful shall have the same force and effect as if such notice
had been duly given. In the event that the action taken by the corporation is such as to require the filing of a certificate under the
Nevada Revised Statutes, the certificate shall state, if such is the fact and if notice is required, that notice was given to all persons
entitled to receive notice except such persons with whom communication is unlawful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 95; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.5 <span style="text-decoration: underline">Waiver of Notice</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whenever
notice or other communication is required to be given to stockholders or other persons under the articles of incorporation, these bylaws
or the Nevada Revised Statutes, a written waiver, signed by the person or persons entitled to the notice or communication, or a waiver
by electronic transmission by the person or persons entitled to the notice or communication, whether before or after the time of the
event for which the notice or communication is to be given, shall be deemed equivalent to such notice or communication. Attendance of
a person at a meeting shall constitute a waiver of notice of such meeting, except when the person attends a meeting solely for the express
purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called
or convened. Neither the business to be transacted at, nor the purpose of, any regular or special meeting of the stockholders or the
board of directors, as the case may be, need be specified in any written waiver of notice or any waiver by electronic transmission unless
so required by the articles of incorporation or these bylaws. Any stockholder or director so waiving notice of such meeting of the stockholders
or the board of directors, as applicable, shall be bound by the proceedings of any such meeting of the stockholders or the board of directors,
as applicable, in all respects as if due notice thereof had been given.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.6 <span style="text-decoration: underline">Participation
in Meetings by Remote Communication</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise restricted by the articles of incorporation or bylaws, stockholders, members of the board of directors or the governing body
of any corporation, or of any committee designated by such board or body, may participate in a meeting of the stockholders, board, governing
body or committee, as the case may be, through remote communication. &#8220;Remote communication&#8221; means electronic communications,
videoconferencing, teleconferencing or other available technology if the corporation has implemented reasonable measures to: (i) verify
the identity of each person participating through such means as a stockholder, director or member of the governing body or committee,
as the case may be, and (ii)&#8194;provide the stockholders, directors or members of the governing body or committee a reasonable opportunity
to participate in the meeting and to vote on matters submitted to the stockholders, directors or members of the governing body or committee,
as the case may be, including an opportunity to communicate and to read or hear the proceedings of the meeting in a substantially concurrent
manner with such proceedings. Participation in a meeting by remote communication pursuant to this Section 6.6 shall constitute presence
in person at the meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE
VII</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDEMNIFICATION
AND LIMITATIONS ON LIABILITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1 <span style="text-decoration: underline">Indemnification of Officers and Directors in Third-Party Proceedings</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the other provisions of this Article VII, the corporation shall, to the fullest extent permitted by the Nevada Revised Statutes, indemnify
any person who is or was a party to, or is threatened to be made a party to, any threatened, pending or completed action, suit or proceeding,
whether civil, criminal, administrative or investigative, except an action, suit or proceeding by or in the right of the corporation,
by reason of the fact that such person is or was an officer or director of the corporation, or, while such person is or was serving as
an officer or director of the corporation, such person is or was serving at the request of the corporation as an officer, director, employee
or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses, including attorneys&#8217;
fees, judgments, fines and amounts paid in settlement, actually and reasonably incurred by such person in connection with such action,
suit or proceeding if such person: (i) is not liable pursuant to Section 78.138 of the Nevada Revised Statutes, or (ii) acted in good
faith and in a manner that such person reasonably believed to be in or not opposed to the best interests of the corporation, and, with
respect to any criminal action or proceeding, had no reasonable cause to believe such person&#8217;s conduct was unlawful. The termination
of any such action, suit or proceeding by judgment, order, settlement or conviction, or upon a plea of <i>nolo contendere</i> or its
equivalent, shall not, of itself, create a presumption that the person: (i) is liable pursuant to Section 78.138 of the Nevada Revised
Statutes, or (ii) did not act in good faith and in a manner which such person reasonably believed to be in or not opposed to the best
interests of the corporation, or, with respect to any criminal action or proceeding, had reasonable cause to believe that such person&#8217;s
conduct was unlawful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 96; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Indemnification of Officers and Directors in Actions by or in the Right of the Corporation</span>.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the other provisions of this Article VII, the corporation shall, to the fullest extent permitted by the Nevada Revised Statutes, indemnify
any person who is or was a party to, or is threatened to be made a party to, any threatened, pending or completed action or suit by or
in the right of the corporation to procure a judgment in its favor by reason of the fact that such person is or was an officer or director
of the corporation, or, while such person is or was serving as an officer or director of the corporation, such person is or was serving
at the request of the corporation as an officer, director, employee or agent of another corporation, partnership, joint venture, trust
or other enterprise, against expenses, including amounts paid in settlement and attorneys&#8217; fees actually and reasonably incurred
by such person in connection with the defense or settlement of the action or suit, if such person: (i) is not liable pursuant to Section
78.138 of the Nevada Revised Statutes, and (ii) acted in good faith and in a manner that such person reasonably believed to be in or
not opposed to the best interests of the corporation. Indemnification may not be made for any claim, issue or matter as to which such
a person has been adjudged by a court of competent jurisdiction, after exhaustion of all appeals therefrom, to be liable to the corporation
or for amounts paid in settlement to the corporation, unless and only to the extent that the court in which the action or suit was brought
or other court of competent jurisdiction determines upon application that in view of all the circumstances of the case, the person is
fairly and reasonably entitled to indemnity for such expenses as the court deems proper.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.3 <span style="text-decoration: underline">Successful Defense</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that a present or former officer, director, employee or agent of the corporation has been successful on the merits or otherwise
in defense of any action, suit or proceeding referred to in Sections 7.1 or 7.2 hereof, or in defense of any claim, issue or matter therein,
the corporation shall indemnify such person against expenses, including attorneys&#8217; fees, actually and reasonably incurred by such
person in connection therewith.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.4 <span style="text-decoration: underline">Indemnification of Employees and Agents</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the other provisions of this Article VII, the corporation shall have the power to indemnify its employees and agents to the fullest
extent permitted by the Nevada Revised Statutes or other applicable law. The board of directors shall have the power to delegate to one
or more persons the determination of whether indemnification shall be provided to employees and agents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 97; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.5 <span style="text-decoration: underline">Advanced Payment of Expenses</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
corporation shall, to the fullest extent permitted by the Nevada Revised Statutes, advance to any person who is or was made a party to,
or is threatened to be made a party to, any threatened, pending or completed civil or criminal action, suit or proceeding by reason of
the fact that such person is or was an officer or director of the corporation, or, while such person is or was serving as an officer
or director of the corporation, such person is or was serving at the request of the corporation as an officer, director, employee or
agent of another corporation, partnership, joint venture, trust or other enterprise, all expenses incurred by such officer or director
in defending against such action, suit or proceeding as they are incurred and in advance of the final disposition of such action, suit
or proceeding, upon receipt of an undertaking by or on behalf of such officer or director to repay the amount if it is ultimately determined
by a court that such officer or director is not entitled to be indemnified by the corporation. The right to advancement of expenses shall
not apply to any action, suit or proceeding for which indemnity is prohibited pursuant to these bylaws, but shall apply to any action,
suit or proceeding referenced in Section 7.6(iii) or (iv) hereof prior to a determination that the person is not entitled to be indemnified
by the corporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.6 <span style="text-decoration: underline">Limitations on Indemnification</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the requirements of Section 7.3 hereof and the Nevada Revised Statutes, the corporation shall not be obligated to indemnify any person
pursuant to this Article VII in connection with any action, suit or proceeding, or any part of any action, suit or proceeding:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) to
the extent the corporation&#8217;s obligation to indemnify such person has been limited pursuant to one or more agreements to which the
corporation and such person are a party;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) for which payment has actually been made to or on behalf of such person under any statute,
insurance policy, indemnity provision, vote or otherwise, except with respect to any excess beyond the amount paid;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii) for an accounting or disgorgement of profits pursuant to Section 16(b) of the Exchange Act,
or similar provisions of federal, state or local statutory law or common law, if such person is held liable therefor (including pursuant
to any settlement arrangements);</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv) for any reimbursement of the corporation by such person of any bonus or other incentive-based
or equity-based compensation or of any profits realized by such person from the sale of securities of the corporation, as required in
each case under the Exchange Act (including any such reimbursements that arise from an accounting restatement of the corporation pursuant
to Section 304 of the Sarbanes-Oxley Act of 2002 (the &#8220;Sarbanes-Oxley Act&#8221;), or the payment to the corporation of profits
arising from the purchase and sale by such person of securities in violation of Section 306 of the Sarbanes-Oxley Act), if such person
is held liable therefor (including pursuant to any settlement arrangements);</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v) initiated by such person, unless: (1) the board of directors authorized the action, suit or
proceeding, or relevant part thereof, (2) the corporation, in its sole discretion, provides the indemnification pursuant to the powers
vested in the corporation under applicable law, (3) the corporation is required to provide the indemnification pursuant to Section 7.7
hereof, or (4) the corporation is required to provide the indemnification pursuant to applicable law; or</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi) if prohibited by applicable law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 98; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.7 <span style="text-decoration: underline">Enforcement</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If,
after final disposition of the applicable action, suit or proceeding, a claim for indemnification or advancement of expenses under this
Article VII is not paid in full within sixty (60) days after receipt by the corporation of a written request therefor from the claimant,
the claimant shall be entitled to an adjudication by a court of competent jurisdiction of his or her entitlement to such indemnification
or advancement of expenses. The corporation shall indemnify such person to the fullest extent permitted by law against any and all expenses
that are incurred by such person in connection with prosecuting or defending any action for indemnification or advancement of expenses
from the corporation under this Article VII to the extent such person is successful in such action and to the extent not prohibited by
law. In any such action, the corporation shall, to the fullest extent not prohibited by law, have the burden of proving that the claimant
is not entitled to the requested indemnification or advancement of expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.8 <span style="text-decoration: underline">Limitation
on Liability</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the fullest extent permitted by the Nevada Revised Statutes, an officer or director of the corporation shall not be personally liable
to the corporation or its stockholders or creditors for any damages as a result of any act or failure to act in his or her capacity as
an officer or director of the corporation unless it is proven that: (i) the officer&#8217;s or director&#8217;s act or failure to act
constituted a breach of his or her fiduciary duties as an officer or director, and (ii) the breach of those duties involved intentional
misconduct, fraud or a knowing violation of law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.9 <span style="text-decoration: underline">Non-Exclusivity of Rights</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rights to indemnification and advancement of expenses granted under this Article VII shall not be deemed exclusive of any other rights
to which a person seeking indemnification or advancement of expenses may be entitled under the articles of incorporation or these bylaws,
any agreement, any vote of stockholders or disinterested directors, or otherwise, for either an action in such person&#8217;s official
capacity or an action in another capacity while holding such office, except that indemnification, unless ordered by a court pursuant
to Section 78.7502 of the Nevada Revised Statutes or for the advancement of expenses made pursuant to Section 7.5 hereof, may not be
made to or on behalf of any officer or director if a final adjudication establishes that the officer&#8217;s or director&#8217;s acts
or omissions involved intentional misconduct, fraud or a knowing violation of the law and was material to the cause of action. The limitations
on personal liability granted under this Article VII shall not be deemed exclusive of any other limitations on personal liability to
which a person may be entitled under the articles of incorporation or these bylaws, any agreement, any vote of stockholders or disinterested
directors, or otherwise. The corporation is specifically authorized to enter into individual contracts with any or all of its directors,
officers, employees or agents with respect to indemnification, advancement of expenses and limitations on personal liability to the fullest
extent permitted by the Nevada Revised Statutes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 99; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.10 <span style="text-decoration: underline">Insurance</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
corporation may, to the fullest extent permitted by the Nevada Revised Statutes, purchase and maintain insurance or make other financial
arrangements on behalf of any person who is required or permitted to be indemnified under this Article VII for any liability asserted
against the person and any liability and expenses incurred by the person in his or her capacity as a director, officer, employee or agent,
as the case may be, or arising out of such person&#8217;s status as such, whether or not the corporation has the authority to indemnify
such a person against such liability and expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.11 <span style="text-decoration: underline">Reliance</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
rights to indemnification, advancement of expenses and limitations on liability and other rights granted in this Article VII shall be
deemed contractual rights of the officers and directors, effective and enforceable to the same extent as if they were set forth in a
written agreement between the corporation and the applicable officer or director. Persons who were serving as officers or directors of
the corporation on the date this Article VII was adopted by the corporation, or who become an officer or director of the corporation
after the date this Article VII was adopted by the corporation, shall be conclusively presumed to have relied upon the rights to indemnity,
advancement of expenses, limitations on liability and other rights granted in this Article VII in deciding to enter into or continue
such service with the corporation. The rights to indemnification, advancement of expenses, limitations on liability and other rights
granted in this Article VII shall apply to claims made against any such officers and directors arising out of acts or omissions that
occurred during or prior to the adoption of this Article VII as well as acts or omissions that occurred subsequent to the adoption of
this Article VII.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.12 <span style="text-decoration: underline">Survival of Rights</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rights to indemnification, advancement of expenses, limitations on liability and other rights conferred by this Article VII shall continue
for any person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of such person&#8217;s heirs,
executors and administrators.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.13 <span style="text-decoration: underline">Amendment or Repeal</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event the Nevada Revised Statutes are hereafter amended to permit the corporation to provide broader rights to indemnification or
advancement of expenses to officers or directors than those provided herein, then the rights of officers and directors to indemnification
and advancement of expenses, in addition to the rights of officers and directors to indemnification and advancement of expenses provided
herein, shall be broadened to the fullest extent permitted by the Nevada Revised Statutes as so amended. In the event the Nevada Revised
Statutes are hereafter amended to further limit or eliminate the liability of officers or directors, then the liability of officers and
directors, in addition to the limitation on personal liability provided herein, shall be limited to the fullest extent permitted by the
Nevada Revised Statutes as so amended. Neither any amendment nor repeal of this Article VII, nor the adoption of any provision in the
articles of incorporation that is inconsistent with this Article VII, shall eliminate or reduce the effect of this Article VII in respect
of any matter occurring, or any action, suit or proceeding accruing or arising or that, but for this Article VII, would accrue or arise,
prior to such amendment, repeal or adoption of such inconsistent provision.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 100; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.14 <span style="text-decoration: underline">Certain
Definitions</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this Article VII, the following definitions shall apply:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) references to the &#8220;corporation&#8221; shall include, in addition to the resulting corporation,
any constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger that, if its separate
existence had continued, would have had power and authority to indemnify its directors, officers, employees or agents, so that any person
who is or was a director, officer, employee or agent of such constituent corporation, or is or was serving at the request of such constituent
corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise,
shall stand in the same position under the provisions of this Article VII with respect to the resulting or surviving corporation as such
person would have with respect to such constituent corporation if its separate existence had continued;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) references to &#8220;other enterprises&#8221; shall include employee benefit plans;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii) references to &#8220;fines&#8221; shall include any excise taxes assessed on a person with
respect to an employee benefit plan;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv) references to &#8220;serving at the request of the corporation&#8221; shall include any service
as a director, officer, employee or agent of the corporation that imposes duties on, or involves services by, such director, officer,
employee or agent with respect to an employee benefit plan, its participants or beneficiaries; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v) a person who acted in good faith and in a manner such person reasonably believed to be in the
best interests of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner &#8220;not
opposed to the best interests of the corporation&#8221; as referred to in this section.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE
VIII</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GENERAL
MATTERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1 <span style="text-decoration: underline">Execution of Corporate Contracts and Instruments</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise provided in the articles of incorporation or these bylaws, the board of directors may authorize any officer, agent or employee
to enter into any contract or execute any document or instrument in the name of and on behalf of the corporation. Such authority may
be general or confined to specific instances. Unless so authorized or ratified by the board of directors or within the agency power of
an officer, no officer, agent or employee shall have any power or authority to bind the corporation by any contract or engagement or
to pledge its credit or to render it liable for any purpose or for any amount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2 <span style="text-decoration: underline">Execution
of Checks, Drafts and Evidences of Indebtedness</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the board of directors or its delegate shall determine by resolution which person or persons may sign or endorse checks,
drafts, other orders for payment of money, or notes or other evidences of indebtedness that are issued in the name of or payable to the
corporation, and only the persons so authorized shall sign or endorse those instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 101; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.3 <span style="text-decoration: underline">Representation
of Shares of Other Corporations</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
chairperson of the board of directors, the chief executive officer, the president or any vice president, the chief financial officer,
the treasurer, or the secretary of the corporation, or any other person authorized by the board of directors or the chief executive officer,
is authorized to vote, represent and exercise on behalf of the corporation all rights incident to any and all securities of any other
corporation, entity or other organization owned or held by the corporation for itself or for other parties in any capacity. The authority
granted herein may be exercised either by such person directly or by any other person authorized to do so by proxy or power of attorney
duly executed by such person having the authority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.4 <span style="text-decoration: underline">Fiscal Year</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fiscal year of the corporation shall be fixed by resolutions of the board of directors and may be changed by resolutions of the board
of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.5 <span style="text-decoration: underline">Corporate Seal</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
board of directors shall have the power to adopt and use a corporate seal or stamp, and alter the same at its pleasure. The use of a
seal or stamp by the corporation on any corporate record is not necessary, and any such use or nonuse must not in any way affect the
legality of any record.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.6 <span style="text-decoration: underline">Construction; Definitions</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
the context requires otherwise, the general provisions, rules of construction and definitions in the Nevada Revised Statutes shall govern
the construction of these bylaws. Without limiting the generality of this provision, the singular number includes the plural, the plural
number includes the singular, and the term &#8220;person&#8221; includes both an entity and a natural person.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.7 <span style="text-decoration: underline">
Certain Conflicts</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent any provision of these bylaws or the application thereof to any person or circumstance conflicts with any provision of the
articles of incorporation, applicable stock exchange rules, the Nevada Revised Statutes or other applicable law, the provisions of the
articles of incorporation, applicable stock exchange rules, the Nevada Revised Statutes or other applicable law, as the case may be,
shall govern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.8 <span style="text-decoration: underline">Severability</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent any provision of these bylaws or the application thereof to any person or circumstance is held to be invalid, illegal or unenforceable
for any reason and to any extent whatsoever: (i) such provision shall be enforced to the fullest extent permitted by law consistent with
such holding, and construed so as to give effect to the intent manifested by the provision, and (ii) the remaining provisions of these
bylaws shall not in any way be affected or impaired thereby and shall remain in full force and effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 102; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE
IX</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AMENDMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
board of directors is expressly authorized and empowered to adopt, amend or repeal these bylaws, including any bylaw adopted by the stockholders
of the corporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 103; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><span id="a_023"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">APPENDIX
F</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AMENDMENT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TO</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022
EQUITY INCENTIVE PLAN</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Adopted
April 12, 2022, and ratified by Stockholders [&#160;&#160;])</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
4.1 is hereby amended and restated in its entirety to read as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.1
Authorized Number of Shares</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to adjustment from time to time as provided in Section 15.1, the aggregate maximum number of shares of Common Stock available for issuance
under the Plan shall be:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,000,000
    shares, plus</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing
    January 1, 2025, an annual increase to be added as of the first day of our fiscal year equal to the least of: (i) 15% of the outstanding
    Common Stock on a fully diluted basis as of the end of our immediately preceding fiscal year, or (ii) a lesser amount determined
    by the Board; <i>provided, however</i>, that any shares from any such increases in previous years that are not actually issued shall
    continue to be available for issuance under the Plan subject to adjustment from time to time as provided in Section 15.1.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 44pt; text-align: justify; text-indent: -20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
issued under the Plan shall be drawn from authorized and unissued shares or shares now held or subsequently acquired by us as treasury
shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 104; Options: NewSection Last; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->
<!-- Field: Set; Name: xdx; ID: xdx_088_labels -->
<!-- eJwdzLEOgkAMgOHdxHdobjaU6Mams8MNbMShd1eVWCkpFw7fXmD//t9dU+pzrwMJ3CmwTO7k3jmPDWIppVqCSaX2wnNdX9BUGGVj7nhwHFPj57GlINzykm+i8bPmnn4wT+DZnmpfGiJDtyPYFOzssQ7+OCopiQ== -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>formpre14a_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 formpre14a_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !- 2P# 2(  A$! Q$!_\0
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M5LDZ(^"-P# X."1GWH$C\C_^"<KJ9/CMA@?^*"N^A^M?-GP)D4_&/X=?,/\
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>C<>*(=+MTU.5G#LUP(U$A+#@G.<D=3DUUM% C__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>rime-20241231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaOEubP9z5Z8WekhvWB+bdkKjy8l/l9MjicvcW528akM -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:RIME="http://algoholdings.com/20241231" elementFormDefault="qualified" targetNamespace="http://algoholdings.com/20241231">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://algoholdings.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="rime-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="rime-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="rime-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
    <element id="RIME_ReportedValueOfEquityAwardsMember" name="ReportedValueOfEquityAwardsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RIME_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember" name="FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RIME_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember" name="FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RIME_FairValueOfAwardsGrantedAndVestedDuringTheYearMember" name="FairValueOfAwardsGrantedAndVestedDuringTheYearMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RIME_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember" name="FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RIME_RichardPerezMember" name="RichardPerezMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RIME_LionelMarquisMember" name="LionelMarquisMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RIME_BernardoMeloMember" name="BernardoMeloMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>rime-20241231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="rime-20241231.xsd#Cover" roleURI="http://algoholdings.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosureWithAdditionalMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpTable" roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsToCompensation" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListsByExecutiveCategory" roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListMeasures" roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpExecutiveCategoriesOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTypeOnly" roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TradingArrangmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ForgoneRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#OutstandingRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardsCloseToMnpiDisc" roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangemenstByInd" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#Defaults" roleURI="http://xbrl.sec.gov/ecd/role/Defaults" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://algoholdings.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:loc xlink:type="locator" xlink:href="rime-20241231.xsd#RIME_ReportedValueOfEquityAwardsMember" xlink:label="loc_RIMEReportedValueOfEquityAwardsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_RIMEReportedValueOfEquityAwardsMember" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="rime-20241231.xsd#RIME_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember" xlink:label="loc_RIMEFairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_RIMEFairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="rime-20241231.xsd#RIME_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember" xlink:label="loc_RIMEFairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_RIMEFairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="rime-20241231.xsd#RIME_FairValueOfAwardsGrantedAndVestedDuringTheYearMember" xlink:label="loc_RIMEFairValueOfAwardsGrantedAndVestedDuringTheYearMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_RIMEFairValueOfAwardsGrantedAndVestedDuringTheYearMember" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="rime-20241231.xsd#RIME_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember" xlink:label="loc_RIMEFairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_RIMEFairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember" xlink:type="arc" order="40" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember" xlink:label="loc_ecdPeoMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecdAllIndividualsMember" xlink:to="loc_ecdPeoMember" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="rime-20241231.xsd#RIME_RichardPerezMember" xlink:label="loc_RIMERichardPerezMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecdAllIndividualsMember" xlink:to="loc_RIMERichardPerezMember" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="rime-20241231.xsd#RIME_LionelMarquisMember" xlink:label="loc_RIMELionelMarquisMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecdAllIndividualsMember" xlink:to="loc_RIMELionelMarquisMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="rime-20241231.xsd#RIME_BernardoMeloMember" xlink:label="loc_RIMEBernardoMeloMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecdAllIndividualsMember" xlink:to="loc_RIMEBernardoMeloMember" xlink:type="arc" order="30" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>rime-20241231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember" xlink:label="ecd_PeoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoMember" xlink:to="ecd_PeoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoMember_lbl" xml:lang="en-US">PEO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="rime-20241231.xsd#RIME_ReportedValueOfEquityAwardsMember" xlink:label="RIME_ReportedValueOfEquityAwardsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RIME_ReportedValueOfEquityAwardsMember" xlink:to="RIME_ReportedValueOfEquityAwardsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RIME_ReportedValueOfEquityAwardsMember_lbl" xml:lang="en-US">Reported Value of Equity Awards [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="rime-20241231.xsd#RIME_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember" xlink:label="RIME_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RIME_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember" xlink:to="RIME_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RIME_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember_lbl" xml:lang="en-US">Fair Value as of Year End for Unvested Awards Granted During the Year [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="rime-20241231.xsd#RIME_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember" xlink:label="RIME_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RIME_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember" xlink:to="RIME_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RIME_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember_lbl" xml:lang="en-US">Fair Value Year Over Year Increase or Decrease in Unvested Awards Granted in Prior Years [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="rime-20241231.xsd#RIME_FairValueOfAwardsGrantedAndVestedDuringTheYearMember" xlink:label="RIME_FairValueOfAwardsGrantedAndVestedDuringTheYearMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RIME_FairValueOfAwardsGrantedAndVestedDuringTheYearMember" xlink:to="RIME_FairValueOfAwardsGrantedAndVestedDuringTheYearMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RIME_FairValueOfAwardsGrantedAndVestedDuringTheYearMember_lbl" xml:lang="en-US">Fair Value of Awards Granted and Vested During the Year [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="rime-20241231.xsd#RIME_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember" xlink:label="RIME_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RIME_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember" xlink:to="RIME_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RIME_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember_lbl" xml:lang="en-US">Fair Value Increase or Decrease from Prior Year end for Awards that Vested during the Year [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="rime-20241231.xsd#RIME_RichardPerezMember" xlink:label="RIME_RichardPerezMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RIME_RichardPerezMember" xlink:to="RIME_RichardPerezMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RIME_RichardPerezMember_lbl" xml:lang="en-US">Richard Perez [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="rime-20241231.xsd#RIME_LionelMarquisMember" xlink:label="RIME_LionelMarquisMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RIME_LionelMarquisMember" xlink:to="RIME_LionelMarquisMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RIME_LionelMarquisMember_lbl" xml:lang="en-US">Lionel Marquis [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="rime-20241231.xsd#RIME_BernardoMeloMember" xlink:label="RIME_BernardoMeloMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RIME_BernardoMeloMember" xlink:to="RIME_BernardoMeloMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RIME_BernardoMeloMember_lbl" xml:lang="en-US">Bernardo Melo [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="ecd_PnsnBnftsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PnsnBnftsAdjFnTextBlock" xlink:to="ecd_PnsnBnftsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PnsnBnftsAdjFnTextBlock_lbl" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock" xlink:label="ecd_EqtyAwrdsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="ecd_EqtyAwrdsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EqtyAwrdsAdjFnTextBlock_lbl" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement does not require Recovery</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems" xlink:label="ecd_AwardTmgDiscLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgDiscLineItems" xlink:to="ecd_AwardTmgDiscLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgDiscLineItems_lbl" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Underlying Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Fair Value as of Grant Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable" xlink:label="ecd_TradingArrByIndTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TradingArrByIndTable" xlink:to="ecd_TradingArrByIndTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TradingArrByIndTable_lbl" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis" xlink:label="ecd_TradingArrAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TradingArrAxis" xlink:to="ecd_TradingArrAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TradingArrAxis_lbl" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="ecd_TrdArrExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrExpirationDate" xlink:to="ecd_TrdArrExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="ecd_TrdArrSecuritiesAggAvailAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt_lbl" xml:lang="en-US">Aggregate Available</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RIME_ReportedValueOfEquityAwardsMember" xlink:to="RIME_ReportedValueOfEquityAwardsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RIME_ReportedValueOfEquityAwardsMember_doc" xml:lang="en-US">Reported Value of Equity Awards [Member]]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RIME_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember" xlink:to="RIME_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RIME_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember_doc" xml:lang="en-US">Fair Value as of Year End for Unvested Awards Granted During the Year [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RIME_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember" xlink:to="RIME_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RIME_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember_doc" xml:lang="en-US">Fair Value Year Over Year Increase or Decrease in Unvested Awards Granted in Prior Years [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RIME_FairValueOfAwardsGrantedAndVestedDuringTheYearMember" xlink:to="RIME_FairValueOfAwardsGrantedAndVestedDuringTheYearMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RIME_FairValueOfAwardsGrantedAndVestedDuringTheYearMember_doc" xml:lang="en-US">Fair Value of Awards Granted and Vested During the Year [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RIME_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember" xlink:to="RIME_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RIME_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember_doc" xml:lang="en-US">Fair Value Increase or Decrease from Prior Year end for Awards that Vested during the Year [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RIME_RichardPerezMember" xlink:to="RIME_RichardPerezMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RIME_RichardPerezMember_doc" xml:lang="en-US">Richard Perez [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RIME_LionelMarquisMember" xlink:to="RIME_LionelMarquisMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RIME_LionelMarquisMember_doc" xml:lang="en-US">Lionel Marquis [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RIME_BernardoMeloMember" xlink:to="RIME_BernardoMeloMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="RIME_BernardoMeloMember_doc" xml:lang="en-US">Bernardo Melo [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_2_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_2_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_2_lbl" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>rime-20241231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="rime-20241231.xsd#Cover" roleURI="http://algoholdings.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" />
    <link:presentationLink xlink:type="extended" xlink:role="http://algoholdings.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember" xlink:label="loc_ecdPeoMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAllIndividualsMember" xlink:to="loc_ecdPeoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rime-20241231.xsd#RIME_RichardPerezMember" xlink:label="loc_RIMERichardPerezMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAllIndividualsMember" xlink:to="loc_RIMERichardPerezMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rime-20241231.xsd#RIME_LionelMarquisMember" xlink:label="loc_RIMELionelMarquisMember" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAllIndividualsMember" xlink:to="loc_RIMELionelMarquisMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rime-20241231.xsd#RIME_BernardoMeloMember" xlink:label="loc_RIMEBernardoMeloMember" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAllIndividualsMember" xlink:to="loc_RIMEBernardoMeloMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="rime-20241231.xsd#RIME_ReportedValueOfEquityAwardsMember" xlink:label="loc_RIMEReportedValueOfEquityAwardsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_RIMEReportedValueOfEquityAwardsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rime-20241231.xsd#RIME_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember" xlink:label="loc_RIMEFairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_RIMEFairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rime-20241231.xsd#RIME_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember" xlink:label="loc_RIMEFairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_RIMEFairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rime-20241231.xsd#RIME_FairValueOfAwardsGrantedAndVestedDuringTheYearMember" xlink:label="loc_RIMEFairValueOfAwardsGrantedAndVestedDuringTheYearMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_RIMEFairValueOfAwardsGrantedAndVestedDuringTheYearMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="rime-20241231.xsd#RIME_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember" xlink:label="loc_RIMEFairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_RIMEFairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="loc_ecdPnsnBnftsAdjFnTextBlock" />
      <link:presentationArc order="2280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPnsnBnftsAdjFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock" xlink:label="loc_ecdEqtyAwrdsAdjFnTextBlock" />
      <link:presentationArc order="2290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdEqtyAwrdsAdjFnTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable" xlink:label="loc_ecdTradingArrByIndTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTradingArrByIndTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis" xlink:label="loc_ecdTradingArrAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrByIndTable" xlink:to="loc_ecdTradingArrAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember" xlink:label="loc_ecdAllTradingArrangementsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrAxis" xlink:to="loc_ecdAllTradingArrangementsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrByIndTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="loc_ecdTrdArrExpirationDate" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="loc_ecdTrdArrSecuritiesAggAvailAmt" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrSecuritiesAggAvailAmt" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">PRE 14A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ALGORHYTHM
HOLDINGS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000923601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTableTextBlock', window );">Pay vs Performance [Table Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_883_eecd--PvpTableTextBlock_zUsDuhRhy85i" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Pay vs Performance Disclosure">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_489_eecd--PeoTotalCompAmt_zBIf65RslFb8" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Table Total</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>for CEO<sup id="xdx_F5D_zk7ii5WVE66h">(1)</sup></b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_484_eecd--PeoActuallyPaidCompAmt_z0KreWFuPnD2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Actually Paid</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>to CEO<sup id="xdx_F50_zx18Z5M7zNWa">(2)</sup></b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_48D_eecd--NonPeoNeoAvgTotalCompAmt_znAsXmjRXPO5" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Table Total for</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-CEO</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NEOs<sup id="xdx_F5D_zwVKRKwGas94">(3)</sup></b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_482_eecd--NonPeoNeoAvgCompActuallyPaidAmt_zzFKE6TCmK8k" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Actually Paid</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>to Non-CEO</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NEOs<sup id="xdx_F5F_zJOjxwtVSeYa">(4)</sup></b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_489_eecd--TotalShareholderRtnAmt_pp2d_zil0wnoWVsXd" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value of Initial</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fixed $100</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Investment</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Based On Total</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stockholder</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Return<sup id="xdx_F5E_zh1gfUjTUPCg">(5)</sup></b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_483_eus-gaap--NetIncomeLoss_zSgSxvsvoz54" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net Income (Loss)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_41D_20240101__20241231_zWb4dlIERxO9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left">Fiscal Year 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">253,535</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">263,535</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">203,635</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">226,302</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">8.74</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(23,257,000</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_41E_20230401__20231231_zZUIqKYclAV7" style="vertical-align: bottom; background-color: White">
    <td>Nine-Month Transition Period Ended December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">169,527</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">250,069</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">244,954</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">256,856</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">63.52</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(6,398,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_41C_20220401__20230331_zImPDYC4LnJ6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fiscal Year 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">307,451</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">263,866</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">415,138</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">388,476</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">12.68</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(4,638,462</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_416_20210401__20220331_zzzI1Gog4olj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Fiscal Year 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">161,414</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">161,414</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">245,935</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">243,829</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">34.15</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">230,471</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NamedExecutiveOfficersFnTextBlock', window );">Named Executive Officers, Footnote [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_898_eecd--NamedExecutiveOfficersFnTextBlock_dU_zDhwZROFZW3f" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    dollar amounts reported are the amounts of total compensation reported for our CEO, <span id="xdx_905_eecd--PeoName_c20240101__20241231__ecd--IndividualAxis__ecd--PeoMember_zJgXVKI8rZWc"><span id="xdx_90C_eecd--PeoName_c20220401__20230331__ecd--IndividualAxis__ecd--PeoMember_zmhztkV0wr96"><span id="xdx_901_eecd--PeoName_c20210401__20220331__ecd--IndividualAxis__ecd--PeoMember_zbDxUKgI8e5b">Gary Atkinson</span></span></span>, in the Summary Compensation Table
    for fiscal years 2024, 2023 and 2022.</span></td></tr>
</table>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoTotalCompAmt', window );">PEO Total Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 169,527<span></span>
</td>
<td class="nump">$ 253,535<span></span>
</td>
<td class="nump">$ 307,451<span></span>
</td>
<td class="nump">$ 161,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoActuallyPaidCompAmt', window );">PEO Actually Paid Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">250,069<span></span>
</td>
<td class="nump">$ 263,535<span></span>
</td>
<td class="nump">263,866<span></span>
</td>
<td class="nump">161,414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToPeoCompFnTextBlock', window );">Adjustment To PEO Compensation, Footnote [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_899_eecd--AdjToPeoCompFnTextBlock_dU_z7XrI8h8PtY5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
calculate the amounts in the &#8220;Compensation Actually Paid to CEO&#8221; column in the table above, the following amounts were deducted
from and added to (as applicable) our CEO&#8217;s &#8220;Total&#8221; compensation as reported in the Summary Compensation Table:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Name and Principal Position</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_489_eecd--PeoTotalCompAmt_z6ftMG61ELhh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Summary Compensation Table Total for CEO</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_48B_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--ReportedValueOfEquityAwardsMember__ecd--IndividualAxis__ecd--PeoMember_zpDLZ1q3Ahe9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reported Value of Equity Awards for CEO </b><sup id="xdx_F58_z5GhudMUb2c4">(1)</sup></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_485_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember__ecd--IndividualAxis__ecd--PeoMember_zyjxr8PkiVXa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value as of Year End for Unvested Awards Granted During the Year</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_483_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember__ecd--IndividualAxis__ecd--PeoMember_zzaOCI9CFNy6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Year over Year Increase or Decrease in Unvested Awards Granted in Prior Years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_48A_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--FairValueOfAwardsGrantedAndVestedDuringTheYearMember__ecd--IndividualAxis__ecd--PeoMember_zbT35384wgS2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value of Awards Granted and Vested During the Year</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_48C_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember__ecd--IndividualAxis__ecd--PeoMember_zjartK9fnHAd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Increase or Decrease from Prior Year end for Awards that Vested during the Year</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_484_eecd--PeoActuallyPaidCompAmt_z2tHWnQll1W3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Compensation Actually Paid to CEO</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_415_20240101__20241231_zFh1KuxefTh6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 10%; text-align: left">Gary Atkinson,</td><td style="width: 2%">&#160;</td>
    <td style="width: 10%; text-align: left">Fiscal Year 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">253,535</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">10,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0061">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0062">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">10,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0064">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">263,535</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_41A_20230401__20231231_z2xi7otJujv9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; font-style: italic; text-align: left">Chief Executive Officer</td><td>&#160;</td>
    <td>Nine-Month Transition Period Ended December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">169,527</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0067">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0068">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0069">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">112,042</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(31,500</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">250,069</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_411_20220401__20230331_zyuhymbHCTTa" style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">Fiscal Year 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">307,451</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">58,586</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">15,001</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0076">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0077">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0078">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">263,866</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_419_20210401__20220331_zlcySPRlT1S3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">Fiscal Year 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">161,414</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0081">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0082">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0083">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0084">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0085">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">161,414</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F09_zoSeDq1U4kTh">(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F13_z9dC7f98hoQ2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    the grant date fair value of the equity awards to our CEO, as reported in the Summary Compensation Table</span></td></tr>
  </table>
<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonPeoNeoAvgTotalCompAmt', window );">Non-PEO NEO Average Total Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">244,954<span></span>
</td>
<td class="nump">$ 203,635<span></span>
</td>
<td class="nump">415,138<span></span>
</td>
<td class="nump">245,935<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonPeoNeoAvgCompActuallyPaidAmt', window );">Non-PEO NEO Average Compensation Actually Paid Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">256,856<span></span>
</td>
<td class="nump">$ 226,302<span></span>
</td>
<td class="nump">388,476<span></span>
</td>
<td class="nump">243,829<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToNonPeoNeoCompFnTextBlock', window );">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_895_eecd--AdjToNonPeoNeoCompFnTextBlock_dU_zLkMaeF6HWvl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
calculate the amounts in the &#8220;Compensation Actually Paid to Non-CEO NEOs&#8221; column in the table above, the following amounts
were deducted from and added to (as applicable) the average &#8220;Total&#8221; compensation of our Non-CEO NEOs as reported in the Summary
Compensation Table.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Name and Principal Position</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Year</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_487_eecd--NonPeoNeoAvgTotalCompAmt_zgKjIfPvIfwl" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Summary Compensation Table Total for Non-CEO NEOs</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_48C_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--ReportedValueOfEquityAwardsMember_zFDnepSmXSd4" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><span style="font-size: 10pt"><b>&#160;Reported Value of Equity Awards for Non-CEO NEOs </b><sup id="xdx_F5B_zvOfZbFutHB4">(1)</sup></span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_488_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember_zEK7GtSVSqVe" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Fair Value as of Year End for Unvested Awards Granted During the Year</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_48A_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember_zkTQZqbfNKah" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Fair Value Year over Year Increase or Decrease in Unvested Awards Granted in Prior Years</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_489_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--FairValueOfAwardsGrantedAndVestedDuringTheYearMember_zGuV0c7slFCl" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Fair Value of Awards Granted and Vested During the Year</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_48D_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember_zseSQAfbrjp7" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Fair Value Increase or Decrease from Prior Year end for Awards that Vested during the Year</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_48B_eecd--NonPeoNeoAvgCompActuallyPaidAmt_zWtQLp3tmOja" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><span style="font-size: 10pt"><b>Compensation Actually Paid to Non-CEO NEOs </b><sup id="xdx_F5C_z4Lqt064fnfk">(2)</sup></span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_41C_20240101__20241231__ecd--IndividualAxis__custom--RichardPerezMember_z1s30Q2gFcSh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 9%; text-align: left">Richard Perez, <i>Former Chief Financial Officer</i><br/></td><td style="width: 2%">&#160;</td>
    <td style="width: 10%; text-align: left">Fiscal Year 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">174,596</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0091">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0092">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0093">-</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0094">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0095">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">174,596</td><td style="width: 2%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 12pt">&#160;</td><td style="font-size: 12pt">&#160;</td>
    <td style="font-size: 12pt">&#160;</td><td style="font-size: 12pt">&#160;</td>
    <td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt; text-align: right">&#160;</td><td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt">&#160;</td>
    <td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt; text-align: right">&#160;</td><td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt">&#160;</td>
    <td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt; text-align: right">&#160;</td><td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt">&#160;</td>
    <td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt; text-align: right">&#160;</td><td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt">&#160;</td>
    <td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt; text-align: right">&#160;</td><td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt">&#160;</td>
    <td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt; text-align: right">&#160;</td><td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt">&#160;</td>
    <td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt; text-align: right">&#160;</td><td style="font-size: 12pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_416_20230401__20231231__ecd--IndividualAxis__custom--LionelMarquisMember_zyq7VHgn7QR8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lionel Marquis,<i> Former</i><i> Chief Financial Officer</i></td><td>&#160;</td>
    <td>Nine-Month Transition Period Ended December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">268,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0098">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0099">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0100">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">48,650</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(20,998</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">295,652</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_416_20220401__20230331__ecd--IndividualAxis__custom--LionelMarquisMember_zI1BuFToe6m4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">Fiscal Year 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">468,224</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">38,419</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">20,400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0107">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0108">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0109">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">450,205</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_414_20210401__20220331__ecd--IndividualAxis__custom--LionelMarquisMember_zRPYcDTnPfU8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">Fiscal Year 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">160,638</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0112">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0113">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0114">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0115">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0116">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">160,638</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_411_20240101__20241231__ecd--IndividualAxis__custom--BernardoMeloMember_zzSHsKDAvDck" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><p style="margin-top: 0; margin-bottom: 0">Bernardo Melo,</p>
                                 <p style="margin-top: 0; margin-bottom: 0"><i>Former</i><i> Chief Revenue Officer</i></p></td><td>&#160;</td>
    <td style="text-align: left">Fiscal Year 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">283,454</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0120">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0121">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0123">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">293,454</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_416_20230401__20231231__ecd--IndividualAxis__custom--BernardoMeloMember_zOEkwtgXDn79" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 12pt">&#160;</td><td>&#160;</td>
    <td>Nine Months Ended December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">221,908</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0126">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0127">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0128">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">48,650</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(52,498</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">218,060</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_412_20220401__20230331__ecd--IndividualAxis__custom--BernardoMeloMember_zpLDL6KFLgIg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">Fiscal Year 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">362,051</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">38,419</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,680</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0135">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0136">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,434</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-size: 10pt"> 326,746 </span></td><td style="text-align: left">&#160;<sup>(2)</sup></td></tr>
  <tr id="xdx_413_20210401__20220331__ecd--IndividualAxis__custom--BernardoMeloMember_zyxJ6VUKUM3j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">Fiscal Year 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">331,232</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9,114</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,901</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0142">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0143">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0144">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-size: 10pt"> 327,019 </span></td><td style="text-align: left">&#160;<sup>(2)</sup></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F0B_zWYV66QsWZq4">(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1E_zfV7QgQNhAUb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    the grant date fair value of the equity awards to our Non-CEO NEOs, as reported in the Summary Compensation Table.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F0C_zzRQ9wBBVnAb">(2)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1C_zUyU6jVnJLyl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
    actually paid to Bernardo Melo for 2023 and 2022 includes adjustments for accrued bonuses of $7,816 and $4,652, respectively, that
    was reported as compensation but not paid.</span></td></tr>
  </table>
<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TotalShareholderRtnAmt', window );">Total Shareholder Return Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">63.52<span></span>
</td>
<td class="nump">$ 8.74<span></span>
</td>
<td class="nump">12.68<span></span>
</td>
<td class="nump">34.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,398,000)<span></span>
</td>
<td class="num">$ (23,257,000)<span></span>
</td>
<td class="num">$ (4,638,462)<span></span>
</td>
<td class="nump">$ 230,471<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=ecd_PeoMember', window );">PEO [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoName', window );">PEO Name</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Gary Atkinson<span></span>
</td>
<td class="text">Gary Atkinson<span></span>
</td>
<td class="text">Gary Atkinson<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=ecd_PeoMember', window );">PEO [Member] | Reported Value of Equity Awards [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 58,586<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=ecd_PeoMember', window );">PEO [Member] | Fair Value as of Year End for Unvested Awards Granted During the Year [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">15,001<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=ecd_PeoMember', window );">PEO [Member] | Fair Value Year Over Year Increase or Decrease in Unvested Awards Granted in Prior Years [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=ecd_PeoMember', window );">PEO [Member] | Fair Value of Awards Granted and Vested During the Year [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">112,042<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=ecd_PeoMember', window );">PEO [Member] | Fair Value Increase or Decrease from Prior Year end for Awards that Vested during the Year [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(31,500)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=RIME_RichardPerezMember', window );">Richard Perez [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonPeoNeoAvgTotalCompAmt', window );">Non-PEO NEO Average Total Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonPeoNeoAvgCompActuallyPaidAmt', window );">Non-PEO NEO Average Compensation Actually Paid Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=RIME_RichardPerezMember', window );">Richard Perez [Member] | Reported Value of Equity Awards [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[8]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=RIME_RichardPerezMember', window );">Richard Perez [Member] | Fair Value as of Year End for Unvested Awards Granted During the Year [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=RIME_RichardPerezMember', window );">Richard Perez [Member] | Fair Value Year Over Year Increase or Decrease in Unvested Awards Granted in Prior Years [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=RIME_RichardPerezMember', window );">Richard Perez [Member] | Fair Value of Awards Granted and Vested During the Year [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=RIME_RichardPerezMember', window );">Richard Perez [Member] | Fair Value Increase or Decrease from Prior Year end for Awards that Vested during the Year [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=RIME_LionelMarquisMember', window );">Lionel Marquis [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonPeoNeoAvgTotalCompAmt', window );">Non-PEO NEO Average Total Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">268,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">468,224<span></span>
</td>
<td class="nump">160,638<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonPeoNeoAvgCompActuallyPaidAmt', window );">Non-PEO NEO Average Compensation Actually Paid Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="nump">295,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,205<span></span>
</td>
<td class="nump">160,638<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=RIME_LionelMarquisMember', window );">Lionel Marquis [Member] | Reported Value of Equity Awards [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[8]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,419<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=RIME_LionelMarquisMember', window );">Lionel Marquis [Member] | Fair Value as of Year End for Unvested Awards Granted During the Year [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,400<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=RIME_LionelMarquisMember', window );">Lionel Marquis [Member] | Fair Value Year Over Year Increase or Decrease in Unvested Awards Granted in Prior Years [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=RIME_LionelMarquisMember', window );">Lionel Marquis [Member] | Fair Value of Awards Granted and Vested During the Year [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">48,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=RIME_LionelMarquisMember', window );">Lionel Marquis [Member] | Fair Value Increase or Decrease from Prior Year end for Awards that Vested during the Year [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(20,998)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=RIME_BernardoMeloMember', window );">Bernardo Melo [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonPeoNeoAvgTotalCompAmt', window );">Non-PEO NEO Average Total Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">221,908<span></span>
</td>
<td class="nump">283,454<span></span>
</td>
<td class="nump">362,051<span></span>
</td>
<td class="nump">331,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonPeoNeoAvgCompActuallyPaidAmt', window );">Non-PEO NEO Average Compensation Actually Paid Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="nump">218,060<span></span>
</td>
<td class="nump">293,454<span></span>
</td>
<td class="nump">326,746<span></span>
</td>
<td class="nump">327,019<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=RIME_BernardoMeloMember', window );">Bernardo Melo [Member] | Reported Value of Equity Awards [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[8]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">38,419<span></span>
</td>
<td class="nump">9,114<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=RIME_BernardoMeloMember', window );">Bernardo Melo [Member] | Fair Value as of Year End for Unvested Awards Granted During the Year [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,680<span></span>
</td>
<td class="nump">4,901<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=RIME_BernardoMeloMember', window );">Bernardo Melo [Member] | Fair Value Year Over Year Increase or Decrease in Unvested Awards Granted in Prior Years [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=RIME_BernardoMeloMember', window );">Bernardo Melo [Member] | Fair Value of Awards Granted and Vested During the Year [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">48,650<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=RIME_BernardoMeloMember', window );">Bernardo Melo [Member] | Fair Value Increase or Decrease from Prior Year end for Awards that Vested during the Year [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (52,498)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,434<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The
    dollar amounts reported are the amounts of total compensation reported for our CEO, Gary Atkinson, in the Summary Compensation Table
    for fiscal years 2024, 2023 and 2022.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The
    dollar amounts reported represent the amount of &#8220;compensation actually paid&#8221;, as computed in accordance with SEC rules.
    The dollar amounts reported are the amounts of total compensation reported for Mr. Atkinson during the applicable year, but also
    include (i) the year-end value of equity awards granted during the reported year, (ii) the change in the value of equity awards that
    were unvested at the end of the prior year, measured through the date the awards vested, or through the end of the reported fiscal
    year, and (iii) value of equity awards issued and vested during the reported fiscal year. See table below for further information.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">The
    dollar amounts reported are the average of the total compensation reported for our NEOs, other than our CEO, in the Summary Compensation
    Table for fiscal years 2024, 2023 and 2022.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">The
    dollar amounts reported represent the average amount of &#8220;compensation actually paid&#8221;, as computed in accordance with
    SEC rules, for our NEOs, other than our CEO. The dollar amounts reported are the average of the total compensation reported for our
    NEOs, other than our CEO in the Summary Compensation Table for fiscal years 2024, 2023 and 2022, but also include: (i) the year-end
    value of equity awards granted during the reported year, (ii) the change in the value of equity awards that were unvested at the
    end of the prior year, measured through the date the awards vested, or through the end of the reported fiscal year, and (iii) value
    of equity awards issued and vested during the reported fiscal year.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">Reflects
    the cumulative stockholder return over the relevant fiscal year, computed in accordance with SEC rules, assuming an investment of
    $100 in our common shares at a price per share equal to the closing price of our common stock on the last trading day before the
    commencement of the earliest applicable fiscal year (March 31, 2021) and the measurement end point of the closing price of our common
    stock on the last trading day in the applicable fiscal year. For 2024, the closing price of our common stock on January 2, 2024 was
    $206 and the closing price of our common stock on December 31, 2024 was $18. For 2023, the closing price of our common stock on March
    31, 2022 was $4.20 and the closing price of our common stock on March 31, 2023 was $1.56. For 2022, the closing price of our common
    stock on March 31, 2021 was $12.30 and the closing price of our common stock on March 31, 2022 was $4.20.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top">Represents
    the grant date fair value of the equity awards to our CEO, as reported in the Summary Compensation Table</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[7]</td>
<td style="vertical-align: top;" valign="top">Compensation
    actually paid to Bernardo Melo for 2023 and 2022 includes adjustments for accrued bonuses of $7,816 and $4,652, respectively, that
    was reported as compensation but not paid.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[8]</td>
<td style="vertical-align: top;" valign="top">Represents
    the grant date fair value of the equity awards to our Non-CEO NEOs, as reported in the Summary Compensation Table.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToNonPeoNeoCompFnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToNonPeoNeoCompFnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToPeoCompFnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToPeoCompFnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NamedExecutiveOfficersFnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NamedExecutiveOfficersFnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonPeoNeoAvgCompActuallyPaidAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonPeoNeoAvgCompActuallyPaidAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonPeoNeoAvgTotalCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonPeoNeoAvgTotalCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PeoActuallyPaidCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PeoActuallyPaidCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PeoName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PeoName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PeoTotalCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PeoTotalCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TotalShareholderRtnAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iv<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TotalShareholderRtnAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=ecd_PeoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=ecd_PeoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=RIME_ReportedValueOfEquityAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=RIME_ReportedValueOfEquityAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=RIME_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=RIME_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=RIME_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=RIME_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=RIME_FairValueOfAwardsGrantedAndVestedDuringTheYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=RIME_FairValueOfAwardsGrantedAndVestedDuringTheYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=RIME_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=RIME_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=RIME_RichardPerezMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=RIME_RichardPerezMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=RIME_LionelMarquisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=RIME_LionelMarquisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=RIME_BernardoMeloMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=RIME_BernardoMeloMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Award Timing Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgDiscLineItems', window );"><strong>Award Timing Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMnpiDiscTextBlock', window );">Award Timing MNPI Disclosure [Text Block]</a></td>
<td class="text">We
have a strict policy of not granting securities to our executive officers, directors and employees when material nonpublic information
is known or a material transaction is anticipated to occur.The
timing of equity award grants is determined with consideration to a variety of factors, including but not limited to, the achievement
of pre-established performance targets, market conditions and internal milestones. We do not follow a predetermined schedule for the
granting of equity awards. Instead, each grant is considered on a case-by-case basis to align with our strategic objectives and to ensure
the competitiveness of our compensation packages.In
determining the timing and terms of an equity award, our board of directors and compensation committee consider material nonpublic information
to ensure that such grants are made in compliance with applicable laws and regulations. Procedures utilized by our board of directors
and compensation committee to prevent the improper use of material nonpublic information in connection with the granting of equity awards
include consultation with legal counsel and, where appropriate, the delay of the grant of applicable equity awards until the public disclosure
of such material nonpublic information has been completed.We
are committed to maintaining transparency in our executive compensation practices and to making equity awards in a manner that is not
influenced by the timing of the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation.
We regularly review our policies and practices related to equity awards to ensure that they meet the evolving standards of corporate
governance and continue to serve the best interests of us and our stockholders.During
the year ended December 31, 2024, no securities were granted to our named executive officers within four business days prior to, or one
business day following, the filing or furnishing of a periodic or current report by us that disclosed material nonpublic information.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgPredtrmndFlag', window );">Award Timing Predetermined [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MnpiDiscTimedForCompValFlag', window );">MNPI Disclosure Timed for Compensation Value [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgDiscLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgDiscLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMnpiDiscTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMnpiDiscTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgPredtrmndFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgPredtrmndFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MnpiDiscTimedForCompValFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MnpiDiscTimedForCompValFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>75</ContextCount>
  <ElementCount>19</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>9</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="formpre14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://algoholdings.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="formpre14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="formpre14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995443 - Disclosure - Award Timing Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure</Role>
      <ShortName>Award Timing Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="PRE 14A" isUsgaap="true" original="formpre14a.htm">formpre14a.htm</File>
    <File>rime-20241231.xsd</File>
    <File>rime-20241231_def.xml</File>
    <File>rime-20241231_lab.xml</File>
    <File>rime-20241231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>formpre14a_001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="4">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="114">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "formpre14a.htm": {
   "nsprefix": "RIME",
   "nsuri": "http://algoholdings.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "formpre14a.htm"
     ]
    },
    "schema": {
     "local": [
      "rime-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "rime-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "rime-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rime-20241231_pre.xml"
     ]
    }
   },
   "keyStandard": 19,
   "keyCustom": 0,
   "axisStandard": 2,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 8,
   "hidden": {
    "total": 44,
    "http://xbrl.sec.gov/ecd/2024": 41,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 75,
   "entityCount": 1,
   "segmentCount": 9,
   "elementCount": 101,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/ecd/2024": 114,
    "http://fasb.org/us-gaap/2024": 4,
    "http://xbrl.sec.gov/dei/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://algoholdings.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formpre14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formpre14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "2",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "ecd:PvpTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formpre14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "ecd:PvpTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formpre14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
     "longName": "995443 - Disclosure - Award Timing Disclosure",
     "shortName": "Award Timing Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "3",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "ecd:AwardTmgMnpiDiscTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formpre14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "ecd:AwardTmgMnpiDiscTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formpre14a.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r41",
      "r51",
      "r61",
      "r86"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r44",
      "r54",
      "r64",
      "r89"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r75"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r45",
      "r55",
      "r65",
      "r82",
      "r90",
      "r94",
      "r102"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "auth_ref": [
      "r100"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://algoholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://algoholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "RIME_BernardoMeloMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://algoholdings.com/20241231",
     "localname": "BernardoMeloMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bernardo Melo [Member]",
        "documentation": "Bernardo Melo [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://algoholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://algoholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://algoholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://algoholdings.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r41",
      "r51",
      "r61",
      "r86"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r38",
      "r48",
      "r58",
      "r83"
     ]
    },
    "RIME_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://algoholdings.com/20241231",
     "localname": "FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value as of Year End for Unvested Awards Granted During the Year [Member]",
        "documentation": "Fair Value as of Year End for Unvested Awards Granted During the Year [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RIME_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://algoholdings.com/20241231",
     "localname": "FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Increase or Decrease from Prior Year end for Awards that Vested during the Year [Member]",
        "documentation": "Fair Value Increase or Decrease from Prior Year end for Awards that Vested during the Year [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RIME_FairValueOfAwardsGrantedAndVestedDuringTheYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://algoholdings.com/20241231",
     "localname": "FairValueOfAwardsGrantedAndVestedDuringTheYearMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Awards Granted and Vested During the Year [Member]",
        "documentation": "Fair Value of Awards Granted and Vested During the Year [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RIME_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://algoholdings.com/20241231",
     "localname": "FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Year Over Year Increase or Decrease in Unvested Awards Granted in Prior Years [Member]",
        "documentation": "Fair Value Year Over Year Increase or Decrease in Unvested Awards Granted in Prior Years [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r45",
      "r55",
      "r65",
      "r90"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r45",
      "r55",
      "r65",
      "r90"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r45",
      "r55",
      "r65",
      "r90"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r45",
      "r55",
      "r65",
      "r90"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r45",
      "r55",
      "r65",
      "r90"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r45",
      "r55",
      "r65",
      "r82",
      "r90",
      "r94",
      "r102"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "auth_ref": [
      "r100"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r37",
      "r106"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r37",
      "r106"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r37",
      "r106"
     ]
    },
    "RIME_LionelMarquisMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://algoholdings.com/20241231",
     "localname": "LionelMarquisMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lionel Marquis [Member]",
        "documentation": "Lionel Marquis [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r12",
      "r13",
      "r14",
      "r15",
      "r16",
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r22",
      "r23",
      "r24",
      "r25",
      "r26",
      "r27",
      "r28",
      "r29",
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r35",
      "r107"
     ]
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r43",
      "r53",
      "r63",
      "r88"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r46",
      "r56",
      "r66",
      "r91"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r46",
      "r56",
      "r66",
      "r91"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r69"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "auth_ref": [
      "r38",
      "r48",
      "r58",
      "r83"
     ]
    },
    "RIME_ReportedValueOfEquityAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://algoholdings.com/20241231",
     "localname": "ReportedValueOfEquityAwardsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reported Value of Equity Awards [Member]",
        "documentation": "Reported Value of Equity Awards [Member]]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r39",
      "r49",
      "r59",
      "r84"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r40",
      "r50",
      "r60",
      "r85"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r47",
      "r57",
      "r67",
      "r92"
     ]
    },
    "RIME_RichardPerezMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://algoholdings.com/20241231",
     "localname": "RichardPerezMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Richard Perez [Member]",
        "documentation": "Richard Perez [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r42",
      "r52",
      "r62",
      "r87"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001493152-25-017100-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-25-017100-xbrl.zip
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M]]9WHIMZ#$7?W6&8#[B2$S/4]L2"[C7V[O=3I#O?=XJC#-/8'$ G\D=,):-
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M9Z5($S"]7A)-93I,]Z1.DQ OB9(R \1SHE236_"PM.D^6W 'JC4)YL/2J?N
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M%*#GV2@;3,%520J$X(5^%<E$SP8*& ^"*M(?) 0(R% 0-$63W##MP/7SC%9
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MS+[[#(N.@I!]CB[R!]%G=A+P43]-S'>L$\.7L(<:2.S-'*746Z'(68"A:._
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M8G?$=3SBM10"JJ0B9PVXRPZ^1P=J[$?LBP@B1SK6DG2X(W9'[(YXU8]X+06
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MG8L1LEPCXS@>8.*LRO(ZX40)W-O*LS)N&,[ 0N#"?F)5A94!I\DJJU$.4&W
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M+7^(3F1S4 ,A<!$23(UG2V\]MEL=Q.UA6":V9"0#?9L=S@B#41K99!++QE*
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M!1-XT)MFTE5'+Z3'9#&C8=C\T^A#?BYAN"/*Q)R"#:[;IJU._AGG)[?:]LB
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M+;W'#T?Y1<,N8DCBN+WM!.MMJ.X7!^Z(4@F.S"FVGA7D7>+Q# ZBKJ+.U2K
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MO1B<AYS6DX/^L 71)]2\%KVCLTL<[!*,9,&XYMG*Q)BXP9*-*O4LC-^9L;5
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M-E00AG%7STRHH3=M[C-WD6AQ/-=!H%?"F70'WWH+PV1;K'C*[%&9C&M%@ZA
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MSM\P^MJ=V461@IJLJF'*R!G'O?S4QB38GC75U>9U3#^3Y%EQVV3AR!!22:Z
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M9!2YAI 1>$+%EN(=-"J'G!94PH0:2:B? QE#\ZH8P,N)->U"% 4O".3<,WJ
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MB/672YC:$SQ00]!\=*T+T,X)^F @]"TP1,N];/"^!GGHGV?IF-&U(\3SEO!
M+#SUC"+7=7ZP^'@V(D0TH5U1;Z.2S6L/@5J9G0]GMS_"D@/(5FOQB"LYEC4_
MQ9+"'LIRT=7N)FOXDM??#JROI'+,PM^;YG.C@WG6S@OM9L$"MR$_-$FO.2W9
MUH<@DG*K:$U7LE"/H;'5BEE6%4!XR6,+CO,*'()V4P/>E+5G+CB=I^+D_;>G
MG_1!S/U9(L.XO$H:Q025%5,4(ZP<$J^-O[4&V!ZHEJR:RO2US2AI6E7V-V,Y
M2[:)9(>.TDD1>&31$LW",,(_L&8%FB:HF5D9BSJ5J0LLP$7CFS#Q/:G*:;U3
M;8DA;SGM(R/R2_=9Z)_*,EC>MYY.!D%KGI=%CUV^*GD@B4*%3#)1B33!8&[L
MQM-:?-4)@+R<M*:S%O.M)SJGR<RA]UAIYE+3:EBB*HJ5/=1E&)]S%96 NAYB
MK@QJT**%IL.2_P:;X2IB;B\WF-U8T@ W:'+AI5*[175WW?+<#XC(IUQL2F;J
M+KKEN>CZ8-^*1=U^9Z19E7<EY4I*\SPLQ9VTQ8X,HC'FH>7^4_5EJ":%KF!A
M);K8_>+*KE'?I$GL^ RD!I/T1[Z!N<C1* JIH#*ED D%P+.@\M>6$L[5J\GK
MZVQ/'PDE0?9](#N:9- 77:&#:E>.HJMH5,+UX5]3&8/!'3[C_P+W]Q46)KA6
M?.\0:J?PG4H;7@%+Z-YH>&U+9M)017)7.44X)+/1E@>9E58[D>)+,VDAM"NF
M/3W=X66I7AZHIZ37^,,;VY%8RI%VTGE9A!I:(AJ$ZYW2FG8B>GE$]-^<'<(_
M;4@9-C \^Q'*<Q_B$&/;-C)&<1M4<BC,+P-=,\]VU/2(->$$&61#U%B?PCL@
M:&/%K/,DQI\%-L$4VB^9&\JS= >-M:$NBOGH#"#-=!DIHTR+T31#P[:>H4JZ
MND7->[>WT0G=91%3Z+J]F2B*NS)37B=SET?F_LZE4>DD,1>#34S%57/<'"VG
M[$>ML[[UI](UFE\UZ!J=F!;]R2/&QK<MC(UOYZ)L7/<S/QMYMM,ASQ:(/.MU
MR+-OE?IZ#(\+BECPL81Q';'(V_!P:-4XMC$^V6?-4A4D*%;DL/ BJ?%LS7\1
MHN0\-$Q^VIHF9\3U932\-,]=:%O8>8A49I*X8+N?%R@H00KGYU(?4#P45^B"
M)I(;X\=&R3K1))U2=C/2?MK,=URLAE%*\E;1YB^SX27R  JS:*N*7B#/5/2%
ML !(T=?BDZZ4*&SDS1*E4@@3P*%W5T%.I#=57;!*GZ6GK]:J5.T>*.*J\JGP
M,MV 893ACOL,BCY#/YX2?=4Y^23JGHUGK68)^QH\W@ 8PISJB*^-?);/@:;
M3#X"TM!?@FM$FYCJ>SO/8$PVA5]X,FZ459;[A? <2,OLO/"4YTG_BEA$]!X]
MI7'QWM=3A\XMY*B$[S[M;3YC5BL=N]7;GP*X&%N1F<,B#;-;UTN)ZTN-8VD'
M=-# 1[Y_Y@:1@UI/SK&MISO2DV<=*N-1!"0M)E6=-*H@%Y[<\.<7F5/UR5NE
M9/--3]YLDYO^@\E-;]J0 F;]8A>G6/#8Q RW!W]O*+5B[R2UO-ND%I]8% V&
MN.)*%/\FGP&Y4*:,B\.>4Q>RE2$=QLQVOQ8"-9]KCBB3UG@L?"$&S5&<T>:J
MG!65Y8W:ML>J7.[&%8/>>!61&1+&::)=)MHE+1X/G&SHG!H+ 1L_?ZO+@N**
M\.' 'Y2%GZ \ ]$62*%OEH88.P E8MAZZW4>D%44DVRZWETR&NQ!JS"\1<E"
MCE"K;GA30QS.MR@ 11QP94S_->U1X3L$6')K ;. DIS5ZF%57M"GN$0UUJ"
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MS"=L$)ZLN;[*-[$ T[&B=QA[&H,9P6V>48S85>&-G5_)KM80KF9F]QURMV$
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MV0TG%L./*E^5":[* E<)SPA/I@/6=>GC0F'H-!B0#>\3$[=1>5R0GS$:U^F
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M3AXF%+$T(T'6FDOD37-;\(NZ;M&UW 02/)\O!;6Q$)4JKNXB>)B9Q)5+B*>
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MX,(?1.E%%DXN\1ZHY W#_S]F&T9-#?Q)K,(<J\DH&U3O!3H:NN?4%3:<"KH
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M/X^^/!_#M%W.U/]]U/\WG)Z WL:*?4SSH?6AFAV [903?&![\WO\RR6\YXS
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MT\BH?PGAUKCQ_UF./L-E5/Q5[_]],QCWIE 8;[U"W]>TEY:(E7K: 'J;*SZ
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M\X(>V%=P^YTFZ&\A7THBRNQ2<7#XYMXV$/@3CBA2?)2O.KE:'X%+>-RZKAF
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M'W;$)]BW(2J>-Z1NWAIGOF2@EXT[RA?CO9>^N CN&00%F O!8%#!)<DSNOK
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M%<[\P2/C6+:%16K" DXY!^I6J^> 3BU;S82[M@/M(ITB24;H6QWB6VA]J>;
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MH_O/D=5$HQF175B6)N+Q<\ OY"='?;'D'YO+/]HS\8]D>G/<:OL9KC^Q,.:
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MP)^IOEHJ9X FZQ$H1=/5'V_)+WI^Y(8ZR*.A2RDL9+R/11/-T&M(J8HI3"1
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MCE+P2]?#ZB_HK"U4V%D9=B 'AVB<P>\Z#O6U2>1N4PC;<+6JAGI.CR/\@X?
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M,)WK^1.[-D[7_":X[HFZ->7KJ1CH+(:1!"EWBQC8HN%G>+O",=5 E]<$RNO
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M6>ORTZ>M8Z&)EW+\R;55:&BMP$;I:-.[Z"&0-/;&8>Y%]'W#8J@730$'<(;
M<9^I/@/@#:@\M-#F@/:0VMLMJ2K>EG9]&\['81##/A)EHK7,^/("Y!ROM4)(
MX*$ !PFVKX^086PUA(@"(!# 7< 0KOJ+'%OZF5PI_"IM;NJ1RPCUP@.OGX7R
MP&H?DW:P2$U%3WVC52J*WB):WJN"R?JE;7YECUK/<C%5!)0<5ZDW'LK_1GI$
M_(V]0K'\4E#H3>CGA1<),W ,4R-;HVW_08MZZ*E+JXK>^#4V8C1+H!]AFN]B
MVUX:AUNY2_"=?N!ENDL4G"'# 7$]#-#49"9JIY&)NK2YNO]E;<)P)+,"1EW]
M"(NSX!S)#[ P%XXS?E<T7$%3U>U9'*49W CED /%QM"CKI6UV=D,%!CMYK[%
M^,9Z+PVY0B).F-02&W7*KU56$8!%@0<1?[A]AG^>VG)97T0$BUX)^-<D"8D5
M.X&NQ_![ZG),\UJCT/J]4<J[B[2A4/VTC^WK$'<FRNJ:**<#494H0.=+H91O
M)"GHCI?R=%(=>!151 6LV]#HS[,@M1SV\K=94QD/W[6[T6>NU,J!5#D0)I4?
M$5$QQ0[3<"*%^A4]&(GUZ^/@-S/XS=5JN]00 %%\BA\J(^ &M5Q6M@!*_IN?
MK@V.+,!"(RF,I?A#3";:1B. Q,$ZLGB5F@D%6@^284IY5D5B94>8AIJV0>Z'
MMOA8HM(@4VO-<;AS=CEVJ\H7]-550NA3C X3YE10WI:UNYZN.^_,2G;JS(&#
M5M8HR5DK,BC2&)I5:N)H:1Y>X1+AV;"M:3 5L@1G)#>:S9W&T^?,?_IN/!\_
M<OAN/-IK'KJ:G7S>[I+/2TT^[W3)Y_N<?-Y=I#G(JP3Z_5[D212@MW(,TB>9
M2B75&6HK*R$O*U$3PPRI7+!8/HM41<490X<733'0;9,P*;)HJIRN^B^8#@K4
M5@1EW-C@(2M2JE^07FA#UV3D00-B$FR:Q H;/5+(ZC2V9+QAW)@R']B6Z PX
M7!%;/_6M6-."4Y=+*O6[B;1AO"#"ZY+IZ^+KZP(A!#2?.?G,"^$'48CA/#0
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M38*R @O"R&0IR:N%#PWT5WP%#1\%G094(9N/,/29LUHQJ<ZW%>^FZ14(#$M
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MQ]S#OHYF(%VZE'-1X,%B_"?\#;QTKO.!3MD JN>>SL(D/UR#VW$9FXBU152
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M>F=CC[IB(SYG\I C&_*'(6V%5S&Y*PBAFU>TH3E2QW9YR];) M69KX LT:,
ME]S.2@"ALT]6RCZI! JX"AU1J""+S*5^K.ZQHJV=S?-4"R-PNBSI10!M+N51
M!E/+B!&UXBHK1M&4O9PM$EU5BP_:].9(;==S;WD3NHV>>Y440'-W83YCC'YH
MCH+K:#]2NU848Q)3E!U"1=C_9:2"6CJ-63+JX4J40NRI-JC79_W7[CC)\V3L
MI3%[TG N=+H##PBZ1W HFJQ-WG#3R#4C,>A*HSHK4K2"QTD4]J>N99+I0*S+
M!;E68LD0O#0 B.$C)%J9)BR%V9J%K/WZ[,WZ'34^:QZU\)0[QOZT=(JNDO1*
MV_[R9 P@J-X$B]_:>]![J'RJDZ_]H1=?!0!Y1,\^DW(,*'#*0?Y!( \FU!DA
MS2*\,4J@CP =TR2=0EA=U6[+=\C_JL)[P!Y'<DL%(4%H"1KW.F^HABL4XZ6%
M7$I3&"=*T(?KLZ=K=T0GZH1"J"8<]>2.EC!@MKZK0,H4#U02%U;J1IX.<.$F
MP:\]+R/*)S N\RG]-T%[XLQ3:"!^BKH!:2#G_ZU>PX3]<I"IP*.&2-!;%XBY
M@Y:"'HMV+8P%,D4@+8&A5;/ODGVJ=<U-:4%4 QZ(MNCN/=:M!A29O&MM:V=?
M%76S'V_NJ*]>>&G/BX/LU_.O43#%$<E/MC<WMYT'\#FS>-2_QAP>#UU%:*(T
M6AV]90D: =/ R(%:5CD^N1H9T3#@&M=WVUIR!%HED7ZNF=)>^Y0>5F6,6$#&
M.)V,N9_3>2!%3"CMG[#$ED,'0 $*_^T\V*+N*PU97N9W_A;X%I!0>W&BXO2E
M020]5+2-4JN;S8/MAW4AP7!H8,P#E0QMIB@$2YE>2A17\\&54!IEG3,!U;L4
M$:M>.[822REM.:#'M0%5N2)M%IE9HS#>^KZP\$0/=I;VAO+@G\JGK\WQ7+O;
M!J#L@1W[A9AV&4^Q-K-=&+MPT&$7EHE=V-[LL NK+GUN,3NP/W]VX"3&5@9@
MJW6I@)6*%Y\.7$%U)8T)6S2YC/J8%7+W"+",#F75F@ ?LR7?J3RR,!.EF#_E
M U5A"F FG)9^2S1\E31N[J1DR*]5^EY[&]H)PN%+DX>1U?Q?5E\L*S?I<?&.
MFN \!3SPR9!@!9R^#ZUB&VJ$45XWT;YNE$V>%_X]!_($0D(*!H#I$D V6J@"
MP0YP4(<7M!>9R?,!;J,.?!G @>FRLMAY$6:[:D9V+7%4KD^JA+<LQ+_J!\DC
M8BY"ZZ=X%&V;2B P]32N4W0L5():>RYY!QK3VBNDN:!<]XEN1&.?3]&0.;=@
M*NB4S+NX74+]YPO@_8V#[\FR"[F1KT)IET5A/NV8CE=_0ES(]/W@OWG!<>74
M.\D[3&Q1F$TTA093BH14F-G[4LB'&(1106+?&TF+FMET@>\GLM/K6(_EA1&4
MG8..)&H>2^5!1_L^Y,(6X0-35:<$W (Y&!!\R#3MY0>97+!YH/Y;X_B$86R%
MOHK@C"#BRQ[T((2VP=" W"\P^MF*5+3*F%%XZZ?E0^A;P#^G)L\HE[FSHQ>)
M49@QGX]+K<-12CO0-!ZD?BG:>NL^_'V^U+<HIY\LTGPQ_O7D:S\JLG#";-5(
M2/)S@-J=I/YA]#;"-#,;2:*L)[2+6WR9J]1#,O,6<[0DF%5W&3XENNJ3\FCT
M?J'!)YH[( N"ST1^/;>'Q1W<M8$X1VNA:KL1%XE/-"J&T.*$8AC4U(8/R24B
M5I!OL[J(E!$/H%.X!XSFN=26>(4Q#X5M*.6DUB!)Y5<:3*V^0.AP&!:VQ3%(
M7HVU8,Z TCIJC@.,TY69&9J2>/L'&_N[F]LW\%MPH3*M>>LN^2W$>!N[ND[8
M4%"(-H0*GJ$FR#(XP>3CESQ72%SVHC ;!IEQ+N94J-@S)N&V-LV:S5E$L\&K
MT0^5=XR*&>0Q@KX^RF9!<CR89-\@JB.#/ 6C6!D\:.Z@=;S$:QF54:X-[\H3
M4;FQR[A^SO=>/]%R_>KA _"(J=51GZJ^K;Q;0K4&L*\H$*52\PL/^>[S%,Z!
M 67"YLK5)()(NYT/'ZG,M:HG565^5L,]U:YEV[6!HS+/KOQ(9>J::^O9.9,G
M7<YDJ3F3K2YGLNKFYFV2YF\N0L+ 8-(N9;)2(K1:W2D5_(_7=I806"-/:EH/
M\"D:3XS\+Y\5J0/8<3$:Q#8*JFX(EDM$-?8C2:V1U6O76NPD%00R:M7+,BE7
MI96A$@=601?Z2>5O0Q_SIAI%NPRL+5X$!60ZS*(K+&L</\U-B.!3AKQ!H_8R
MCEL;M B/Q? .?&J:C2;$"-U$'816G&Y ;]<="$H*5/EW\*_-2_(SK8SN?L^6
MT@OT-GD7R.W\64+ZSFW%^SVAPRAJC^PLY&.4K[ =L]'>)F(!&UU-Z;VSFZD<
M*'"F^.?L!B<VW;'EQ 6# <0%)J0H L)5V"R/F30XE?JA'JE8L7TM'4) SX(4
MSX<8,1$J):X=2SFR_#H(ZB!&5?YG00$:8@P;SANFV &%PV_4=?AZ1M8O,D4-
M4')^Z?T^4OA45Q!Y OQD;.G4:KM&>'E/7M91,'_21)@^TM_W7HT2@!9T%#J(
MIMP3@90L)G53H"?UJ<P]5^7@]FG,IU*%-9]#=TF'$"O_^R'&Q<JN/9:$ *"]
M"$A_X?9)ZT,SQC;7LR]TG1:8AKCY+NFR=<R'*_X+"\=@U_!7;E/5*,!(1BFB
M!0$QD?395/&+E($,NJR=(GK)V$2P*J.4Q^8Z@'%F+8]W]..AE2&Z@WG#DT7U
MR5VN_K:-@.U%:$3E/9EXT4].]'2:?RDYG66(*H?:X6J/IE%8:>&J7"G+/P-W
M0FKR3'MD\SD\5+'#T"].;&/R.8B#0=CJZPR#$(*RP5= 9R4L&*VV9/)/G26[
M&G=12J(%"(T/Y1GV5>>G=P$0@W>B:*7.XFE,= 83Q6;0EC0$K"4D_L@T]6!C
MN6X'8S<U(]VJZ.FEB><;V=20Q@8BJA9W!PS!1EM=FBLQ8UDT&R:3$<-@2A9M
M,F@SNNJ#$3-RZBY12_FAFN)WOF-FWE[-1JC9:&N>%C(VL,KO#/!A5"E1FXC(
MT5F'0-Q\" 9%:E*2L$]!A)1L.2%'C::R5\G>3FO/FK\L5\Q.'S;L@]&.+7FW
MVC'1"ZL8..9;5C'GLIYI0,&4_C@BE"W PT$4-E/@QCHU;PQYKDJFJGJNZQ/M
M"5O"$F!84YH*4H?">]EKJKZ.UL!L%X[.+_JT<>3@-_H28:Q2I*HY(%."DPMA
M$]_,XG#K]]."_1CM %%3#>(#(Z1"==3721'Y].- _31PA?:$*-ZIUMS5"YZ6
MEI51[M8BZ45><WMC9I9U:W.S2[,N-<VZ_0],LZ[*4;_?$Y+V]@),^4? 31G&
MXEAZ6S$JQ\[U7ZW]? 8L 44*W9]F4. /I+ C1)IO=M*.,78D<2L\(2@$T,2D
MNA$!TZ94V.*VMY[J@ G0C 3-+@86-\!Y*#53Q[XL7#, UHMM U9(9.RO806B
M]8>'CM?+DK07<&,S^ CTN/+-H/G,5:",LI# =%DP]N2K A%\1=M)JC-H'JR"
M2KZRT3#1 )]01P1T?!ISU!6(GC,3HN>"H4TU@(:VL=H#<:Z(E3(#6]91]4^\
MD7VY^I R.]\BPUDB$[.@HP4=QS0="*;D=%6MP7_.;LU1PT26CR6P?V'4N7)&
M%7Y!M>6QSD3U@;-VH7KHG)9#MTY29 W%8DTNLDRLGMNL43*:VZ+"R>/(B[-U
M6J)UW/.V31] [\3FC6:>26 WR[VO&%B1AP)"+2!1=)Y""A!18J=L/B'KM)YK
M>$ F+>=C[D8'[6>( 0-B(?5;"V1C,&U$%CM732J[@$I,,O4BZ/K-?1OJ;Q/U
MM]7Y59M/L(O*;XP!OU"N/&7NZ1M0#"J']!0LJS4Z%^MWT.4Y]^P4ZSR]A>=N
M*PSQX.8FPJ53 \\O'1ON:M%XZDQXG/%A"C:D1Z['R5=6&JYBT<[&ZO8B26:I
M126:H!G5G:UY./:6)D0AS&6._3^]WP[?79X>O3H1TBDX_<^CWF_W=B)J'^[Q
M%)Z?G)V\.WPE7A]>7IZ\N[C7<_E)VW%KU_I@8P&<]@E"73@-=<32,)#_4B6,
M(*E/I2^<%EA,T45Q5TJ$GV#--MB5NH;59)<YSK) /6T+V2P4C.C"5[N4VE76
M:JHUMRAC9SGDAX<)OX;GC1[B)_U"87)"?<34L&,(#W&/E5(%3PUP>X$Y5AW+
MDZ.5)H@C!P9T[XS>!2</];FJYL4W NPAVW#>4W$[I,Q->2_DG^4+[+95#4L#
MX3CB7\.EEB_M3SG"F PL-A=(I\]8-;MK*P82Z0EI.439"QEP7B$@KRUR?.4I
M'OT4-F0<!?Y5@,8[L=<X"7<"PZB;_&\FF]8(/,H,J I] @X JW=G_ZSPA XV
M%@#G:LD/J(FC8=#_+)]\G'H#%OHG($30%9:?0^.JGC2V8WE/NI*>U9_0LS09
MB5Q^!]T?^;^MLIU)KG1W:!)$NOL?M:O,DHB,!&X0P^SWJ6X>#1HBDQ,DZ>/+
M!TLA16=*^'BF7$X*()R"J+/&IF/K*(F#J<LUA8'5.2&P3V%HG4+'$"]F66&T
MG5(;]'RK!$B4TABD52*[RK*J #AE49D5 ?V,NEIW0/ - )VM#J"S5(#.XW\@
M0*>3Y#-U^@(P]W<!E-;)@7A*L5\,I8A$X7F.\O3(",%.D=^#"2&KPM +4]-Q
MIEF1,\7N, P&[&0131-[')18#S+0IKF"PV(1H_ZK_03-I&"R!O!A#K'?(H4'
M,C@X"Z!!"-! -O>CMEBB5,V_T; SW:I9TP%VWS(3$] ^(;J6SC]3" 0IYNYF
MN8_(R\3(>>D=T_JH?K],]EQNJZ1G5+8HD,EJ:BR7)+WRXO ;>]K7,;F4V-FG
M@8Q[0'98$ V4S\6+!MX[$D.0E\?4#U1EJIU#71%*@')-KL4+X"M&N0HU-:UW
MA(-F-[)MJ^2*^ D82#T$@'_%WR@_U_&D]DZE!2?\(IHJ'[_&A"V]6^)JMD;>
M"9\5GM#!Q@*0SV=A!MWT_@J\M%,LJS\A4"P#VK*IW+)VQN0>-*W_2K?9>()9
MNR9BKAZ40-1,;N9OA?W;[LBL1J#\8&-W ;"W3AM<='65JW8*X9XWW%$KWIRK
M?FUH]D!5$MY@X!3UM#P 2X^"Z5GNC<8NVT:*'02QG !/ 7A(1$8BV2B*FE24
M?M_8CX1-'/W&%(Z;KWJ>Q 'TI9"6IJM)M-"X*"A,'4/'S< 9 0(5OLX&TS6D
M+JAV#&) $.12%7W4WA->T7%,W86$V5M$PF"\#1$83YVNJ&15A0TETIBZ*(9W
M*7:]S.:XAL]5>LZ@O:7[5G":LF_M-]4P6]4G'.AMJWTER7:53((T5B,Q#R/+
M0Z<\-YR/TC,"HANLO%7N"0^.!07B?ZP^Y2CPY%<+Z#$=%Z,>=?@%M!]QWXVC
M AM-FW^+IJ^I9[B:2 J"[@K#9*@I )6D?]A+$)ZEW$T4A4XLYXZ+B;_IC*@5
MGM#!(@WB!-?1 1YC$(7]KE/"?9@0][11;'.EDOF*_%&!+F:08YPOTMJK()1)
MMO7#M%^,"+6 F 8\$89DO/J6]L)\UZ:L0Z9T@+E3XV\4PNY,$:NC4]7^O4WE
M.W<PC :R4V&KA>[VK/"$#A;I_'41R/WLVGW=FPG]%-$89A1F5Z#TB9RC[SIA
MA-X??+V(+8I033M&P';5YY!J?XBQ9.CE60)'C9IK45!;#]QJA8D/G8N^!1IZ
M5$A1B%R2>[.04<BV*Z 1$A1KB7,%B1"F0^'W4&,1P,"' VHOH^BCC=%:ZL&5
M!L"E#=9N35IG@>#U-PU +%\:&-CPW93."$=CC_JFP\[TIA;O&KU#=RG%E:&T
M#/[^OOK<[0#A&Y 2VQU28JE(B9T.*7%/D.X_HPCD],][/8UUV(G7)V?'\O\N
MN^J/U3.[FI, TE *O@)B(BMWMD(M/<*< /?UAJR 2SQFCJ&-*Q</E'D^\*]5
M;G"[*9=H@/+?SU.S.&KR<6<++-46V.UL@7OB9R+22@T]]/_[+^]_F]N/_Z6%
M[3)%^?SLP&_>2-UU^J=XII?@YXC_TFK<KXV\71OB_IH0]WP'+L^[I;^CI=_>
MW-X6)V_?GU[^Y9R>'<E;</KAQ'GSZO"LVY([VI('AV2_BL-Q&D;.UK;KP"Y1
M-,VN#KVPN\W^7YHU_?__[V&W>W<2J.-&T6)G8XLBPA2?9*IPW$!H\LP,(@!<
M@I1Z&E"IK;0&?0BX$@%F]C-I+KL=-!=0;IXX-([I&:$H=%W+3W;3NYU1=ZOH
M?0*^=0P-P/.QCG.0)B,L-E5%IW"!;#8"U;M]:W=CR^6"^:N4ZDY'WM=P5(P4
MG@:(+'7ITE$R&LF?H9!UO(D71KI8'8H_(>DC#'_D&YLRZ$[Y:;=_0CK0>/VV
MEU^- BP\ZY)7+OU9R^V?_R$- 8)_L7-L8@(+C^G6US7WES7(6[^(#[R'RQGV
M+8]SU]W<W(3_PQ'2S78!&Y?9P\<XS4H<ME4]73]7*=VOH7:GYXZWY$'O?@@C
M,">"&'0E#O&%%Q=0P+J%SMTN.'?R_\70?#:,^P *"53O.1]=!UV_- C3+'=\
MCQH$%=" W!14!5_@":HED'P*$%T0?F1K]__HAK9%CJ38:C E4P=)9@$],77\
M,**22B\+,VL(F)"AEX=R5GXH;2GJL-JGOC;6D+ >%S$@G@,X;>R<!*0^AN[#
MQT%PMN9WR!@]=?X3_J:,.-<9)M> @_G/H_ WU_">LZF&!J NS%"+AXAM.:!)
MF!09#L0B[P!X"77ZE:-F)@^TW7 @BD];K7^CZ>=433\R3IT?,$XW&N4*)Q"6
M9D7N[(SS>0S)7[?)'>I\#_0]\*P)/BLM9K_CI]YUS >RG-@L8G/,4D*1\K_B
MY)J 8T@BK[K.0FJTCS4,&.DI\/9Q(?Q4T$_O%'/X,[R,F=G,G:?..;:RROX-
MKU$7Z944>5V>LSG/^>R[\IQ;WYGFO(L&2_]J.#H70:XF]=7_^M0Y/<9__&_S
MX/?_(4:2@(@P.OQ9\&*Z]>'9D\GVI\.WCZ[?'0RWSH,OW_X^V?ZZNY-\??OV
M^=7TY/EYLOFD?Q)%VZ=YYL=_;[YZ,<F?_[*;[6YE+]]O?W[_9?/TY5]_[#^Z
M+ ;[%^%>^/KOO1=_O/Y<O-H*+D?/GWV]V/GSV>CYB^?O7GXYOGP1OGX3]P\?
M[Q0'[T^\B\T7?S_:?QT>?WKW[?/Q:/!J?+;_*#_X=/SDQ=5V<E8,?O_PJ#A)
M?GF;#GH77U\EW_9>GG^Y_F5S.KIX.?W\Y=W5UN'XU<FGR<7+TP_^X?7+EX^>
M?XXN]LX?CT9G?[]\]_'5'_V_AX]>3"[.7Q2'T:/-MY=?O_PR>G9U/MPZB=].
M'NV]?_=I<Y+YR<[?;YZ-/WRZ_G3\QU6Q]?JO-X_V?_ETT9OTGN_M'6U]'1]$
M83'L[?Y1#/X^./>#[=&;1^\__/[E[^A3__3;R>:G\?GGYX_\3X^WSP^O#H+C
M;^'A]>FSXZM@>NP__GO[]][[JZV3\>G!E^U'H^W+_ONS9Y?CB[.S/_WWQ\?A
MYV=7^Z?>T5Y_.QC_,?ZKY_\Q''TZW<\N7QZ_/MI[+I^4OOWRUXN7V>:7#][G
MEV_?]3(Y@U^BB??H:-_;WM\Y_G:X^V+_,K]X_O[WL+]YO?T\WXF^_/GBZ,7'
M\?'[.'^]<[TU/OCCX.W?PU>#EX=I>#:]NOCLC;9?7#S9EX]]_.HDW>Z]^Z7X
M\JUW%N\]>?;GGC]^%>^?708OD_BM/WUQ?/EE\OCW?!)]_)3O_?+^_/F+D^+1
MU<Y^_.+95>$G+X/'^Y>?>F]>;+]\O7V8_3Z-=X,G'__TOHP^CP?YQ?YD[\VK
MT!^?]UX-7O\Y>#EYY*7?SM\.-P^2H_WW'S\-MT9O7CP+'T6O3YX]R3]):^7P
MY>\G6R__]%[N]4=;F^'+S5^N_MY-TQ?)WI?CPR<7SSY>38*=MX]>;WTX?V].
M\XV7X.!_TK@)HM(%N/:_O3HYO_I\^/KJ_ __ZQ]^TOODO=][[8VR@]=GO=<7
M0W\K^/#QZ//XV?7^X,_1\:-'^1/__2_C;^GUZQ>/CT;7E^?[GQ]_&KTY_G@Z
M'G_X<G3A_;E]'9_Y?S[Y_?WSYQ\^[<?#ZS^>O?FTN_\\.CW[-OT\^B4\Z+T9
MQ?'.]>4OQW_'H_'@>?CB.)^^^>O9^;<L>[O_R_E1,@[?_O>_--)'O<2?PO\.
M\U'TV_\'4$L#!!0    (  Z(1ENMU!Y[J2   +$A   2    9F]R;7!R93$T
M85\P,#$N:G!GG7=Y.)1?^/=CSQ;*$F'*DB2D+%DRENR)2$1,* Q?9,O(F$EE
MR3:6HF1)6:+&4)9L,W;1M^S&EEG(KF;$&(R9=_K]WO6ZWC_>WWL_S_GKG/M<
M]^><^_Z<S\V:9!$!45M+&TN @X,#N,W^ -8,8 YP<7+^_=G&S?YY#O'P<'/S
M"/#Q\1X2$A 2$A00%!0^?$14^+#884%!44E1L:/B$A(20B)2QR3%CQT1EQ#_
MNPD'%]N'FX>?AX=?7%A06/R_;*QV0.P08,]QEHM# > 4X^ 2XV!U R  X.#A
M^ \#_KMQ<+)CY.4[Q"\@R%Y0+PIP<G!Q<7)S_8V:/1O'G@>XQ7B.G-0RY3UZ
MS9M/(4S\?'Q6R2%%L]H.":=ABM(%G_!'_ *24L>D991/J9Q6/:.MHZMW4=_
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M!SQO<,;;FO*(81#@E\@"NIT(<RNFG9\"E36#(>#..TXW+\QD>:JL+U'7>EC
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M:5E4S40CG:,>RXA;4A,3'WH2/K_4.]9A]%RXP+^!+_#@!Z8'0U?=8132VEC
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M':DU&DJ""$,1<G8?T?>:[[XQ43YSR&G&Y/OYL&)WOKBSD>/T6G;S 8Z"3+,
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M'=DS/9B."T#[@$4L2NEO/%I4ZWX<=WIVS[( YV>7:)[@QV$'7/TQ.2BQ;*Q
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M.#>C7'FM^QD8\P%;$-/=E"6]Q[F!=4$2#"*C2ZF^O.K)7WZ=R(<QCVL+4_M
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MBH($(_CK$<)'O__VSW\ _L^[?PT&X"J&270&+G X&*$Y_@7<!"MX!CY !$G
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M     &9O<FUP<F4Q-&$N:'1M4$L! A0#%     @ #HA&6ZW4'GNI(   L2$
M !(              ( !,0\" &9O<FUP<F4Q-&%?,# Q+FIP9U!+ 0(4 Q0
M   (  Z(1EL%260P:00   P5   1              "  0HP @!R:6UE+3(P
M,C0Q,C,Q+GAS9%!+ 0(4 Q0    (  Z(1EMEP9I?R00  -4D   5
M      "  :(T @!R:6UE+3(P,C0Q,C,Q7V1E9BYX;6Q02P$"% ,4    "  .
MB$9;12C:\"@3  #]\@  %0              @ &>.0( <FEM92TR,#(T,3(S
M,5]L86(N>&UL4$L! A0#%     @ #HA&6S!97<<1#0  8:8  !4
M     ( !^4P" ')I;64M,C R-#$R,S%?<')E+GAM;%!+!08     !@ & (0!
(   ]6@(    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>formpre14a_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:RIME="http://algoholdings.com/20241231"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="rime-20241231.xsd" xlink:type="simple"/>
    <context id="From2024-01-01to2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_ecd_PeoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_ecd_PeoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_ecd_PeoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ReportedValueOfEquityAwardsMember_ecd_PeoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:ReportedValueOfEquityAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember_ecd_PeoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember_ecd_PeoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_FairValueOfAwardsGrantedAndVestedDuringTheYearMember_ecd_PeoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueOfAwardsGrantedAndVestedDuringTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember_ecd_PeoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-12-31_custom_ReportedValueOfEquityAwardsMember_ecd_PeoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:ReportedValueOfEquityAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-12-31_custom_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember_ecd_PeoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-12-31_custom_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember_ecd_PeoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-12-31_custom_FairValueOfAwardsGrantedAndVestedDuringTheYearMember_ecd_PeoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueOfAwardsGrantedAndVestedDuringTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-12-31_custom_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember_ecd_PeoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_custom_ReportedValueOfEquityAwardsMember_ecd_PeoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:ReportedValueOfEquityAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_custom_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember_ecd_PeoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_custom_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember_ecd_PeoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_custom_FairValueOfAwardsGrantedAndVestedDuringTheYearMember_ecd_PeoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueOfAwardsGrantedAndVestedDuringTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_custom_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember_ecd_PeoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_ReportedValueOfEquityAwardsMember_ecd_PeoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:ReportedValueOfEquityAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember_ecd_PeoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember_ecd_PeoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_FairValueOfAwardsGrantedAndVestedDuringTheYearMember_ecd_PeoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueOfAwardsGrantedAndVestedDuringTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember_ecd_PeoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_RichardPerezMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:RichardPerezMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_RichardPerezMember_custom_ReportedValueOfEquityAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:ReportedValueOfEquityAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:RichardPerezMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_RichardPerezMember_custom_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:RichardPerezMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_RichardPerezMember_custom_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:RichardPerezMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_RichardPerezMember_custom_FairValueOfAwardsGrantedAndVestedDuringTheYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueOfAwardsGrantedAndVestedDuringTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:RichardPerezMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_RichardPerezMember_custom_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:RichardPerezMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-12-31_custom_LionelMarquisMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:LionelMarquisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-12-31_custom_LionelMarquisMember_custom_ReportedValueOfEquityAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:ReportedValueOfEquityAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:LionelMarquisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-12-31_custom_LionelMarquisMember_custom_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:LionelMarquisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-12-31_custom_LionelMarquisMember_custom_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:LionelMarquisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-12-31_custom_LionelMarquisMember_custom_FairValueOfAwardsGrantedAndVestedDuringTheYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueOfAwardsGrantedAndVestedDuringTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:LionelMarquisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-12-31_custom_LionelMarquisMember_custom_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:LionelMarquisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_custom_LionelMarquisMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:LionelMarquisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_custom_LionelMarquisMember_custom_ReportedValueOfEquityAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:ReportedValueOfEquityAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:LionelMarquisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_custom_LionelMarquisMember_custom_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:LionelMarquisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_custom_LionelMarquisMember_custom_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:LionelMarquisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_custom_LionelMarquisMember_custom_FairValueOfAwardsGrantedAndVestedDuringTheYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueOfAwardsGrantedAndVestedDuringTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:LionelMarquisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_custom_LionelMarquisMember_custom_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:LionelMarquisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_LionelMarquisMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:LionelMarquisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_LionelMarquisMember_custom_ReportedValueOfEquityAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:ReportedValueOfEquityAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:LionelMarquisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_LionelMarquisMember_custom_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:LionelMarquisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_LionelMarquisMember_custom_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:LionelMarquisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_LionelMarquisMember_custom_FairValueOfAwardsGrantedAndVestedDuringTheYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueOfAwardsGrantedAndVestedDuringTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:LionelMarquisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_LionelMarquisMember_custom_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:LionelMarquisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_BernardoMeloMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:BernardoMeloMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_BernardoMeloMember_custom_ReportedValueOfEquityAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:ReportedValueOfEquityAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:BernardoMeloMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_BernardoMeloMember_custom_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:BernardoMeloMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_BernardoMeloMember_custom_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:BernardoMeloMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_BernardoMeloMember_custom_FairValueOfAwardsGrantedAndVestedDuringTheYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueOfAwardsGrantedAndVestedDuringTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:BernardoMeloMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_BernardoMeloMember_custom_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:BernardoMeloMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-12-31_custom_BernardoMeloMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:BernardoMeloMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-12-31_custom_BernardoMeloMember_custom_ReportedValueOfEquityAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:ReportedValueOfEquityAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:BernardoMeloMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-12-31_custom_BernardoMeloMember_custom_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:BernardoMeloMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-12-31_custom_BernardoMeloMember_custom_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:BernardoMeloMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-12-31_custom_BernardoMeloMember_custom_FairValueOfAwardsGrantedAndVestedDuringTheYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueOfAwardsGrantedAndVestedDuringTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:BernardoMeloMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-12-31_custom_BernardoMeloMember_custom_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:BernardoMeloMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_custom_BernardoMeloMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:BernardoMeloMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_custom_BernardoMeloMember_custom_ReportedValueOfEquityAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:ReportedValueOfEquityAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:BernardoMeloMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_custom_BernardoMeloMember_custom_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:BernardoMeloMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_custom_BernardoMeloMember_custom_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:BernardoMeloMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_custom_BernardoMeloMember_custom_FairValueOfAwardsGrantedAndVestedDuringTheYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueOfAwardsGrantedAndVestedDuringTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:BernardoMeloMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012023-03-31_custom_BernardoMeloMember_custom_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:BernardoMeloMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_BernardoMeloMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:BernardoMeloMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_BernardoMeloMember_custom_ReportedValueOfEquityAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:ReportedValueOfEquityAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:BernardoMeloMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_BernardoMeloMember_custom_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:BernardoMeloMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_BernardoMeloMember_custom_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:BernardoMeloMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_BernardoMeloMember_custom_FairValueOfAwardsGrantedAndVestedDuringTheYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueOfAwardsGrantedAndVestedDuringTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:BernardoMeloMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_BernardoMeloMember_custom_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000923601</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">RIME:FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">RIME:BernardoMeloMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Ratio">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2024-01-01to2024-12-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="From2024-01-01to2024-12-31" id="Fact000004">0000923601</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0011">PRE 14A</dei:DocumentType>
    <ecd:AdjToCompAmt
      contextRef="From2024-01-012024-12-31_custom_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember_ecd_PeoMember"
      id="xdx2ixbrl0061"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2024-01-012024-12-31_custom_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember_ecd_PeoMember"
      id="xdx2ixbrl0062"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2024-01-012024-12-31_custom_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember_ecd_PeoMember"
      id="xdx2ixbrl0064"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2023-04-012023-12-31_custom_ReportedValueOfEquityAwardsMember_ecd_PeoMember"
      id="xdx2ixbrl0067"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2023-04-012023-12-31_custom_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember_ecd_PeoMember"
      id="xdx2ixbrl0068"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2023-04-012023-12-31_custom_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember_ecd_PeoMember"
      id="xdx2ixbrl0069"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2022-04-012023-03-31_custom_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember_ecd_PeoMember"
      id="xdx2ixbrl0076"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2022-04-012023-03-31_custom_FairValueOfAwardsGrantedAndVestedDuringTheYearMember_ecd_PeoMember"
      id="xdx2ixbrl0077"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2022-04-012023-03-31_custom_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember_ecd_PeoMember"
      id="xdx2ixbrl0078"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2021-04-012022-03-31_custom_ReportedValueOfEquityAwardsMember_ecd_PeoMember"
      id="xdx2ixbrl0081"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2021-04-012022-03-31_custom_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember_ecd_PeoMember"
      id="xdx2ixbrl0082"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2021-04-012022-03-31_custom_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember_ecd_PeoMember"
      id="xdx2ixbrl0083"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2021-04-012022-03-31_custom_FairValueOfAwardsGrantedAndVestedDuringTheYearMember_ecd_PeoMember"
      id="xdx2ixbrl0084"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2021-04-012022-03-31_custom_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember_ecd_PeoMember"
      id="xdx2ixbrl0085"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2024-01-012024-12-31_custom_RichardPerezMember_custom_ReportedValueOfEquityAwardsMember"
      id="xdx2ixbrl0091"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2024-01-012024-12-31_custom_RichardPerezMember_custom_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember"
      id="xdx2ixbrl0092"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2024-01-012024-12-31_custom_RichardPerezMember_custom_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember"
      id="xdx2ixbrl0093"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2024-01-012024-12-31_custom_RichardPerezMember_custom_FairValueOfAwardsGrantedAndVestedDuringTheYearMember"
      id="xdx2ixbrl0094"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2024-01-012024-12-31_custom_RichardPerezMember_custom_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember"
      id="xdx2ixbrl0095"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2023-04-012023-12-31_custom_LionelMarquisMember_custom_ReportedValueOfEquityAwardsMember"
      id="xdx2ixbrl0098"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2023-04-012023-12-31_custom_LionelMarquisMember_custom_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember"
      id="xdx2ixbrl0099"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2023-04-012023-12-31_custom_LionelMarquisMember_custom_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember"
      id="xdx2ixbrl0100"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2022-04-012023-03-31_custom_LionelMarquisMember_custom_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember"
      id="xdx2ixbrl0107"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2022-04-012023-03-31_custom_LionelMarquisMember_custom_FairValueOfAwardsGrantedAndVestedDuringTheYearMember"
      id="xdx2ixbrl0108"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2022-04-012023-03-31_custom_LionelMarquisMember_custom_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember"
      id="xdx2ixbrl0109"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2021-04-012022-03-31_custom_LionelMarquisMember_custom_ReportedValueOfEquityAwardsMember"
      id="xdx2ixbrl0112"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2021-04-012022-03-31_custom_LionelMarquisMember_custom_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember"
      id="xdx2ixbrl0113"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2021-04-012022-03-31_custom_LionelMarquisMember_custom_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember"
      id="xdx2ixbrl0114"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2021-04-012022-03-31_custom_LionelMarquisMember_custom_FairValueOfAwardsGrantedAndVestedDuringTheYearMember"
      id="xdx2ixbrl0115"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2021-04-012022-03-31_custom_LionelMarquisMember_custom_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember"
      id="xdx2ixbrl0116"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2024-01-012024-12-31_custom_BernardoMeloMember_custom_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember"
      id="xdx2ixbrl0120"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2024-01-012024-12-31_custom_BernardoMeloMember_custom_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember"
      id="xdx2ixbrl0121"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2024-01-012024-12-31_custom_BernardoMeloMember_custom_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember"
      id="xdx2ixbrl0123"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2023-04-012023-12-31_custom_BernardoMeloMember_custom_ReportedValueOfEquityAwardsMember"
      id="xdx2ixbrl0126"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2023-04-012023-12-31_custom_BernardoMeloMember_custom_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember"
      id="xdx2ixbrl0127"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2023-04-012023-12-31_custom_BernardoMeloMember_custom_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember"
      id="xdx2ixbrl0128"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2022-04-012023-03-31_custom_BernardoMeloMember_custom_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember"
      id="xdx2ixbrl0135"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2022-04-012023-03-31_custom_BernardoMeloMember_custom_FairValueOfAwardsGrantedAndVestedDuringTheYearMember"
      id="xdx2ixbrl0136"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2021-04-012022-03-31_custom_BernardoMeloMember_custom_FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember"
      id="xdx2ixbrl0142"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2021-04-012022-03-31_custom_BernardoMeloMember_custom_FairValueOfAwardsGrantedAndVestedDuringTheYearMember"
      id="xdx2ixbrl0143"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2021-04-012022-03-31_custom_BernardoMeloMember_custom_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember"
      id="xdx2ixbrl0144"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:EntityRegistrantName contextRef="From2024-01-01to2024-12-31" id="Fact000012">ALGORHYTHM HOLDINGS, INC.</dei:EntityRegistrantName>
    <ecd:AwardTmgMnpiDiscTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000018">We
have a strict policy of not granting securities to our executive officers, directors and employees when material nonpublic information
is known or a material transaction is anticipated to occur.The
timing of equity award grants is determined with consideration to a variety of factors, including but not limited to, the achievement
of pre-established performance targets, market conditions and internal milestones. We do not follow a predetermined schedule for the
granting of equity awards. Instead, each grant is considered on a case-by-case basis to align with our strategic objectives and to ensure
the competitiveness of our compensation packages.In
determining the timing and terms of an equity award, our board of directors and compensation committee consider material nonpublic information
to ensure that such grants are made in compliance with applicable laws and regulations. Procedures utilized by our board of directors
and compensation committee to prevent the improper use of material nonpublic information in connection with the granting of equity awards
include consultation with legal counsel and, where appropriate, the delay of the grant of applicable equity awards until the public disclosure
of such material nonpublic information has been completed.We
are committed to maintaining transparency in our executive compensation practices and to making equity awards in a manner that is not
influenced by the timing of the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation.
We regularly review our policies and practices related to equity awards to ensure that they meet the evolving standards of corporate
governance and continue to serve the best interests of us and our stockholders.During
the year ended December 31, 2024, no securities were granted to our named executive officers within four business days prior to, or one
business day following, the filing or furnishing of a periodic or current report by us that disclosed material nonpublic information.</ecd:AwardTmgMnpiDiscTextBlock>
    <ecd:MnpiDiscTimedForCompValFlag contextRef="From2024-01-01to2024-12-31" id="Fact000019">true</ecd:MnpiDiscTimedForCompValFlag>
    <ecd:AwardTmgPredtrmndFlag contextRef="From2024-01-01to2024-12-31" id="Fact000020">true</ecd:AwardTmgPredtrmndFlag>
    <ecd:PvpTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000022">&lt;table cellpadding="0" cellspacing="0" id="xdx_883_eecd--PvpTableTextBlock_zUsDuhRhy85i" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Pay vs Performance Disclosure"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_489_eecd--PeoTotalCompAmt_zBIf65RslFb8" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Summary&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Compensation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Table Total&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;for CEO&lt;sup id="xdx_F5D_zk7ii5WVE66h"&gt;(1)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_484_eecd--PeoActuallyPaidCompAmt_z0KreWFuPnD2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Compensation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Actually Paid&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;to CEO&lt;sup id="xdx_F50_zx18Z5M7zNWa"&gt;(2)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_48D_eecd--NonPeoNeoAvgTotalCompAmt_znAsXmjRXPO5" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Summary&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Compensation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Table Total for&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Non-CEO&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NEOs&lt;sup id="xdx_F5D_zwVKRKwGas94"&gt;(3)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_482_eecd--NonPeoNeoAvgCompActuallyPaidAmt_zzFKE6TCmK8k" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Compensation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Actually Paid&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;to Non-CEO&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NEOs&lt;sup id="xdx_F5F_zJOjxwtVSeYa"&gt;(4)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_489_eecd--TotalShareholderRtnAmt_pp2d_zil0wnoWVsXd" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Value of Initial&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Fixed $100&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Investment&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Based On Total&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Stockholder&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Return&lt;sup id="xdx_F5E_zh1gfUjTUPCg"&gt;(5)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_483_eus-gaap--NetIncomeLoss_zSgSxvsvoz54" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Net Income (Loss)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41D_20240101__20241231_zWb4dlIERxO9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: left"&gt;Fiscal Year 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;253,535&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;263,535&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;203,635&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;226,302&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;8.74&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;(23,257,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41E_20230401__20231231_zZUIqKYclAV7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Nine-Month Transition Period Ended December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;169,527&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;250,069&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;244,954&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;256,856&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;63.52&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,398,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41C_20220401__20230331_zImPDYC4LnJ6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Fiscal Year 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;307,451&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;263,866&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;415,138&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;388,476&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;12.68&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,638,462&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_416_20210401__20220331_zzzI1Gog4olj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Fiscal Year 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;161,414&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;161,414&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;245,935&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;243,829&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;34.15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;230,471&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ecd:PvpTableTextBlock>
    <ecd:PeoTotalCompAmt
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000023"
      unitRef="USD">253535</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000024"
      unitRef="USD">263535</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000025"
      unitRef="USD">203635</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000026"
      unitRef="USD">226302</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:TotalShareholderRtnAmt
      contextRef="From2024-01-01to2024-12-31"
      decimals="2"
      id="Fact000027"
      unitRef="USD">8.74</ecd:TotalShareholderRtnAmt>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000028"
      unitRef="USD">-23257000</us-gaap:NetIncomeLoss>
    <ecd:PeoTotalCompAmt
      contextRef="From2023-04-012023-12-31"
      decimals="0"
      id="Fact000029"
      unitRef="USD">169527</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2023-04-012023-12-31"
      decimals="0"
      id="Fact000030"
      unitRef="USD">250069</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="From2023-04-012023-12-31"
      decimals="0"
      id="Fact000031"
      unitRef="USD">244954</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="From2023-04-012023-12-31"
      decimals="0"
      id="Fact000032"
      unitRef="USD">256856</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:TotalShareholderRtnAmt
      contextRef="From2023-04-012023-12-31"
      decimals="2"
      id="Fact000033"
      unitRef="USD">63.52</ecd:TotalShareholderRtnAmt>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-12-31"
      decimals="0"
      id="Fact000034"
      unitRef="USD">-6398000</us-gaap:NetIncomeLoss>
    <ecd:PeoTotalCompAmt
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000035"
      unitRef="USD">307451</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000036"
      unitRef="USD">263866</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000037"
      unitRef="USD">415138</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000038"
      unitRef="USD">388476</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:TotalShareholderRtnAmt
      contextRef="From2022-04-012023-03-31"
      decimals="2"
      id="Fact000039"
      unitRef="USD">12.68</ecd:TotalShareholderRtnAmt>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000040"
      unitRef="USD">-4638462</us-gaap:NetIncomeLoss>
    <ecd:PeoTotalCompAmt
      contextRef="From2021-04-012022-03-31"
      decimals="0"
      id="Fact000041"
      unitRef="USD">161414</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2021-04-012022-03-31"
      decimals="0"
      id="Fact000042"
      unitRef="USD">161414</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="From2021-04-012022-03-31"
      decimals="0"
      id="Fact000043"
      unitRef="USD">245935</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="From2021-04-012022-03-31"
      decimals="0"
      id="Fact000044"
      unitRef="USD">243829</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:TotalShareholderRtnAmt
      contextRef="From2021-04-012022-03-31"
      decimals="2"
      id="Fact000045"
      unitRef="USD">34.15</ecd:TotalShareholderRtnAmt>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012022-03-31"
      decimals="0"
      id="Fact000046"
      unitRef="USD">230471</us-gaap:NetIncomeLoss>
    <ecd:NamedExecutiveOfficersFnTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000053">&lt;p id="xdx_898_eecd--NamedExecutiveOfficersFnTextBlock_dU_zDhwZROFZW3f" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    dollar amounts reported are the amounts of total compensation reported for our CEO, &lt;span id="xdx_905_eecd--PeoName_c20240101__20241231__ecd--IndividualAxis__ecd--PeoMember_zJgXVKI8rZWc"&gt;&lt;span id="xdx_90C_eecd--PeoName_c20220401__20230331__ecd--IndividualAxis__ecd--PeoMember_zmhztkV0wr96"&gt;&lt;span id="xdx_901_eecd--PeoName_c20210401__20220331__ecd--IndividualAxis__ecd--PeoMember_zbDxUKgI8e5b"&gt;Gary Atkinson&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;, in the Summary Compensation Table
    for fiscal years 2024, 2023 and 2022.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</ecd:NamedExecutiveOfficersFnTextBlock>
    <ecd:PeoName
      contextRef="From2024-01-012024-12-31_ecd_PeoMember"
      id="Fact000054">Gary Atkinson</ecd:PeoName>
    <ecd:PeoName
      contextRef="From2022-04-012023-03-31_ecd_PeoMember"
      id="Fact000055">Gary Atkinson</ecd:PeoName>
    <ecd:PeoName
      contextRef="From2021-04-012022-03-31_ecd_PeoMember"
      id="Fact000056">Gary Atkinson</ecd:PeoName>
    <ecd:AdjToPeoCompFnTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000058">&lt;p id="xdx_899_eecd--AdjToPeoCompFnTextBlock_dU_z7XrI8h8PtY5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;To
calculate the amounts in the &#x201c;Compensation Actually Paid to CEO&#x201d; column in the table above, the following amounts were deducted
from and added to (as applicable) our CEO&#x2019;s &#x201c;Total&#x201d; compensation as reported in the Summary Compensation Table:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Name and Principal Position&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_489_eecd--PeoTotalCompAmt_z6ftMG61ELhh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Summary Compensation Table Total for CEO&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_48B_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--ReportedValueOfEquityAwardsMember__ecd--IndividualAxis__ecd--PeoMember_zpDLZ1q3Ahe9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Reported Value of Equity Awards for CEO &lt;/b&gt;&lt;sup id="xdx_F58_z5GhudMUb2c4"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_485_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember__ecd--IndividualAxis__ecd--PeoMember_zyjxr8PkiVXa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value as of Year End for Unvested Awards Granted During the Year&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_483_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember__ecd--IndividualAxis__ecd--PeoMember_zzaOCI9CFNy6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value Year over Year Increase or Decrease in Unvested Awards Granted in Prior Years&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_48A_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--FairValueOfAwardsGrantedAndVestedDuringTheYearMember__ecd--IndividualAxis__ecd--PeoMember_zbT35384wgS2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value of Awards Granted and Vested During the Year&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_48C_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember__ecd--IndividualAxis__ecd--PeoMember_zjartK9fnHAd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value Increase or Decrease from Prior Year end for Awards that Vested during the Year&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_484_eecd--PeoActuallyPaidCompAmt_z2tHWnQll1W3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Compensation Actually Paid to CEO&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_415_20240101__20241231_zFh1KuxefTh6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 10%; text-align: left"&gt;Gary Atkinson,&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10%; text-align: left"&gt;Fiscal Year 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;253,535&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;10,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0061"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0062"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;10,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0064"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;263,535&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41A_20230401__20231231_z2xi7otJujv9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; font-style: italic; text-align: left"&gt;Chief Executive Officer&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;Nine-Month Transition Period Ended December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;169,527&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0067"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0068"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0069"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;112,042&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(31,500&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;250,069&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_411_20220401__20230331_zyuhymbHCTTa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Fiscal Year 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;307,451&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;58,586&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;15,001&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0076"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0077"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0078"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;263,866&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_419_20210401__20220331_zlcySPRlT1S3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Fiscal Year 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;161,414&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0081"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0082"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0083"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0084"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0085"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;161,414&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;sup id="xdx_F09_zoSeDq1U4kTh"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F13_z9dC7f98hoQ2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Represents
    the grant date fair value of the equity awards to our CEO, as reported in the Summary Compensation Table&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</ecd:AdjToPeoCompFnTextBlock>
    <ecd:PeoTotalCompAmt
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000059"
      unitRef="USD">253535</ecd:PeoTotalCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2024-01-012024-12-31_custom_ReportedValueOfEquityAwardsMember_ecd_PeoMember"
      decimals="0"
      id="Fact000060"
      unitRef="USD">10000</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2024-01-012024-12-31_custom_FairValueOfAwardsGrantedAndVestedDuringTheYearMember_ecd_PeoMember"
      decimals="0"
      id="Fact000063"
      unitRef="USD">10000</ecd:AdjToCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000065"
      unitRef="USD">263535</ecd:PeoActuallyPaidCompAmt>
    <ecd:PeoTotalCompAmt
      contextRef="From2023-04-012023-12-31"
      decimals="0"
      id="Fact000066"
      unitRef="USD">169527</ecd:PeoTotalCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2023-04-012023-12-31_custom_FairValueOfAwardsGrantedAndVestedDuringTheYearMember_ecd_PeoMember"
      decimals="0"
      id="Fact000070"
      unitRef="USD">112042</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2023-04-012023-12-31_custom_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember_ecd_PeoMember"
      decimals="0"
      id="Fact000071"
      unitRef="USD">-31500</ecd:AdjToCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2023-04-012023-12-31"
      decimals="0"
      id="Fact000072"
      unitRef="USD">250069</ecd:PeoActuallyPaidCompAmt>
    <ecd:PeoTotalCompAmt
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000073"
      unitRef="USD">307451</ecd:PeoTotalCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2022-04-012023-03-31_custom_ReportedValueOfEquityAwardsMember_ecd_PeoMember"
      decimals="0"
      id="Fact000074"
      unitRef="USD">58586</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2022-04-012023-03-31_custom_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember_ecd_PeoMember"
      decimals="0"
      id="Fact000075"
      unitRef="USD">15001</ecd:AdjToCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2022-04-012023-03-31"
      decimals="0"
      id="Fact000079"
      unitRef="USD">263866</ecd:PeoActuallyPaidCompAmt>
    <ecd:PeoTotalCompAmt
      contextRef="From2021-04-012022-03-31"
      decimals="0"
      id="Fact000080"
      unitRef="USD">161414</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2021-04-012022-03-31"
      decimals="0"
      id="Fact000086"
      unitRef="USD">161414</ecd:PeoActuallyPaidCompAmt>
    <ecd:AdjToNonPeoNeoCompFnTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000089">&lt;p id="xdx_895_eecd--AdjToNonPeoNeoCompFnTextBlock_dU_zLkMaeF6HWvl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;To
calculate the amounts in the &#x201c;Compensation Actually Paid to Non-CEO NEOs&#x201d; column in the table above, the following amounts
were deducted from and added to (as applicable) the average &#x201c;Total&#x201d; compensation of our Non-CEO NEOs as reported in the Summary
Compensation Table.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Name and Principal Position&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Year&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_487_eecd--NonPeoNeoAvgTotalCompAmt_zgKjIfPvIfwl" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Summary Compensation Table Total for Non-CEO NEOs&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_48C_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--ReportedValueOfEquityAwardsMember_zFDnepSmXSd4" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;Reported Value of Equity Awards for Non-CEO NEOs &lt;/b&gt;&lt;sup id="xdx_F5B_zvOfZbFutHB4"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_488_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember_zEK7GtSVSqVe" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Fair Value as of Year End for Unvested Awards Granted During the Year&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_48A_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--FairValueYearOverYearIncreaseOrDecreaseInUnvestedAwardsGrantedInPriorYearsMember_zkTQZqbfNKah" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Fair Value Year over Year Increase or Decrease in Unvested Awards Granted in Prior Years&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_489_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--FairValueOfAwardsGrantedAndVestedDuringTheYearMember_zGuV0c7slFCl" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Fair Value of Awards Granted and Vested During the Year&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_48D_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember_zseSQAfbrjp7" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Fair Value Increase or Decrease from Prior Year end for Awards that Vested during the Year&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_48B_eecd--NonPeoNeoAvgCompActuallyPaidAmt_zWtQLp3tmOja" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Compensation Actually Paid to Non-CEO NEOs &lt;/b&gt;&lt;sup id="xdx_F5C_z4Lqt064fnfk"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41C_20240101__20241231__ecd--IndividualAxis__custom--RichardPerezMember_z1s30Q2gFcSh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 9%; text-align: left"&gt;Richard Perez, &lt;i&gt;Former Chief Financial Officer&lt;/i&gt;&lt;br/&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10%; text-align: left"&gt;Fiscal Year 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;174,596&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0091"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0092"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0093"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0094"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0095"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;174,596&lt;/td&gt;&lt;td style="width: 2%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 12pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 12pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_416_20230401__20231231__ecd--IndividualAxis__custom--LionelMarquisMember_zyq7VHgn7QR8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Lionel Marquis,&lt;i&gt; Former&lt;/i&gt;&lt;i&gt; Chief Financial Officer&lt;/i&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;Nine-Month Transition Period Ended December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;268,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0098"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0099"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0100"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;48,650&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(20,998&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;295,652&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_416_20220401__20230331__ecd--IndividualAxis__custom--LionelMarquisMember_zI1BuFToe6m4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Fiscal Year 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;468,224&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;38,419&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;20,400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0107"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0108"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0109"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;450,205&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_414_20210401__20220331__ecd--IndividualAxis__custom--LionelMarquisMember_zRPYcDTnPfU8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Fiscal Year 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;160,638&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0112"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0113"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0114"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0115"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0116"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;160,638&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_411_20240101__20241231__ecd--IndividualAxis__custom--BernardoMeloMember_zzSHsKDAvDck" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Bernardo Melo,&lt;/p&gt;
                                 &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;i&gt;Former&lt;/i&gt;&lt;i&gt; Chief Revenue Officer&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Fiscal Year 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;283,454&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;10,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0120"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0121"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;10,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0123"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;293,454&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_416_20230401__20231231__ecd--IndividualAxis__custom--BernardoMeloMember_zOEkwtgXDn79" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 12pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;Nine Months Ended December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;221,908&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0126"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0127"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0128"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;48,650&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(52,498&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;218,060&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_412_20220401__20230331__ecd--IndividualAxis__custom--BernardoMeloMember_zpLDL6KFLgIg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Fiscal Year 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;362,051&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;38,419&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,680&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0135"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0136"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,434&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt; 326,746 &lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_413_20210401__20220331__ecd--IndividualAxis__custom--BernardoMeloMember_zyxJ6VUKUM3j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Fiscal Year 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;331,232&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;9,114&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4,901&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0142"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0143"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0144"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt; 327,019 &lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;sup id="xdx_F0B_zWYV66QsWZq4"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1E_zfV7QgQNhAUb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Represents
    the grant date fair value of the equity awards to our Non-CEO NEOs, as reported in the Summary Compensation Table.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;sup id="xdx_F0C_zzRQ9wBBVnAb"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1C_zUyU6jVnJLyl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Compensation
    actually paid to Bernardo Melo for 2023 and 2022 includes adjustments for accrued bonuses of $7,816 and $4,652, respectively, that
    was reported as compensation but not paid.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</ecd:AdjToNonPeoNeoCompFnTextBlock>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="From2024-01-012024-12-31_custom_RichardPerezMember"
      decimals="0"
      id="Fact000090"
      unitRef="USD">174596</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="From2024-01-012024-12-31_custom_RichardPerezMember"
      decimals="0"
      id="Fact000096"
      unitRef="USD">174596</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="From2023-04-012023-12-31_custom_LionelMarquisMember"
      decimals="0"
      id="Fact000097"
      unitRef="USD">268000</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2023-04-012023-12-31_custom_LionelMarquisMember_custom_FairValueOfAwardsGrantedAndVestedDuringTheYearMember"
      decimals="0"
      id="Fact000101"
      unitRef="USD">48650</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2023-04-012023-12-31_custom_LionelMarquisMember_custom_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember"
      decimals="0"
      id="Fact000102"
      unitRef="USD">-20998</ecd:AdjToCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="From2023-04-012023-12-31_custom_LionelMarquisMember"
      decimals="0"
      id="Fact000103"
      unitRef="USD">295652</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="From2022-04-012023-03-31_custom_LionelMarquisMember"
      decimals="0"
      id="Fact000104"
      unitRef="USD">468224</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2022-04-012023-03-31_custom_LionelMarquisMember_custom_ReportedValueOfEquityAwardsMember"
      decimals="0"
      id="Fact000105"
      unitRef="USD">38419</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2022-04-012023-03-31_custom_LionelMarquisMember_custom_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember"
      decimals="0"
      id="Fact000106"
      unitRef="USD">20400</ecd:AdjToCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="From2022-04-012023-03-31_custom_LionelMarquisMember"
      decimals="0"
      id="Fact000110"
      unitRef="USD">450205</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="From2021-04-012022-03-31_custom_LionelMarquisMember"
      decimals="0"
      id="Fact000111"
      unitRef="USD">160638</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="From2021-04-012022-03-31_custom_LionelMarquisMember"
      decimals="0"
      id="Fact000117"
      unitRef="USD">160638</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="From2024-01-012024-12-31_custom_BernardoMeloMember"
      decimals="0"
      id="Fact000118"
      unitRef="USD">283454</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2024-01-012024-12-31_custom_BernardoMeloMember_custom_ReportedValueOfEquityAwardsMember"
      decimals="0"
      id="Fact000119"
      unitRef="USD">10000</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2024-01-012024-12-31_custom_BernardoMeloMember_custom_FairValueOfAwardsGrantedAndVestedDuringTheYearMember"
      decimals="0"
      id="Fact000122"
      unitRef="USD">10000</ecd:AdjToCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="From2024-01-012024-12-31_custom_BernardoMeloMember"
      decimals="0"
      id="Fact000124"
      unitRef="USD">293454</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="From2023-04-012023-12-31_custom_BernardoMeloMember"
      decimals="0"
      id="Fact000125"
      unitRef="USD">221908</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2023-04-012023-12-31_custom_BernardoMeloMember_custom_FairValueOfAwardsGrantedAndVestedDuringTheYearMember"
      decimals="0"
      id="Fact000129"
      unitRef="USD">48650</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2023-04-012023-12-31_custom_BernardoMeloMember_custom_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember"
      decimals="0"
      id="Fact000130"
      unitRef="USD">-52498</ecd:AdjToCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="From2023-04-012023-12-31_custom_BernardoMeloMember"
      decimals="0"
      id="Fact000131"
      unitRef="USD">218060</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="From2022-04-012023-03-31_custom_BernardoMeloMember"
      decimals="0"
      id="Fact000132"
      unitRef="USD">362051</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2022-04-012023-03-31_custom_BernardoMeloMember_custom_ReportedValueOfEquityAwardsMember"
      decimals="0"
      id="Fact000133"
      unitRef="USD">38419</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2022-04-012023-03-31_custom_BernardoMeloMember_custom_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember"
      decimals="0"
      id="Fact000134"
      unitRef="USD">1680</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2022-04-012023-03-31_custom_BernardoMeloMember_custom_FairValueIncreaseOrDecreaseFromPriorYearEndForAwardsThatVestedDuringTheYearMember"
      decimals="0"
      id="Fact000137"
      unitRef="USD">1434</ecd:AdjToCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="From2022-04-012023-03-31_custom_BernardoMeloMember"
      decimals="0"
      id="Fact000138"
      unitRef="USD">326746</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="From2021-04-012022-03-31_custom_BernardoMeloMember"
      decimals="0"
      id="Fact000139"
      unitRef="USD">331232</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2021-04-012022-03-31_custom_BernardoMeloMember_custom_ReportedValueOfEquityAwardsMember"
      decimals="0"
      id="Fact000140"
      unitRef="USD">9114</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2021-04-012022-03-31_custom_BernardoMeloMember_custom_FairValueAsOfYearEndForUnvestedAwardsGrantedDuringTheYearMember"
      decimals="0"
      id="Fact000141"
      unitRef="USD">4901</ecd:AdjToCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="From2021-04-012022-03-31_custom_BernardoMeloMember"
      decimals="0"
      id="Fact000145"
      unitRef="USD">327019</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact000023"
          xlink:label="Fact000023"
          xlink:type="locator"/>
        <link:footnote id="Footnote000047" xlink:label="Footnote000047" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The
    dollar amounts reported are the amounts of total compensation reported for our CEO, Gary Atkinson, in the Summary Compensation Table
    for fiscal years 2024, 2023 and 2022.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000023"
          xlink:to="Footnote000047"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000029"
          xlink:label="Fact000029"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000029"
          xlink:to="Footnote000047"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000035"
          xlink:label="Fact000035"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000035"
          xlink:to="Footnote000047"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000041"
          xlink:label="Fact000041"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000041"
          xlink:to="Footnote000047"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000024"
          xlink:label="Fact000024"
          xlink:type="locator"/>
        <link:footnote id="Footnote000048" xlink:label="Footnote000048" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The
    dollar amounts reported represent the amount of &#x201c;compensation actually paid&#x201d;, as computed in accordance with SEC rules.
    The dollar amounts reported are the amounts of total compensation reported for Mr. Atkinson during the applicable year, but also
    include (i) the year-end value of equity awards granted during the reported year, (ii) the change in the value of equity awards that
    were unvested at the end of the prior year, measured through the date the awards vested, or through the end of the reported fiscal
    year, and (iii) value of equity awards issued and vested during the reported fiscal year. See table below for further information.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000024"
          xlink:to="Footnote000048"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000030"
          xlink:label="Fact000030"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000030"
          xlink:to="Footnote000048"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000036"
          xlink:label="Fact000036"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000036"
          xlink:to="Footnote000048"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000042"
          xlink:label="Fact000042"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000042"
          xlink:to="Footnote000048"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000025"
          xlink:label="Fact000025"
          xlink:type="locator"/>
        <link:footnote id="Footnote000049" xlink:label="Footnote000049" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The
    dollar amounts reported are the average of the total compensation reported for our NEOs, other than our CEO, in the Summary Compensation
    Table for fiscal years 2024, 2023 and 2022.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000025"
          xlink:to="Footnote000049"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000031"
          xlink:label="Fact000031"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000031"
          xlink:to="Footnote000049"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000037"
          xlink:label="Fact000037"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000037"
          xlink:to="Footnote000049"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000043"
          xlink:label="Fact000043"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000043"
          xlink:to="Footnote000049"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000026"
          xlink:label="Fact000026"
          xlink:type="locator"/>
        <link:footnote id="Footnote000050" xlink:label="Footnote000050" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The
    dollar amounts reported represent the average amount of &#x201c;compensation actually paid&#x201d;, as computed in accordance with
    SEC rules, for our NEOs, other than our CEO. The dollar amounts reported are the average of the total compensation reported for our
    NEOs, other than our CEO in the Summary Compensation Table for fiscal years 2024, 2023 and 2022, but also include: (i) the year-end
    value of equity awards granted during the reported year, (ii) the change in the value of equity awards that were unvested at the
    end of the prior year, measured through the date the awards vested, or through the end of the reported fiscal year, and (iii) value
    of equity awards issued and vested during the reported fiscal year.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000026"
          xlink:to="Footnote000050"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000032"
          xlink:label="Fact000032"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000032"
          xlink:to="Footnote000050"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000038"
          xlink:label="Fact000038"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000038"
          xlink:to="Footnote000050"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000044"
          xlink:label="Fact000044"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000044"
          xlink:to="Footnote000050"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000027"
          xlink:label="Fact000027"
          xlink:type="locator"/>
        <link:footnote id="Footnote000051" xlink:label="Footnote000051" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Reflects
    the cumulative stockholder return over the relevant fiscal year, computed in accordance with SEC rules, assuming an investment of
    $100 in our common shares at a price per share equal to the closing price of our common stock on the last trading day before the
    commencement of the earliest applicable fiscal year (March 31, 2021) and the measurement end point of the closing price of our common
    stock on the last trading day in the applicable fiscal year. For 2024, the closing price of our common stock on January 2, 2024 was
    $206 and the closing price of our common stock on December 31, 2024 was $18. For 2023, the closing price of our common stock on March
    31, 2022 was $4.20 and the closing price of our common stock on March 31, 2023 was $1.56. For 2022, the closing price of our common
    stock on March 31, 2021 was $12.30 and the closing price of our common stock on March 31, 2022 was $4.20.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000027"
          xlink:to="Footnote000051"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000033"
          xlink:label="Fact000033"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000033"
          xlink:to="Footnote000051"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000039"
          xlink:label="Fact000039"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000039"
          xlink:to="Footnote000051"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000045"
          xlink:label="Fact000045"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000045"
          xlink:to="Footnote000051"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000060"
          xlink:label="Fact000060"
          xlink:type="locator"/>
        <link:footnote id="Footnote000087" xlink:label="Footnote000087" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents
    the grant date fair value of the equity awards to our CEO, as reported in the Summary Compensation Table</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000060"
          xlink:to="Footnote000087"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0067"
          xlink:label="xdx2ixbrl0067"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0067"
          xlink:to="Footnote000087"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000074"
          xlink:label="Fact000074"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000074"
          xlink:to="Footnote000087"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0081"
          xlink:label="xdx2ixbrl0081"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0081"
          xlink:to="Footnote000087"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0091"
          xlink:label="xdx2ixbrl0091"
          xlink:type="locator"/>
        <link:footnote id="Footnote000146" xlink:label="Footnote000146" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents
    the grant date fair value of the equity awards to our Non-CEO NEOs, as reported in the Summary Compensation Table.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0091"
          xlink:to="Footnote000146"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0098"
          xlink:label="xdx2ixbrl0098"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0098"
          xlink:to="Footnote000146"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000105"
          xlink:label="Fact000105"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000105"
          xlink:to="Footnote000146"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0112"
          xlink:label="xdx2ixbrl0112"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0112"
          xlink:to="Footnote000146"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000119"
          xlink:label="Fact000119"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000119"
          xlink:to="Footnote000146"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0126"
          xlink:label="xdx2ixbrl0126"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0126"
          xlink:to="Footnote000146"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000133"
          xlink:label="Fact000133"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000133"
          xlink:to="Footnote000146"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000140"
          xlink:label="Fact000140"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000140"
          xlink:to="Footnote000146"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000096"
          xlink:label="Fact000096"
          xlink:type="locator"/>
        <link:footnote id="Footnote000147" xlink:label="Footnote000147" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Compensation
    actually paid to Bernardo Melo for 2023 and 2022 includes adjustments for accrued bonuses of $7,816 and $4,652, respectively, that
    was reported as compensation but not paid.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000096"
          xlink:to="Footnote000147"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000103"
          xlink:label="Fact000103"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000103"
          xlink:to="Footnote000147"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000110"
          xlink:label="Fact000110"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000110"
          xlink:to="Footnote000147"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000117"
          xlink:label="Fact000117"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000117"
          xlink:to="Footnote000147"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000124"
          xlink:label="Fact000124"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000124"
          xlink:to="Footnote000147"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000131"
          xlink:label="Fact000131"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000131"
          xlink:to="Footnote000147"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000138"
          xlink:label="Fact000138"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000138"
          xlink:to="Footnote000147"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000145"
          xlink:label="Fact000145"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000145"
          xlink:to="Footnote000147"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
